-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 T2FV/0LOXe4BPjCmW4mYN2DzrW0PrRFYabgfhljRxdehne0J47e/CMYH9KA0qcR/
 A9uylBKCecAC9AuEHvTcZQ==

<SEC-DOCUMENT>0000950123-11-017213.txt : 20110223
<SEC-HEADER>0000950123-11-017213.hdr.sgml : 20110223
<ACCEPTANCE-DATETIME>20110223171908
ACCESSION NUMBER:		0000950123-11-017213
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20101231
FILED AS OF DATE:		20110223
DATE AS OF CHANGE:		20110223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		11633114

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>y04571e10vk.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e10vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 14pt">UNITED STATES SECURITIES AND
    EXCHANGE COMMISSION</FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 12pt">Washington,&#160;D.C.
    20549</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 15%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 18pt"><FONT style="white-space: nowrap">Form&#160;10-K</FONT></FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 15%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 12pt">FOR ANNUAL AND TRANSITION
    REPORTS PURSUANT TO SECTIONS&#160;13 OR 15(d)<BR>
    OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></B>
</DIV>

<DIV style="margin-top: 1pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 12pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="10%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="89%">&nbsp;</TD> <!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 10pt">(Mark One)</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="center" valign="top">
<DIV style="text-indent: -12pt; margin-left: 12pt">
    <B><FONT style="font-family: Wingdings; font-variant: normal">&#254;</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <B>ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934</B> <!-- XBRL,dc -->
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <B><FONT style="font-size: 10pt">For the fiscal year ended
    December&#160;31,
    2010</FONT></B><FONT style="font-size: 10pt"><!-- /XBRL,dc -->
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" align="center" valign="top">
<DIV style="text-indent: -12pt; margin-left: 12pt">
    <B><FONT style="font-size: 10pt">or</FONT></B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
<DIV style="text-indent: -12pt; margin-left: 12pt">
    <B><FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT></B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <B>TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934</B>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    <B><FONT style="font-size: 10pt">For the transition period
    from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to
    </FONT></B>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="white-space: nowrap">001-33357</FONT><BR>
    (Commission file number)</B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 15%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="font-size: 24pt">PROTALIX BIOTHERAPEUTICS,
    INC.<BR>
    </FONT></B><I><FONT style="font-size: 8pt">(Exact name of
    registrant as specified in its charter)</FONT></I>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 15%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="49%">&nbsp;</TD> <!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="center" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Florida</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    <B>65-0643773</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">State or other jurisdiction
    of<BR>
    incorporation or organization</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <I><FONT style="font-size: 8pt">(I.R.S. Employer<BR>
    Identification No.)</FONT></I>
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="center" valign="top">
    <B>2 Snunit Street<BR>
    Science Park<BR>
    POB 455<BR>
    Carmiel, Israel<BR>
    </B><I><FONT style="font-size: 8pt">(Address of principal
    executive offices)</FONT></I>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <B>20100<BR>
    </B><I><FONT style="font-size: 8pt">(Zip Code) </FONT></I>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Registrant&#146;s telephone number, including area code</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><FONT style="white-space: nowrap">972-4-988-9488</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 15%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Securities registered pursuant to Section&#160;12(b) of the
    Act:</B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="49%">&nbsp;</TD> <!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Title of Each Class</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name of Each Exchange on Which Registered</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="center" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Common stock, par value $0.001 per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    NYSE AMEX
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Securities registered pursuant to Section&#160;12(g) of the
    Act:</B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>None</B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 15%; border-bottom: 1pt solid #000000"></CENTER>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Indicate by check mark if the registrant is a well-known
    seasoned issuer, as defined in Rule&#160;405 of the Securities
    Act.&#160;&#160;Yes&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;&#160;&#160;&#160;No&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#254;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Indicate by check mark if the registrant is not required to file
    reports pursuant to Section&#160;13 or Section&#160;15(d) of the
    Act.&#160;&#160;Yes&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;&#160;&#160;&#160;No&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#254;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Indicate by check mark whether the registrant (1)&#160;has filed
    all reports required to be filed by Section&#160;13 or 15(d) of
    the Securities Exchange Act of 1934 during the preceding
    12&#160;months (or for such shorter period that the registrant
    was required to file such reports), and (2)&#160;has been
    subject to such filing requirements for the past
    90&#160;days.&#160;&#160;Yes&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#254;</FONT>&#160;&#160;&#160;&#160;&#160;No&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Indicate by check mark whether the registrant has submitted
    electronically and posted on its corporate Web site, if any,
    every Interactive Data File required to be submitted and posted
    pursuant to Rule&#160;405 of
    <FONT style="white-space: nowrap">Regulation&#160;S-T</FONT>
    during the preceding 12&#160;months (or for such shorter period
    that the registrant was required to submit and post such
    files).&#160;&#160;Yes&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;&#160;&#160;&#160;No&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Indicate by check mark if disclosure of delinquent filers
    pursuant to Item&#160;405 of
    <FONT style="white-space: nowrap">Regulation&#160;S-K</FONT>
    is not contained herein, and will not be contained, to the best
    of registrant&#146;s knowledge, in definitive proxy or
    information statements incorporated by reference in
    Part&#160;III of this
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    or any amendment to this
    <FONT style="white-space: nowrap">Form&#160;10-K.&#160;&#160;</FONT><FONT style="font-family: Wingdings; font-variant: normal">&#111;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Indicate by check mark whether the registrant is a large
    accelerated filer, an accelerated filer, a non-accelerated
    filer, or a smaller reporting company. See the definitions of
    &#147;large accelerated filer,&#148; &#147;accelerated
    filer&#148; and &#147;smaller reporting company&#148; in
    <FONT style="white-space: nowrap">Rule&#160;12b-2</FONT>
    of the Exchange Act. (Check one):
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="25%"></TD>
    <TD width="25%"></TD>
    <TD width="25%"></TD>
    <TD width="25%"></TD>
</TR>

<TR valign="top">
    <TD nowrap align="left">    <FONT style="font-size: 9pt; font-family: 'Times New Roman', Times">Large
    accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>
    </FONT></TD>
    <TD nowrap align="center">    <FONT style="font-size: 9pt; font-family: 'Times New Roman', Times">
    Accelerated
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#254;</FONT>
    </FONT></TD>
    <TD nowrap align="center">    <FONT style="font-size: 9pt; font-family: 'Times New Roman', Times">
    <FONT style="white-space: nowrap">Non-accelerated</FONT>
    filer&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>
    </FONT></TD>
    <TD nowrap align="right">    <FONT style="font-size: 9pt; font-family: 'Times New Roman', Times">
    Smaller reporting
    company&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>
    </FONT></TD>
</TR>

</TABLE>



<DIV align="center" style="margin-left: 22%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <FONT style="font-size: 9pt">(Do not check if a smaller
    reporting company)
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Indicate by check mark whether the registrant is a shell company
    (as defined in
    <FONT style="white-space: nowrap">Rule&#160;12b-2</FONT>
    of the Exchange
    Act).&#160;&#160;Yes&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#111;</FONT>&#160;&#160;&#160;&#160;&#160;No&#160;<FONT style="font-family: Wingdings; font-variant: normal">&#254;
    </FONT>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The aggregate market value of the voting stock held by
    non-affiliates of the Registrant, as of June&#160;30, 2010 was
    approximately $316.6&#160;million (based upon the closing price
    for shares of the Registrant&#146;s common stock as reported by
    the NYSE Amex) as of June&#160;30, 2010 of $6.11). Shares of
    common stock held by each officer, director and holder of 5% or
    more of the outstanding common stock have been excluded in that
    such persons may be deemed to be affiliates. This determination
    of affiliate status is not necessarily a conclusive
    determination for other purposes.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 3%; font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On February&#160;15, 2011, approximately 81,328,699&#160;shares
    of the Registrant&#146;s common stock, par value $0.001 per
    share, were outstanding.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 2pt solid #000000"></CENTER>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 94%; margin-left: 3%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
</DIV><!-- END PAGE WIDTH -->
<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times"><FONT style="white-space: nowrap">FORM&#160;10-K</FONT><BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>
<DIV align="left">
<!-- TOC -->
</DIV>

<DIV align="left">
<A name="Y04571tocpage"></A>
</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="4%">&nbsp;</TD>  <!-- colindex=01 type=quadleft -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=01 type=maindata -->
    <TD width="4%">&nbsp;</TD>  <!-- colindex=01 type=quadright -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="84%">&nbsp;</TD> <!-- colindex=02 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=03 type=quadleft -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=03 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD colspan="9" align="center" valign="top">
    <A HREF='#Y04571101'><B>PART&#160;I</B></A>
</TD>
</TR>
<TR valign="bottom">
<TD colspan="5" valign="top">
    <A HREF='#Y04571102'>Cautionary Statement Regarding Forward-Looking
    Statements</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571103'>Item 1.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <A HREF='#Y04571103'>Business</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571104'>Item 1A.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <A HREF='#Y04571104'>Risk Factors</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    35
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571105'>Item 1B.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <A HREF='#Y04571105'>Unresolved Staff Comments</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571106'>Item 2.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <A HREF='#Y04571106'>Properties</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571107'>Item 3.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <A HREF='#Y04571107'>Legal Proceedings</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571108'>Item 4.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <A HREF='#Y04571108'>(Removed and Reserved)</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="9">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="9" align="center" valign="top">
    <A HREF='#Y04571109'><B>PART&#160;II</B></A>
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571110'>Item 5.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
<A HREF='#Y04571110'>Market for Registrant&#146;s Common Equity, Related Stockholder
    Matters and Issuer Purchases of Equity Securities</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    59
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571111'>Item 6.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <A HREF='#Y04571111'>Selected Financial Data</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571112'>Item 7.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <A HREF='#Y04571112'>Management&#146;s Discussion and Analysis of
    Financial Condition and Results of Operations</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571113'>Item 7A.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <A HREF='#Y04571113'>Quantitative and Qualitative Disclosures About
    Market Risk</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571114'>Item 8.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <A HREF='#Y04571114'>Financial Statements and Supplementary Data</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    72
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571115'>Item 9.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <A HREF='#Y04571115'>Changes in and Disagreements with Accountants on
    Accounting and Financial Disclosure</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571116'>Item 9A.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <A HREF='#Y04571116'>Controls and Procedures</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571117'>Item 9B.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <A HREF='#Y04571117'>Other Information</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    74
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="9">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="9" align="center" valign="top">
    <A HREF='#Y04571118'><B>PART&#160;III</B></A>
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571119'>Item 10.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
<A HREF='#Y04571119'>Directors, Executive Officers and Corporate Governance</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571120'>Item 11.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    <A HREF='#Y04571120'>Executive Compensation</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    79
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571121'>Item 12.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <A HREF='#Y04571121'>Security Ownership of Certain Beneficial Owners
    and Management and Related Stockholder Matters</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571122'>Item 13.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <A HREF='#Y04571122'>Certain Relationships and Related Transactions,
    and Director Independence</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    92
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571123'>Item 14.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <A HREF='#Y04571123'>Principal Accountant Fees and Services</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="9">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="9" align="center" valign="top">
    <A HREF='#Y04571124'><B>PART&#160;IV</B></A>
</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    <A HREF='#Y04571125'>Item 15.</A>
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    <A HREF='#Y04571125'>Exhibits and Financial Statement Schedules</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="5" valign="top">
    <A HREF='#Y04571126'>Signatures</A>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="y04571exv23w1.htm">EX-23.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="y04571exv31w1.htm">EX-31.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="y04571exv31w2.htm">EX-31.2</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="y04571exv32w1.htm">EX-32.1</A></FONT></TD></TR>
<TR><TD colspan="9"><FONT size="2">&nbsp;<A HREF="y04571exv32w2.htm">EX-32.2</A></FONT></TD></TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV align="left">
<!-- /TOC -->
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    i
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='Y04571101'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PART&#160;I</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Except where the context otherwise requires, the terms,
    &#147;we,&#148; &#147;us,&#148; &#147;our&#148; or &#147;the
    Company,&#148; refer to the business of Protalix
    BioTherapeutics, Inc. and its consolidated subsidiaries, and
    &#147;Protalix&#148; or &#147;Protalix Ltd.&#148; refers to the
    business of Protalix Ltd., our wholly-owned subsidiary and sole
    operating unit.</I>
</DIV>

<A name='Y04571102'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CAUTIONARY
    STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The statements set forth under the captions
    &#147;Business,&#148; &#147;Management&#146;s Discussion and
    Analysis of Financial Condition and Results of Operations&#148;
    and &#147;Risk Factors,&#148; and other statements included
    elsewhere in this Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K,</FONT>
    which are not historical, constitute &#147;forward-looking
    statements&#148; within the meaning of Section&#160;27A of the
    Securities Act of 1933, as amended, and Section&#160;21E of the
    Securities Exchange Act of 1934, as amended, including
    statements regarding expectations, beliefs, intentions or
    strategies for the future. When used in this report, the terms
    &#147;anticipate,&#148; &#147;believe,&#148;
    &#147;estimate,&#148; &#147;expect&#148; and &#147;intend&#148;
    and words or phrases of similar import, as they relate to our or
    our subsidiaries or our management, are intended to identify
    forward-looking statements. We intend that all forward-looking
    statements be subject to the safe-harbor provisions of the
    Private Securities Litigation Reform Act of 1995. These
    forward-looking statements are only predictions and reflect our
    views as of the date they are made with respect to future events
    and financial performance, and we undertake no obligation to
    update any forward-looking statement to reflect events or
    circumstances after the date on which the statement is made or
    to reflect the occurrence of unanticipated events, except as may
    be required under applicable law. Forward-looking statements are
    subject to many risks and uncertainties that could cause our
    actual results to differ materially from any future results
    expressed or implied by the forward-looking statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Examples of the risks and uncertainties include, but are not
    limited to, the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delays in the approval or the potential rejection of any
    applications we file with the U.S.&#160;Food and Drug
    Administration, or FDA, or other regulatory authorities,
    including the New Drug Application (NDA) we filed with the FDA,
    the marketing application we submitted to the Israeli Ministry
    of Health, and the Marketing Authorization Application (MAA) we
    submitted to each of the European Medicines Agency and the
    National Sanitary Vigilance Agency, an agency of the Ministry of
    Health of Brazil, for taliglucerase alfa;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the inherent risks and uncertainties in developing the types of
    drug platforms and products we are developing;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delays in our preparation and filing of applications for
    regulatory approval in the United States, the European Union,
    Israel, Brazil and elsewhere;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any lack of progress of our research and development (including
    the results of our clinical trials);
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to establish and maintain strategic license,
    collaboration and distribution arrangements and to manage our
    relationship with Pfizer Inc., Teva Ltd. or with any other
    collaborator, distributor or partner;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    obtaining on a timely basis sufficient patient enrollment in our
    clinical trials;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the impact of development of competing therapies
    <FONT style="white-space: nowrap">and/or</FONT>
    technologies by other companies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    risks relating to biogeneric legislation
    <FONT style="white-space: nowrap">and/or</FONT>
    healthcare reform in the United States or elsewhere;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to obtain additional financing required to fund our
    research programs and the expansion of our manufacturing
    capabilities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the risk that we will not be able to develop a successful sales
    and marketing organization in a timely manner, if at all;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our ability to enter into supply arrangements with the Ministry
    of Health of Brazil or other parties and to supply drug product
    pursuant to such arrangements;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    potential product liability risks, and risks of securing
    adequate levels of product liability and clinical trial
    insurance coverage;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the availability of reimbursement to patients from health care
    payors for any of our product candidates, if approved;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the possibility of infringing a third party&#146;s patents or
    other intellectual property rights;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the uncertainty of obtaining patents covering our products and
    processes and in successfully enforcing our intellectual
    property rights against third parties;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the possible disruption of our operations due to terrorist
    activities and armed conflict, including as a result of the
    disruption of the operations of regulatory authorities, our
    subsidiaries, our manufacturing facilities and our customers,
    suppliers, distributors, collaborative partners, licensees and
    clinical trial sites;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    other risks and uncertainties detailed in Section&#160;1A of
    this Annual Report on Form
    <FONT style="white-space: nowrap">10-K.</FONT>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, companies in the pharmaceutical and biotechnology
    industries have suffered significant setbacks in advanced or
    late-stage clinical trials, even after obtaining promising
    earlier trial results or preliminary findings for such clinical
    trials. Even if favorable testing data is generated by clinical
    trials of drug products, the FDA or foreign regulatory
    authorities may not accept or approve an NDA or MAA, as
    applicable, filed by a pharmaceutical or biotechnology company
    for such drug product. These and other risks and uncertainties
    are detailed under the heading &#147;Risk Factors&#148; in this
    Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    and are described from time to time in the reports we file with
    the Securities and Exchange Commission. We undertake no
    obligation to update, and we do not have a policy of updating or
    revising, these forward-looking statements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="8%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;1.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571103'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Business</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are a biopharmaceutical company focused on the development
    and commercialization of recombinant therapeutic proteins based
    on our proprietary
    ProCellEx<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    protein expression system, or ProCellEx. Using our ProCellEx
    system, we are developing a pipeline of proprietary and
    biosimilar or &#147;generic&#148; versions of recombinant
    therapeutic proteins based on our plant cell-based expression
    technology that target large, established pharmaceutical markets
    and that rely upon known biological mechanisms of action. Our
    initial commercial focus has been on complex therapeutic
    proteins, including proteins for the treatment of genetic
    disorders, such as Gaucher disease and Fabry disease. We believe
    our ProCellEx protein expression system will enable us to
    develop proprietary recombinant proteins that are
    therapeutically equivalent or superior to existing recombinant
    proteins currently marketed for the same indications. Because we
    are primarily targeting biologically equivalent versions of
    highly active, well-tolerated and commercially successful
    therapeutic proteins, we believe our development process is
    associated with relatively less risk compared to other
    biopharmaceutical development processes for completely novel
    therapeutic proteins.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our lead product development candidate is taliglucerase alfa for
    the treatment of Gaucher disease, which we are developing using
    our ProCellEx protein expression system. Gaucher disease is a
    rare and serious lysosomal storage disorder with severe and
    debilitating symptoms. Taliglucerase alfa is our proprietary
    recombinant form of glucocerebrosidase (GCD), an enzyme
    naturally found in human cells that is mutated or deficient in
    patients with Gaucher disease. In July 2007, we reached an
    agreement with the U.S.&#160;Food and Drug Administration, or
    the FDA, on the final design of our pivotal phase&#160;III
    clinical trial of taliglucerase alfa through the FDA&#146;s
    special protocol assessment (SPA) process. The phase&#160;III
    clinical trial was completed in September 2009 and, on
    October&#160;15, 2009, we announced positive top-line results
    from the trial. On December&#160;9, 2009, we filed our New Drug
    Application (NDA) for taliglucerase alfa, and in January 2010
    the FDA requested additional data regarding the Chemistry,
    Manufacturing and Controls (CMC)&#160;section of our NDA. We
    provided the requested data to the FDA in April 2010 and in July
    2010 we received notification from the FDA that it had accepted
    the filing of our NDA and assigned a Prescription Drug User Fee
    Act (PDUFA) date of February&#160;25, 2011 to taliglucerase alfa
    for the treatment of Gaucher disease. In addition, in November
    2010 we submitted a marketing application to the Israeli
    Ministry of Health, or the Israeli MOH,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    and a Marketing Authorization Application (MAA) to each of the
    European Medicines Agency, or the EMEA, and ANVISA, the National
    Sanitary Vigilance Agency, an agency of the Brazilian Ministry
    of Health, or the ANVISA, for taliglucerase alfa for the
    treatment of Gaucher disease.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In February 2010, the Israeli MOH completed a successful good
    manufacturing practices (GMP) audit of our manufacturing
    facilities in Carmiel, Israel. The audit was performed as part
    of the Israeli MOH&#146;s evaluation of our manufacturing
    process for taliglucerase alfa. On February&#160;20, 2011, we
    received a letter from the FDA notifying us that the FDA had
    completed its review of the Establishment Inspection Report in
    connection with the FDA&#146;s inspection of our facility in
    Carmiel, Israel, and that the FDA had classified our facility as
    acceptable.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to our recently completed phase&#160;III clinical
    trial, we initiated a double-blind, follow-on extension study as
    part of the trial during the second quarter of 2008. We also
    initiated a home care treatment program for patients enrolled in
    the extension study and, in December 2008, we initiated a
    nine-month, worldwide, multi-center, open-label, switch-over
    clinical study evaluating the safety and efficacy of switching
    Gaucher patients currently treated under the current standard of
    care to treatment with taliglucerase alfa. The current standard
    of care for Gaucher patients is enzyme replacement therapy with
    Cerezyme<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>,

    which is produced by Genzyme Corporation and, until the recent
    approval of
    VPRIV<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    by Shire plc in February 2010, was the only approved enzyme
    replacement therapy for Gaucher disease. Enzyme replacement
    therapy is a medical treatment in which recombinant enzymes are
    infused into patients in whom the enzyme is lacking or
    dysfunctional. Taliglucerase alfa has an amino acid, glycan and
    three-dimensional structure that is very similar to Cerezyme,
    which is a mammalian cell expressed version of the same protein.
    We believe taliglucerase alfa may prove more cost-effective than
    the currently marketed alternative due to the cost benefits of
    expression through our ProCellEx protein expression system.
    Under our SPA, the switch-over study is not a prerequisite for
    approval of taliglucerase alfa by the FDA. In December 2009, we
    filed a proposed pediatric investigation plan to the Pediatric
    Committee of the EMEA which was approved during the first
    quarter of 2010 and have since initiated the study. In November
    2010, we announced positive preliminary data from the first
    15&#160;patients that completed the switchover clinical study of
    taliglucerase alfa.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Orphan Drug designation for taliglucerase alfa for the
    treatment of Gaucher Disease provides special status to
    taliglucerase alfa provided that it meets certain criteria. As a
    result of the orphan designation, we are qualified for the tax
    credit and marketing incentives provided under the Orphan Drug
    Act of 1983. A marketing application for a prescription drug
    product that has been designated as a drug for a rare disease or
    condition is not subject to a prescription drug user fee unless
    the application includes an indication for other than a rare
    disease or condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On November&#160;30, 2009, Protalix Ltd., our wholly-owned
    subsidiary, and Pfizer Inc., or Pfizer, entered into an
    exclusive license and supply agreement pursuant to which Pfizer
    was granted an exclusive, worldwide license to develop and
    commercialize taliglucerase alfa. Under the terms and conditions
    of the Pfizer agreement, Protalix Ltd. retained the right to
    commercialize taliglucerase alfa in Israel. In connection with
    the execution of the Pfizer agreement, Pfizer made an upfront
    payment to Protalix Ltd. of $60.0&#160;million in connection
    with the execution of the agreement and subsequently paid
    Protalix Ltd. an additional $5.0&#160;million upon its filing of
    a proposed pediatric investigation plan to the Pediatric
    Committee of the EMEA. Protalix Ltd. is also eligible to receive
    potential milestone payments totaling $50.0&#160;million for the
    successful achievement of other regulatory milestones. Pfizer
    and Protalix Ltd. will also share future revenues and expenses
    for the development and commercialization of taliglucerase alfa
    on a 60% and 40% basis, respectively, and have also agreed to a
    specific allocation of the responsibilities for the continued
    development efforts for taliglucerase alfa.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In July 2009, following a request by the FDA, we submitted a
    treatment protocol to the FDA in order to address an expected
    shortage of the current enzyme replacement therapy approved for
    Gaucher disease. The treatment protocol was approved by the FDA
    in August 2009. In September 2009, the FDA&#146;s Office of
    Orphan Product Development granted taliglucerase alfa Orphan
    Drug Status. In January 2010, the Committee for Orphan Medicinal
    Products (COMP) of the EMEA, after reviewing all relevant
    clinical data, recommended that the European Commission grant
    Orphan Drug designation to taliglucerase alfa for the treatment
    of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Gaucher disease. The Orphan Drug designation in the United
    States for taliglucerase alfa for the treatment of Gaucher
    disease provides special status to taliglucerase alfa provided
    that it meets certain criteria. As a result of the Orphan Drug
    designation, we are qualified for the tax credit and marketing
    incentives of the Orphan Drug Act of 1983. A marketing
    application for a prescription drug product that has been
    designated as a drug for a rare disease or condition is not
    subject to a prescription drug user fee unless the application
    includes an indication for other than a rare disease or
    condition.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On July&#160;13, 2010, we announced that the French regulatory
    authority had granted an Autorisation Temporaire
    d&#146;Utilisation (ATU), or Temporary Authorization for Use,
    for taliglucerase alfa for the treatment of Gaucher disease. An
    ATU is the regulatory mechanism used by the French Health
    Products and Safety Agency to make non-approved drugs available
    to patients in France when a genuine public health need exists.
    This ATU allows patients with Gaucher disease in France to
    receive treatment with taliglucerase alfa before marketing
    authorization for the product is granted in the European Union.
    Payment for taliglucerase alfa has been secured through
    government allocations to hospitals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On August&#160;10, 2010, Pfizer entered into a $30&#160;million
    short-term supply agreement with the Ministry of Health of
    Brazil pursuant to which Protalix and Pfizer have provided
    taliglucerase alfa to the Ministry of Health of Brazil for the
    treatment of patients with Gaucher disease. Revenue generated
    from the Ministry of Health of Brazil will be recorded by Pfizer
    and we are entitled to our share of the revenue in accordance
    with the terms and conditions of the Pfizer agreement. In
    addition, we and the Ministry of Health of Brazil are in
    discussions relating to a possible long-term supply agreement
    that contemplates, among other matters, providing certain
    components of our manufacturing technology to the Ministry of
    Health of Brazil for implementation by it in Brazil. We are
    currently unable to assess whether these discussions will result
    in an agreement and we can make no assurance that we will be
    able to enter into such an agreement on favorable terms, if at
    all. In any event, we do not expect to enter into a long-term
    supply agreement with the Ministry of Health of Brazil until we
    receive marketing approval of taliglucerase alfa from the FDA or
    ANVISA, if at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Although Gaucher disease is a relatively rare disease, it
    represents a large commercial market due to the severity of the
    symptoms and the chronic nature of the disease. The annual
    worldwide sales of Cerezyme were approximately
    $722.0&#160;million in 2010, compared with $793.0&#160;million
    for the previous year, according to public reports by Genzyme.
    According to Genzyme, it suffered a temporary interruption in
    production of Cerezyme in 2009 associated with the remediation
    of a contamination in one of its manufacturing facilities, and,
    as a result, shipments of Cerezyme were limited. Shire reported
    annual worldwide sales of VPRIV of approximately
    $143.0&#160;million in 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to taliglucerase alfa, we are developing an
    innovative product pipeline using our ProCellEx protein
    expression system. Our product pipeline currently includes,
    among other candidates, (1)&#160;PRX-102, a therapeutic protein
    candidate for the treatment of Fabry disease, a rare, genetic
    lysosomal disorder in humans, (2)&#160;PRX-105, a plant cell
    expressed pegylated recombinant acetylcholinesterase product
    candidate for biodefense and other indications,
    (3)&#160;pr-antiTNF, a plant cell expressed recombinant fusion
    protein made from the soluble form of the human TNF receptor
    (TNFR) and an antibody portion, which is being developed as a
    treatment of certain immune diseases such as rheumatoid
    arthritis, juvenile idiopathic arthritis, ankylosing,
    spondylitis, psoriatic arthritis and plaque psoriasis,
    (4)&#160;an orally administrated glucocerebrosidase enzyme for
    treating Gaucher patients utilizing the oral delivery of the
    recombinant enzyme produced within carrot cells and
    (5)&#160;additional undisclosed therapeutic proteins, all of
    which are currently being evaluated in animal studies. In March
    2010, we initiated a preliminary phase I clinical trial of
    PRX-105 which we completed in June 2010. We are currently
    preparing for further efficacy trials of this product candidate
    in larger animals. In our preclinical studies we utilized an
    analogue to nerve gas. However, we anticipate that we will use
    live nerve gas rather than an analogue in the proposed
    additional efficacy trials in animals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In December 2010 we held a pre-investigational new drug, or IND,
    meeting with the FDA with respect to PRX-102. We expect to
    submit an IND to the FDA within the next 12&#160;months in
    connection with an anticipated phase I/II study of PRX-102 and
    to initiate the trial once approved, if at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In September 2009, we announced preliminary preclinical data
    regarding pr-antiTNF. Our pr-antiTNF product candidate has an
    amino acid sequence that is similar to
    Enbrel<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    which is one of the treatments for
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    patients of those diseases. We believe that we may be able to
    reduce the development risks and time to market for our product
    candidates as our product candidates are based on
    well-understood proteins with known biological mechanisms of
    action. Except for the rights to commercialize taliglucerase
    alfa worldwide (other than Israel) which we licensed to Pfizer,
    we hold the worldwide commercialization rights to our
    proprietary development candidates, and we intend to establish
    an internal, commercial infrastructure and targeted sales force
    to market taliglucerase alfa in Israel and our other products,
    if approved, in North America, the European Union and in other
    significant markets, including Israel. In addition we are
    continuously evaluating potential strategic marketing
    partnerships.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our ProCellEx protein expression system consists of a
    comprehensive set of technologies and capabilities for the
    development of recombinant proteins, including advanced genetic
    engineering technology and plant cell-based protein expression
    methods. Through our ProCellEx protein expression system, we can
    develop highly complex recombinant therapeutic proteins all the
    way to the
    <FONT style="white-space: nowrap">scale-up</FONT> of
    a purified product produced in compliance with current good
    manufacturing practices, or cGMP. We believe that our plant
    cell-based expression technology will enable us, in certain
    cases, to develop and commercialize recombinant proteins without
    infringing upon the method-based patents or other intellectual
    property rights of third parties. The major elements of our
    ProCellEx system are patent protected in most major countries.
    Moreover, we expect to enjoy method-based patent protection for
    the proteins we develop using our proprietary ProCellEx protein
    expression technology, although there can be no assurance that
    any such patents will be granted. In some cases, we may be able
    to obtain patent protection for the compositions of the proteins
    themselves. We have filed for United States and international
    composition of matter patents for taliglucerase alfa.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our ProCellEx protein expression system is built on flexible
    custom-designed bioreactors made of polyethylene and optimized
    for the development of complex proteins in plant cell cultures.
    These bioreactors entail low initial capital investment, are
    rapidly scalable at a low cost and require less hands-on
    maintenance between cycles, compared to the highly complex,
    expensive, stainless steel bioreactors typically used in
    mammalian cell-based production systems. As a result, through
    our ProCellEx protein expression system, we believe that we can
    develop recombinant therapeutic proteins yielding substantial
    cost advantages, accelerated development and other competitive
    benefits as compared to mammalian cell-based protein expression
    systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have successfully demonstrated the feasibility of our
    ProCellEx system through clinical and preclinical studies
    performed by us to date including the positive efficacy and
    safety data in our phase&#160;III study for taliglucerase alfa,
    preclinical results in well-known models in our enzyme for Fabry
    disease and pr-antiTNF, and extensive animal studies for our
    acetylcholinesterase enzyme, and by expressing, on an
    exploratory, research scale, many additional complex therapeutic
    proteins belonging to different drug classes, such as enzymes,
    hormones, monoclonal antibodies, cytokines and vaccines. The
    therapeutic proteins we have expressed to date in research
    models have produced the intended composition and similar
    biological activity compared to their respective
    human-equivalent proteins. Moreover, several of such proteins
    demonstrated advantageous biological activity when compared to
    the biotherapeutics currently available in the market to treat
    the applicable disease or disorder. We believe that the clinical
    success of taliglucerase alfa represents a strong
    <FONT style="white-space: nowrap">proof-of-concept</FONT>
    for our ProCellEx protein expression system and plant cell-based
    protein expression technology. We also believe that the
    significant benefits of our ProCellEx protein expression system,
    if further substantiated in clinical trials and
    commercialization of our product candidates, have the potential
    to transform the industry standard for the development of
    complex therapeutic proteins.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our goal is to become a leading fully integrated
    biopharmaceutical company focused on the development and
    commercialization of proprietary and biosimilar or generic
    versions of recombinant therapeutic proteins. To that end, we
    are leveraging our ProCellEx protein expression system to
    develop a pipeline of proprietary and biosimilar versions of
    recombinant therapeutic proteins. In addition to the product
    candidates that we are developing internally, we have entered
    into agreements for additional compounds with academic
    institutions, including a licensing agreement with the
    technology transfer arm of Israel&#146;s Weizmann Institute of
    Science and an agreement with the technology transfer arm of the
    Hebrew University of Jerusalem. In addition, we are
    collaborating with other pharmaceutical companies to develop
    therapeutic proteins that can benefit from the significant cost,
    intellectual property and other competitive advantages of our
    ProCellEx protein expression system. We entered into an
    agreement with Teva Pharmaceutical Industries Ltd., or Teva, in
    September 2006
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    under which we have agreed to collaborate on several matters. We
    and Teva identified two proteins for research and development
    activities under the agreement, but in 2009 both of the projects
    were terminated for commercial reasons. Other elements of our
    collaboration with Teva are currently ongoing. We also
    continuously review and consider additional development and
    commercialization alliances with other pharmaceutical companies
    and academic institutions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Industry
    Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Recombinant proteins have revolutionized the treatment of a
    variety of diseases and disorders. Recombinant proteins are
    forms of human proteins that are produced, or expressed, using a
    mammalian, plant, bacterial or yeast cell as a production
    engine. In the early 1970s, a number of key scientific
    breakthroughs, including, among others, the demonstration of
    genetic engineering and genetic sequencing techniques, as well
    as the synthesis of genes, led to the advancement of recombinant
    protein technology.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As a result, the market for pharmaceutical therapeutics has
    undergone a transformation as recombinant proteins and other
    biologic products have become an increasingly significant
    portion of the global drug market and the focus of research
    worldwide. Based upon data from the Biotechnology Industry
    Organization, an organization that provides information,
    advocacy and business support to the biotechnology industry,
    since the introduction in 1982 of recombinant human insulin, the
    world&#146;s first genetically engineered pharmaceutical
    product, over 254 biotechnology drugs have been approved for
    over 392 indications. According to Datamonitor, a provider of
    business information to the pharmaceutical and other industries,
    the overall global biologics market size is expected to grow to
    $105.2&#160;billion in 2010, from $56.1&#160;billion in 2004,
    representing a compounded annual growth rate (CAGR) of 11.1%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Mammalian cell-based systems are the current industry standard
    for expression of recombinant therapeutic glycoproteins (complex
    proteins that contain sugar residues), including catalytic
    enzymes and monoclonal antibodies. Mammalian cell-based systems
    were first introduced in the late 1980s and are currently used
    to produce many of the biotechnology industry&#146;s largest and
    most successful therapeutic proteins, including
    Epogen<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,

    Neupogen<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,

    Cerezyme,
    Rituxan<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,

    Enbrel<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>,

    Neulasta<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>

    and
    Herceptin<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP>.

    Mammalian cell-based expression technology is based on the
    introduction of a human gene encoding for a specific therapeutic
    protein into the genome of a mammalian cell. The cells most
    often used in connection with mammalian cell-based protein
    expression are Chinese hamster ovary (CHO) cells.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Mammalian cell-based expression systems have become the dominant
    system for the expression of recombinant proteins due to their
    capacity for sophisticated, proper protein folding (which is
    necessary for proteins to carry out their intended biological
    activity), assembly and post-expression modification, such as
    glycosilation (the addition of sugar residues to a protein which
    is necessary to enable specific biological activity by the
    protein). While bacterial and yeast cell-based expression
    systems were the first protein expression systems developed by
    the biotechnology industry and remain cost-effective compared to
    mammalian cell-based production methodologies, proteins
    expressed in bacterial and yeast cell-based systems lack the
    capacity for sophisticated protein folding, assembly and
    post-expression modifications, which are key factors of
    mammalian cell-based systems. Accordingly, such systems cannot
    be used to produce glycoproteins or other complex proteins and,
    therefore, bacterial and yeast cell-based systems are limited to
    the expression of the most basic, simple proteins, such as
    insulin and growth hormones. Due to their significant
    advantages, mammalian cell-based expression systems can produce
    proteins with superior quality and efficacy compared to proteins
    expressed in bacteria and yeast cell-based systems. As a result,
    the majority of currently approved therapeutic proteins, as well
    as those under development, are produced in mammalian cell-based
    systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Despite the utility and widespread use of mammalian cell-based
    systems, they are subject to a number of disadvantages. CHO
    cells and other mammalian cells are highly sensitive and can
    only be grown under near perfect conditions, requiring highly
    complex, expensive, stainless steel bioreactors which tightly
    regulate the required temperature, pH and oxygen levels. As a
    result, such bioreactor systems are very costly and complicated
    to operate. CHO cells and other mammalian cells are also
    susceptible to viral infections, including human viruses, and
    several cases of viral contamination have occurred recently. The
    FDA and other regulatory authorities require viral inactivation
    and other rigorous and detailed procedures for mammalian
    cell-based
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    manufacturing processes in order to address these potential
    hazards, thereby increasing the cost and time demands of such
    expression systems. Furthermore, the current FDA and other
    procedures only ensure screening for scientifically identified,
    known viruses. Accordingly, compliance with current FDA and
    other procedures does not fully guarantee that patients are
    protected against transmission of unknown or new potentially
    fatal viruses that may infect mammalian cells. In addition,
    mammalian cell-based expression systems require large quantities
    of sophisticated and expensive growth medium to accelerate the
    expression process.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Several companies and research institutions have explored
    alternatives to mammalian cell-based production technologies
    that overcome some of these disadvantages, focusing primarily on
    the expression of human proteins in genetically-modified
    organisms, or GMOs, such as transgenic field-grown, whole plants
    and transgenic animals. However, these alternate techniques may
    be restricted by regulatory and environmental risks regarding
    contamination of agricultural crops and by the difficulty in
    applying cGMP standards of the pharmaceutical industry to these
    expression technologies.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">ProCellEx:
    Our Proprietary Protein Expression System</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    ProCellEx is our proprietary production system that we have
    developed based on our plant cell culture technology for the
    development, expression and manufacture of recombinant proteins.
    Our expression system consists of a comprehensive set of
    capabilities and proprietary technologies, including advanced
    genetic engineering and plant cell culture technology, which
    enables us to produce complex, proprietary and biologically
    equivalent proteins for a variety of human diseases. Our protein
    expression system facilitates the creation and selection of high
    expressing, genetically stable cell lines capable of expressing
    recombinant proteins. The entire protein expression process,
    from initial nucleotide cloning to large-scale production of the
    protein product, occurs under cGMP-compliant, controlled
    processes. Our plant cell culture technology uses plant cells,
    such as carrot and tobacco cells, which undergo advanced genetic
    engineering and are grown on an industrial scale in a flexible
    bioreactor system. Cell growth, from scale up through
    large-scale production, takes place in flexible, sterile,
    polyethylene bioreactors which are confined to a clean-room
    environment. Our bioreactors are well-suited for plant cell
    growth using a simple, inexpensive, chemically-defined growth
    medium as a catalyst for growth. The reactors are
    custom-designed and optimized for plant cell cultures, easy to
    use, entail low initial capital investment, are rapidly scalable
    at a low cost and require less hands-on maintenance between
    cycles. Our protein expression system does not involve mammalian
    or animal components or transgenic field-grown, whole plants at
    any point in the production process.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our ProCellEx system is capable of producing proteins with an
    amino acid structure practically equivalent to that of the
    desired human protein, and with a very similar, although not
    identical, glycan, or sugar, structure. Our internal research
    and external laboratory studies have demonstrated that ProCellEx
    is capable of producing recombinant proteins that exhibit a
    glycan and amino acid structure similar to their
    naturally-produced human counterparts. In collaboration with
    Israel&#146;s Weizmann Institute of Science, we have
    demonstrated that the three-dimensional structure of a protein
    expressed in our proprietary plant cell-based expression system
    retains the same three-dimensional structure as exhibited by the
    mammalian cell-based expressed version of the same protein. In
    addition, proteins produced by our ProCellEx system maintain the
    biological activity that characterize that of the
    naturally-produced proteins. Based on these results, we believe
    that proteins developed using our ProCellEx protein expression
    system have the intended composition and correct biological
    activity of their human equivalent proteins.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Competitive
    Advantages of Our ProCellEx Protein Expression System</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We believe that our ProCellEx protein expression system,
    including our advanced genetic engineering technology and plant
    cell-based protein expression methods, affords us a number of
    significant advantages over mammalian, bacterial, yeast and
    transgenic cell-based expression technologies, including the
    following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Ability to Penetrate Certain Patent-Protected
    Markets.</I>&#160;&#160;We seek to develop recombinant proteins
    that we believe we can produce and commercialize without
    infringing upon the method-based patents or other intellectual
    property rights of third parties. Certain biotherapeutic
    proteins available for commercial
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    sale are not protected by patents that cover the compound and
    are available for use in the public domain. Rather, the process
    of expressing the protein product in mammalian or bacterial cell
    systems is protected by method-based patents. Using our plant
    cell-based protein expression technology, we are able to express
    an equivalent protein without infringing upon these method-based
    patents. Moreover, we expect to enjoy method-based patent
    protection for the proteins we develop using our proprietary
    ProCellEx protein expression technology, although there can be
    no assurance that any such patents will be granted. In some
    cases, we may be able to obtain patent protection for the
    compositions of the proteins themselves. We have filed for
    United States and international composition of matter patents
    for taliglucerase alfa.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Significantly Lower Capital and Production
    Costs.</I>&#160;&#160;Plant cells have a number of dynamic
    qualities that make them well-suited for the production of
    therapeutic proteins. Plant cells grow rapidly under a variety
    of conditions and are not as sensitive to temperature, pH and
    oxygen levels as mammalian cells. Our ProCellEx protein
    expression system, therefore, requires significantly less
    upfront capital expenditures as it does not use the highly
    complex, expensive, stainless steel bioreactors typically used
    in mammalian cell-based production systems to maintain very
    specific temperature, pH and oxygen levels. Instead, we use
    simple polyethylene bioreactors that are able to be maintained
    at the room temperature of the clean-room in which they are
    placed. This system also reduces ongoing production and
    monitoring costs typically incurred by companies using mammalian
    cell-based expression technologies. Furthermore, while mammalian
    cell-based systems require very costly growth media at various
    stages of the production process to achieve target yields of
    their proteins, plant cells require only simple and much less
    expensive solutions based on sugar, water and microelements at
    infrequent intervals to achieve target yields. We believe that
    these factors will potentially result in lower capital and
    production costs for the commercial scale production of proteins
    by our ProCellEx system thereby providing us with a competitive
    advantage over competing protein expression technologies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Elimination of the Risk of Viral Transmission or Infection by
    Mammalian Components.</I>&#160;&#160;By nature, plant cells do
    not carry the risk of infection by human or other animal
    viruses. As a result, the risk of contamination of our products
    under development and the potential risk of viral transmission
    from our products under development to future patients, whether
    from known or unknown viruses, is eliminated. Because our
    product candidates do not bear the risk of viral transmission,
    we are not required by the FDA or other regulatory authorities
    to perform the constant monitoring procedures for mammalian
    viruses during the protein expression process that mammalian
    cell-based manufacturers are required to undertake. In addition,
    the production process of our ProCellEx protein expression
    system is void of any mammalian components which are susceptible
    to the transmission of prions, such as those related to bovine
    spongiform encephalopathy (commonly known as &#147;mad-cow
    disease&#148;). These factors further reduce the risks and
    operating costs of our ProCellEx system compared to mammalian
    cell-based expression systems.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>More Effective and Potent End Product Relative to Mammalian
    Based Systems.</I>&#160;&#160;Our ProCellEx protein expression
    system produces enzymes which have uniform glycosilation
    patterns and therefore do not require the lengthy and expensive
    post-expression modifications that are required for certain
    proteins produced by mammalian cell-based systems, including the
    proteins for the treatment of Gaucher disease. Such
    post-expression modifications in mammalian cell-produced
    proteins are made in order to expose the terminal mannose sugar
    residues, which are structures on a protein that are key
    elements in allowing the produced protein to bind to a target
    cell and subsequently be taken into the target cell for
    therapeutic benefit. In the production of Cerezyme, exposing
    these terminal mannose sugar residues involves a multitude of
    highly technical steps which add time and cost to the production
    process. In addition, these steps do not guarantee the exposure
    of all of the required terminal mannose sugar residues,
    resulting in potentially lower effective yields and
    inconsistency in potency from batch to batch. Our ProCellEx
    protein expression system, by contrast, produces taliglucerase
    alfa in a &#147;ready to use&#148; form that does not require
    additional glycosilation or other modifications to make
    taliglucerase alfa suitable for use in enzyme replacement
    therapy for Gaucher disease. We believe this quality increases
    the potency and consistency of the expressed proteins, thereby
    further increasing the cost advantages of our ProCellEx protein
    expression system over competing protein expression
    methodologies.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Broad Range of Expression Capabilities.</I>&#160;&#160;Unlike
    bacterial and yeast cell-based systems, which are unable to
    produce complex proteins, our ProCellEx protein expression
    system is able to produce a broad array of complex glycosilated
    proteins. We have successfully demonstrated the feasibility of
    our ProCellEx system by producing, on an exploratory, research
    scale, a variety of therapeutic proteins belonging to different
    classes of recombinant drugs, such as enzymes, hormones,
    monoclonal antibodies, cytokines and vaccines. We have
    demonstrated that the recombinant proteins we have expressed to
    date have the intended composition and correct biological
    activity of their human-equivalent protein, with several of such
    proteins demonstrating advantageous biological activity compared
    to the currently available biotherapeutics. In specific cases,
    we have been successful in expressing proteins that have not
    been successfully expressed in other production systems.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Strategy</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our goal is to become a leading fully integrated
    biopharmaceutical company focused on the development and
    commercialization of proprietary and biosimilar or generic
    versions of recombinant therapeutic proteins. To achieve our
    goal, we intend to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Facilitate the successful development and commercialization
    of taliglucerase alfa by Pfizer.</I>&#160;&#160;We intend to
    work with our licensee, Pfizer, to develop and commercialize
    taliglucerase alfa. We have begun collaborating with Pfizer to
    facilitate the transition of certain of our taliglucerase alfa
    assets to Pfizer&#146;s organization. We are cooperating with
    Pfizer with respect to our Expanded Access protocol for
    taliglucerase alfa in order to facilitate the participation of
    additional physicians in additional sites in the protocol.
    Pfizer is promoting the protocol to new clinical sites and is
    recruiting additional patients. We have also begun to facilitate
    relationships between Pfizer and the Gaucher community and
    third-party payors. We intend to actively participate and
    provide our expertise in Pfizer&#146;s development and
    commercialization efforts with respect to taligluerase alfa.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Obtain Regulatory Approval for Taliglucerase Alfa for the
    Treatment of Gaucher Disease.</I>&#160;&#160;We completed
    successfully our pivotal phase&#160;III clinical trial of
    taliglucerase alfa in September 2009 and announced the positive
    top-line study results in October 2009 and full study results in
    February 2010. We filed an NDA with the FDA in December 2009 and
    in January 2010, the FDA requested additional data regarding the
    Chemistry, Manufacturing and Controls (CMC)&#160;section of the
    NDA. We provided the requested data to the FDA in April 2010 and
    in July 2010 we received notification from the FDA that it had
    accepted the filing of our NDA and assigned it a PDUFA date of
    February&#160;25, 2011. In addition, in November 2010 we
    submitted a marketing application to the Israeli MOH, and with
    our partner Pfizer, an MAA to each of the EMEA and to ANVISA for
    taliglucerase alfa. Our phase&#160;III clinical trial was
    conducted in selected leading medical centers worldwide in North
    America, South America, Israel, Europe and South Africa. In the
    third quarter of 2008, we initiated a double blind, follow-on
    extension study as part of the phase&#160;III clinical trial in
    which patients that successfully completed treatment in the
    trial were given the opportunity to continue to be treated with
    taliglucerase alfa at the same dose that they received in the
    trial. We are compiling additional information relating to the
    long term safety and efficacy of taliglucerase alfa through the
    follow-on study. In addition, in the fourth quarter of 2008 we
    announced the enrollment of the first patient in a worldwide,
    multi-center, open-label, switch-over trial to assess the safety
    and efficacy of taliglucerase alfa. The switch-over trial, which
    is not a pre requisite for marketing approval from the FDA, was
    designed to include 15&#160;patients with Gaucher disease that
    are currently undergoing enzyme replacement therapy with
    imiglucerase (Cerezyme). Due to the shortage in 2009 of the
    currently available enzyme replacement therapy for Gaucher
    disease, after fully enrolling the 15&#160;patients we extended
    the trial to include up to 30&#160;patients in total. In
    December 2009, we filed a proposed pediatric investigation plan
    to the Pediatric Committee of the EMEA and have since initiated
    pediatric studies. We believe that taliglucerase alfa may have
    cost, efficacy and potency advantages over the currently
    available enzyme replacement therapy for Gaucher disease and we
    intend to pursue post-marketing studies to confirm these
    advantages. Although Gaucher disease is a relatively rare
    disease, it represents a substantial commercial market due to
    the severity of the symptoms and the chronic nature of the
    disease. We believe that the approval of taliglucerase alfa as a
    treatment for Gaucher disease, if at all,
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    with its potentially longer acting profile and more
    cost-effective development process, may lead to an increase in
    the number of patients who will be able to have access to and
    afford such treatment, thereby expanding the size of the market
    for Gaucher disease treatments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Develop a Pipeline of Innovative or Biosimilar Versions of
    Recombinant Therapeutic Proteins.</I>&#160;&#160;We are
    leveraging our ProCellEx protein expression system to develop a
    pipeline of innovative or biosimilar versions of recombinant
    proteins, with an emphasis on therapeutic treatments with large
    market opportunities. We select additional therapeutic
    candidates for development through in-house testing, licensing
    agreements with academic institutions and collaborations with
    pharmaceutical partners. We have currently identified several
    product candidates that are mainly oriented towards the
    specialty disease and therapeutic market segments, including
    treatments for Fabry disease and an acetylcholinesterase enzyme
    based therapy for biodefense and nerve gas toxicity treatments.
    We have also identified several other product candidates that
    are chemical equivalents of approved therapeutic products that
    will no longer be patent protected within the next couple of
    years, such as pr-antiTNF, our proprietary product candidate for
    the treatment of certain immune diseases such as rheumatoid
    arthritis. We believe our cost-effective technology will be an
    important asset for the commercialization of such drug
    candidates. We believe that the clinical and regulatory pathway
    for many of our pipeline product programs candidates is already
    established, and that this may reduce the risks and costs
    associated with our clinical development programs. Furthermore,
    established markets already exist for the development of most of
    our current product candidates. We plan to apply the
    manufacturing, clinical and regulatory experience we have gained
    from the development of our lead product candidate to advance a
    number of our preclinical product candidates into clinical
    trials over the next few years.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Collaborate with Third Party Pharmaceutical Suppliers and
    build a Targeted Sales and Marketing
    Infrastructure.</I>&#160;&#160;We have licensed to Pfizer the
    right to commercialize taliglucerase worldwide, except in
    Israel. We plan to establish our own, internal sales and
    marketing capabilities for taliglucerase in Israel, and, for our
    other product candidates, in North America, the European Union
    and in other significant markets, including Israel. We believe
    that the focus of our current clinical pipeline on relatively
    rare genetic disorders with small patient populations and a
    highly concentrated group of physicians focused on treating
    patients with such disorders may facilitate our creation of a
    targeted internal sales force. In addition we are continuously
    evaluating potential strategic marketing partnerships with
    respect to our other product candidates.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Establish Development and Commercialization Alliances with
    Corporate Partners.</I>&#160;&#160;We believe that our
    technology and know-how has broad applicability to many classes
    of proteins and can be used to develop and potentially enhance
    numerous existing marketed protein therapeutics. We intend to
    leverage our technology and know-how by pursuing development and
    commercialization alliances with corporate partners for specific
    products and territories in order to enable us to optimize our
    resources and effectively penetrate a wider range of target
    diseases and therapeutic markets. In November 2009, we entered
    into a license and supply agreement with Pfizer for the
    development and commercialization of taliglucerase alfa. We
    entered into an agreement with Teva in September 2006 for the
    development of two proteins. Although programs relating to two
    proteins to be developed under the agreement were terminated for
    commercial reasons in 2009, other elements of our collaboration
    are still ongoing. Last, we are in various stages of discussions
    with a number of multinational pharmaceutical companies
    regarding additional collaboration agreements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Acquire or In-License New Technologies, Products or
    Companies.</I>&#160;&#160;We continuously seek attractive
    product candidates and innovative technologies to in-license or
    acquire. We intend to focus on product candidates that would be
    synergistic with our ProCellEx protein expression system and
    expertise and that represent large potential market
    opportunities. We believe that by pursuing selective
    acquisitions of technologies in businesses that complement our
    own, we will be able to enhance our competitiveness and
    strengthen our market position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Leverage Strength and Experience of Our Management Team and
    Board of Directors.</I>&#160;&#160;Our management team has
    extensive experience in the biotechnology and pharmaceutical
    industry. The Interim
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Chairman of our Board of Directors, Mr.&#160;Zeev Bronfeld, is a
    highly experienced Israeli health care investor. In February
    2008, we appointed Professor Roger D. Kornberg, a renowned
    biochemist and laureate of the Nobel Prize in Chemistry, to our
    Board of Directors. We will continue to leverage their
    experience and established track record as well as their
    relationships across the biotechnology and pharmaceutical
    industries.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    Pipeline Drug Candidates</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    Lead Product Candidate, Taliglucerase Alfa</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Taliglucerase alfa, our lead proprietary product candidate, is a
    plant cell expressed recombinant glucocerebrosidase enzyme (GCD)
    for the treatment of Gaucher disease. In July 2007, we reached
    an agreement with the FDA on the final design of our pivotal
    phase&#160;III clinical trial of taliglucerase alfa through the
    FDA&#146;s special protocol assessment (SPA) process. We
    successfully completed our phase&#160;III pivotal clinical trial
    of taliglucerase alfa in September 2009 and announced positive
    top line results of the clinical trial in October 2009 and full
    study results in February 2010. We submitted an NDA to the FDA
    in December 2009. In January 2010, the FDA requested additional
    data regarding the Chemistry, Manufacturing and Controls
    (CMC)&#160;section of the NDA. We provided the requested data to
    the FDA in April 2010 and in July 2010 we received notification
    from the FDA that it had accepted the filing of our NDA and
    assigned it a PDUFA date of February&#160;25, 2011. In addition,
    in November 2010 we submitted a marketing application to the
    Israeli MOH and an MAA to each of the EMEA and ANVISA for
    taliglucerase alfa for the treatment of Gaucher disease. During
    the third quarter of 2008, we initiated a double blind,
    follow-on extension study as part of our phase&#160;III clinical
    trial of taliglucerase alfa in which patients that successfully
    completed treatment in the trial were given the opportunity to
    continue to be treated with taliglucerase alfa at the same dose
    that they received in the trial. We are compiling additional
    information relating to the long term safety and efficacy of
    taliglucerase alfa through the follow-on study.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the fourth quarter of 2008 we announced the enrollment of the
    first patient in a worldwide, multi-center, open-label,
    switch-over trial which has been reviewed by the FDA and is
    designed to assess the safety and efficacy of taliglucerase
    alfa. The switch-over trial, which is not a pre requisite for
    approval, is designed to include 15&#160;patients with Gaucher
    disease that are currently undergoing enzyme replacement therapy
    with imiglucerase (Cerezyme). Due to the then shortage of the
    currently available enzyme replacement therapy for Gaucher
    disease, after fully enrolling the 15&#160;patients, we extended
    the trial to include up to 30&#160;patients in total. In
    November 2010, we announced positive preliminary data from the
    first 15&#160;patients that completed the switchover trial. The
    data indicate that patients can safely be switched to
    taliglucerase alfa from Cerezyme. Patients enrolled in the trial
    were switched from Cerezyme (doses ranging from
    <FONT style="white-space: nowrap">10-60</FONT> U/kg
    every other week) to an equivalent dose using the same number of
    units of taliglucerase alfa. The data from the first
    15&#160;patients demonstrate that maintenance of efficacy was
    achieved over a nine-month period with no increased safety
    concerns. Patients&#146; hemoglobin and platelet counts remained
    stable demonstrating hematological stability. As measured by
    MRI, mean spleen volume and liver volume also remained stable.
    There was no evidence of increased safety concerns in patients
    switched from Cerezyme to taliglucerase alfa and there were no
    drug related serious adverse events. Hypersensitivity reactions
    were not reported in this patient group. One patient developed
    non-neutralizing IgG antibodies to taliglucerase at the end of
    the study.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, in December 2009, we filed a proposed pediatric
    investigation plan to the Pediatric Committee of the EMEA and
    have since initiated pediatric studies. In clinical trials in
    healthy subjects and in vivo primate studies, taliglucerase alfa
    has demonstrated an increased half-life and prolonged presence
    of the enzyme in the blood serum of the subjects as compared to
    Cerezyme, the only enzyme replacement therapy currently marketed
    to treat Gaucher disease.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We believe that taliglucerase alfa, if approved, has the
    potential to offer patients and healthcare payors a more
    effective and cost efficient treatment of Gaucher disease
    because of the following features:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Increased Glycan Efficacy and Consistency.</I>&#160;&#160;We
    believe that our ProCellEx protein expression system produces
    recombinant proteins that exhibit consistent enzymatic activity
    from batch to batch. This results in a highly active product
    that may achieve a desired therapeutic effect more effectively
    than the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    activity demonstrated in proteins produced through mammalian
    cell-based expression systems due to its greater glycan efficacy
    and consistency. This quality increases the effective
    consistency in potency and further increases the cost advantages
    from using our plant cell-based expression technology compared
    to competing protein expression methodologies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Longer Half-Life.</I>&#160;&#160;The data generated in
    preclinical and human clinical trials relating to the half-life
    of taliglucerase alfa in the subjects&#146; blood serum after
    infusion showed that the half-life of taliglucerase alfa is
    significantly longer than that of Cerezyme when measured and
    compared to publicly available data on Cerezyme.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Cost-Effective.</I>&#160;&#160;Taliglucerase alfa is
    potentially less expensive to produce as the manufacturing
    process does not require the large initial
    <FONT style="white-space: nowrap">set-up</FONT>
    investments involved in mammalian cell-based protein production,
    the extensive ongoing costs associated with growth media and
    monitoring throughout the production process nor any of the
    post-expression modification costs in order to modify the
    glycosilation of the proteins produced through the mammalian
    cell-based methodologies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As such, we believe that taliglucerase alfa&#146;s potential
    advantages may lead taliglucerase alfa to become a highly
    efficacious and cost-effective treatment alternative for Gaucher
    disease patients.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, we are developing a new method for delivering
    active recombinant proteins systemically through oral
    administration of transgenic plant cells expressing
    biotherapeutic proteins. We have commenced pre-clinical studies
    of an oral form of taliglucerase alfa. If proven effective, our
    experimental oral taliglucerase alfa would be the first protein
    to be administered orally rather than through intravenous
    therapy. Our oral taliglucerase alfa is a plant cell expressed
    form of GCD that is naturally encapsulated within carrot cells
    genetically engineered to express the GCD enzyme. Pre-clinical
    studies of oral taliglucerase alfa demonstrate the stability of
    the enzyme in the cell and the capacity of the cell&#146;s
    cellulose wall to protect the enzyme against degradation in the
    digestive tract in an <I>in-vitro </I>model of the stomach and
    intestines. Additionally, rats fed with lyophilized carrot cells
    expressing GCD have accumulated the active enzyme in the target
    organs; the spleen and liver.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We believe that oral delivery of taliglucerase alfa presents a
    number of advantages. First, the development of oral
    taliglucerase alfa has the advantage of leveraging the
    well-characterized mechanism of action of our
    intravenously-administered taliglucerase alfa product candidate.
    In addition, we believe that oral delivery of taliglucerase alfa
    may dramatically change the treatment paradigm for Gaucher
    patients, compared to the intravenous delivery of taliglucerase
    alfa, and contribute to increased compliance and the
    facilitation of treatment management. Further, oral delivery of
    GCD targets the disease-specific organs without the need for
    lifetime dependence on repeated intravenous infusions. Last, our
    oral enzyme replacement therapy does not have the unpredictable
    long term untoward effects of the inhibition of other
    non-disease-specific compounds that are common in oral substrate
    reduction therapy.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our oral taliglucerase alfa product candidate is a recombinant
    form of the GCD enzyme, not a small molecule. This
    differentiates our oral product candidate from other early
    clinical stage, experimental, small molecule, oral drugs which
    are being developed for the treatment of Gaucher disease by
    Genzyme and Amicus Therapeutics, Inc., or Amicus Therapeutics.
    Small molecule based treatments for Gaucher disease, such as
    Zavesca, have different mechanisms of action than those
    associated with enzyme replacement therapy, and may be
    associated with a number of side effects. We have filed patent
    applications with respect to this new protein delivery mechanism
    in other countries with commercially significant markets.
    Currently, we are the exclusive owners of all rights to this
    technology.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Gaucher
    Disease Background</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Gaucher disease, a hereditary, genetic disorder with severe and
    debilitating symptoms, is the most prevalent lysosomal storage
    disorder in humans. Lysosomal storage disorders are metabolic
    disorders in which a lysosomal enzyme, a protein that degrades
    cellular substrates in the lysosomes of cells, is mutated or
    deficient. Lysosomes are small membrane-bound cellular
    structures within cells that contain enzymes necessary for
    intracellular digestion. Gaucher disease is caused by mutations
    or deficiencies in the gene
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    encoding GCD, a lysosomal enzyme that catalyzes the degradation
    of the fatty substrate, glucosylceramide (GlcCer). The normal
    degradation products of GlcCer are glucose and ceramide, which
    are easily excreted by the cells through normal biological
    processes. Patients with Gaucher disease lack or otherwise have
    dysfunctional GCD and, accordingly, are not able to break down
    GlcCer. The absence of an active GCD enzyme leads to the
    accumulation of GlcCer in lysosomes of certain white blood cells
    called macrophages. Macrophages affected by the disease become
    highly enlarged due to the accumulation of GlcCer and are
    referred to as &#147;Gaucher cells.&#148; Gaucher cells
    accumulate in the spleen, liver, lungs, bone marrow and brain.
    Signs and symptoms of Gaucher disease may include enlarged liver
    and spleen, abnormally low levels of red blood cells and
    platelets and skeletal complications. In some cases, the patient
    may suffer an impairment of the central nervous system.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Current
    Treatments for Gaucher Disease</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The standard of care for Gaucher disease is enzyme replacement
    therapy using recombinant GCD to replace the mutated or
    deficient natural GCD enzyme. The latest studies estimate that
    there are approximately 10,000&#160;patients suffering from
    Gaucher disease worldwide. Enzyme replacement therapy is a
    medical treatment in which recombinant enzymes are injected into
    patients in whom the enzyme is lacking or dysfunctional.
    Cerezyme, an enzyme replacement therapy commercialized by
    Genzyme, and VPRIV, an enzyme replacement therapy commercialized
    by Shire, are the only recombinant GCDs currently available on
    the market for the treatment of Gaucher disease. According to
    public reports issued by Genzyme, Cerezyme had annual sales of
    approximately $722&#160;million in 2010, compared to
    $793&#160;million in 2009. According to Genzyme it suffered a
    temporary interruption in production of Cerezyme in 2009
    associated with the remediation of a contamination in one of its
    manufacturing facilities, and, as a result, shipments of
    Cerezyme were limited during the second half of 2009. Shire has
    reported sales of VPRIV equal to $143&#160;million during 2010
    after the approval of VPRIV in February 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Cerezyme is produced through a mammalian cell-based protein
    expression process in CHO cells. There are no known severe side
    effects to the use of Cerezyme and its approved use over the
    past decade suggests that it is an effective treatment of
    Gaucher disease. However, Cerezyme is subject to the limitations
    of most mammalian cell-based therapeutic proteins, including
    lengthy and costly production processes and contamination risks.
    As enzyme replacement therapy does not cure the genetic
    disorder, but rather provides an external source for transfusion
    of the missing or mutated enzyme, Gaucher disease patients
    generally receive the treatment over their entire lifetime.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Zavesca (miglustat), which is marketed by Actelion Ltd., or
    Actelion, is a small molecule drug for the treatment of Gaucher
    disease. Zavesca has been approved by the FDA for use in the
    United States as an oral treatment. However, it has many side
    effects and the FDA has approved it only for administration to
    those patients who cannot be treated through enzyme replacement
    therapy, and, accordingly, have no other treatment alternative.
    As a result, Zavesca&#146;s use has been extremely limited.
    Actelion has reported sales of Zavesca of approximately CHF
    68.7&#160;million (approximately $72.0&#160;million) in 2010.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Taliglucerase
    Alfa Development Program</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We believe the clinical development path for taliglucerase alfa
    will be similar to that followed by the existing enzyme
    replacement therapy currently on the market. The primary
    efficacy endpoint for our pivotal phase&#160;III study was the
    reduction in size of spleen and the secondary endpoints for our
    pivotal phase&#160;III study included increase in platelet and
    hemoglobin counts and reduction in liver size, all of which are
    generally well-established and accepted by regulatory agencies
    and specifically agreed to by the FDA in the special protocol
    assessment (SPA) of the final design of our pivotal
    phase&#160;III clinical trial for taliglucerase alfa. The
    phase&#160;III clinical trial was successfully completed in
    September 2009 and we announced positive top-line results from
    the trial in October 2009 and full study results in February
    2010. The trial met its primary endpoint, mean reduction in
    spleen volume after nine months compared with baselines, in both
    60 U/kg dose and in the lower 30 U/kg dose treatment groups
    (P&#060;0.0001). In addition, the primary endpoint was observed
    already after six months of treatment in both treatment groups.
    Statistically significant improvements compared with baselines
    were also observed in the secondary endpoints, including
    increase in hemoglobin level, decrease
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    in liver size and increase in platelet count at the 60 U/kg
    dose. Statistically significant improvements compared with
    baselines were observed in hemoglobin level and liver size and
    significant nominal elevation in platelet count in the lower
    dose of 30 U/kg. However, the lower dose group did not meet the
    secondary endpoint relating to platelet count. See
    &#147;&#151;&#160;Phase&#160;III Clinical Trial.&#148; The
    primary end point for our switch-over study, which is not a
    prerequisite for approval, is non deterioration in the
    patient&#146;s clinical condition as measured through
    significant, well established end points such as platelet and
    hemoglobin counts and spleen and liver size.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Laboratory
    Testing and Preclinical Studies of Taliglucerase Alfa</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We conducted several in&#160;vitro tests and in vivo preclinical
    studies of taliglucerase alfa. Our preclinical rodent and
    primate trials generated extensive toxicological and safety data
    that demonstrated no adverse effects, even with very high doses
    of taliglucerase alfa being administered via intravenous
    infusions. In short term repeat dose studies in rodents and
    primates and nine month repeat dose studies in primates, no
    toxicity was observed at dosage levels of up to 10 times the
    current dose recommended for GCD in clinical use. Furthermore,
    no neutralizing antibodies were detected in any of the primates
    treated in the studies. The presence of neutralizing antibodies
    would have implied a likelihood of the host rejecting the
    therapeutic enzyme or reacting to it in a less efficient manner.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our laboratory and preclinical data demonstrate that
    taliglucerase alfa has the potential to be an efficacious enzyme
    replacement therapy for the treatment of Gaucher disease. Data
    produced from these preliminary development studies show that,
    relative to Cerezyme, taliglucerase alfa has:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    an equivalent to superior level of enzymatic activity;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    enhanced uptake based on observed GlcCer substrate degradation;
    and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a prolonged half-life.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Phase I
    Clinical Trial</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We completed a phase I clinical trial of taliglucerase alfa in
    June 2006. The phase I clinical trial was a single-center,
    non-randomized, open label, dose ranging study designed to
    evaluate the safety and pharmacokinetics of taliglucerase alfa
    in healthy subjects. The trial was conducted on healthy subjects
    over a four-week period in which subjects received three single
    escalating doses of taliglucerase alfa administered as
    intravenous infusions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    All doses administered to subjects in the phase I clinical
    trial, including the highest dose, which was the same dosage
    currently suggested with respect to the treatment by Cerezyme,
    demonstrated a strong safety profile. The data from our phase I
    clinical trial showed that taliglucerase alfa was safe and well
    tolerated at all doses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    There were no serious adverse events and no subjects withdrew
    from the trial or discontinued treatment due to an adverse event.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, the half-life of taliglucerase alfa was found to be
    significantly longer than that of Cerezyme, based upon data
    disclosed publicly by Genzyme, which was consistent with our
    preclinical data.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Further, no neutralizing antibodies or adverse immunological
    responses were detected in any of the subjects treated in the
    phase I clinical trial. The presence of neutralizing antibodies
    would imply that the human body may reject the therapeutic
    enzyme.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Phase&#160;III
    Clinical Trial</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    After the conclusion of the phase I clinical trial and
    discussions with the FDA, we applied to commence a pivotal
    phase&#160;III clinical trial of taliglucerase alfa without the
    requirement to first complete a phase&#160;II clinical trial. In
    April 2007, we received approval from the FDA to initiate a
    pivotal phase&#160;III clinical trial. We submitted to the FDA a
    request for a special protocol assessment (SPA) of the final
    design of our pivotal
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    phase&#160;III clinical trial for taliglucerase alfa. In July
    2007, we reached an agreement with the FDA on the design that we
    submitted in the SPA request and in the third quarter of 2007 we
    initiated enrollment and treatment of naive patients in the
    phase&#160;III clinical trial. In accordance with the terms of
    the SPA, the phase&#160;III clinical trial was a multi-center,
    world-wide, randomized, double-blind, parallel group,
    dose-ranging study to assess the safety and efficacy of
    taliglucerase alfa in 31 treatment-naive patients suffering from
    Gaucher disease. In the trial, patients were selected randomly
    for one of two dosing arms (60 U/kg or 30 U/kg) and received
    intravenous infusions of taliglucerase alfa once every two weeks
    for a nine-month period. The primary endpoint of the study was a
    20% mean reduction from baseline in spleen volume after nine
    months, as measured by MRI. Major secondary endpoints were an
    increase in hemoglobin, decrease in liver volume and increase in
    platelet count. Patients enrolled in the trial were treated in
    11 centers throughout Europe, Israel, North America, South
    America and South Africa. We commenced enrollment and treatment
    of patients in our phase&#160;III clinical trial in the third
    quarter of 2007 and completed enrollment in the fourth quarter
    of 2008. During the third quarter of 2008, we initiated a double
    blind, follow-on extension study as part of our phase&#160;III
    clinical trial in which patients that successfully completed
    treatment in the trial were given the opportunity to continue to
    be treated with taliglucerase alfa at the same dose that they
    received in the trial. We are compiling additional information
    relating to the long term safety and efficacy of taliglucerase
    alfa through the follow-on study. In addition, in the fourth
    quarter of 2008, we announced the enrollment of the first
    patient in a worldwide, multi-center, open-label, switch-over
    trial to assess the safety and efficacy of taliglucerase alfa.
    The switch-over trial, which is not a pre requisite for
    approval, was originally designed to include 15&#160;patients
    with Gaucher disease that are currently undergoing enzyme
    replacement therapy with imiglucerase (Cerezyme). Due to the
    shortage of Cerezyme in 2009, after fully enrolling the
    15&#160;patients, we extended the trial to include up to
    30&#160;patients in total. We successfully completed the
    phase&#160;III clinical trial in September&#160;2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In July 2009, following a request by the FDA, we submitted a
    treatment protocol to the FDA in order to address an expected
    shortage of the current enzyme replacement therapy approved for
    Gaucher disease. The treatment protocol was approved by the FDA
    in August 2009. In September 2009, the FDA&#146;s Office of
    Orphan Product Development granted taliglucerase alfa Orphan
    Drug Status. In January 2010, the Committee for Orphan Medicinal
    Products (COMP) of the EMEA, after reviewing all relevant
    clinical data, recommended that the European Commission grant
    Orphan Drug designation to taliglucerase alfa for the treatment
    of Gaucher disease. The Orphan Drug designation in the United
    States for taliglucerase alfa for the treatment of Gaucher
    disease provides special status to taliglucerase alfa provided
    that it meets certain criteria. As a result of the Orphan Drug
    designation, we are qualified for the tax credit and marketing
    incentives of the Orphan Drug Act of 1983. A marketing
    application for a prescription drug product that has been
    designated as a drug for a rare disease or condition is not
    subject to a prescription drug user fee unless the application
    includes an indication for other than a rare disease or
    condition.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Phase&#160;III
    Clinical Trial Results</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We reported positive top line results of our phase&#160;III
    clinical trial of taliglucerase alfa in October 2009 and full
    study results in February 2010. In the clinical trial,
    taliglucerase alfa significantly reduced mean spleen volume
    after nine months compared with baseline in both treatment
    groups. The 60 U/kg group demonstrated a statistically
    significant mean reduction in spleen volume of 38.0%
    (p&#060;0.0001) and the
    <FONT style="white-space: nowrap">30&#160;U/kg</FONT>
    group demonstrated a significant mean reduction in spleen volume
    of 26.9% (p&#060;0.0001). In addition, the primary endpoint was
    achieved in both treatment groups after only six months of
    therapy. See Figure 1 (range of spleen volume at baseline is
    8X&#160;&#151; 54X).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    * P-value&#060;0.0001.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Figure 1.&#160;&#160;MRI validated method-2 blinded readers,
    Intra-reader variability
    <FONT style="font-family: Symbol; font-variant: normal">&#163;</FONT>
    0.5%; Inter-reader variability
    <FONT style="font-family: Symbol; font-variant: normal">&#163;</FONT>
    1.00%</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y04571y0457101.gif" alt="(GRAPH)">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Statistically significant improvements were also observed for
    the secondary endpoints after nine months when compared to
    baseline for the 60 U/kg dose. Patients demonstrated a mean
    increase in hemoglobin of 2.2 g/dL or 22.2% (p&#060;0.0001), a
    mean decrease in liver volume of 11.1% (p&#060;0.0001) and a
    mean elevation in platelet count of 41,494 ml or 72.1%
    (p=0.0031). For patients in the 30 U/kg dose, statistically
    significant improvements after nine months compared with
    baselines were observed for hemoglobin level (increased 1.6 g/dL
    or 14.8%; p=0.0010) and liver size (decreased 10.48%; p=0.0041);
    a nominal elevation in platelet count was also seen (11,427 ml
    or 13.7%; p=0.0460). See Figures 2 through 4.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Figure 2.&#160;&#160;1st&#160;Major Secondary endpoint:
    Change in Hemoglobin (g/dL) From Baseline&#160;&#151; ITT vs.
    Anemic patients </B>(both anemic and non anemic patients showed
    an increase in Hb)
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y04571y0457102.gif" alt="(GRAPH)">
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Figure 3.&#160;&#160;2nd&#160;Major Secondary Endpoint: Liver
    Volume % Change from Baseline, MRI validated method-2 blinded
    readers; Intra-reader variability
    <FONT style="font-family: Symbol; font-variant: normal">&#163;</FONT>
    0.5%; Inter-reader variability
    <FONT style="font-family: Symbol; font-variant: normal">&#163;</FONT>
    1.00% </B>(16 (52%) of the patients who presented hepatomegaly
    showed a reduction of 14% on liver volume)
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y04571y0457103.gif" alt="(GRAPH LOGO)">
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Figure 4.&#160;&#160;3rd&#160;Major Secondary Endpoint:
    Platelet Counts Change from Baseline</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y04571y0457104.gif" alt="(GRAPH LOGO)"><B> </B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Thirty patients in the trial had Chitotriosidase measurements, a
    biomarker for clinical symptoms of Gaucher disease. In these
    patients, Chitotriosidase decreased from baseline in both the
    30U/kg and 60U/kg groups by 47.3% and 58.4%, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The safety analysis for both treatment groups showed that
    taliglucerase alfa was well tolerated and no serious or severe
    adverse events were reported. Two patients in the trial
    developed antibodies to taliglucerase alfa and no patients
    developed neutralizing antibodies. In addition, two patients
    experienced hypersensitivity reactions to taliglucerase alfa. No
    anti-taliglucerase antibodies were detected in these patients
    and both reactions were treated in the physicians&#146; clinic
    and reversed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Most adverse events were considered unrelated to taliglucerase
    alfa. The most frequent mild to moderate adverse event was
    headache. Other mild to moderate adverse events included
    dizziness, muscle spasm, chest discomfort, nausea, skin
    irritation and arthalgia.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In November 2010, we announced positive preliminary data from
    the first 15&#160;patients that completed our switchover trial
    of taliglucerase alfa. The data indicate that patients can
    safely be switched to taliglucerase alfa
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    from Cerezyme. Patients enrolled in the trial were switched from
    Cerezyme (doses ranging from
    <FONT style="white-space: nowrap">10-60</FONT> U/kg
    every other week) to an equivalent dose of taliglucerase alfa
    using the same number of units of taliglucerase alfa. The data
    from the interim report regarding the switchover trial
    demonstrates that, on average, hemoglobin and platelet count,
    spleen volume and liver volume (as measured by MRI) all remained
    stable over the nine-month period, and no patients showed a
    sustained clinical deterioration. The safety analysis from the
    interim report (n=25, as performed at the time of data lock)
    demonstrates that taliglucerase alfa was well tolerated and no
    drug related severe adverse events were reported. No patients
    experienced hypersensitivity reactions, one patient developed
    antibodies to taliglucerase alfa and no patients developed
    neutralizing antibodies. Most adverse events were considered
    unrelated to taliglucerase alfa. The most frequent mild to
    moderate adverse event was nasopharyngitis, a viral infection of
    the upper respiratory system.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Other
    Drug Candidates in Our Pipeline</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are developing other recombinant therapeutic proteins to be
    expressed by our ProCellEx protein expression system, with an
    emphasis on treatments for which there are large, established
    pharmaceutical markets and where our proprietary protein
    expression system enables us to develop and commercialize
    recombinant proteins that are patent-protected and
    therapeutically equivalent or superior to the existing
    treatments. We select additional therapeutic candidates for
    development by testing candidates in-house and through
    collaborations with academic partners. We have identified
    several product candidates oriented towards specialty disease
    and therapeutic market segments, including treatments for Fabry
    disease. We are also conducting initial research programs in the
    fields of monoclonal antibodies, cytokines and vaccines. We
    filed an IND with the FDA for PRX-105, our plant cell expressed
    pegylated recombinant acetylcholinesterase enzyme (AChE) product
    candidate, during the last quarter of 2009, and in March 2010 we
    initiated a preliminary phase I clinical trial of PRX-105. We
    completed the preliminary phase I clinical trial in June 2010.
    We are currently preparing for further efficacy trials of this
    product candidate in larger animals. In addition, we recently
    held a pre-IND meeting with the FDA regarding PRX-102, our
    product candidate for the treatment of Fabry disease, and we
    plan to file an IND with the FDA for PRX-102 within the next
    12&#160;months. Last, we are developing a new method for
    delivering active recombinant proteins systemically through oral
    administration of transgenic plant cells expressing such
    biotherapeutic proteins.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PRX-102</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are developing PRX-102, our proprietary plant cell expressed
    modified version of the recombinant alpha-GAL-A protein, a
    therapeutic enzyme for the treatment of Fabry disease. Fabry
    disease is a rare, hereditary, genetic lysosomal storage
    disorder in humans caused by an X-lined deficiency of the
    alpha-GAL-A enzyme. Fabry disease causes harmful accumulations
    of lipids in the kidneys, automatic nervous system and
    cardiovascular system that result in the risk of heart attack
    and stroke, and can be life-threatening. Fabry disease affects
    more than 8,000&#160;people globally. We believe that the
    treatment of Fabry disease is a specialty clinical niche with
    the potential for high growth. Currently there are two drugs
    available on the market to treat Fabry disease. Fabrazyme, made
    by Genzyme, was approved for the treatment of Fabry disease in
    the European Union in 2001 and the United States in 2003.
    Genzyme reported $188&#160;million in worldwide sales of
    Fabrazyme in 2010, compared to $431&#160;million in 2009.
    According to Genzyme, it suffered a temporary interruption in
    production of Fabrazyme in 2009 associated with the remediation
    of a contamination in one of its manufacturing facilities, and,
    as a result, shipments of Fabrazyme were limited during the
    second half of 2009. The other approved drug for the treatment
    of Fabry disease in the European Union is Replagal, which is
    sold by Shire plc. Shire reported $351&#160;million in sales of
    Replagal in 2009. According to public reports by Shire, it filed
    a BLA with the FDA for Replagal in the United States in December
    2009. Shire subsequently received Fast Track designation for
    Replagal and withdrew its December 2009 BLA in favor of a
    rolling BLA submission. Shire has reported that it withdrew that
    filing in August 2010 in order to update the filing with
    additional clinical information.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are currently in the animal evaluation testing phase of the
    development of PRX-102, which tests are based on a well
    established mouse model for Fabry disease. In pre-clinical
    studies, PRX-102 demonstrated preliminary efficacy in a Fabry
    animal model. Chemical modifications made to PRX-102 improved
    the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    enzyme&#146;s activity and stability resulting in prolonged
    activity profiles and enhanced bioavailability in animals. The
    modifications also have the potential to decrease the
    immunogenicity of the enzyme, which is a major drawback of
    currently approved therapies for Fabry disease. We held a
    pre-IND meeting with the FDA in 2010 regarding PRX-102, and we
    expect to file an IND with the FDA within the next
    12&#160;months. As was the case in our development of
    taliglucerase alfa, our development of PRX-102 involves the
    expression by our proprietary protein expression system of a
    naturally occurring enzyme to be used in enzyme replacement
    therapy for the treatment of Fabry disease. Based on our
    experience with taliglucerase alfa, the experience of other
    companies developing enzyme replacement therapies for Fabry
    disease and the pre IND meeting we held with FDA in 2010, we
    have reason to believe that, if favorable data is accumulated in
    preclinical and phase I/II clinical trials, the FDA may allow us
    to proceed directly with a pivotal phase&#160;III clinical
    trial. However, there can be no assurance that we will initiate
    phase I/II clinical trials and if we do, that such trials will
    result in favorable data. In addition, there can be no assurance
    that the FDA will allow us to proceed directly with a
    phase&#160;III clinical trial after completion of a phase I/II
    clinical trial.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Acetylcholinesterase</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In August 2007, Protalix Ltd. licensed the rights to certain
    technology under a research and license agreement with Yissum
    Research and Development Company, or Yissum, and the Boyce
    Thompson Institute, Inc., or Boyce Thompson. Pursuant to the
    agreement, we are developing PRX-105, a proprietary plant
    cell-based acetylcholinesterase (AChE) and its molecular
    variants for the use in several therapeutic and prophylactic
    indications, as well as in a biodefense program and an
    organophosphate-based pesticide treatment program. Under the
    terms of the agreement, Yissum and Boyce Thompson granted us an
    exclusive, worldwide right and license to certain technology,
    including patents and certain patent applications relating to
    AChE for the therapeutic and prophylactic indications as well as
    an exclusive license not limited to such indications with
    respect to certain of those patents and patent applications. As
    consideration for the license, we are obligated to pay Yissum
    and Boyce Thompson, collectively, an annual, non-refundable
    initial maintenance fee of $20,000, commencing on the fourth
    anniversary of the execution of the agreement, which is subject
    to a 12% annual increase. In addition, we are obligated to make
    royalty payments equal to varying low, single-digit percentages
    of net sales of products under the agreement. These royalty
    rates are evaluated on a
    <FONT style="white-space: nowrap">country-by-country</FONT>
    basis, and are subject to reduction if a third party
    commercializes a competing product or commercializes an
    authorized generic version of the applicable product, subject to
    certain conditions. We also have the right to grant sublicenses
    relating to the licensed technology under the agreement, subject
    to the payment of sublicensing fees. The fees payable in
    connection with any sublicense are equal to varying percentages,
    in the low-teens through the low-twenties, of the consideration
    we receive in connection with the sublicense, depending on the
    level of clinical development of the product at the time we
    enter into the sublicense. Last, we are obligated to pay Yissum
    and Boyce Thompson, collectively, milestone payments equal to
    $700,000, in the aggregate, upon the achievement of certain
    milestones under the license agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The license agreement remains in effect until the expiration of
    all obligations to Yissum and Boyce Thompson under the
    agreement, determined on a
    <FONT style="white-space: nowrap">country-by-country</FONT>
    basis. We have the right to terminate the agreement for any
    reason upon 60&#160;days&#146; prior written notice to Yissum
    and Boyce Thompson. Subject to certain conditions, Yissum and
    Boyce Thompson may terminate the agreement immediately upon
    written notice to us in connection with certain events relating
    to bankruptcy, lapses in our insurance coverage, failures to
    defend against third party claims or claims we may make
    regarding the validity or enforceability of any licensed patent.
    We or Yissum and Boyce Thompson may terminate the agreement
    within 60&#160;days after receiving written notice if the
    non-terminating party passes a resolution for a voluntary wind
    up, if a receiver or liquidator is appointed for the
    non-terminating party, or the non-terminating party enters into
    an insolvency or bankruptcy proceeding. In addition, either
    party may terminate the agreement due to a material breach by
    the other party if the breaching party is unable to cure the
    breach within 60&#160;days after receiving written notice of the
    breach from the non-breaching party. Any termination of the
    agreement will result in a loss of our rights to the licensed
    technology, which will revert back to Yissum and Boyce Thompson.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    To date, our in&#160;vitro experiments of PRX-105 have shown
    that the acetylcholinesterase enzyme expressed in our ProCellEx
    protein expression system demonstrates promising biological
    activity on biochemical and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    cellular levels. In addition, early animal studies demonstrated
    that the acetylcholinesterase expressed in our ProCellEx protein
    expression system was able to successfully treat animals exposed
    to the nerve gas agent analogues, both when injected with our
    acetylcholinesterase product candidate immediately before
    exposure or when injected after exposure. In March 2010 we
    initiated a preliminary phase I clinical trial of PRX-105 which
    we completed in June 2010. The trial established the
    pharmokinetics of PRX-105 and demonstrated that single dose
    intravenous administration of PRX-105 is safe and well
    tolerated. We are currently preparing for further efficacy
    trials of PRX-105 in larger animals. In our preclinical studies
    we utilized an analogue to nerve gas. However, we anticipate
    that we will use live nerve gas in the proposed additional
    efficacy trials in animals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are currently in discussions with different U.S.&#160;civil
    and military organizations regarding certain grants for which
    our acetylcholinesterase program is eligible. We anticipate
    applying for specific grants during 2011 to support the further
    development of our acetylcholinesterase program.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">pr-antiTNF</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In September 2009, we announced preliminary preclinical data
    regarding an antiTNF (Tumor, Necrosis Factor) protein that we
    are expressing through our proprietary ProCellEx system. We have
    designed this antiTNF as pr-antiTNF. pr-antiTNF is a candidate
    for the treatment of certain autoimmune diseases such as
    rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing,
    spondylitis, psoriatic arthritis and plaque psoriasis. Amgen
    Inc. reported total sales of Enbrel of $3.5&#160;billion in the
    United States and Canada for 2010 and Pfizer has reported total
    sales of Enbrel outside of the United States and Canada of
    $865.0&#160;million for 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    pr-antiTNF is a plant cell-expressed recombinant fusion protein
    made from the soluble form of the human TNF receptor (TNFR),
    fused to the Fc component of a human antibody domain. pr-antiTNF
    has an identical amino acid sequence to Enbrel and our
    in&#160;vitro and preclinical animal studies have demonstrated
    that pr-antiTNF exhibits similar activity to Enbrel.
    Specifically, pr-antiTNF binds TNF thereby inhibiting it from
    binding to cellular surface TNF receptors and protects L929
    cells from TNF-induced apoptosis in a dose-dependent manner. In
    a
    <FONT style="white-space: nowrap">proof-of-concept</FONT>
    in vivo study using an established arthritis animal model,
    pr-antiTNF, when injected in mice, significantly improved the
    clinical arthritis parameters associated with this accepted
    arthritis mouse model, including joint inflammation, swelling
    and tissue degradation. We intend to conduct additional animal
    studies to collect additional data to form a basis for a
    discussion with the FDA to explore the regulatory pathway for
    our antiTNF program. Patents for the Enbrel start to expire as
    early as 2012, and we expect to use our cost effective
    manufacturing platform to facilitate entry into this market upon
    approval of our pr-antiTNF product, if at all. We have scheduled
    a pre-IND meeting with the FDA regarding our antiTNF program in
    March 2011.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Commercialization
    Agreement</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On November&#160;30, 2009, Protalix Ltd. and Pfizer entered into
    a license and supply agreement pursuant to which Pfizer was
    granted an exclusive, worldwide license to develop and
    commercialize taliglucerase alfa. Under the terms and conditions
    of the Pfizer agreement, Protalix Ltd. retained the right to
    commercialize taliglucerase alfa in Israel. In connection with
    the execution of the Pfizer agreement, Pfizer made an upfront
    payment to Protalix Ltd. of $60.0&#160;million in connection
    with the execution of the agreement and subsequently paid to
    Protalix Ltd. an additional $5.0&#160;million upon our filing of
    a proposed pediatric investigation plan to the Pediatric
    Committee of the EMEA. Protalix Ltd. is also eligible to receive
    potential milestone payments of up to $50.0&#160;million, in the
    aggregate, for the successful achievement of other
    regulatory-related milestones and to payments equal to 40% of
    the net profits earned by Pfizer on sales of taliglucerase alfa.
    In calculating the net profits, there are certain agreed upon
    limits on the amounts that may be deducted from gross sales for
    certain expenses and costs of goods sold. Protalix Ltd. retained
    the manufacturing rights to taliglucerase alfa and Pfizer and
    Protalix Ltd. have agreed to a specific allocation of the
    responsibilities for the continued development efforts for
    taliglucerase alfa. Protalix Ltd. will manufacture all of the
    taliglucerase alfa needed for all purposes under the agreement
    and Pfizer will purchase the taliglucerase alfa from Protalix
    Ltd., subject to certain terms and conditions. The Pfizer
    agreement also provides for reimbursement by Pfizer of certain
    costs to be incurred by Protalix Ltd.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In connection with the upfront and milestone payments made under
    the Pfizer agreement, Protalix Ltd. has paid a sublicense fee
    equal to $1.6&#160;million to the academic institution from who
    it licensed certain technology relating to taliglucerase alfa.
    Future milestone payments will be subject to a 2.5% royalty, and
    all of revenues generated under the agreement will be subject to
    a 0.75% royalty payable to the same institution until 2016, when
    a patent related to taliglucerase alfa licensed to us will
    expire. We are also required to pay a royalty equal to 3% of the
    revenues of taliglucerase alfa Pizer records under the Pfizer
    agreement to the OCS.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On August&#160;10, 2010, Pfizer entered into a $30&#160;million
    short-term supply agreement with the Ministry of Health of
    Brazil pursuant to which Protalix and Pfizer have provided
    taliglucerase alfa to the Ministry of Health of Brazil for the
    treatment of patients with Gaucher disease. In addition, we and
    the Ministry of Health of Brazil are in discussions relating to
    a possible long-term supply agreement that contemplates, among
    other matters, providing certain components of our manufacturing
    technology to the Ministry of Health of Brazil for
    implementation by it in Brazil. At this time, we are unable to
    assess whether these discussions will result in an agreement and
    there can be no assurance that we will be able to enter into
    such an agreement on favorable terms, if at all. In any event,
    we do not expect to enter into a long-term supply agreement with
    the Ministry of Health of Brazil until we receive marketing
    approval of taliglucerase alfa from the FDA or ANVISA, if at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We will be subject to a withholding tax on the U.S.&#160;revenue
    source portion of the payments made to us for our share of
    Pfizer&#146;s in net profits under the Pfizer agreement.
    Currently, the withholding tax rate is 15%.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Strategic
    Collaborations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Teva
    Pharmaceutical Industries</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In September 2006, we entered into a Collaboration and Licensing
    Agreement with Teva for the development and manufacture of two
    proteins to be identified by Teva and us using our ProCellEx
    protein expression system. The agreement also identifies
    additional matters for collaboration between Teva and us.
    Subsequently, two proteins were identified to be researched and
    developed under the agreement but in 2009, both of the projects
    were terminated for commercial reasons. Pursuant to the
    agreement, we have agreed to collaborate on certain additional
    matters regarding proteins, including the research and
    development of proteins utilizing our ProCellEx protein
    expression system. See &#147;Risk Factors&#160;&#151; Our
    strategy, in many cases, is to enter into collaboration
    agreements with third parties to leverage our ProCellEx system
    to develop product candidates. If we fail to enter into these
    agreements or if we or the third parties do not perform under
    such agreements or terminate or elect to discontinue the
    collaboration, it could have a material adverse affect on our
    revenues.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Weizmann
    Institute of Science</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In March 2006, Protalix Ltd. entered into a research and license
    agreement with the Yeda Research and Development Company
    Limited, or Yeda, the technology transfer arm of the Weizmann
    Institute of Science. Under the terms of the agreement, Yeda
    agreed to use its technology to design a next generation of
    glucoceribrosidase (GCD) for the treatment of Gaucher disease
    that can be expressed using our ProCellEx protein expression
    system and that may have certain benefits over the first
    generation treatments used today. The technology licensed from
    Yeda provides a methodology for the rational design of an
    improved drug for the treatment of Gaucher disease by enzyme
    replacement therapy, based on the three-dimensional crystal
    structure of glucoceribrosidase (GCD) that was solved by
    scientists from the Weizmann Institute of Science. Yeda has
    granted us an exclusive worldwide license to use their
    technology and discoveries for the development, production and
    sale of enzymatically active mutations of glucoceribrosidase
    (GCD) and derivatives thereof for the treatment of Gaucher
    disease. Under the terms of the agreement, we are required to
    take all necessary steps to develop and commercialize the
    products subject to the agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As consideration for the license, we agreed to pay Yeda a fixed
    research budget amount, subject to certain conditions. We have
    since completed the research phase of the arrangement with Yeda.
    Accordingly, we are no longer making any research-related
    payments to Yeda under the agreement. In addition, we are
    obligated to make an annual non-refundable license fee of
    $10,000 during the term of the agreement, commencing on the
    fifth anniversary of the execution of the agreement until, and
    including, the 19th anniversary thereof. We are
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    also obligated to make royalty payments equal to varying low,
    single-digit percentages of net sales of products under the
    agreement. Sublicenses relating to the licensed technology may
    be granted under the agreement, subject to the payment of
    sublicensing fees. The fee for any sublicense is equal to a
    percentage, ranging from the low-teens through the low-twenties,
    of the consideration we receive in connection with the
    sublicense, depending on the level of clinical and regulatory
    development of the products under the agreement at the time we
    enter into the sublicense.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The license agreement remains in effect until the earlier of the
    expiration of the last patent licensed under the agreement or if
    there are no commercial sales of any products for a continuous
    period of 20&#160;years. Yeda may modify the exclusivity
    component of the agreement by written notice to us and without
    our consent. Yeda may terminate the agreement by written notice
    to us if we fail to satisfy any one or more specified
    milestones, and we fail to cure any such failure within a
    certain time period after we receive the notice. Yeda is not
    entitled to exercise this termination right if we demonstrate
    that we are making all necessary efforts to achieve such
    milestones, that our inability to satisfy the milestones is due
    to factors beyond our control, and that the total delay with
    respect to any one milestone does not exceed 12&#160;months and
    the total cumulative delay in respect of all milestones has not
    exceeded 30&#160;months. Yeda may also terminate the agreement
    if we contest the validity of any of the patents included in the
    agreement. We or Yeda may terminate the agreement due to a
    material breach by the other party if the breach is unable to be
    cured or, if curable, the breach is not cured within
    21&#160;days after the breaching party&#146;s receipt of written
    notice of the breach from the non-breaching party. In addition,
    either party may terminate the agreement in connection with
    certain events relating to a wind up or bankruptcy.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Intellectual
    Property</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We maintain a proactive intellectual property strategy which
    includes patent filings in multiple jurisdictions, including the
    United States and other commercially significant markets. At the
    end of the first quarter of 2011, we held 20 granted patents and
    84 pending patent applications with respect to various
    compositions, methods of production and methods of use relating
    to our ProCellEx protein expression system and our proprietary
    product pipeline. At the end of the first quarter of 2011 we
    also held one joint patent with a third party and held licensed
    rights to six patents and seven patent applications.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our competitive position and future success depend in part on
    our ability, and that of our licensees, to obtain and leverage
    the intellectual property covering our product candidates,
    know-how, methods, processes and other technologies, to protect
    our trade secrets, to prevent others from using our intellectual
    property and to operate without infringing the intellectual
    property of third parties. We seek to protect our competitive
    position by filing United States, European Union, Israeli and
    other foreign patent applications covering our technology,
    including both new technology and improvements to existing
    technology. Our patent strategy includes obtaining patents,
    where possible, on methods of production, compositions of matter
    and methods of use. We also rely on know-how, continuing
    technological innovation, licensing and partnership
    opportunities to develop and maintain our competitive position.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As of December&#160;31, 2010, our patent portfolio consists of
    several patent families (consisting of patents
    <FONT style="white-space: nowrap">and/or</FONT>
    patent applications) covering our technology, protein expression
    methodologies and system and product candidates, as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    With respect to our ProCellEx protein expression system, we have
    been issued, and hold licensed rights to, patents in the United
    States, the European Union, Israel, Canada, the Czech Republic,
    Hungary, Japan, Poland, Mexico, Hong Kong and India, and to 10
    pending patent applications. Among other things, the patents
    cover the methods that we use for culturing and harvesting plant
    cells <FONT style="white-space: nowrap">and/or</FONT>
    tissues in consecutive cycles. The issued patents in this patent
    family are expected to expire in 2017.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    With respect to our ProCellEx protein expression system, we also
    hold 14 patent applications relating to the large scale
    production of proteins in cultured plant cells. The patents to
    issue in the future based on the pending patent applications in
    this patent family are expected to expire in 2028.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We hold a patent family containing five granted patents in
    India, South Africa, Russia, Australia and the Ukraine, and 36
    patent applications, relating to the production of glycosylated
    lysosomal proteins in our plant culture platform, particularly
    proteins having a terminal mannose glycosylation, including
    taliglucerase alfa. The issued patents and any patents to issue
    in the future based on pending patent applications in this
    patent family are expected to expire in 2024.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We hold a patent family containing one granted and three pending
    patent applications relating to a system and method for
    production of antibodies in a plant cell culture, and antibodies
    produced in such a system. The patents to issue in the future
    based on the patent applications in this patent family are
    expected to expire in 2025.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We hold a patent family containing one issued patent in South
    Africa and 12 pending patent applications relating to a new
    method for delivering active recombinant proteins systemically
    through oral administration of transgenic plant cells. The
    issued patents and any patents to issue in the future based on
    patent applications in this patent family are expected to expire
    in 2026.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    We hold a patent family containing seven pending patent
    applications relating to saccharide containing protein
    conjugates. The patents to issue in the future based on the
    patent applications in this patent family will expire in 2028.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Our patent portfolio includes a patent that we co-own that
    covers human glycoprotein hormone and chain splice variants,
    including isolated nucleic acids encoding these variants. More
    specifically, this patent covers a new splice variant of human
    FSH. This patent was issued in the United States and is expected
    to expire in 2026.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    With respect to taliglucerase alfa, we have licensed the rights
    to two patents from Virginia Tech Intellectual Properties, Inc.,
    or Virginia Tech, that are expected to expire in 2016. We also
    hold the licensed rights from Yeda to one granted and two
    pending patent applications with respect to the research and
    development of the glucocerebrosidase (GCD) protein.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    With respect to acetylcholinesterase, we have licensed the
    rights to three patents issued in the United States that are
    expected to expire in 2013, 2017 and 2021, and to five patent
    applications from Yissum.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We monitor third parties for activities that may infringe our
    intellectual property, as well as the progression of third party
    patent applications that may cover our product candidates or
    expression methods and thus, potentially, interfere with the
    development of our business. We are aware, for example, of
    U.S.&#160;patents, and corresponding international counterparts
    of such patents, owned by third parties that contain claims
    covering methods of producing GCD. We do not believe that, if
    any claim of infringement were to be asserted against us based
    upon such patents, taliglucerase alfa would be found to infringe
    any valid claim under such patents. However, there can be no
    assurance that a court would find in our favor or that, if we
    choose or are required to seek a license to any one or more of
    such patents, a license would be available to us on acceptable
    terms or at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In April 2005, Protalix Ltd. entered into a license agreement
    with Icon Genetics AG, or Icon, pursuant to which we received an
    exclusive worldwide license to develop, test, use and
    commercialize Icon&#146;s technology to express certain proteins
    in our ProCellEx protein expression system. Under the terms of
    the agreement, we are also entitled to a non-exclusive worldwide
    license to make and have made other proteins expressed by using
    Icon&#146;s technology in our technology. As consideration for
    the license, we are obligated to make royalty payments equal to
    varying low, single-digit percentages of net sales of products
    by us, our affiliates, or any sublicensees under the agreement.
    In addition, we are obligated to make milestone payments equal
    to $350,000, in aggregate, upon the achievement of certain
    milestones.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our license agreement with Icon remains in effect until the
    earlier of the expiration of the last patent under the agreement
    or, if all of the patents under the agreement expire,
    20&#160;years after the first commercial sale of any product
    under the agreement. Icon may terminate the agreement upon
    written notice to us that we are in material breach of our
    obligations under the agreement and we are unable to remedy such
    material breach within 30&#160;days after we receive such
    notice. Further, Icon may terminate the agreement in connection
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    with certain events relating to a wind up or bankruptcy, if we
    make a general assignment for the benefit of our creditors, or
    if we cease to conduct operations for a certain period. Icon may
    also terminate the exclusivity granted to us by written notice
    if we fail to reach certain milestones within a designated
    period of time. Notwithstanding the termination date of the
    agreement, our obligation to pay royalties under the agreement
    to Icon may expire prior to the termination of this agreement,
    subject to certain conditions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In January 2005, Protalix Ltd. entered into a license agreement
    with Virginia Tech, pursuant to which we received a
    non-exclusive worldwide license to make, have made, use, sell,
    offer for sale and import certain of Virginia Tech&#146;s
    patents. As consideration for the license, we made a one-time
    license fee payment to Virginia Tech within 10&#160;days of the
    effective date of the agreement, and we are obligated to make
    royalty payments equal to varying low, single-digit percentages
    of net sales of licensed products by Protalix Ltd., its
    subsidiaries
    <FONT style="white-space: nowrap">and/or</FONT> their
    affiliates. Upon commercialization of a licensed product, the
    royalty payment is subject to a low, annual minimum amount. In
    addition, we are obligated to make milestone payments equal to
    $150,000, in aggregate, upon the achievement of certain
    milestones. We have the right to grant sublicenses under the
    agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our license agreement with Virginia Tech remains in effect until
    the earlier of the expiration of the last patent under the
    agreement or 10&#160;years after the first commercial sale of
    any licensed product. Virginia Tech may terminate the agreement
    upon written notice to us that we are in material breach of our
    obligations under the agreement if we are unable to remedy such
    material breach within a fixed number of days after we receive
    such notice, which number may be doubled if we are making good
    faith efforts to achieve a cure and the extension will not
    increase the damages suffered by Virginia Tech. We have the
    right to terminate the agreement at any time upon prior written
    notice delivered an
    <FONT style="white-space: nowrap">agreed-upon</FONT>
    number of days prior to the date of termination.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Manufacturing</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are obligated to manufacture all of the taliglucerase alfa
    drug product needed under the Pfizer agreement, subject to
    certain terms and conditions. Our drug product candidates,
    including taliglucerase alfa, must be manufactured in a sterile
    environment and in compliance with cGMPs set by the FDA and
    other relevant foreign regulatory authorities. We use our
    current facility, which has approximately 20,000 sq/ft of clean
    rooms built according to industry standards, to develop, process
    and manufacture taliglucerase alfa and other recombinant
    proteins. We believe that the manufacturing space complies with
    the good laboratory, clinical and manufacturing practices
    required by the FDA and other comparable regulatory authorities
    for production of pharmaceutical products on a commercial scale.
    We intend to use our current manufacturing space to produce all
    of the taliglucerase alfa we need in the near future, included
    the taliglucerase alfa to be purchased by Pfizer. Current
    capacity of our facility can serve approximately 20% of the
    Gaucher disease patients that are currently under treatment. We
    intend to expand our current facility in order to reach a
    capacity of approximately 50% of the Gaucher disease patients
    that are currently under treatment and to house the laboratory
    space necessary for further development of other product
    candidates in our pipeline. Total expected cost for such
    expansion is currently estimated to be approximately
    $25&#160;million and the process is expected to be completed
    during 2012.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have entered into a contract with Teva pursuant to which Teva
    is required to perform the final filling and freeze drying steps
    for taliglucerase alfa. In addition, we have engaged a contract
    manufacturer in Europe to act as an additional source of fill
    and finish activities for taliglucerase alfa. According to our
    agreement with Pfizer, Pfizer will be responsible for the fill
    and finish activities for taliglucerase alfa. We have the right
    to terminate the agreement at any time upon written notice of a
    fixed number of days.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our current facility in Israel has been granted &#147;Approved
    Enterprise&#148; status, and we have elected to participate in
    the alternative benefits program. Our facility is located in a
    Zone A location, and, therefore, our income from the Approved
    Enterprise will be tax exempt in Israel for a period of
    10&#160;years commencing with the year in which we first
    generate taxable income from the relevant Approved Enterprise.
    We currently anticipate that the benefits of this program will
    be available to Protalix Ltd. until 2017 and, accordingly, we
    expect to be entitled to similar tax benefits for a number of
    years thereafter. To remain eligible for these tax benefits, we
    must continue to meet certain conditions, and if we increase our
    activities outside of Israel, for
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    example, by future acquisitions, such increased activities
    generally may not be eligible for inclusion in Israeli tax
    benefit programs. In addition, our technology is subject to
    certain restrictions with respect to the transfer of technology
    and manufacturing rights. &#147;See Risk Factors&#160;&#151; The
    manufacture of our products is an exacting and complex process,
    and if we or one of our materials suppliers encounter problems
    manufacturing our products, it will have a material adverse
    effect on our business and results of operations.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Raw
    Materials and Suppliers</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We believe that the raw materials that we require throughout the
    manufacturing process of our current and potential drug product
    candidates are widely available from numerous suppliers and are
    generally considered to be generic industrial biological
    supplies. We rely on a single approved supplier for certain
    materials relating to the current expression of our proprietary
    biotherapeutic proteins through ProCellEx. We are currently in
    the process of identifying additional suppliers that can provide
    the same materials.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Development and regulatory approval of our pharmaceutical
    products are dependent upon our ability to procure active
    ingredients and certain packaging materials from sources
    approved by the FDA and other regulatory authorities. Since the
    FDA and other regulatory approval processes require
    manufacturers to specify their proposed suppliers of active
    ingredients and certain packaging materials in their
    applications, FDA approval of a supplemental application to use
    a new supplier in connection with any drug candidate or approved
    product, if any, would be required if active ingredients or such
    packaging materials were no longer available from the specified
    supplier, which could result in manufacturing delays. From time
    to time, we intend to continue to identify alternative
    FDA-approved suppliers to ensure the continued supply of
    necessary raw materials.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Competition</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The biotechnology and pharmaceutical industries are
    characterized by rapidly evolving technology and significant
    competition. Competition from numerous existing companies and
    others entering the fields in which we operate is intense and
    expected to increase. Most of these companies have substantially
    greater research and development, manufacturing, marketing,
    financial, technological personnel and managerial resources than
    we do. In addition, many specialized biotechnology companies
    have formed collaborations with large, established companies to
    support research, development and commercialization of products
    that may be competitive with our current and future product
    candidates and technologies. Acquisitions of competing companies
    by large pharmaceutical or biotechnology companies could further
    enhance such competitors&#146; financial, marketing and other
    resources. Academic institutions, governmental agencies and
    other public and private research organizations are also
    conducting research activities and seeking patent protection and
    may commercialize competitive products or technologies on their
    own or through collaborations with pharmaceutical and
    biotechnology companies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We specifically face competition from companies with approved
    treatments of Gaucher disease, including Genzyme, which recently
    announced a proposed merger into Sanofi Aventis, and to a much
    lesser extent, Actelion. In February 2010, the FDA approved
    VPRIV, Shire&#146;s enzyme replacement therapy for the treatment
    of Gaucher disease and the European Commission granted marketing
    authorization to VPRIV in August 2010. In addition, we are aware
    of other early clinical stage, experimental, small molecule,
    oral drugs which are being developed for the treatment of
    Gaucher disease by Genzyme and Amicus Therapeutics, which
    according to public filings by Amicus Therapeutics has been
    suspended. We also face competition from companies with approved
    enzyme treatments of Fabry disease, including Genzyme and Shire,
    and we are aware of other early stage drugs which are being
    developed for the treatment of Fabry disease, including a drug
    being developed by Amicus Therapeutics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We also face competition from companies that are developing
    other platforms for the expression of recombinant therapeutic
    pharmaceuticals. We are aware of companies that are developing
    alternative technologies to develop and produce therapeutic
    proteins in anticipation of the expiration of certain patent
    claims covering marketed proteins. Competitors developing
    alternative expression technologies include Crucell N.V. (which
    was acquired by Johnson&#160;&#038; Johnson during 2010), Shire
    and GlycoFi, Inc. (which was acquired by
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Merck&#160;&#038; Co. Inc.). Other companies are developing
    alternate plant-based technologies, include Biolex, Inc.,
    Chlorogen, Inc., Greenovation Biotech GmbH, and Symbiosys, none
    of which are cell-based. Rather, such companies base their
    product development on transgenic plants or whole plants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Several biogeneric companies are pursuing the opportunity to
    develop and commercialize follow-on versions of other currently
    marketed biologic products, including growth factors, hormones,
    enzymes, cytokines and monoclonal antibodies, which are areas
    that interest us. These companies include, among others,
    Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada
    Arzneimittel AG, BioPartners GmbH and Teva.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Key differentiating elements affecting the success of our
    product candidates are likely to be their potency and efficacy
    profiles, as well as their cost-effectiveness as compared to
    other existing therapies. See &#147;Risk Factors&#160;&#151;
    Developments by competitors may render our products or
    technologies obsolete or non-competitive which would have a
    material adverse effect on our business and results of
    operations.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Scientific
    Advisory Board</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Members of our scientific advisory board, who are experts in the
    fields of plant molecular and cell biology as well as Gaucher
    disease and various hematological and genetic disorders, consult
    with our management within their professional areas of
    expertise; exchange strategic and business development ideas
    with our management; attend scientific, medical and business
    meetings with our management, such as meetings with the FDA and
    comparable foreign regulatory authorities, meetings with
    strategic or potential strategic partners and other meetings
    relevant to their areas of expertise; and attend meetings of our
    scientific advisory board. We expect our scientific advisory
    board to convene at least twice annually, and we frequently
    consult with the individual members of our Scientific Advisory
    Board. Our scientific advisory board currently includes the
    following people:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="48%">&nbsp;</TD> <!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Affiliation</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Professor Aaron Ciechanover,&#160;M.D., D.Sc.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Laureate of the Nobel Prize in Chemistry
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Distinguished research Professor at the Cancer and Vascular
    Biology Research Center of the Rappaport Research Institute and
    Faculty of Medicine at the Technion
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    American Academy of Arts and Sciences, Member
</TD>
</TR>



<tr><td>&nbsp;</td></tr>

<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Professor Gad Galili,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Former Chairman of the Department of Plant
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Sciences, The Weizmann Institute of Science,
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Rehovot, Israel
</TD>
</TR>


<tr><td>&nbsp;</td></tr>


<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Professor Ari Zimran,&#160;M.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Director of the Gaucher Clinic, Shaare Zedek Medical Center,
    Jerusalem, Israel
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Associate Professor of Medicine, Hebrew University-Hadassah
    Medical School, Jerusalem, Israel
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Government
    Regulation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The testing, manufacture, distribution, advertising and
    marketing of drug products are subject to extensive regulation
    by federal, state and local governmental authorities in the
    United States, including the FDA, and by similar authorities in
    other countries. Any product that we develop must receive all
    relevant regulatory approvals or clearances, as the case may be,
    before it may be marketed in a particular country.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The regulatory process, which includes overseeing preclinical
    studies and clinical trials of each pharmaceutical compound to
    establish its safety and efficacy and confirmation by the FDA
    that good laboratory, clinical and manufacturing practices were
    maintained during testing and manufacturing, can take many
    years, requires the expenditure of substantial resources and
    gives larger companies with greater financial resources a
    competitive advantage over us. Delays or terminations of
    clinical trials that we undertake would likely impair
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    our development of product candidates. Delays or terminations
    could result from a number of factors, including stringent
    enrollment criteria, slow rate of enrollment, size of patient
    population, having to compete with other clinical trials for
    eligible patients, geographical considerations and others.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The FDA review process can be lengthy and unpredictable, and we
    may encounter delays or rejections of our applications when
    submitted. Generally, in order to gain FDA approval, we must
    first conduct preclinical studies in a laboratory and in animal
    models to obtain preliminary information on a compound and to
    identify any potential safety problems. The results of these
    studies are submitted as part of an IND application that the FDA
    must review before human clinical trials of an investigational
    drug can commence. Clinical trials may be terminated by the
    clinical trial site, sponsor or the FDA if toxicities appear
    that are either worse than expected or unexpected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Clinical trials are normally performed in three sequential
    phases and generally take two to five years, or longer, to
    complete. Phase I consists of testing the drug product in a
    small number of humans, normally healthy volunteers, to
    determine preliminary safety and tolerable dose range.
    Phase&#160;II usually involves studies in a limited patient
    population to evaluate the effectiveness of the drug product in
    humans having the disease or medical condition for which the
    product is indicated, determine dosage tolerance and optimal
    dosage and identify possible common adverse effects and safety
    risks. Phase&#160;III consists of additional controlled testing
    at multiple clinical sites to establish clinical safety and
    effectiveness in an expanded patient population of
    geographically dispersed test sites to evaluate the overall
    benefit-risk relationship for administering the product and to
    provide an adequate basis for product labeling. Phase&#160;IV
    clinical trials may be conducted after approval to gain
    additional experience from the treatment of patients in the
    intended therapeutic indication.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    After completion of clinical trials of a new drug product, FDA
    and foreign regulatory authority marketing approval must be
    obtained. Assuming that the clinical data support the
    product&#146;s safety and effectiveness for its intended use, a
    New Drug Application (NDA) is submitted to the FDA for its
    review. Generally, it takes one to three years to obtain
    approval. If questions arise during the FDA review process,
    approval may take a significantly longer period of time. The
    testing and approval processes require substantial time and
    effort and approval on a timely basis, if at all, or the
    approval that we receive may be for a narrower indication than
    we had originally sought, potentially undermining the commercial
    viability of the product. Even if regulatory approvals are
    obtained, approved products are subject to continual review and
    holders of an approved product are required, for example, to
    report certain adverse reactions and production problems, if
    any, to the FDA, and to comply with certain requirements
    concerning advertising and promotional labeling for the product.
    Also, quality control and manufacturing procedures relating to a
    product must continue to conform to cGMP after approval, and the
    FDA periodically inspects manufacturing facilities to assess
    compliance with cGMP. Accordingly, manufacturers must continue
    to expend time, money and effort in the area of production and
    quality control to comply with cGMP and other aspects of
    regulatory compliance. The later discovery of previously unknown
    problems or failure to comply with the applicable regulatory
    requirements with respect to any product may result in
    restrictions on the marketing of the product or withdrawal of
    the product from the market as well as possible civil or
    criminal sanctions. See also &#147;&#151;&#160;International
    Regulation.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the Orphan Drug Act of 1983, the FDA may grant orphan drug
    designation to drugs and biological products intended to treat a
    rare disease or condition, which is generally a disease or
    condition that affects fewer than 200,000 individuals in the
    United States. In September 2009, we received orphan drug
    designation for taliglucerase alfa for the treatment of Gaucher
    disease. The FDA grants orphan drug designation to drugs that
    may provide a significant therapeutic advantage over existing
    treatments and target conditions affecting 200,000 or fewer
    U.S.&#160;patients per year. Orphan drug designation does not
    convey any advantage in or shorten the duration of the
    regulatory review and approval process. Among the other benefits
    of orphan drug designation are possible funding and tax savings
    to support clinical trials and for other financial incentives
    and a waiver of the marketing application user fee and most
    likely priority review. If a significant therapeutic advantage
    over existing treatments is shown in the marketing application,
    FDA may grant orphan drug approval and provide a seven-year
    period of marketing exclusivity.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The FDA has a fast track program that is intended to expedite or
    facilitate the process for reviewing new drugs and biological
    products that meet certain criteria. Specifically, new drugs and
    biological products are
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    eligible for fast track designation if they are intended to
    treat a serious or life-threatening condition and demonstrate
    the potential to address unmet medical needs for the condition.
    Fast track designation applies to the combination of the product
    and the specific indication for which it is being studied. For a
    fast track product, the FDA may consider for review on a rolling
    basis sections of the NDA before the complete application is
    submitted, if the sponsor provides a schedule for the submission
    of the sections of the NDA, the FDA agrees to accept sections of
    the NDA as they become available and determines that the
    schedule is acceptable, and the sponsor pays any required user
    fees upon submission of the first section of the NDA. We used
    the rolling submission option for our NDA for our lead product
    candidate, taliglucerase alfa, which we completed in April 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    None of our products under development has been approved for
    marketing in the United States or elsewhere. We may not be able
    to obtain regulatory approval for any of our products under
    development in a timely manner, if at all. Failure to obtain
    requisite governmental approvals or failure to obtain approvals
    of the scope requested will delay or preclude us, or our
    licensees or marketing partners, from marketing our products, or
    limit the commercial use of our products, and thereby would have
    a material adverse effect on our business, financial condition
    and results of operations. See &#147;Risk Factors&#160;&#151; We
    may not obtain the necessary U.S.&#160;or worldwide regulatory
    approvals to commercialize our drug candidates in a timely
    manner, if at all, which would have a material adverse effect on
    our business and results of operations.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The United States federal government regulates healthcare
    through various agencies, including but not limited to the
    following: (i)&#160;the FDA, which administers the Federal Food,
    Drug, and Cosmetic Act (FDCA), as well as other relevant laws;
    (ii)&#160;the Center for Medicare&#160;&#038; Medicaid Services
    (CMS), which administers the Medicare and Medicaid programs;
    (iii)&#160;the Office of Inspector General (OIG) which enforces
    various laws aimed at curtailing fraudulent or abusive
    practices, including by way of example, the Anti-Kickback Law,
    the Anti-Physician Referral Law, commonly referred to as Stark,
    the Anti-Inducement Law, the Civil Money Penalty Law and the
    laws that authorize the OIG to exclude healthcare providers and
    others from participating in federal healthcare programs; and
    (iv)&#160;the Office of Civil Rights, which administers the
    privacy aspects of the Health Insurance Portability and
    Accountability Act of 1996 (HIPAA). All of the aforementioned
    are agencies within the Department of Health and Human Services
    (HHS). Healthcare is also provided or regulated, as the case may
    be, by the Department of Defense through its TriCare program,
    the Department of Veterans Affairs, especially through the
    Veterans Health Care Act of 1992, the Public Health Service
    within HHS under Public Health Service Act &#167;&#160;340B
    (42&#160;U.S.C. &#167;&#160;256b), the Department of Justice
    through the Federal False Claims Act and various criminal
    statutes, and state governments under the Medicaid and other
    state sponsored or funded programs and their internal laws
    regulating all healthcare activities. Many states also have
    anti-kickback and anti-physician referral laws that are similar
    to the federal laws, but may be applicable in situations where
    federal laws do not apply.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Medicare is the federal healthcare program for those who are
    (i)&#160;over 65&#160;years of age, (ii)&#160;disabled,
    (iii)&#160;suffering from end-stage renal disease or
    (iv)&#160;suffering from Lou Gehrig&#146;s disease. Medicare
    consists of part&#160;A, which covers inpatient costs,
    part&#160;B, which covers services by physicians and
    laboratories, durable medical equipment and certain drugs,
    primarily those administered by physicians, and part&#160;D,
    which provides drug coverage for most prescription drugs other
    than those covered under part&#160;B. Medicare also offers a
    managed care option under part&#160;C. Medicare is administered
    by CMS. In contrast, Medicaid is a state-federal healthcare
    program for the poor and is administered by the states pursuant
    to an agreement with the Secretary of Health and Human Services.
    Most state Medicaid programs cover most outpatient prescription
    drugs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">International
    Regulation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are subject to regulations and product registration
    requirements in many foreign countries in which we may sell our
    products, including in the areas of product standards, packaging
    requirements, labeling requirements, import and export
    restrictions and tariff regulations, duties and tax
    requirements. The time required to obtain clearance required by
    foreign countries may be longer or shorter than that required
    for FDA clearance, and requirements for licensing a product in a
    foreign country may differ significantly from FDA requirements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    28
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Pharmaceutical products may not be imported into, or
    manufactured or marketed in, the State of Israel absent drug
    registration. The three basic criteria for the registration of
    pharmaceuticals in Israel is quality, safety and efficacy of the
    pharmaceutical product and the Israeli MOH requires
    pharmaceutical companies to conform to international
    developments and standards. Regulatory requirements are
    constantly changing in accordance with scientific advances as
    well as social and ethical values.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The relevant legislation of the European Union requires that
    medicinal products, including generic versions of previously
    approved products, and new strengths, dosage forms and
    formulations, of previously approved products, shall have a
    marketing authorization before they are placed on the market in
    the European Union. Authorizations are granted after the
    assessment of quality, safety and efficacy by the respective
    health authorities. In order to obtain an authorization, an
    application must be made to the competent authority of the
    member state concerned or in a centralized procedure to the
    EMEA. Besides various formal requirements, the application must
    contain the results of pharmaceutical (physico-chemical,
    biological or microbiological) tests, of preclinical
    (toxicological and pharmacological) tests as well as of clinical
    trials. All of these tests must have been conducted in
    accordance with relevant European Union regulations and must
    allow the reviewer to evaluate the quality, safety and efficacy
    of the medicinal product. On January 2010, the Committee for
    Orphan Medicinal Products (COMP) of the EMEA recommended that
    the European Commission grant orphan drug designation to
    taliglucerase alfa. Orphan drug designation in the European
    Union is granted to medicinal products intended for the
    diagnosis, prevention and treatment of life-threatening diseases
    and very serious conditions that affect not more than five in
    10,000&#160;people in the European Union. Orphan drug
    designation is generally given to medicinal products that treat
    conditions for which no current therapy exists or are expected
    to bring a significant benefit to patients over existing
    therapies. If granted by the European Commission, orphan drug
    designation will provide us a centralized procedure for
    obtaining marketing authorization for taliglucerase alfa, with a
    single marketing authorization valid throughout all EU Member
    States. We may also be eligible for a number of additional
    incentives including protocol assistance, reduction in
    registration fees and eligibility for grants and initiatives
    supporting research and development related to the orphan drug
    designation.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Israeli
    Government Programs</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following is a summary of the current principal Israeli tax
    laws applicable to us and Protalix Ltd., and of the Israeli
    Government programs from which Protalix Ltd. benefits. Some
    parts of this discussion are based on new tax legislation that
    has not been subject to judicial or administrative
    interpretation. Therefore, the views expressed in the discussion
    may not be accepted by the tax authorities in question. The
    discussion should not be construed as legal or professional tax
    advice and does not cover all possible tax considerations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">General
    Corporate Tax Structure in Israel</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Generally, Israeli companies are subject to corporate tax at the
    rate of 25% on taxable income and are subject to real capital
    gains tax at a rate of 25% on capital gains (other than gains
    derived from the sale of listed securities that are taxed at the
    prevailing corporate tax rates) derived after January&#160;1,
    2003. The corporate tax rate was reduced in June 2004, from 36%
    to 35% for the 2004 tax year, 34% for the 2005 tax year, 31% for
    the 2006 tax year, 29% for the 2007 tax year, 27% for the 2008
    tax year, 26% for the 2009 tax year and 25% for the 2010 tax
    year and thereafter. Additional, gradual corporate tax
    reductions were adopted in 2008, as follows: 24% for the 2011
    tax year; 23% for the 2012 tax year; 22% for the 2013 tax year;
    21% for the 2014 tax year; 20% for the 2015 tax year; and 18%
    thereafter. As discussed below, the corporate tax rate may be
    less for income derived from an Approved Enterprise. In addition
    to the corporate taxes in Israel, we are subject to a
    withholding tax on the U.S.&#160;revenue source portion of the
    payments made to us for our share of Pfizer&#146;s net profits
    under the Pfizer agreement. The withholding tax rate is 15%. See
    &#147;Business&#160;&#151; Commercialization Agreement.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Law for
    the Encouragement of Capital Investments, 1959</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Law for the Encouragement of Capital Investments, 1959,
    known as the Investment Law, provides certain incentives for
    capital investments in a production facility (or other eligible
    assets). Generally, an
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    29
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    investment program that is implemented in accordance with the
    provisions of the Investment Law, referred to as an
    &#147;Approved Enterprise,&#148; is entitled to benefits. These
    benefits may include cash grants from the Israeli government and
    tax benefits, based upon, among other things, the location of
    the facility in which the investment is made and specific
    elections made by the grantee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Investment Law was significantly amended effective in April
    2005. Protalix Ltd. will continue to enjoy the tax benefits
    under the pre-revision provisions of the Investment Law. If any
    new benefits are granted to Protalix Ltd. in the future,
    Protalix Ltd. will be subject to the provisions of the amended
    Investment Law with respect to these new benefits. Therefore,
    the following discussion is a summary of the Investment Law
    prior to its amendment as well as the relevant changes contained
    in the new legislation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the Investment Law prior to its amendment, a company that
    wished to receive benefits had to receive approval from the
    &#147;Investment Center&#148; of the Israeli Ministry of
    Industry, Trade and Labor, or the Investment Center. Each
    certificate of approval for an Approved Enterprise relates to a
    specific investment program in the Approved Enterprise,
    delineated both by the financial scope of the investment and by
    the physical characteristics of the facility or the asset, e.g.,
    the equipment to be purchased and utilized pursuant to the
    program.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    An Approved Enterprise may elect to forego any entitlement to
    the grants otherwise available under the Investment Law and,
    instead, participate in an alternative benefits program under
    which the undistributed income from the Approved Enterprise is
    fully exempt from corporate tax for a defined period of time.
    Under the alternative package of benefits, a company&#146;s
    undistributed income derived from an Approved Enterprise will be
    exempt from corporate tax for a period of between two and
    10&#160;years from the first year of taxable income, depending
    upon the geographic location within Israel of the Approved
    Enterprise. Upon expiration of the exemption period, the
    Approved Enterprise is eligible for the reduced tax rates
    otherwise applicable under the Investment Law for any remainder
    of the otherwise applicable benefits period (up to an aggregate
    benefits period of either seven or 10&#160;years, depending on
    the location of the company or its definition as a foreign
    investors&#146; company). If a company has more than one
    Approved Enterprise program or if only a portion of its capital
    investments are approved, its effective tax rate is the result
    of a weighted combination of the applicable rates. The tax
    benefits from any certificate of approval relate only to taxable
    profits attributable to the specific Approved Enterprise. Income
    from activity that is derived from different Approved
    Enterprises does not enjoy these tax benefits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A company that has an Approved Enterprise program is eligible
    for further tax benefits if it qualifies as a foreign
    investors&#146; company. A foreign investors&#146; company
    eligible for benefits is essentially a company in which more
    than 25% of the share capital (in terms of shares, rights to
    profit, voting and appointment of directors) is owned (measured
    by both share capital and combined share and loan capital) by
    non-Israeli residents. A company that qualifies as a foreign
    investors&#146; company and has an Approved Enterprise program
    is eligible for tax benefits for a
    <FONT style="white-space: nowrap">10-year</FONT>
    benefit period and may enjoy a reduced corporate tax rate of 10%
    to 25%, depending on the amount of the company&#146;s shares
    held by non-Israeli shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If a company that has an Approved Enterprise program is a wholly
    owned subsidiary of another company, then the percentage of
    foreign investments is determined based on the percentage of
    foreign investment in the parent company. The tax rates and
    related levels of foreign investments are set forth in the
    following table:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="88%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Rate of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Percent of Foreign Ownership</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Reduced Tax</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    &#160;0-&#160;49%
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    25
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="white-space: nowrap">49-&#160;74%</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="white-space: nowrap">74-&#160;90%</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <FONT style="white-space: nowrap">90-100%</FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our original facility in Israel has been granted &#147;Approved
    Enterprise&#148; status, and it has elected to participate in
    the alternative benefits program. Under the terms of its
    Approved Enterprise program, the facility is located in a top
    priority location, or &#147;Zone A,&#148; and, therefore, the
    income from that Approved Enterprise will be tax exempt in
    Israel for a period of 10&#160;years, commencing with the year
    in which taxable income is
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    30
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>


<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    first generated from the relevant Approved Enterprise. The
    current benefits program may not continue to be available and
    Protalix Ltd. may not continue to qualify for its benefits.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A company that has elected to participate in the alternative
    benefits program and that subsequently pays a dividend out of
    the income derived from the Approved Enterprise during the tax
    exemption period will be subject to corporate tax in respect of
    the amount distributed at the rate that would have been
    applicable had the company not elected the alternative benefits
    program (generally 10% to 25%, depending on the extent to which
    non-Israeli shareholders hold such company&#146;s shares). If
    the dividend is distributed within 12&#160;years after the
    commencement of the benefits period (or, in the case of a
    foreign investor&#146;s company, without time limitation), the
    dividend recipient is taxed at the reduced withholding tax rate
    of 15% applicable to dividends from approved enterprises, or at
    the lower rate under an applicable tax treaty. After this
    period, the withholding tax rate is 25%, or at the lower rate
    under an applicable tax treaty. In the case of a company with a
    foreign investment level (as defined by the Investment Law) of
    25% or more, the
    <FONT style="white-space: nowrap">12-year</FONT>
    limitation on reduced withholding tax on dividends does not
    apply. The company must withhold this tax at its source,
    regardless of whether the dividend is converted into foreign
    currency.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Investment Law also provides that an Approved Enterprise is
    entitled to accelerated depreciation on its property and
    equipment that are included in an approved investment program.
    This benefit is an incentive granted by the Israeli government
    regardless of whether the alternative benefits program is
    elected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The benefits available to an Approved Enterprise are conditioned
    upon terms stipulated in the Investment Law and regulations and
    the criteria set forth in the applicable certificate of
    approval. If Protalix Ltd. does not fulfill these conditions in
    whole or in part, the benefits can be canceled and Protalix Ltd.
    may be required to refund the received benefits, linked to the
    Israeli consumer price index with the addition of interest or
    alternatively with an additional penalty payment. We believe
    that Protalix Ltd. currently operates in compliance with all
    applicable conditions and criteria, but there can be no
    assurance that Protalix Ltd. will continue to do so.
    Furthermore, there can be no assurance that any Approved
    Enterprise status granted to Protalix Ltd.&#146;s facilities
    will entitle Protalix Ltd. to the same benefits to which it is
    currently entitled.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Pursuant to the March 2005 amendment to the Investment Law, the
    approval of the Investment Center is required only for Approved
    Enterprises that receive cash grants. Approved Enterprises that
    do not receive benefits in the form of governmental cash grants,
    but only tax benefits, are no longer required to obtain this
    approval. Instead, these Approved Enterprises are required to
    make certain investments as specified in the Investment Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The amended Investment Law specifies certain conditions for an
    Approved Enterprise to be entitled to benefits. These conditions
    include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the Approved Enterprise&#146;s revenues from any single country
    or a separate customs territory may not exceed 75% of the
    Approved Enterprise&#146;s total revenues;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at least 25% of the Approved Enterprise&#146;s revenues during
    the benefits period must be derived from sales into a single
    country or a separate customs territory with a population of at
    least 12&#160;million.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    There can be no assurance that Protalix Ltd. will comply with
    the above conditions in the future or that Protalix Ltd. will be
    entitled to any additional benefits under the Investment Law. In
    addition, it is possible that Protalix Ltd. may not be able to
    operate in a way that maximizes utilization of the benefits
    under the Investment Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    From time to time, the Israeli Government has discussed reducing
    the benefits available to companies under the Investment Law.
    The termination or substantial reduction of any of the benefits
    available under the Investment Law could materially impact the
    cost of our future investments.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Encouragement
    of Industrial Research and Development Law, 1984</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the past, Protalix Ltd. received grants from the Office of
    the Chief Scientist of the Israeli Ministry of Industry, Trade
    and Labor, the OCS, for the financing of a portion of its
    research and development expenditures in Israel. As of
    December&#160;31, 2010, the OCS approved grants in respect of
    Protalix Ltd.&#146;s
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    31
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    continuing operations totaling approximately $21.5&#160;million,
    measured from inception. Protalix Ltd. is required to repay up
    to 100% of grants actually received (plus interest at the LIBOR
    rate applied to the grants received on or after January&#160;1,
    1999)&#160;to the OCS through payments of royalties at a rate of
    3% to 6% of the revenues generated from an OCS-funded project,
    depending on the period in which revenues were generated. As of
    December&#160;31, 2010, Protalix Ltd. either paid or accrued
    royalties payable of $2.7&#160;million and Protalix Ltd.&#146;s
    contingent liability to the OCS with respect to grants received
    was approximately $17.2&#160;million,
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the Israeli Law for the Encouragement of Industrial
    Research and Development, 1984 and related regulations, the
    Research Law, recipients of grants from the OCS are prohibited
    from manufacturing products developed using these grants outside
    of the State of Israel without special approvals, although the
    Research Law does enable companies to seek prior approval for
    conducting manufacturing activities outside of Israel without
    being subject to increased royalties. If Protalix Ltd. receives
    approval to manufacture the products developed with government
    grants outside of Israel, it will be required to pay an
    increased total amount of royalties (possibly up to 300% of the
    grant amounts plus interest), depending on the manufacturing
    volume that is performed outside of Israel, as well as at a
    possibly increased royalty rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Additionally, under the Research Law, Protalix Ltd. is
    prohibited from transferring the OCS financed technologies and
    related intellectual property rights outside of the State of
    Israel except under limited circumstances and only with the
    approval of the Research Committee of the OCS. Protalix Ltd. may
    not receive the required approvals for any proposed transfer
    and, if received, Protalix Ltd. may be required to pay the OCS a
    portion of the consideration that it receives upon any sale of
    such technology by a non-Israeli entity. The scope of the
    support received, the royalties that Protalix Ltd. has already
    paid to the OCS, the amount of time that has elapsed between the
    date on which the know-how was transferred and the date on which
    the OCS grants were received and the sale price and the form of
    transaction will be taken into account in order to calculate the
    amount of the payment to the OCS. Approval of the transfer of
    technology to residents of the State of Israel is required, and
    may be granted in specific circumstances only if the recipient
    abides by the provisions of applicable laws, including the
    restrictions on the transfer of know-how and the obligation to
    pay royalties. No assurance can be made that approval to any
    such transfer, if requested, will be granted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In March 2005, an amendment to the Research Law was enacted. One
    of the main modifications included in the amendment was an
    authorization of the Research Committee to allow the transfer
    outside of Israel of know-how derived from an approved program
    and the related manufacturing rights. In general, the Research
    Committee may approve transfer of know-how in limited
    circumstances as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in the event of a sale of the know-how itself to a non
    affiliated third party, provided that upon such sale the owner
    of the know-how pays to the OCS an amount, in cash, as set forth
    in the Research Law. In addition, the amendment provides that if
    the purchaser of the know-how gives the selling Israeli company
    the right to exploit the know-how by way of an exclusive,
    irrevocable and unlimited license, the research committee may
    approve such transfer in special cases without requiring a cash
    payment.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in the event of a sale of the company which is the owner of
    know-how, pursuant to which the company ceases to be an Israeli
    company, provided that upon such sale, the owner of the know-how
    makes a cash payment to the OCS as set forth in the Research Law.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    in the event of an exchange of know-how such that in exchange
    for the transfer of know-how outside of Israel, the recipient of
    the know-how transfers other know-how to the company in Israel
    in a manner in which the OCS is convinced that the Israeli
    economy realizes a greater, overall benefit from the exchange of
    know-how.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Another provision in the amendment concerns the transfer of
    manufacturing rights. The research committee may, in special
    cases, approve the transfer of manufacture or of manufacturing
    rights of a product developed within the framework of the
    approved program or which results therefrom, outside of Israel.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The State of Israel does not own intellectual property rights in
    technology developed with OCS funding and there is no
    restriction on the export of products manufactured using
    technology developed with OCS funding. The technology is,
    however, subject to transfer of technology and manufacturing
    rights restrictions as
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    32
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    described above. For a description of such restrictions, please
    see &#147;Risk Factors&#160;&#151; Risks Relating to Our
    Operations in Israel.&#148; OCS approval is not required for the
    export of any products resulting from the research or
    development or for the licensing of any technology in the
    ordinary course of business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Special
    Provisions Relating to Taxation under Inflationary
    Conditions</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Protalix Ltd. is taxed in Israel under the Income Tax Law
    (Inflationary Adjustments), 1985, generally referred to as the
    Inflationary Adjustments Law. The Inflationary Adjustments Law
    is highly complex, and represents an attempt to overcome the
    problems presented to a traditional tax system by an economy
    undergoing rapid inflation. The provisions that are material to
    us are summarized below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Where a company&#146;s equity, as calculated under the
    Inflationary Adjustments Law, exceeds the depreciated cost of
    its fixed assets (as defined in the Inflationary Adjustments
    Law), a deduction from taxable income is permitted equal to this
    excess multiplied by the applicable annual rate of inflation.
    The maximum deduction permitted under this provision in any
    single tax year is 70% of taxable income. The unused portion
    linked to the Israeli consumer price index, may be carried
    forward.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Where a company&#146;s depreciated cost of fixed assets exceeds
    its equity, the excess multiplied by the applicable annual rate
    of inflation is added to taxable income.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Subject to specified limitations, depreciation deductions
    carryforwards on fixed assets and losses are adjusted for
    inflation based on the change in the consumer price index.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the Inflationary Adjustments Law, results for tax purposes
    are measured in real terms, in accordance with changes in the
    Israeli consumer price index. The difference between the change
    in the Israeli consumer price index and the exchange rate of
    Israeli currency in relation to the U.S.&#160;dollar may in
    future periods cause significant differences between taxable
    income and the income measured in dollars as reflected in our
    consolidated financial statements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Law for
    the Encouragement of Industry (Taxes), 1969</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We believe that Protalix Ltd. currently qualifies as an
    &#147;Industrial Company&#148; within the meaning of the Law for
    the Encouragement of Industry (Taxes), 1969, or the Industry
    Encouragement Law. The Industry Encouragement Law defines
    &#147;Industrial Company&#148; as a company resident in Israel
    that derives 90% or more of its income in any tax year (other
    than specified kinds of passive income such as capital gains,
    interest and dividends) from an &#147;Industrial
    Enterprise&#148; that it owns. An &#147;Industrial
    Enterprise&#148; is defined as an enterprise whose major
    activity in a given tax year is industrial production.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following corporate tax benefits, among others, are
    available to Industrial Companies:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    amortization of the cost of purchased know-how and patents over
    an eight-year period for tax purposes;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    accelerated depreciation rates on equipment and buildings;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    under specified conditions, an election to file consolidated tax
    returns with other related Israeli Industrial Companies;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    expenses related to a public offering are deductible in equal
    amounts over three years.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Eligibility for the benefits under the Industry Encouragement
    Law is not subject to receipt of prior approval from any
    governmental authority. It is possible that Protalix Ltd. may
    fail to qualify or may not continue to qualify as an
    &#147;Industrial Company&#148; or that the benefits described
    above will not be available in the future.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Tax
    Benefits for Research and Development</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under specified conditions, Israeli tax laws allow a tax
    deduction by a company for research and development
    expenditures, including capital expenditures, for the year in
    which such expenditures are incurred. These expenditures must
    relate to scientific research and development projects and must
    be approved by the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    33
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    OCS. Furthermore, the research and development projects must be
    for the promotion of the company and carried out by or on behalf
    of the company seeking such tax deduction. However, the amount
    of such deductible expenditures is reduced by the sum of any
    funds received through government grants for the finance of such
    scientific research and development projects. Expenditures not
    so approved are deductible over a three-year period.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Employees</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As of December&#160;31, 2010, we had 240&#160;employees, of who
    35 have an M.D. or a Ph.D. in their respective scientific
    fields. We believe that our relations with these employees are
    good. We intend to continue to hire additional employees in
    research and development, manufacturing and administration in
    order to meet our operating plans. We believe that our success
    will greatly depend on our ability to identify, attract and
    retain capable employees. The Israeli Ministry of Labor and
    Welfare is authorized to make certain industry-wide collective
    bargaining agreements that apply to types of industries or
    employees including ours (&#147;Expansion Orders&#148;). These
    agreements affect matters such as cost of living adjustments to
    salaries, length of working hours and week, recuperation, travel
    expenses, and pension rights. Otherwise, our employees are not
    represented by a labor union or represented under a collective
    bargaining agreement. See &#147;Risk Factors&#160;&#151; We
    depend upon key employees and consultants in a competitive
    market for skilled personnel. If we are unable to attract and
    retain key personnel, it could adversely affect our ability to
    develop and market our products.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Company
    Background</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our principal business address is set forth below. Our executive
    offices and our main research manufacturing facility are located
    at that address. Our telephone number is +972-4-988-9488. From
    May 2001 through December&#160;31, 2006, our company had no
    operations. We were originally formed as Embassy Acquisition
    Corp., a Florida corporation, in November 2005 and changed our
    name to Orthodontix, Inc., in April, 1992. On December&#160;31,
    2006, we acquired, through a merger with our wholly-owned
    subsidiary, Protalix Acquisition Co. Ltd., all of the
    outstanding shares of Protalix Ltd., in exchange for shares of
    our common stock. As a result, Protalix Ltd. is now our
    wholly-owned subsidiary. In connection with the merger, we
    completed a
    <FONT style="white-space: nowrap">one-for-ten</FONT>
    reverse stock split and on February&#160;26, 2007, we changed
    our name to Protalix BioTherapeutics, Inc. Unless otherwise
    indicated, all share numbers in this Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    give effect to such reverse stock split.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our wholly-owned subsidiary and sole operating unit, Protalix
    Ltd., is an Israeli corporation and was originally incorporated
    in Israel as Metabogal Ltd. on December&#160;27, 1993. During
    1999, Protalix Ltd. changed its focus from plant secondary
    metabolites to the expression of recombinant therapeutic
    proteins in plant cells, and in April 2004 changed its name to
    Protalix Ltd.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    ProCellEx<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    is our trademark. Each of the other trademarks, trade names or
    service marks appearing in this Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    belongs to its respective holder.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Available
    Information</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our corporate website is www.protalix.com. We make available on
    our website, free of charge, our Securities and Exchange
    Commission, or the Commission, filings, including our Annual
    Report on
    <FONT style="white-space: nowrap">Form&#160;10-K,</FONT>
    Quarterly Reports on
    <FONT style="white-space: nowrap">Form&#160;10-Q,</FONT>
    Current Reports on
    <FONT style="white-space: nowrap">Form&#160;8-K</FONT>
    and any amendments to these reports, as soon as reasonably
    practicable after we electronically file these documents with,
    or furnish them to, the Commission. Additionally, from time to
    time, we provide notifications of material news including press
    releases and conferences on our website. Webcasts of
    presentations made by our company at certain conferences may
    also be available from time to time on our website, to the
    extent the webcasts are available. The content of our website is
    not intended to be incorporated by reference into this report or
    in any other report or document we file and any references to
    these websites are intended to be inactive textual references
    only.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are also listed on the Tel Aviv Stock Exchange and,
    accordingly, we submit copies of all our filings with the
    Commission to the Israeli Securities Authority and the Tel Aviv
    Stock Exchange. Such copies can be
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    34
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    retrieved electronically through the Tel Aviv Stock
    Exchange&#146;s internet messaging system (www.maya.tase.co.il)
    and through the MAGNA distribution site of the Israeli
    Securities Authority (www.magna.isa.gov.il).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our website also includes printable versions of our Code of
    Business Conduct and Ethics and the charters for each of the
    Audit, Compensation and Nominating Committees of our Board of
    Directors. Each of these documents is also available in print to
    any shareholder who requests a copy by addressing a request to:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Protalix BioTherapeutics, Inc.
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    2 Snunit Street
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Science Park
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    POB 455
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Carmiel 20100, Israel
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Attn: Mr.&#160;Yossi Maimon, Chief Financial Officer
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;1A.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571104'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Risk
    Factors</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>You should carefully consider the risks described below
    together with the other information included in this Annual
    Report on
    <FONT style="white-space: nowrap">Form&#160;10-K.</FONT>
    Our business, financial condition or results of operations could
    be adversely affected by any of these risks. If any of these
    risks occur, the value of our common stock could decline.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Our Business</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    currently have no significant product revenues and will need to
    raise additional capital to operate our business, which may not
    be available on favorable terms, or at all, and which will have
    a dilutive effect on our shareholders.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    To date, we have generated no significant revenues from product
    sales and only minimal revenues from research and development
    services and other fees, other than the milestone payments we
    received in connection with our license and supply agreement
    with Pfizer. For the years ended December&#160;31, 2010, 2009
    and 2008, we had net losses of $29.0&#160;million,
    $31.4&#160;million and $22.4&#160;million, respectively,
    primarily as a result of expenses incurred through a combination
    of research and development activities and expenses supporting
    those activities, which includes share-based compensation
    expense. Drug development and commercialization is very capital
    intensive. Until we receive approval from the FDA and other
    regulatory authorities for our drug candidates, we cannot
    generate significant sales from our drugs and will not have
    product revenues, except for certain regulatory-related
    milestone payments under the Pfizer agreement which we expect to
    earn prior to any sales of taliglucerase alfa. Therefore, for
    the foreseeable future, we will have to fund all of our
    operations and capital expenditures from our cash on hand,
    potential regulatory-related milestone payments under the Pfizer
    agreement, other licensing fees and grants and the net proceeds
    of any equity or debt offerings. Over the next 12&#160;months,
    we expect to spend a minimum of approximately $35.0&#160;million
    building an internal sales and marketing force for the sale of
    taliglucerase alfa in Israel, expanding our manufacturing
    capacity and on preclinical and clinical development for our
    products candidates. Based on our current plans and capital
    resources, we believe that our cash and cash equivalents
    together with the regulatory milestones payments we anticipate
    receiving from Pfizer will be sufficient to enable us to meet
    our planned operating needs for at least 12&#160;months.
    However, changes may occur that could consume our existing
    capital at a faster rate than projected, including, among
    others, changes in the progress of our research and development
    efforts, the cost and timing of regulatory approvals and the
    costs of protecting our intellectual property rights. We may
    seek additional financing to implement and fund product
    development, preclinical studies and clinical trials for the
    drugs in our pipeline, as well as additional drug candidates and
    other research and development projects. If we are unable to
    secure additional financing in the future on acceptable terms,
    or at all, we may be unable to commence or complete planned
    preclinical and clinical trials or obtain approval of our drug
    candidates from the FDA and other regulatory authorities. In
    addition, we may be forced to reduce or discontinue product
    development or product licensing, reduce or forego sales and
    marketing efforts and other commercialization activities or
    forego attractive business opportunities in order to improve our
    liquidity and to enable us to continue operations which would
    have a material adverse effect on our business and results of
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    35
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    operations. Any additional sources of financing will likely
    involve the issuance of our equity securities, which will have a
    dilutive effect on our shareholders.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We are
    not currently profitable and may never become profitable which
    would have a material adverse effect on our business and results
    of operations and could negatively impact the value of our
    common stock.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We expect to incur substantial losses for the foreseeable future
    and may never become profitable. We also expect to continue to
    incur significant operating and capital expenditures, and we
    anticipate that our expenses will increase substantially in the
    foreseeable future as we:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    continue to undertake preclinical development and clinical
    trials for our current and new drug candidates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    seek regulatory approvals for our drug candidates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    implement additional internal systems and infrastructure;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    seek to license-in additional technologies to develop;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    hire additional personnel.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We also expect to continue to experience negative cash flow for
    the foreseeable future as we fund our operating losses and
    capital expenditures. As a result, we will need to generate
    significant revenues in order to achieve and maintain
    profitability. We may not be able to generate these revenues or
    achieve profitability in the future. Any failure to achieve or
    maintain profitability would have a material adverse effect on
    our business and results of operations and could negatively
    impact the value of our common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    have a limited operating history which may limit the ability of
    investors to make an informed investment decision.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are a clinical stage biopharmaceutical company. To date, we
    have not commercialized any of our drug candidates or received
    any FDA or other approval to market any drug. The successful
    commercialization of our drug candidates will require us to
    perform a variety of functions, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    continuing to undertake preclinical development and clinical
    trials;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    participating in regulatory approval processes;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    formulating and manufacturing products;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    conducting sales and marketing activities.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our operations have been limited to organizing and staffing our
    company, acquiring, developing and securing our proprietary
    technology and undertaking, through third parties, preclinical
    trials and clinical trials of our principal drug candidates. To
    date, we have commenced a phase&#160;III clinical trial in
    connection with only one drug candidate, taliglucerase alfa,
    which trial was completed in August 2009, and we have not
    commenced the preclinical trial phase of development under Good
    Laboratory Practice (GLP) standards for any of our other drug
    candidates, except for our pr-antiTNF and acetylcholinesterase
    product candidates. These operations provide a limited basis for
    investors to assess our ability to commercialize our drug
    candidates and whether to invest in us.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    ProCellEx protein expression system is based on our proprietary
    plant cell-based expression technology which has a limited
    history and any material problems with the system, which may be
    unforeseen, may have a material adverse effect on our business
    and results of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our ProCellEx protein expression system is based on our
    proprietary plant cell-based expression technology. Our business
    is dependent upon the successful development and approval of our
    product candidates produced through our protein expression
    system. Our ProCellEx protein expression system is novel and is
    still in the early stages of development and optimization, and,
    accordingly, is subject to certain risks.
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    36
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Mammalian cell-based protein expression systems have been used
    in connection with recombinant therapeutic protein expression
    for more than 20&#160;years and are the subject of a wealth of
    data; in contrast, there is not a significant amount of data
    generated regarding plant cell-based protein expression and,
    accordingly, plant cell-based protein expression systems may be
    subject to unknown risks. In addition, the protein glycosilation
    pattern created by our protein expression system is not
    identical to the natural human glycosilation pattern and its
    long term effect on human patients is still unknown. Lastly, as
    our protein expression system is a new technology, we cannot
    always rely on existing equipment; rather, there is a need to
    design custom-made equipment and to generate specific growth
    media for the plant cells, which may not be available at
    favorable prices, if at all. Any material problems with the
    technology underlying our plant cell-based protein expression
    system may have a material adverse effect on our business and
    results of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    currently depend heavily on the success of taliglucerase alfa,
    our lead product candidate. Any failure to commercialize
    taliglucerase alfa, or the experience of significant delays in
    doing so, will have a material adverse effect on our business,
    results of operations and financial condition.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have invested a significant portion of our efforts and
    financial resources in the development of taliglucerase alfa.
    Our ability to generate product revenue, depends heavily on the
    successful development and commercialization of taliglucerase
    alfa. In November 2009, we granted to Pfizer an exclusive
    worldwide license to develop and commercialize taliglucerase
    alfa except in Israel. We retained such rights in Israel. The
    successful commercialization of taliglucerase alfa will depend
    on several factors, including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    successful completion of our ongoing studies of taliglucerase
    alfa;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    obtaining marketing approvals from the FDA and other foreign
    regulatory authorities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    maintaining the cGMP compliance of our manufacturing facility or
    establishing manufacturing arrangements with third parties;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the successful audit of our facilities by the FDA and other
    foreign regulatory authorities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Pfizer&#146;s efforts under the Pfizer agreement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our development of a successful sales and marketing organization
    for taliglucerase in Israel;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the availability of reimbursement to patients from healthcare
    payors for our drug products, if approved;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a continued acceptable safety and efficacy profile of our
    product candidates following approval;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    other risks described in these Risk Factors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any failure to commercialize taliglucerase alfa or the
    experience of significant delays in doing so will have a
    material adverse effect on our business, results of operations
    and financial condition.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    strategy, in many cases, is to enter into collaboration
    agreements with third parties to leverage our ProCellEx system
    to develop product candidates. If we fail to enter into these
    agreements or if we or the third parties do not perform under
    such agreements or terminate or elect to discontinue the
    collaboration, it could have a material adverse affect on our
    revenues.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our strategy, in many cases, is to enter into arrangements with
    pharmaceutical companies to leverage our ProCellEx system to
    develop additional product candidates. Under these arrangements,
    we may grant to our partners rights to license and commercialize
    pharmaceutical products developed under the applicable
    agreements. Our partners may control key decisions relating to
    the development of the products and we may depend on our
    partners&#146; expertise and dedication of sufficient resources
    to develop and commercialize our product candidates. The rights
    of our partners limit our flexibility in considering
    alternatives for the commercialization of our product
    candidates. To date, we have entered into a license and supply
    agreement with Pfizer relating to the development and
    commercialization of taliglucerase alfa and an agreement with
    Teva, which relates to the development by us of two proteins,
    and the licensing by Teva of such proteins in consideration for
    royalties and milestone payments. Subsequently, two proteins
    were identified to be researched and developed under the
    agreement but in 2009, both of the projects were terminated for
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    37
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    commercial reasons. We may not identify any additional proteins
    to be developed in a collaboration between us and Teva under the
    agreement, which may have a material adverse effect on our
    business, results of operations and financial condition. If we
    or any of our partners breach or terminate the agreements that
    make up such arrangements, our partners otherwise fail to
    conduct their obligations under such arrangements in a timely
    manner, there is a dispute about their obligations or if either
    party terminates the applicable agreement or elects not to
    continue the arrangement, we may not enjoy the benefits of the
    agreements or receive a sufficient amount of royalty or
    milestone payments from them, if any.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">All of
    our product candidates other than taliglucerase alfa and our
    acetycholinesterase product are in preclinical or research
    stages. If we are unable to develop and commercialize our
    product candidates, our business will be adversely
    affected.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A key element of our strategy is to develop and commercialize a
    portfolio of new products in addition to taliglucerase alfa. We
    are seeking to do so through our internal research programs and
    strategic collaborations for the development of new products.
    Research programs to identify new product candidates require
    substantial technical, financial and human resources, whether or
    not any product candidates are ultimately identified. Our
    research programs may initially show promise in identifying
    potential product candidates, yet fail to yield product
    candidates for clinical development for many reasons, including
    the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the research methodology used may not be successful in
    identifying potential product candidates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    competitors may develop alternatives that render our product
    candidates obsolete;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a product candidate may on further study be shown to have
    harmful side effects or other characteristics that indicate it
    is unlikely to be effective or otherwise does not meet
    applicable regulatory approval;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a product candidate is not capable of being produced in
    commercial quantities at an acceptable cost, or at all;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a product candidate may not be accepted by patients, the medical
    community or third-party payors.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any failure to develop or commercialize any of our other product
    candidates may have a material adverse effect on our business,
    results of operations and financial condition.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    not obtain the necessary U.S. or worldwide regulatory approvals
    to commercialize our drug candidates in a timely manner, if at
    all, which would have a material adverse effect on our business
    and results of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We will need FDA approval to commercialize our drug candidates
    in the United States and approvals from foreign regulators to
    commercialize our drug candidates elsewhere. In order to obtain
    FDA approval of any of our drug candidates, we must submit to
    the FDA an NDA or a Biologic License Application, a BLA,
    demonstrating that the drug candidate is safe for humans and
    effective for its intended use. This demonstration requires
    significant research and animal tests, which are referred to as
    preclinical studies, as well as human tests, which are referred
    to as clinical trials. In the European Union, we must submit an
    MAA to the EMEA. Satisfaction of the FDA&#146;s and foreign
    regulatory authorities&#146; regulatory requirements typically
    takes many years, and depends upon the type, complexity and
    novelty of the drug candidate and requires substantial resources
    for research, development and testing. In December 2009 we
    completed the filing of an NDA for taliglucerase alfa for the
    treatment of Gaucher disease and received a PDUFA date of
    February&#160;25, 2011, and in November 2010, we submitted a
    marketing application to the Israeli MOH and an MAA to each of
    the EMEA and ANVISA for taliglucerase alfa. Our research and
    clinical efforts may not result in drugs that the FDA or foreign
    regulatory authorities consider safe for humans and effective
    for indicated uses, which would have a material adverse effect
    on our business and results of operations. After clinical trials
    are completed for any drug candidate, if at all, the FDA and
    foreign regulatory authorities have substantial discretion in
    the drug approval process of the drug candidate in their
    respective jurisdictions and may require us to conduct
    additional clinical testing or to perform post-marketing studies
    which would cause us to incur additional costs. Incurring such
    costs could have a material adverse effect on our business and
    results of operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    38
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The approval process for any drug candidate may also be delayed
    by changes in government regulation, future legislation or
    administrative action or changes in policy of the FDA and
    comparable foreign authorities that occur prior to or during
    their respective regulatory reviews of such drug candidate.
    Delays in obtaining regulatory approvals with respect to any
    drug candidate may:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delay commercialization of, and our ability to derive product
    revenues from, such drug candidate;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    delay the regulatory-related milestone payments we anticipate
    receiving from Pfizer;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    require us to perform costly procedures with respect to such
    drug candidate;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    otherwise diminish any competitive advantages that we may have
    with respect to such drug candidate.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Even if we comply with all the requests of the FDA and
    comparable foreign authorities, the authorities may ultimately
    reject the NDA or other filing or submission we filed for
    taliglucerase alfa or one or more of the NDAs or other filing or
    submission we file in the future, if any, or we might not obtain
    regulatory clearance in a timely manner for taliglucerase alfa
    or any of our other product candidates. Companies in the
    pharmaceutical and biotechnology industries have suffered
    significant setbacks in advanced or late-stage clinical trials,
    even after obtaining promising earlier trial results or in
    preliminary findings or other comparable authorities for such
    clinical trials. Further, even if favorable testing data is
    generated by the clinical trials of a drug product, the FDA may
    not accept or approve an NDA, MAA or other comparable submission
    filed by a pharmaceutical or biotechnology company for the drug
    product. Failure to obtain approval of the FDA or comparable
    foreign authorities any of our drug candidates in a timely
    manner, if at all, will severely undermine our business and
    results of operation by reducing our potential marketable
    products and our ability to generate corresponding product
    revenues.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    &#147;fast track&#148; designation for the development program
    of taliglucerase alfa for the treatment of Gaucher disease may
    not lead to a faster development or regulatory review or
    approval process or increase the likelihood that taliglucerase
    alfa will receive regulatory approval for the treatment of
    Gaucher disease.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If a human medicine is intended for the treatment of a serious
    or life-threatening condition and the medicine demonstrates the
    potential to address unmet medical needs for this condition, the
    sponsor of an IND may apply for FDA &#147;fast track&#148;
    designation for a particular indication. Marketing applications
    submitted by sponsors of product candidates in fast track
    development may qualify for expedited FDA review under the
    policies and procedures offered by the FDA, but the fast track
    designation does not assure any such qualification. However,
    although the FDA has granted fast track designation for
    taliglucerase alfa for the treatment of Gaucher disease, we were
    granted the standard review period of 10&#160;months. The fast
    track designation does not increase the likelihood that
    taliglucerase alfa will receive regulatory approval for the
    treatment of Gaucher disease.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Clinical
    trials are very expensive, time-consuming and difficult to
    design and implement and may result in unforeseen costs which
    may have a material adverse effect on our business and results
    of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Human clinical trials are very expensive and difficult to design
    and implement, in part because they are subject to rigorous
    regulatory requirements. The clinical trial process is also
    time-consuming. Other than taliglucerase alfa and our
    acetylcholinesterase product, our drug candidates are in early
    stages of preclinical studies or research stages. Other, ongoing
    clinical trials of taliglucerase alfa and our
    acetylcholinesterase product, and anticipated clinical trials of
    our other potential drug candidates which have not yet been
    initiated, will take at least several years to complete.
    Preliminary and initial results from a clinical trial do not
    necessarily predict final results, and failure can occur at any
    stage of the trials. We may encounter problems that cause us to
    abandon or repeat preclinical studies or clinical trials.
    Companies in the pharmaceutical and biotechnology industries
    have suffered significant setbacks in advanced clinical trials,
    even after obtaining promising results in earlier trials. Data
    obtained from tests are susceptible to varying interpretations
    which
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    39
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    may delay, limit or prevent regulatory approval. Failure or
    delay in the commencement or completion of our clinical trials
    may be caused by several factors, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    unforeseen safety issues;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    determination of dosing issues;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    lack of effectiveness during clinical trials;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    slower than expected rates of patient recruitment;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    inability to monitor patients adequately during or after
    treatment;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    inability or unwillingness of medical investigators and
    institutional review boards to follow our clinical
    protocols;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    lack of sufficient funding to finance the clinical trials.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any failure or delay in commencement or completion of any
    clinical trials may have a material adverse effect on our
    business and results of operations. In addition, we or the FDA
    or other regulatory authorities may suspend any clinical trial
    at any time if it appears that we are exposing participants in
    the trial to unacceptable safety or health risks or if the FDA
    or such other regulatory authorities, as applicable, find
    deficiencies in our IND submissions or the conduct of the trial.
    Any suspension of a clinical trial may have a material adverse
    effect on our business, financial condition and results of
    operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If the
    results of our clinical trials do not support our claims
    relating to any drug candidate or if serious side effects are
    identified, the completion of development of such drug candidate
    may be significantly delayed or we may be forced to abandon
    development altogether, which will significantly impair our
    ability to generate product revenues.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The results of our clinical trials with respect to any drug
    candidate might not support our claims of safety or efficacy,
    the effects of our drug candidates may not be the desired
    effects or may include undesirable side effects or the drug
    candidates may have other unexpected characteristics. Further,
    success in preclinical testing and early clinical trials does
    not ensure that later clinical trials will be successful, and
    the results of later clinical trials may not replicate the
    results of prior clinical trials and preclinical testing. The
    clinical trial process may fail to demonstrate that our drug
    candidates are safe for humans and effective for indicated uses.
    In addition, our clinical trials may involve a specific and
    small patient population. Results of early clinical trials
    conducted on a small patient population may not be indicative of
    future results. Adverse or inconclusive results may cause us to
    abandon a drug candidate and may delay development of other drug
    candidates. Any delay in, or termination of, our clinical trials
    will delay the filing of NDAs with the FDA, or other filings
    with other regulatory authorities, and, ultimately,
    significantly impair our ability to commercialize our drug
    candidates and generate product revenues which would have a
    material adverse effect on our business, financial condition and
    results of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    find it difficult to enroll patients in our clinical trials,
    which could cause significant delays in the completion of such
    trials or may cause us to abandon one or more clinical
    trials.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Most of the diseases or disorders that our product candidates
    are intended to treat are relatively rare and we expect only a
    subset of the patients with these diseases to be eligible for
    our clinical trials. Given that each of our product candidates
    other than taliglucerase alfa is in the early stages of
    preclinical or research stages, we may not be able to initiate
    clinical trials for each or all of our product candidates if we
    are unable to locate a sufficient number of eligible subjects to
    participate in the clinical trials required by the FDA
    <FONT style="white-space: nowrap">and/or</FONT> other
    foreign regulatory authorities. The requirements of our clinical
    trials generally mandate that a patient cannot be involved in
    another clinical trial for the same indication. We are aware
    that our competitors have ongoing clinical trials for products
    that are competitive with our product candidates and subjects
    who would otherwise be eligible for our clinical trials may be
    involved in such testing, rendering them unavailable for testing
    of our product candidates. Our inability to enroll a sufficient
    number of patients for any of our current
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    40
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    or future clinical trials would result in significant delays or
    may require us to abandon one or more clinical trials
    altogether, which would have a material adverse effect on our
    business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If
    physicians, patients, third party payors and others in the
    medical community do not accept and use our drugs, our ability
    to generate revenue from sales of our products under development
    will be materially impaired.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Even if the FDA or other foreign regulatory authorities approve
    any of our drug candidates for commercialization, physicians and
    patients, and other healthcare providers, may not accept and use
    such candidates. Future acceptance and use of our products will
    depend upon a number of factors including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    perceptions by physicians, patients, third party payors and
    others in the medical community, about the safety and
    effectiveness of our drug candidates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the willingness of the target patient population to try new
    therapies and of physicians to prescribe these therapies;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the prevalence and severity of any side effects, including any
    limitations or warnings contained in our products&#146; approved
    labeling;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    pharmacological benefit of our products relative to competing
    products and products under development;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the efficacy and potential advantages relative to competing
    products and products under development;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    relative convenience and ease of administration;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    effectiveness of education, marketing and distribution efforts
    by us and our licensees and distributors, if any;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    publicity concerning our products or competing products and
    treatments;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    reimbursement of our products by third party payors;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the price for our products and competing products.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Because we expect sales of our current drug candidates, if
    approved, to generate substantially all of our product revenues
    for the foreseeable future, the failure of any of these drugs to
    find market acceptance would have a material adverse effect on
    our business and revenues from sales of our products would be
    materially impaired.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Because
    our clinical trials depend upon third-party researchers, the
    results of our clinical trials and such research activities are
    subject to delays and other risks which are, to a certain
    extent, beyond our control, which could impair our clinical
    development programs and our competitive position.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We depend upon independent investigators and collaborators, such
    as universities and medical institutions, to conduct our
    preclinical and clinical trials. These collaborators are not our
    employees, and we cannot control the amount or timing of
    resources that they devote to our clinical development programs.
    The investigators may not assign as great a priority to our
    clinical development programs or pursue them as diligently as we
    would if we were undertaking such programs directly. If outside
    collaborators fail to devote sufficient time and resources to
    our clinical development programs, or if their performance is
    substandard, the approval of our NDA, MAA and other
    applications, if any, and our introduction of new drugs, if any,
    may be delayed which could impair our clinical development
    programs and would have a material adverse effect on our
    business and results of operations. The collaborators may also
    have relationships with other commercial entities, some of whom
    may compete with us. If our collaborators also assist our
    competitors, our competitive position could be harmed.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    41
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    manufacture of our products is an exacting and complex process,
    and if we or one of our materials suppliers encounter problems
    manufacturing our products, it will have a material adverse
    effect on our business and results of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The FDA and foreign regulators require manufacturers to register
    manufacturing facilities. The FDA and foreign regulators also
    inspect these facilities to confirm compliance with cGMP or
    similar requirements that the FDA or foreign regulators
    establish. We or our materials suppliers may face manufacturing
    or quality control problems causing product production and
    shipment delays or a situation where we or the supplier may not
    be able to maintain compliance with the FDA&#146;s cGMP
    requirements, or those of foreign regulators, necessary to
    continue manufacturing our drug candidates. Any failure to
    comply with cGMP requirements or other FDA or foreign regulatory
    requirements could adversely affect our clinical research
    activities and our ability to market and develop our products.
    To date, our current facility has been audited by the FDA and
    the Israeli MOH, but remains subject to audit by other foreign
    regulatory authorities. There can be no assurance that we will
    be able to comply with FDA or foreign regulatory manufacturing
    requirements for our current facility or any facility we may
    establish in the future, which would have a material adverse
    effect on our business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    rely on third parties for final processing of taliglucerase
    alfa, which exposes us to a number of risks that may delay
    development, regulatory approval and commercialization of our
    product candidates or result in higher product
    costs.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have no experience in the final filling and freeze drying
    steps of the drug manufacturing process. According to our
    license and supply agreement with Pfizer, Pfizer will be
    responsible for the fill and finish activities for taliglucerase
    alfa. In addition, we have engaged a European contract
    manufacturer to act as an additional source of fill and finish
    activities for taliglucerase alfa. We currently rely primarily
    on other third-party contractors to perform the final
    manufacturing steps for taliglucerase alfa on a commercial
    scale. We may be unable to identify manufacturers
    <FONT style="white-space: nowrap">and/or</FONT>
    replacement manufacturers on acceptable terms or at all because
    the number of potential manufacturers is limited and the FDA and
    other regulatory authorities, as applicable, must approve any
    manufacturer
    <FONT style="white-space: nowrap">and/or</FONT>
    replacement manufacturer, including us, and we or any such third
    party manufacturer might be unable to formulate and manufacture
    our drug products in the volume and of the quality required to
    meet our clinical and commercial needs. If we engage any
    contract manufacturers, such manufacturers may not perform as
    agreed or may not remain in the contract manufacturing business
    for the time required to supply our clinical or commercial
    needs. In addition, contract manufacturers are subject to the
    rules and regulations of the FDA and comparable foreign
    regulatory authorities and face the risk that any of those
    authorities may find that they are not in compliance with
    applicable regulations. Each of these risks could delay our
    clinical trials, the approval, if any, of taliglucerase alfa and
    our other potential drug candidates by the FDA or other
    regulatory authorities, or the commercialization of
    taliglucerase alfa and our other drug candidates or could result
    in higher product costs or otherwise deprive us of potential
    product revenues.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    have no experience selling, marketing or distributing products
    and no internal capability to do so.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We currently have very limited sales, marketing or distribution
    capabilities and no experience in building a sales force and
    distribution capabilities. To be able to commercialize
    taliglucerase alfa upon approval, if at all, in Israel, and to
    commercialize any of our other product candidates, we must
    either develop internal sales, marketing and distribution
    capabilities, which will be expensive and time consuming, or
    make arrangements with third parties to perform these services.
    In November 2009, we granted to Pfizer an exclusive, worldwide
    right to develop and commercialize taliglucerase alfa, but
    retained such rights in Israel. If we decide to market any of
    our products directly, we must commit significant financial and
    managerial resources to develop a marketing and sales force with
    technical expertise and with supporting distribution
    capabilities. Factors that may inhibit our efforts to
    commercialize our products directly and without strategic
    partners include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our inability to recruit and retain adequate numbers of
    effective sales and marketing personnel;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the inability of sales personnel to obtain access to or persuade
    adequate numbers of physicians to prescribe our products;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    42
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the lack of complementary products to be offered by sales
    personnel, which may put us at a competitive disadvantage
    relative to companies with more extensive product lines;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    unforeseen costs and expenses associated with creating and
    sustaining an independent sales and marketing organization.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We may not be successful in recruiting the sales and marketing
    personnel necessary to sell any of our products upon approval,
    if at all, and even if we do build a sales force, it may not be
    successful in marketing our products, which would have a
    material adverse effect on our business, financial condition and
    results of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If the
    market opportunities for our current product candidates are
    smaller than we believe they are, our revenues may be adversely
    affected and our business may suffer.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A substantial focus of our current clinical pipeline is on
    relatively rare disorders with small patient populations, in
    particular Gaucher disease and Fabry disease. Currently, most
    reported estimates of the prevalence of these diseases are based
    on studies of small subsets of the population of specific
    geographic areas, which are then extrapolated to estimate the
    prevalence of the diseases in the broader world population. As
    new studies are performed, the estimated prevalence of these
    diseases may change. There can be no assurance that the
    prevalence of Gaucher disease or Fabry disease in the study
    populations, particularly in these newer studies, accurately
    reflect the prevalence of these diseases in the broader world
    population. If the market opportunities for our current product
    candidates are smaller than we believe they are, our revenues
    may be adversely affected and our business may suffer.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    enter into distribution arrangements and marketing alliances for
    certain products and any failure to successfully identify and
    implement these arrangements on favorable terms, if at all, may
    impair our ability to commercialize our product
    candidates.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    While we intend to build a sales force to market taliglucerase
    alfa in Israel and other product candidates worldwide, we do not
    anticipate having the resources in the foreseeable future to
    develop global sales and marketing capabilities for all of the
    products we develop, if any. We may pursue arrangements
    regarding the sales and marketing and distribution of one or
    more of our product candidates, such as our license and supply
    agreement with Pfizer, and our future revenues may depend, in
    part, on our ability to enter into and maintain arrangements
    with other companies having sales, marketing and distribution
    capabilities and the ability of such companies to successfully
    market and sell any such products. Any failure to enter into
    such arrangements and marketing alliances on favorable terms, if
    at all, could delay or impair our ability to commercialize our
    product candidates and could increase our costs of
    commercialization. Any use of distribution arrangements and
    marketing alliances to commercialize our product candidates will
    subject us to a number of risks, including the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we may be required to relinquish important rights to our
    products or product candidates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we may not be able to control the amount and timing of resources
    that our distributors or collaborators may devote to the
    commercialization of our product candidates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our distributors or collaborators may experience financial
    difficulties;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our distributors or collaborators may not devote sufficient time
    to the marketing and sales of our products;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    business combinations or significant changes in a
    collaborator&#146;s business strategy may adversely affect a
    collaborator&#146;s willingness or ability to complete its
    obligations under any arrangement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We may need to enter into additional co-promotion arrangements
    with third parties where our own sales force is neither well
    situated nor large enough to achieve maximum penetration in the
    market. We may not be successful in entering into any
    co-promotion arrangements, and the terms of any co-promotion
    arrangements we enter into may not be favorable to us.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    43
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Developments
    by competitors may render our products or technologies obsolete
    or non-competitive which would have a material adverse effect on
    our business and results of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We compete against fully integrated pharmaceutical companies and
    smaller companies that are collaborating with larger
    pharmaceutical companies, academic institutions, government
    agencies and other public and private research organizations.
    Our drug candidates will have to compete with existing therapies
    and therapies under development by our competitors. In addition,
    our commercial opportunities may be reduced or eliminated if our
    competitors develop and market products that are less expensive,
    more effective or safer than our drug products. Other companies
    have drug candidates in various stages of preclinical or
    clinical development to treat diseases for which we are also
    seeking to develop drug products. Some of these potential
    competing drugs are further advanced in development than our
    drug candidates and may be commercialized earlier. Even if we
    are successful in developing effective drugs, our products may
    not compete successfully with products produced by our
    competitors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We specifically face competition from companies with approved
    treatments of Gaucher disease, including Genzyme, Shire plc and
    to a much lesser extent, Actelion. In February 2010, the FDA
    approved VPRIV, Shire&#146;s enzyme replacement therapy for the
    treatment of Gaucher disease and the European Commission granted
    marketing authorization to VPRIV in August 2010. In addition, we
    are aware of other early stage, experimental, small molecule,
    oral drugs which are being developed for the treatment of
    Gaucher disease by each of Genzye and Amicus Therapeutics.
    According to Amicus Therapeutics, its trial of a small molecule,
    oral drug for the treatment of Gaucher disease has been
    suspended. We also face competition from companies with approved
    treatments of Fabry disease, including Genzyme and Shire, and we
    are aware of other early stage drugs which are being developed
    for the treatment of Fabry disease, including a drug being
    developed by Amicus Therapeutics.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We also face competition from companies that are developing
    other platforms for the expression of recombinant therapeutic
    pharmaceuticals. We are aware of companies that are developing
    alternative technologies to develop and produce therapeutic
    proteins in anticipation of the expiration of certain patent
    claims covering marketed proteins. Competitors developing
    alternative expression technologies include Crucell N.V. (which
    was acquired by Johnson&#160;&#038; Johnson), Shire and GlycoFi
    Inc. (which was acquired by Merck). Other companies are
    developing alternate plant-based technologies, include Biolex,
    Inc., Chlorogen, Inc., Greenovation Biotech GmbH and Dow
    Agroscience.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Several biogeneric companies are pursuing the opportunity to
    develop and commercialize follow-on versions of other currently
    marketed biologic products, including growth factors, hormones,
    enzymes, cytokines and monoclonal antibodies, which are areas
    that interest us. These companies include, among others,
    Novartis AG/Sandoz Pharmaceuticals, BioGeneriX AG, Stada
    Arzneimittel AG, BioPartners GmbH and Teva.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Most of our competitors, either alone or together with their
    collaborative partners, operate larger research and development
    programs, staff and facilities and have substantially greater
    financial resources than we do, as well as significantly greater
    experience in:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    developing drugs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    undertaking preclinical testing and human clinical trials;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    obtaining FDA and other regulatory approvals of drugs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    formulating and manufacturing drugs;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    launching, marketing and selling drugs.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    These organizations also compete with us to attract qualified
    personnel, acquisitions and joint ventures candidates and for
    other collaborations. Activities of our competitors may impose
    unanticipated costs on our business which would have a material
    adverse effect on our business, financial condition and results
    of operations.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    44
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If we
    fail to adequately protect or enforce our intellectual property
    rights or secure rights to third party patents, the value of our
    intellectual property rights would diminish and our business,
    competitive position and results of operations would
    suffer.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As of December&#160;31, 2010, we had 86 pending patent
    applications and held licensed rights to seven pending patent
    applications. However, the filing of a patent application does
    not mean that we will be issued a patent, or that any patent
    eventually issued will be as broad as requested in the patent
    application or sufficient to protect our technology. Any
    modification required to a current patent application may delay
    the approval of such patent application which would have a
    material adverse effect on our business and results of
    operations. In addition, there are a number of factors that
    could cause our patents, if granted, to become invalid or
    unenforceable or that could cause our patent applications to not
    be granted, including known or unknown prior art, deficiencies
    in the patent application or the lack of originality of the
    technology.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our competitive position and future revenues will depend in part
    on our ability and the ability of our licensors and
    collaborators to obtain and maintain patent protection for our
    products, methods, processes and other technologies, to preserve
    our trade secrets, to prevent third parties from infringing on
    our proprietary rights and to operate without infringing the
    proprietary rights of third parties. We have filed U.S.&#160;and
    international patent applications for process patents, as well
    as composition of matter patents, for taliglucerase alfa.
    However, we cannot predict:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the degree and range of protection any patents will afford us
    against competitors and those who infringe upon our patents,
    including whether third parties will find ways to invalidate or
    otherwise circumvent our licensed patents;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    if and when patents will issue;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    whether or not others will obtain patents claiming aspects
    similar to those covered by our licensed patents and patent
    applications;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    whether we will need to initiate litigation or administrative
    proceedings, which may be costly, and whether we win or lose.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As of December&#160;31, 2010, we hold, or have license rights
    to, 26 patents. If patent rights covering our products are not
    sufficiently broad, they may not provide us with sufficient
    proprietary protection or competitive advantages against
    competitors with similar products and technologies. Furthermore,
    if the U.S.&#160;Patent and Trademark Office or foreign patent
    offices issue patents to us or our licensors, others may
    challenge the patents or circumvent the patents, or the patent
    office or the courts may invalidate the patents. Thus, any
    patents we own or license from or to third parties may not
    provide any protection against our competitors and those who
    infringe upon our patents.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Furthermore, the life of our patents is limited. The patents we
    hold relating to our ProCellEx protein expression system will
    expire in 2017. If patents issue from other currently pending
    patent applications, those patents will expire between 2024 and
    2028.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    rely on confidentiality agreements that could be breached and
    may be difficult to enforce which could have a material adverse
    effect on our business and competitive position.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our policy is to enter agreements relating to the non-disclosure
    of confidential information with third parties, including our
    contractors, consultants, advisors and research collaborators,
    as well as agreements that purport to require the disclosure and
    assignment to us of the rights to the ideas, developments,
    discoveries and inventions of our employees and consultants
    while we employ them. However, these agreements can be difficult
    and costly to enforce. Moreover, to the extent that our
    contractors, consultants, advisors and research collaborators
    apply or independently develop intellectual property in
    connection with any of our projects, disputes may arise as to
    the proprietary rights to the intellectual property. If a
    dispute arises, a court may determine that the right belongs to
    a third party, and enforcement of our rights can be costly and
    unpredictable. In addition, we rely on trade secrets and
    proprietary know-how that we seek to protect in part by
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    45
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    confidentiality agreements with our employees, contractors,
    consultants, advisors or others. Despite the protective measures
    we employ, we still face the risk that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    these agreements may be breached;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    these agreements may not provide adequate remedies for the
    applicable type of breach;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    our trade secrets or proprietary know-how will otherwise become
    known.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any breach of our confidentiality agreements or our failure to
    effectively enforce such agreements would have a material
    adverse effect on our business and competitive position.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If we
    infringe the rights of third parties we could be prevented from
    selling products, forced to pay damages and required to defend
    against litigation which could result in substantial costs and
    may have a material adverse effect on our business and results
    of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have not received to date any claims of infringement by any
    third parties. However, as our drug candidates progress into
    clinical trials and commercialization, if at all, our public
    profile and that of our drug candidates may be raised and
    generate such claims. Defending against such claims, and
    occurrence of a judgment adverse to us, could result in
    unanticipated costs and may have a material adverse effect on
    our business and competitive position. If our products, methods,
    processes and other technologies infringe the proprietary rights
    of other parties, we may incur substantial costs and we may have
    to:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    obtain licenses, which may not be available on commercially
    reasonable terms, if at all;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    redesign our products or processes to avoid infringement;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    stop using the subject matter claimed in the patents held by
    others, which could cause us to lose the use of one or more of
    our drug candidates;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    defend litigation or administrative proceedings that may be
    costly whether we win or lose, and which could result in a
    substantial diversion of management resources;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    pay damages.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Any costs incurred in connection with such events or the
    inability to sell our products may have a material adverse
    effect on our business, financial condition and results of
    operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If we
    cannot meet requirements under our license agreements, we could
    lose the rights to our products, which could have a material
    adverse effect on our business.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We depend on licensing agreements with third parties to maintain
    the intellectual property rights to certain of our products
    under development. Presently, we have licensed rights from the
    Yeda Research and Development Company Limited, the technology
    transfer arm of the Weizman Institute of Science, which allow us
    to use their technology and discoveries for the development,
    production and sale of enzymatically active mutations of GCD and
    derivatives thereof for the treatment of Gaucher disease. In
    addition, pursuant to our agreement with the Yissum Research and
    Development Company, or Yissum, the technology transfer arm of
    the Hebrew University of Jerusalem, Israel, and the Boyce
    Thompson Institute for Plant Research, at Cornell University, we
    have received an exclusive worldwide right and license to
    certain technology, including patents and additional patent
    applications relating to acetylcholinesterase (AChE), for all
    therapeutic and prophylactic indications as well as an exclusive
    license not limited to such indications with respect to certain
    of these patents and patent applications. Under the agreement
    with Yissum, we intend to develop a proprietary plant cell-based
    acetylcholinesterase (AChE) and its molecular variants for the
    use in several therapeutic and prophylactic indications,
    including a biodefense program. In addition, we have licensed
    certain rights relating to our production of taliglucerase alfa
    from Virginia Tech. Our license agreements require us to make
    payments and satisfy performance obligations in order to
    maintain our rights under these agreements. All of these
    agreements last either throughout the life of the patents that
    are the subject of the agreements, or with respect to other
    licensed technology, for a number of years after the first
    commercial sale of the relevant product.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    46
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition, we are responsible for the cost of filing and
    prosecuting certain patent applications and maintaining certain
    issued patents licensed to us. If we do not meet our obligations
    under our license agreements in a timely manner, we could lose
    the rights to our proprietary technology which could have a
    material adverse effect on our business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If we
    in-license drug candidates, we may delay or otherwise adversely
    affect the development of our existing drug candidates, which
    may negatively impact our business, results of operations and
    financial condition.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to our own internally developed drug candidates, we
    proactively seek opportunities to in-license and advance other
    drug candidates that are strategic and have value-creating
    potential to take advantage of our development know-how and
    technology. If we in-license any additional drug candidates, our
    capital requirements may increase significantly. In addition,
    in-licensing additional drug candidates may place a strain on
    the time of our existing personnel, which may delay or otherwise
    adversely affect the development of our existing drug candidates
    or cause us to re-prioritize our drug pipeline if we do not have
    the necessary capital resources to develop all of our drug
    candidates, which may delay the development of our drug
    candidates and negatively impact our business, results of
    operations and financial condition.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If we
    are unable to successfully manage our growth, there could be a
    material adverse impact on our business, results of operations
    and financial condition.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have grown rapidly and expect to continue to grow. We expect
    to hire more employees, particularly in the areas of drug
    development, manufacturing, regulatory affairs and sales and
    marketing, and increase our facilities and corporate
    infrastructure, further increasing the size of our organization
    and related expenses. To manage our anticipated future growth,
    we must continue to implement and improve our managerial,
    operational and financial systems, expand our facilities and
    continue to recruit and train additional qualified personnel.
    Due to our limited resources, we may not be able to effectively
    manage the expansion of our operations or recruit and train
    additional qualified personnel. The expansion of our operations
    may lead to significant costs and may divert our management and
    business development resources. Any inability on the part of our
    management to manage growth could delay the execution of our
    business plans or disrupt our operations. If we are unable to
    manage our growth effectively, we may not use our resources in
    an efficient manner, which may delay the development of our drug
    candidates and negatively impact our business, results of
    operations and financial condition.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If we
    acquire companies, products or technologies, we may face
    integration risks and costs associated with those acquisitions
    that could negatively impact our business, results from
    operations and financial condition.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If we are presented with appropriate opportunities, we may
    acquire or make investments in complementary companies, products
    or technologies. We may not realize the anticipated benefit of
    any acquisition or investment. If we acquire companies or
    technologies, we will face risks, uncertainties and disruptions
    associated with the integration process, including difficulties
    in the integration of the operations of an acquired company,
    integration of acquired technology with our products, diversion
    of our management&#146;s attention from other business concerns,
    the potential loss of key employees or customers of the acquired
    business and impairment charges if future acquisitions are not
    as successful as we originally anticipate. In addition, our
    operating results may suffer because of acquisition-related
    costs or amortization expenses or charges relating to acquired
    intangible assets. Any failure to successfully integrate other
    companies, products or technologies that we may acquire may have
    a material adverse effect on our business and results of
    operations. Furthermore, we may have to incur debt or issue
    equity securities to pay for any additional future acquisitions
    or investments, the issuance of which could be dilutive to our
    existing shareholders.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    47
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We
    depend upon key employees and consultants in a competitive
    market for skilled personnel. If we are unable to attract and
    retain key personnel, it could adversely affect our ability to
    develop and market our products.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are highly dependent upon the principal members of our
    management team, especially our President and Chief Executive
    Officer, Dr.&#160;David Aviezer,&#160;Ph.D., as well as the
    Interim Chairman of our Board of Directors, Zev Bronfeld, our
    other directors, our scientific advisory board members,
    consultants and collaborating scientists. Many of these people
    have been involved with us for many years and have played
    integral roles in our progress, and we believe that they will
    continue to provide value to us. A loss of any of these
    personnel may have a material adverse effect on aspects of our
    business and clinical development and regulatory programs. We
    have employment agreements with Dr.&#160;Aviezer and five other
    officers that may be terminated by us or the applicable officer
    at any time with varying notice periods of 60 to 90&#160;days.
    Although these employment agreements generally include
    non-competition covenants and provide for severance payments
    that are contingent upon the applicable employee&#146;s
    refraining from competition with us, the applicable
    noncompetition provisions can be difficult and costly to monitor
    and enforce. The loss of any of these persons&#146; services may
    adversely affect our ability to develop and market our products
    and obtain necessary regulatory approvals. Further, we do not
    maintain key-man life insurance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We also depend in part on the continued service of our key
    scientific personnel and our ability to identify, hire and
    retain additional personnel, including marketing and sales
    staff. We experience intense competition for qualified
    personnel, and the existence of non-competition agreements
    between prospective employees and their former employers may
    prevent us from hiring those individuals or subject us to suit
    from their former employers. While we attempt to provide
    competitive compensation packages to attract and retain key
    personnel, many of our competitors are likely to have greater
    resources and more experience than we have, making it difficult
    for us to compete successfully for key personnel.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    collaborations with outside scientists and consultants may be
    subject to restriction and change.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We work with chemists, biologists and other scientists at
    academic and other institutions, and consultants who assist us
    in our research, development, regulatory and commercial efforts,
    including the members of our scientific advisory board. These
    scientists and consultants have provided, and we expect that
    they will continue to provide, valuable advice on our programs.
    These scientists and consultants are not our employees, may have
    other commitments that would limit their future availability to
    us and typically will not enter into non-compete agreements with
    us. If a conflict of interest arises between their work for us
    and their work for another entity, we may lose their services.
    In addition, we will be unable to prevent them from establishing
    competing businesses or developing competing products. For
    example, if a key scientist acting as a principal investigator
    in any of our clinical trials identifies a potential product or
    compound that is more scientifically interesting to his or her
    professional interests, his or her availability to remain
    involved in our clinical trials could be restricted or
    eliminated.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Under
    current U.S. and Israeli law, we may not be able to enforce
    employees&#146; covenants not to compete and therefore may be
    unable to prevent our competitors from benefiting from the
    expertise of some of our former employees.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have entered into non-competition agreements with all of our
    employees. These agreements prohibit our employees, if they
    cease working for us, from competing directly with us or working
    for our competitors for a limited period. Under current
    U.S.&#160;and Israeli law, we may be unable to enforce these
    agreements against most of our employees and it may be difficult
    for us to restrict our competitors from gaining the expertise
    our former employees gained while working for us. If we cannot
    enforce our employees&#146; non-compete agreements, we may be
    unable to prevent our competitors from benefiting from the
    expertise of our former employees.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    48
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">If
    product liability claims are brought against us, it may result
    in reduced demand for our products or damages that exceed our
    insurance coverage.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The clinical testing, marketing and use of our products exposes
    us to product liability claims in the event that the use or
    misuse of those products causes injury, disease or results in
    adverse effects. Use of our products in clinical trials, as well
    as commercial sale, could result in product liability claims. We
    presently carry clinical trial liability insurance with
    coverages of up to $5.0&#160;million per occurrence and
    $5.0&#160;million in the aggregate, an amount we consider
    reasonable and customary. However, this insurance coverage
    includes various deductibles, limitations and exclusions from
    coverage, and in any event might not fully cover any potential
    claims. We may need to obtain additional clinical trial
    liability coverage prior to initiating additional clinical
    trials. We expect to obtain product liability insurance coverage
    before commercialization of our proposed products; however, such
    insurance is expensive and insurance companies may not issue
    this type of insurance when we need it. We may not be able to
    obtain adequate insurance in the future at an acceptable cost.
    Any product liability claim, even one that was not in excess of
    our insurance coverage or one that is meritless
    <FONT style="white-space: nowrap">and/or</FONT>
    unsuccessful, could adversely affect our cash available for
    other purposes, such as research and development, which could
    have a material adverse effect on our business, financial
    condition and results of operations. Product liability claims
    may result in reduced demand for our products, if approved,
    which would have a material adverse effect on our business,
    financial condition and results of operations. In addition, the
    existence of a product liability claim could affect the market
    price of our common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Reimbursement
    may not be available for our product candidates, which could
    diminish our sales or affect our ability to sell our products
    profitably.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Market acceptance and sales of our product candidates will
    depend on worldwide reimbursement policies. Government
    authorities and third-party payors, such as private health
    insurers and health maintenance organizations, decide which
    drugs they will pay for and establish reimbursement levels. We
    cannot be sure that reimbursement will be available for any of
    our product candidates, if approved for marketing and sale.
    Obtaining reimbursement approval for an approved product from
    every government or other third party payor is a time consuming
    and costly process that could require us to provide supporting
    scientific, clinical and cost-effectiveness data for the use of
    our products, if and when approved, to every payor. We may not
    be able to provide data sufficient to gain acceptance with
    respect to reimbursement or we might need to conduct
    post-marketing studies in order to demonstrate the
    cost-effectiveness of any approved products, if any, to such
    payors&#146; satisfaction. Such studies might require us to
    commit a significant amount of management time and financial and
    other resources. Even if a payor determines that an approved
    product is eligible for reimbursement, the payor may impose
    coverage limitations that preclude payment for some uses that
    are approved by the FDA or other regulatory authorities. In
    addition, there is a risk that full reimbursement may not be
    available for high priced products. Moreover, eligibility for
    coverage does not imply that any approved product will be
    reimbursed in all cases or at a rate that allows us to make a
    profit or even cover our costs. Also, we cannot be sure that
    reimbursement amounts will not reduce the demand for, or the
    price of, our product candidates. Except with respect to
    taliglucerase alfa, we have not commenced efforts to have our
    product candidates reimbursed by government or third-party
    payors. If reimbursement is not available or is available only
    to limited levels, the sales of our products, if approved may be
    diminished or we may not be able to sell such products
    profitably.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Reforms
    in the healthcare industry and the uncertainty associated with
    pharmaceutical pricing, reimbursement and related matters could
    adversely affect the marketing, pricing and demand for our
    products, if approved.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Increasing expenditures for healthcare have been the subject of
    considerable public attention in the United States. Both private
    and government entities are seeking ways to reduce or contain
    healthcare costs. Numerous proposals that would effect changes
    in the U.S.&#160;healthcare system have been introduced or
    proposed in the U.S.&#160;Congress and in some state
    legislatures within the United States, including reductions in
    the pricing of prescription products and changes in the levels
    at which consumers and healthcare providers are reimbursed for
    purchases of pharmaceutical products. For example, the Medicare
    Prescription Drug Improvement, and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    49
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Modernization Act of 2003 and the proposed rules thereunder
    impose new requirements for the distribution and pricing of
    prescription drugs that began in 2006, which could reduce
    reimbursement of prescription drugs for healthcare providers and
    insurers. Although we cannot predict the full effect on our
    business of the implementation of this legislation, it is
    possible that the new Medicare prescription drug benefit, which
    will be managed by private health insurers and other managed
    care organizations, will result in additional government
    reimbursement for prescription drugs, which may make some
    prescription drugs more affordable but may further exacerbate
    industry-wide pressure to reduce prescription drug prices. We
    believe that legislation that reduces reimbursement for our
    product candidates could adversely impact how much or under what
    circumstances healthcare providers will prescribe or administer
    our products, if approved. This could materially and adversely
    impact our business by reducing our ability to generate revenue,
    raise capital, obtain additional collaborators and market our
    products, if approved. In addition, we believe the increasing
    emphasis on managed care in the United States has and will
    continue to put pressure on the price and usage of
    pharmaceutical products, which may adversely impact product
    sales, upon approval, if at all.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We are
    subject to healthcare reform measures, including legislation,
    regulatory proposals and healthcare payor initiatives that may
    increase our costs and adversely affect our profitability and/or
    ability to obtain adequate reimbursement for our product
    candidates.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The United States and some foreign jurisdictions are considering
    or have enacted a number of legislative and regulatory proposals
    to change the healthcare system in ways that could affect our
    ability to sell our products profitably. Among policymakers and
    payors in the United States and elsewhere, there is significant
    interest in promoting changes in healthcare systems with the
    stated goals of containing healthcare costs, improving quality
    <FONT style="white-space: nowrap">and/or</FONT>
    expanding access. In the United States, the pharmaceutical
    industry has been a particular focus of these efforts and has
    been significantly affected by major legislative initiatives.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In March 2010, the Patient Protection and Affordable Care Act,
    as amended by the Health Care and Education Affordability
    Reconciliation Act, or collectively, PPACA, became law in the
    United States. PPACA substantially changes the way healthcare is
    financed by both governmental and private insurers and
    significantly affects the pharmaceutical industry. Key
    provisions of PPACA specific to the pharmaceutical industry,
    among others, include the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    An annual, nondeductible fee on any entity that manufactures or
    imports certain branded prescription drugs and biologic agents
    into the United States, apportioned among these entities
    according to their market share in certain federal government
    healthcare programs (excluding sales of any drug or biologic
    product marketed for an orphan indication), beginning in 2011;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    An increase in the rebates a manufacturer must pay under the
    Medicaid Drug Rebate Program, retroactive to January&#160;1,
    2010, to 23.1% and 13% of the average manufacturer price for
    branded and generic drugs, respectively;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    A new Medicare Part&#160;D coverage gap discount program, in
    which manufacturers must agree to offer 50% point-of sale
    discounts off negotiated prices of applicable brand drugs to
    eligible beneficiaries during their coverage gap period, as a
    condition for the manufacturer&#146;s outpatient drugs to be
    covered under Medicare Part&#160;D, beginning in 2011;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Extension of manufacturers&#146; Medicaid rebate liability to
    covered drugs dispensed to individuals who are enrolled in
    Medicaid managed care organizations, effective March&#160;23,
    2010;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Expansion of eligibility criteria for Medicaid programs by,
    among other things, allowing states to offer Medicaid coverage
    to additional individuals beginning in April 2010 and by adding
    new mandatory eligibility categories for certain individuals
    with income at or below 133% of the Federal Poverty Level
    beginning in 2014, thereby potentially increasing both the
    volume of sales and manufacturers&#146; Medicaid rebate
    liability;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Expansion of the entities eligible for discounts under the
    Public Health Service pharmaceutical pricing program, effective
    January 2010;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    50
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    New requirements to report certain financial arrangements with
    physicians and others, including reporting any &#147;transfer of
    value&#148; made or distributed to prescribers and other
    healthcare providers and reporting any investment interests held
    by physicians and their immediate family members during each
    calendar year beginning in 2012, with reporting starting in 2013;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    A new requirement to annually report drug samples that
    manufacturers and distributors provide to physicians, effective
    April&#160;1, 2012;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    A licensure framework for follow-on biologic products;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    A new Patient-Centered Outcomes Research Institute to oversee,
    identify priorities in, and conduct comparative clinical
    effectiveness research, along with funding for such research.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Although we cannot predict their full impact, we anticipate that
    PPACA, as well as other healthcare reform measures that may be
    adopted in the future, may result in more rigorous coverage and
    reimbursement criteria and in additional downward pressure on
    the price that we receive for any approved product, and could
    adversely affect our profits and our business generally.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We may
    be subject, directly or indirectly, to federal and state
    healthcare fraud and abuse and false claims laws and
    regulations. If we are unable to comply, or have not fully
    complied, with such laws, we could face substantial
    penalties.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If we obtain FDA approval for any of our product candidates and
    begin commercializing those products in the United States, our
    operations may be directly, or indirectly through our customers,
    subject to various state and federal fraud and abuse laws,
    including, without limitation, the federal Anti-Kickback Statute
    and the federal False Claims Act. These laws may impact, among
    other things, our proposed sales, marketing and education
    programs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The federal Anti-Kickback Statute prohibits persons from
    knowingly and willfully soliciting, receiving, offering or
    paying remuneration, directly or indirectly, to induce either
    the referral of an individual, or the furnishing, recommending,
    or arranging for a good or service, for which payment may be
    made under a federal healthcare program, such as the Medicare
    and Medicaid programs. The term &#147;remuneration&#148; is not
    defined in the federal Anti-Kickback Statute and has been
    broadly interpreted to include anything of value, including for
    example, gifts, discounts, the furnishing of supplies or
    equipment, credit arrangements, payments of cash, waivers of
    payment, ownership interests and providing anything at less than
    its fair market value. The reach of the Anti-Kickback Statute
    was also broadened by PPACA, which, among other things, amends
    the intent requirement of the federal Anti-Kickback Statute and
    the applicable criminal healthcare fraud statutes contained
    within 42&#160;U.S.C.
    <FONT style="white-space: nowrap">&#167;&#160;1320a-7b,</FONT>
    effective March&#160;23, 2010. Pursuant to the statutory
    amendment, a person or entity no longer needs to have actual
    knowledge of this statute or specific intent to violate it in
    order to have committed a violation. In addition, PPACA provides
    that the government may assert that a claim including items or
    services resulting from a violation of the federal Anti-Kickback
    Statute constitutes a false or fraudulent claim for purposes of
    the civil False Claims Act (discussed below) or the civil
    monetary penalties statute, which imposes penalties against any
    person who is determined to have presented or caused to be
    presented a claim to a federal health program that the person
    knows or should know is for an item or service that was not
    provided as claimed or is false or fraudulent. The federal
    Anti-Kickback Statute is broad, and despite a series of narrow
    safe harbors, prohibits may arrangements and practices that are
    lawful in businesses outside of the healthcare industry.
    Penalties for violations of the federal Anti-Kickback Statute
    include criminal penalties and civil sanctions such as fines,
    imprisonment and possible exclusion from Medicare, Medicaid and
    other healthcare programs. Many states have also adopted laws
    similar to the federal Anti-Kickback Statute, some of which
    apply to the referral of patients for healthcare items or
    services reimbursed by any source, not only the Medicare and
    Medicaid programs, and do not contain identical safe harbors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The federal False Claims Act imposes liability on any person
    who, among other things, knowingly presents, or causes to be
    presented, a false or fraudulent claim for payment by a federal
    healthcare program. The &#147;qui tam&#148; provisions of the
    False Claims Act allow a private individual to bring civil
    actions on behalf of the federal government alleging that the
    defendant has submitted a false claim to the federal government,
    and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    51
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    to share in any monetary recovery. In addition, various states
    have enacted false claims laws analogous to the False Claims
    Act. Many of these state laws apply where a claim is submitted
    to any third-party payer and not merely a federal healthcare
    program. When an entity is determined to have violated the False
    Claims Act, it may be required to pay up to three times the
    actual damages sustained by the government, plus civil penalties
    of $5,500 to $11,000 for each separate false claim.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Also, the Health Insurance Portability and Accountability Act of
    1996, or HIPAA, created several new federal crimes, including
    health care fraud, and false statements relating to health care
    matters. The health care fraud statute prohibits knowingly and
    willfully executing a scheme to defraud any health care benefit
    program, including private third-party payers. The false
    statements statute prohibits knowingly and willfully falsifying,
    concealing or covering up a material fact or making any
    materially false, fictitious or fraudulent statement in
    connection with the delivery of or payment for health care
    benefits, items or services.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are unable to predict whether we could be subject to actions
    under any of these or other fraud and abuse laws, or the impact
    of such actions. Moreover, to the extent that our products will
    be sold in a foreign country, we may be subject to similar
    foreign laws and regulations. If we are found to be in violation
    of any of the laws described above and other applicable state
    and federal fraud and abuse laws, we may be subject to
    penalties, including civil and criminal penalties, damages,
    fines, exclusion from government healthcare reimbursement
    programs and the curtailment or restructuring or our operations,
    all of which could have a material adverse effect on our
    business and the results of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Governments
    outside the United States tend to impose strict price controls
    and reimbursement approval policies, which may adversely affect
    our prospects for generating revenue.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In some countries, particularly European Union countries, the
    pricing of prescription pharmaceuticals is subject to
    governmental control. In these countries, pricing negotiations
    with governmental authorities can take considerable time (six to
    12&#160;months or longer) after the receipt of marketing
    approval for a product. To obtain reimbursement or pricing
    approval in some countries with respect to any product candidate
    that achieves regulatory approval, we may be required to conduct
    a clinical trial that compares the cost-effectiveness of our
    product candidate to other available therapies. If reimbursement
    of our products upon approval, if at all, is unavailable or
    limited in scope or amount, or if pricing is set at
    unsatisfactory levels, our prospects for generating revenue, if
    any, could be adversely affected which would have a material
    adverse effect on our business and results of operations.
    Further, if we achieve regulatory approval of any product, we
    must successfully negotiate product pricing for such product in
    individual countries. As a result, the pricing of our products,
    if approved, in different countries may vary widely, thus
    creating the potential for third-party trade in our products in
    an attempt to exploit price differences between countries. This
    third-party trade of our products could undermine our sales in
    markets with higher prices.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Relating to Our Operations in Israel</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Potential
    political, economic and military instability in the State of
    Israel, where the majority of our senior management and our
    research and development facilities are located, may adversely
    affect our results of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our executive office and operations are located in the State of
    Israel. Accordingly, political, economic and military conditions
    in Israel directly affect our business. Since the State of
    Israel was established in 1948, a number of armed conflicts have
    occurred between Israel and its Arab neighbors. Any hostilities
    involving Israel or the interruption or curtailment of trade
    between Israel and its present trading partners, or a
    significant downturn in the economic or financial condition of
    Israel, could affect adversely our operations. Since October
    2000 there have been increasing occurrences of terrorist
    violence. Ongoing and revived hostilities or other Israeli
    political or economic factors could harm our operations and
    product development and cause our revenues to decrease.
    Furthermore, several countries, principally those in the Middle
    East, still restrict business with Israel and Israeli companies.
    These restrictive laws and policies may limit seriously our
    ability to sell our products in these countries.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    52
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Although Israel has entered into various agreements with Egypt,
    Jordan and the Palestinian Authority, there have been times
    since October 2000 when Israel has experienced an increase in
    unrest and terrorist activity. The establishment in 2006 of a
    government in the Palestinian Authority by representatives of
    the Hamas militant group has created additional unrest and
    uncertainty in the region. In mid-2006, there was a war between
    Israel and the Hezbollah in Lebanon, resulting in thousands of
    rockets being fired from Lebanon up to 50&#160;miles into
    Israel. Our current facilities are located in northern Israel,
    are in range of rockets that were fired from Lebanon into Israel
    during the war and suffered minimal damages during one of the
    rocket attacks. If our facilities are damaged as a result of
    hostile action, our operations may be materially adversely
    affected.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Our
    operations may be disrupted by the obligations of our personnel
    to perform military service which could have a material adverse
    effect on our business.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Many of our male employees in Israel, including members of
    senior management, are obligated to perform up to one month (in
    some cases more) of annual military reserve duty until they
    reach the age of 45 and, in the event of a military conflict,
    could be called to active duty. Our operations could be
    disrupted by the absence of a significant number of our
    employees related to military service or the absence for
    extended periods of military service of one or more of our key
    employees. A disruption could have a material adverse effect on
    our business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Because
    a certain portion of our expenses is incurred in New Israeli
    Shekels, or NIS, our results of operations may be seriously
    harmed by currency fluctuations and inflation.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We report our financial statements in U.S.&#160;dollars, our
    functional currency, but we pay a meaningful portion of our
    expenses in New Israeli Shekels, or NIS. As a result, we are
    exposed to risk to the extent that the inflation rate in Israel
    exceeds the rate of devaluation of the NIS in relation to the
    U.S.&#160;dollar or if the timing of these devaluations lags
    behind inflation in Israel. In that event, the U.S.&#160;dollar
    cost of our operations in Israel will increase and our
    U.S.&#160;dollar-measured results of operations will be
    adversely affected. To the extent that the value of the NIS
    increases against the dollar, our expenses on a dollar cost
    basis increase. Our operations also could be adversely affected
    if we are unable to guard against currency fluctuations in the
    future. To date, we have not engaged in hedging transactions. In
    the future, we may enter into currency hedging transactions to
    decrease the risk of financial exposure from fluctuations in the
    exchange rate of the U.S.&#160;dollar against the NIS. These
    measures, however, may not adequately protect us from material
    adverse effects.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    tax benefits available to us require that we meet several
    conditions and may be terminated or reduced in the future, which
    would increase our taxes and would have a material adverse
    effect on our business and results of operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are able to take advantage of tax exemptions and reductions
    resulting from the &#147;Approved Enterprise&#148; status of our
    facilities in Israel. To remain eligible for these tax benefits,
    we must continue to meet certain conditions, including making
    specified investments in property and equipment, and financing
    at least 30% of such investments with share capital. If we fail
    to meet these conditions in the future, the tax benefits would
    be canceled and we may be required to refund any tax benefits we
    already have enjoyed. These tax benefits are subject to
    investment policy by the Investment Center and may not be
    continued in the future at their current levels or at any level.
    In recent years the Israeli government has reduced the benefits
    available and has indicated that it may further reduce or
    eliminate some of these benefits in the future. The termination
    or reduction of these tax benefits or our inability to qualify
    for additional &#147;Approved Enterprise&#148; approvals may
    increase our tax expenses in the future, which would reduce our
    expected profits and adversely affect our business and results
    of operations. Additionally, if we increase our activities
    outside of Israel, for example, by future acquisitions, such
    increased activities generally may not be eligible for inclusion
    in Israeli tax benefit programs.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    53
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Israeli government grants we have received for certain research
    and development expenditures restrict our ability to manufacture
    products and transfer technologies outside of Israel and require
    us to satisfy specified conditions. If we fail to satisfy these
    conditions, we may be required to refund grants previously
    received together with interest and penalties which could have a
    material adverse effect on our business and results of
    operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our research and development efforts have been financed, in
    part, through grants that we have received from the OCS. We,
    therefore, must comply with the requirements of the Israeli Law
    for the Encouragement of Industrial Research and Development,
    1984, and related regulations, or the Research Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the Research Law, the discretionary approval of an OCS
    committee is required for any transfer of technology developed
    with OCS funding. OCS approval is not required for the export of
    any products resulting from the research or development, or for
    the licensing of the technology in the ordinary course of
    business. We may not receive the required approvals for any
    proposed transfer. Such approvals, if granted, may be subject to
    the following additional restrictions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    we may be required to pay the OCS a significant portion of the
    consideration we receive upon any sale of such technology to an
    entity that is not Israeli. The scope of the support received,
    the royalties that were paid by us, the amount of time that
    elapses between the date on which the know-how is transferred
    and the date on which the grants were received, as well as the
    sale price, will be taken into account in order to calculate the
    amount of the payment;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the transfer of manufacturing rights could be conditioned upon
    an increase in the royalty rate and payment of increased
    aggregate royalties (up to 300% of the amount of the grant plus
    interest, depending on the percentage of the manufacturing that
    is foreign).
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    These restrictions may impair our ability to sell our technology
    assets or to outsource manufacturing outside of Israel. The
    restrictions will continue to apply for a certain period of time
    even after we have repaid the full amount of royalties payable
    for the grants. If we fail to satisfy these conditions, we may
    be required to refund grants previously received together with
    interest and penalties which could have a material adverse
    effect on our business and results of operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Investors
    may have difficulties enforcing a U.S. judgment, including
    judgments based upon the civil liability provisions of the U.S.
    federal securities laws against us, our executive officers and
    most of our directors or asserting U.S. securities laws claims
    in Israel.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Most of our directors and officers are not residents of the
    United States and most of their assets and our assets are
    located outside the United States. Service of process upon our
    <FONT style="white-space: nowrap">non-U.S.&#160;resident</FONT>
    directors and officers and enforcement of judgments obtained in
    the United States against us, some of our directors and
    executive officers may be difficult to obtain within the United
    States. We have been informed by our legal counsel in Israel
    that investors may find it difficult to assert claims under
    U.S.&#160;securities laws in original actions instituted in
    Israel or obtain a judgment based on the civil liability
    provisions of U.S.&#160;federal securities laws against us, our
    officers and our directors. Israeli courts may refuse to hear a
    claim based on a violation of U.S.&#160;securities laws against
    us or our officers and directors because Israel is not the most
    appropriate forum to bring such a claim. In addition, even if an
    Israeli court agrees to hear a claim, it may determine that
    Israeli law and not U.S.&#160;law is applicable to the claim. If
    U.S.&#160;law is found to be applicable, the content of
    applicable U.S.&#160;law must be proved as a fact which can be a
    time-consuming and costly process. Certain matters of procedure
    will also be governed by Israeli law. There is little binding
    case law in Israel addressing the matters described above.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Israeli courts might not enforce judgments rendered outside
    Israel which may make it difficult to collect on judgments
    rendered against us. Subject to certain time limitations, an
    Israeli court may declare a foreign civil judgment enforceable
    only if it finds that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the judgment was rendered by a court which was, according to the
    laws of the state of the court, competent to render the judgment;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    54
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the judgment may no longer be appealed;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the obligation imposed by the judgment is enforceable according
    to the rules relating to the enforceability of judgments in
    Israel and the substance of the judgment is not contrary to
    public policy;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the judgment is executory in the state in which it was given.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Even if these conditions are satisfied, an Israeli court will
    not enforce a foreign judgment if it was given in a state whose
    laws do not provide for the enforcement of judgments of Israeli
    courts (subject to exceptional cases) or if its enforcement is
    likely to prejudice the sovereignty or security of the State of
    Israel. An Israeli court also will not declare a foreign
    judgment enforceable if:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the judgment was obtained by fraud;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    there is a finding of lack of due process;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the judgment was rendered by a court not competent to render it
    according to the laws of private international law in Israel;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the judgment is at variance with another judgment that was given
    in the same matter between the same parties and that is still
    valid;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    at the time the action was brought in the foreign court, a suit
    in the same matter and between the same parties was pending
    before a court or tribunal in Israel.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Risks
    Related to Investing in Our Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    market price of our common stock may fluctuate
    significantly.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The market price of our common stock may fluctuate significantly
    in response to numerous factors, some of which are beyond our
    control, such as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the announcement of new products or product enhancements by us
    or our competitors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    developments concerning intellectual property rights and
    regulatory approvals;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    variations in our and our competitors&#146; results of
    operations;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the results of our ongoing studies regarding our lead product
    candidate taliglucerase alfa, or communications from the FDA or
    other regulatory authorities regarding our NDA or MAA for
    taliglucerase alfa or similar filings or submissions, including
    the approval of any such filings by the FDA or other applicable
    regulatory authorities, or any delay of failure by the FDA or
    other applicable regulatory authorities to approve any such
    filings;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    changes in earnings estimates or recommendations by securities
    analysts, if our common stock is covered by analysts;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    developments in the biotechnology industry;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    general market conditions and other factors, including factors
    unrelated to our operating performance.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Further, stock markets in general, and the market for
    biotechnology companies in particular, have recently experienced
    price and volume fluctuations. Continued market fluctuations
    could result in extreme volatility in the price of our common
    stock, which could cause a decline in the value of our common
    stock. Price volatility of our common stock may be worse if the
    trading volume of our common stock is low. We have not paid, and
    do not expect to pay, any cash dividends on our common stock as
    any earnings generated from future operations will be used to
    finance our operations. As a result, investors will not realize
    any income from an investment in our common stock until and
    unless their shares are sold at a profit.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    55
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">All
    liabilities of our company have survived the merger and there
    may be undisclosed liabilities that could harm our revenues,
    business, prospects, financial condition and results of
    operations.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Protalix Ltd.&#160;and its counsel conducted due
    diligence on us that was customary and appropriate for the
    reverse merger transaction consummated on December&#160;31,
    2006. However, the due diligence process may not have revealed
    all our material liabilities then existing or that could be
    asserted in the future against us relating to our activities
    before the consummation of the merger. Any such potential
    liabilities survive the merger and could harm our revenues,
    business, prospects, financial condition and results of
    operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Future
    sales of our common stock could reduce our stock
    price.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The market price of our common stock could drop significantly if
    our existing shareholders sell a large number of shares of our
    common stock or are perceived by the market as intending to sell
    them. All of the shares sold in our public offering in October
    2007 were freely tradable without restriction or further
    registration under the federal securities laws, unless purchased
    by our &#147;affiliates&#148; as that term is defined in
    Rule&#160;144 under the Securities Act. In addition, all of the
    outstanding shares of our common stock are freely tradable
    without restriction or further registration under the federal
    securities laws, unless owned by our affiliates. At
    December&#160;31, 2010, there were options issued and
    outstanding to purchase 7,806,671&#160;shares of our common
    stock with a weighted average exercise price of $3.73 per share.
    Also at December&#160;31, 2010, there were 3,064&#160;shares of
    common stock remaining available for future for issuance in
    connection with future grants of incentives under our 2006 Stock
    Incentive Plan. In addition, four of our executive officers have
    entered into trading plans established under
    <FONT style="white-space: nowrap">Rule&#160;10b5-1</FONT>
    under the Securities Act that allow for sales of approximately
    1.3&#160;million shares upon receipt of FDA approval of
    taliglucerase alfa, if at all.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Directors,
    executive officers, principal shareholders and affiliated
    entities own a significant percentage of our capital stock, and
    they may make decisions that an investor may not consider to be
    in the best interests of our shareholders.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our directors, executive officers, principal shareholders and
    affiliated entities beneficially own, in the aggregate,
    approximately 30% of our outstanding common stock. As a result,
    if some or all of them acted together, they would have the
    ability to exert substantial influence over the election of our
    Board of Directors and the outcome of issues requiring approval
    by our shareholders. This concentration of ownership may have
    the effect of delaying or preventing a change in control of our
    company that may be favored by other shareholders. This could
    prevent the consummation of transactions favorable to other
    shareholders, such as a transaction in which shareholders might
    otherwise receive a premium for their shares over current market
    prices.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Failure
    to maintain effective internal controls in accordance with
    Section&#160;404 of the Sarbanes-Oxley Act could have a material
    adverse effect on our business and operating results. In
    addition, current and potential shareholders could lose
    confidence in our financial reporting, which could have a
    material adverse effect on the price of our common
    stock.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Effective internal controls are necessary for us to provide
    reliable financial reports and effectively prevent fraud. If we
    cannot provide reliable financial reports or prevent fraud, our
    results of operation could be harmed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Section&#160;404 of the Sarbanes-Oxley Act of 2002 requires
    annual management assessments of the effectiveness of our
    internal controls over financial reporting and a report by our
    independent registered public accounting firm addressing these
    assessments. We continuously monitor our existing internal
    controls over financial reporting systems to confirm that they
    are compliant with Section&#160;404, and we may identify
    deficiencies that we may not be able to remediate in time to
    meet the deadlines imposed by the Sarbanes-Oxley Act. This
    process may divert internal resources and will take a
    significant amount of time and effort to complete.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If, at any time, it is determined that we are not in compliance
    with Section&#160;404, we may be required to implement new
    internal control procedures and reevaluate our financial
    reporting. We may experience higher
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    56
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    than anticipated operating expenses as well as increased
    independent auditor fees during the implementation of these
    changes and thereafter. Further, we may need to hire additional
    qualified personnel. If we fail to maintain the adequacy of our
    internal controls, as such standards are modified, supplemented
    or amended from time to time, we may not be able to conclude on
    an ongoing basis that we have effective internal controls over
    financial reporting in accordance with Section&#160;404 of the
    Sarbanes-Oxley Act, which could result in our being unable to
    obtain an unqualified report on internal controls from our
    independent auditors. Failure to maintain an effective internal
    control environment could also cause investors to lose
    confidence in our reported financial information, which could
    have a material adverse effect on the price of our common stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Compliance
    with changing regulation of corporate governance and public
    disclosure may result in additional expenses, divert
    management&#146;s attention from operating our business which
    could have a material adverse effect on our
    business.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    There have been other changing laws, regulations and standards
    relating to corporate governance and public disclosure in
    addition to the Sarbanes-Oxley Act, as well as new regulations
    promulgated by the Commission and rules promulgated by the
    national securities exchanges, including the NYSE Amex and the
    NASDAQ. These new or changed laws, regulations and standards are
    subject to varying interpretations in many cases due to their
    lack of specificity, and as a result, their application in
    practice may evolve over time as new guidance is provided by
    regulatory and governing bodies, which could result in
    continuing uncertainty regarding compliance matters and higher
    costs necessitated by ongoing revisions to disclosure and
    governance practices. As a result, our efforts to comply with
    evolving laws, regulations and standards are likely to continue
    to result in increased general and administrative expenses and a
    diversion of management time and attention from
    revenue-generating activities to compliance activities. Our
    board members, Chief Executive Officer and Chief Financial
    Officer could face an increased risk of personal liability in
    connection with the performance of their duties. As a result, we
    may have difficulty attracting and retaining qualified board
    members and executive officers, which could have a material
    adverse effect on our business. If our efforts to comply with
    new or changed laws, regulations and standards differ from the
    activities intended by regulatory or governing bodies, we may
    incur additional expenses to comply with standards set by
    regulatory authorities or governing bodies which would have a
    material adverse effect on our business and results of
    operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">We are
    a holding company with no operations of our own.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are a holding company with no operations of our own.
    Accordingly, our ability to conduct our operations, service any
    debt that we may incur in the future and pay dividends, if any,
    is dependent upon the earnings from the business conducted by
    Protalix Ltd. The distribution of those earnings or advances or
    other distributions of funds by our subsidiary to us, as well as
    our receipt of such funds, are contingent upon the earnings of
    our subsidiary and are subject to various business
    considerations and U.S.&#160;and Israeli law. If Protalix Ltd.
    is unable to make sufficient distributions or advances to us, or
    if there are limitations on our ability to receive such
    distributions or advances, we may not have the cash resources
    necessary to conduct our corporate operations which would have a
    material adverse effect on our business and results of
    operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    issuance of preferred stock or additional shares of common stock
    could adversely affect the rights of the holders of shares of
    our common stock.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our Board of Directors is authorized to issue up to
    100,000,000&#160;shares of preferred stock without any further
    action on the part of our shareholders. Our Board of Directors
    has the authority to fix and determine the voting rights, rights
    of redemption and other rights and preferences of preferred
    stock. Currently, we have no shares of preferred stock
    outstanding.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our Board of Directors may, at any time, authorize the issuance
    of a series of preferred stock that would grant to holders the
    preferred right to our assets upon liquidation, the right to
    receive dividend payments before dividends are distributed to
    the holders of common stock and the right to the redemption of
    the shares, together with a premium, before the redemption of
    our common stock, which may have a material adverse effect on
    the rights of the holders of our common stock. In addition, our
    Board of Directors, without further shareholder approval, may,
    at any time, issue large blocks of preferred stock. In addition,
    the ability of our
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    57
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Board of Directors to issue shares of preferred stock without
    any further action on the part of our shareholders may impede a
    takeover of our company and may prevent a transaction that is
    favorable to our shareholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the rules of the Tel Aviv Stock Exchange, other than
    incentives under our 2006 Stock Option Plan, we may not issue
    any securities of any class or series different than the common
    stock that is listed on the Tel Aviv Stock Exchange for the
    <FONT style="white-space: nowrap">12-month</FONT>
    period immediately succeeding our initial listing, which
    occurred on September&#160;6, 2010. Subsequent to such
    <FONT style="white-space: nowrap">12-month</FONT>
    period, the rules of the Tel Aviv Stock Exchange allow us to
    issue securities with preferential rights with respect to
    dividends but such other securities may not include voting
    rights. The foregoing does not limit our ability to issue and
grant options and warrants for the purchase of shares of our common
stock.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;1B.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571105'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Unresolved
    Staff Comments</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    None.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="8%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;2.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571106'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Properties</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our manufacturing facility and executive offices are located in
    Carmiel, Israel. The facilities currently contain approximately
    16,000 sq/ft of manufacturing space and additional 48,000 sq/ft
    of laboratory, warehouse and office space and are leased at a
    rate of approximately $71,000 per month. In addition, we are
    entitled to use an additional 13,000 sq/ft in the same facility,
    which we intend to utilize in connection with an anticipated
    expansion of our manufacturing facilities. Our facilities are
    equipped with the requisite laboratory services required to
    conduct our business, and we believe that the existing
    facilities are adequate to meet our needs for the foreseeable
    future. We have leased the facility through 2017, subject to
    three options exercisable by us to extend the term for a
    five-year period, for an aggregate of 15 additional years. Upon
    the exercise of each option to extend the term of the lease, if
    any, the then current base rent shall be increased by 10%. We
    also lease an office in Ramat Gan, Israel, for approximately
    $2,200 per month.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="8%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;3.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571107'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Legal
    Proceedings</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are not involved in any material legal proceedings.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    58
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="8%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;4.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571108'></A><B><I><FONT style="font-family: 'Times New Roman', Times">(Removed
    and Reserved)</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">


    <A name='Y04571109'><B><FONT style="font-family: 'Times New Roman', Times">PART&#160;II</FONT></B></A>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="8%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;5.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571110'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Market
    for Registrant&#146;s Common Equity, Related Stockholder Matters
    and Issuer Purchases of Equity Securities</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our common stock began trading on the NYSE Amex on
    March&#160;12, 2007 under the symbol &#147;PLX.&#148; The
    following table sets forth the quarterly high and low closing
    prices for our common stock, as reported by the NYSE Amex.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="85%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price Range</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>High</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Low</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Fourth Quarter 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.40
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Third Quarter 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.99
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Second Quarter 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.84
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    First Quarter 2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.70
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6.56
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Fourth Quarter 2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    12.14
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6.62
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Third Quarter 2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8.31
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.51
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Second Quarter 2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    First Quarter 2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.89
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    These quotations reflect prices between dealers and do not
    include retained
    <FONT style="white-space: nowrap">mark-ups,</FONT>
    mark-downs and commissions and may not necessarily represent
    actual transactions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    There were approximately 44 holders of record of our common
    stock at February&#160;15, 2011. A substantially greater number
    of holders of our common stock are &#147;street name&#148; or
    beneficial holders, whose shares are held of record by banks,
    brokers and other financial institutions. To date, we have not
    declared or paid any cash dividends on our common stock. We do
    not anticipate paying any dividends on our common stock in the
    foreseeable future.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    59
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">STOCK
    PERFORMANCE GRAPH</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following graph compares the cumulative total shareholder
    return data for our common stock from December&#160;31, 2005
    through December&#160;31, 2010 to the cumulative return over
    such time period of (i)&#160;The AMEX Composite Index and
    (ii)&#160;The AMEX Biotechnology Index. The graph assumes an
    investment of $100 on December&#160;31, 2005 in each of our
    common stock, and the stocks comprising the AMEX Composite Index
    and the stocks comprising the AMEX Biotechnology Index,
    including dividend reinvestment, if any.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>The stock price performance shown on the graph below
    represents historical price performance and is not necessarily
    indicative of any future stock price performance. Specifically,
    during the period from December&#160;31, 2005 through
    December&#160;31, 2006, our company did not have any operations
    and our common stock was quoted on the
    OTC<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></I></B>

    <B><I>Bulletin&#160;Board. The historical performance of our
    common stock prior to January&#160;2, 2007, represents the
    performance of our company prior to the merger on
    December&#160;31, 2006, and, therefore, is not indicative of the
    performance of our common stock after the merger or the
    performance of our common stock after it was listed for trade on
    the NYSE AMEX on March&#160;12, 2007.</I></B>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">COMPARISON
    OF 5 YEAR CUMULATIVE TOTAL
    RETURN<SUP style="font-size: 85%; vertical-align: top">*<BR>

    </SUP>Among Protalix BioTherapeutics, Inc., the NYSE Amex
    Composite Index<BR>
    and the NYSE Arca Biotechnology Index</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <IMG src="y04571y0457105.gif" alt="(PERFORMANCECHART)"><B> </B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    <B>* </B></TD>
    <TD></TD>
    <TD valign="bottom">
    $100 invested on 12/31/05 in stock or index, including
    reinvestment of dividends.<BR>
    Fiscal year ending December 31.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B><I>Notwithstanding anything to the contrary set forth in any
    of our previous filings under the Securities Act of 1933, as
    amended, or the Exchange Act, which might incorporate future
    filings made by us under those statutes, this Stock Performance
    Graph will not be incorporated by reference into any of those
    prior filings, nor will such report or graph be incorporated by
    reference into any future filings made by us under those
    Acts.</I></B>
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    60
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="8%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;6.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571111'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Selected
    Financial Data</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The selected consolidated financial data below should be read in
    conjunction with &#147;Management&#146;s Discussion and Analysis
    of Financial Condition and Results of Operations&#148; and our
    consolidated financial statements and the related notes included
    elsewhere in this Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K.</FONT>
    The selected consolidated statements of operations data for the
    years ended December&#160;31, 2010, 2009 and 2008 and the
    selected consolidated balance sheet data as of December&#160;31,
    2010 and 2009, are derived from the audited consolidated
    financial statements included elsewhere in this Annual Report.
    The statement of operations data for the years ended
    December&#160;31, 2006 and 2007 and the balance sheet data as of
    December&#160;31, 2006, 2007 and 2008 are derived from audited
    financial statements not included in this Annual Report. The
    historical results presented below are not necessarily
    indicative of future results.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="45%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom">
    <B>(In thousands, except share and per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Consolidated Statement of Operations Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,244
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cost of revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,383
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Gross profit (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,187
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,861
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Research and development expenses, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,246
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,570
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    17,401
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    21,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,951
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,525
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,594
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,770
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,876
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Finance income
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    344
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,080
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    968
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss before change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    32,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    22,414
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    31,440
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    28,998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cumulative effect of change in accounting principle
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (37
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,390
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    32,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    22,414
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    31,440
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    28,998
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock, basic and diluted(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.32
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.48
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average number of shares of common stock used in
    computing net loss per share of common stock(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29,300,987
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    67,187,329
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,890,633
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,942,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80,960,300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Consolidated Balance Sheet Data:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    15,378
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    61,813
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    42,596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    81,266
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    35,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,610
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,324
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,405
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,829
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    26,988
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,137
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,811
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    98,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    64,729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Current liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,268
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,762
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,527
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,530
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,903
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,704
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,452
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,464
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,788
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,052
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Shareholders&#146; equity (net of capital deficiency)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,284
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,685
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,347
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,883
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,323
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="center" valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents less than $1.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Reflects the retroactive effects of the impact of our merger
    with Protalix Ltd. in December 2006 and the resulting exchange
    of shares of common stock for the ordinary shares of Protalix
    Ltd. at an exchange ratio of approximately 61.08&#160;shares of
    our common stock per ordinary share of Protalix Ltd. for all
    periods presented.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    In connection with the merger, we completed a
    <FONT style="white-space: nowrap">one-for-ten</FONT>
    reverse stock split in December 2006, therefore all share
    numbers presented in this Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    give retroactive effect to the reverse stock split, as
    applicable.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    61
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="8%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;7.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571112'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Management&#146;s
    Discussion and Analysis of Financial Condition and Results of
    Operations</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>You should read the following discussion and analysis of our
    financial condition and results of operations together with our
    consolidated financial statements and the related notes included
    elsewhere in this Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K.</FONT>
    Some of the information contained in this discussion and
    analysis, particularly with respect to our plans and strategy
    for our business and related financing, includes forward-looking
    statements that involve risks and uncertainties. You should read
    &#147;Risk Factors&#148; in Item&#160;1A of this Annual Report
    on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for a discussion of important factors that could cause actual
    results to differ materially from the results described in or
    implied by the forward-looking statements contained in the
    following discussion and analysis.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We are a biopharmaceutical company focused on the development
    and commercialization of recombinant therapeutic proteins based
    on our proprietary
    ProCellEx<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>

    protein expression system, or ProCellEx. Using our ProCellEx
    system, we are developing a pipeline of proprietary and
    biosimilar or &#147;generic&#148; versions of recombinant
    therapeutic proteins based on our plant cell-based expression
    technology that target large, established pharmaceutical markets
    and that rely upon known biological mechanisms of action. Our
    initial commercial focus has been on complex therapeutic
    proteins, including proteins for the treatment of genetic
    disorders, such as Gaucher disease and Fabry disease. We believe
    our ProCellEx protein expression system will enable us to
    develop proprietary recombinant proteins that are
    therapeutically equivalent or superior to existing recombinant
    proteins currently marketed for the same indications. Because we
    are primarily targeting biologically equivalent versions of
    highly active, well-tolerated and commercially successful
    therapeutic proteins, we believe our development process is
    associated with relatively less risk compared to other
    biopharmaceutical development processes for completely novel
    therapeutic proteins.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our lead product development candidate is taliglucerase alfa for
    the treatment of Gaucher disease, which we are developing using
    our ProCellEx protein expression system. On December&#160;9,
    2009, we filed a New Drug Application (NDA) for taliglucerase
    alfa with the FDA, and in July 2010 we received notification
    from the FDA that it had accepted the filing of our NDA and
    assigned taliglucerase alfa a Prescription Drug User Fee Act
    (PDUFA) date of February&#160;25, 2011. In addition, in November
    2010 we submitted a marketing application to the Israeli MOH and
    an MAA to each of the EMEA and ANVISA for taliglucerase alfa for
    the treatment of Gaucher disease.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to our recently completed phase&#160;III clinical
    trial, we initiated a double-blind, follow-on extension study as
    part of the trial during the second quarter of 2008. We also
    initiated a home care treatment program for patients enrolled in
    the extension study and, in December 2008, we initiated a
    nine-month, worldwide, multi-center, open-label, switch-over
    clinical study evaluating the safety and efficacy of switching
    Gaucher patients currently treated under the current standard of
    care to treatment with taliglucerase alfa. In December 2009, we
    filed a proposed pediatric investigation plan to the Pediatric
    Committee of the EMEA which was approved during the first
    quarter of 2010, and have since initiated pediatric studies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On November&#160;30, 2009, Protalix Ltd. and Pfizer entered into
    an exclusive license and supply agreement pursuant to which
    Pfizer was granted an exclusive, worldwide license to develop
    and commercialize taliglucerase alfa. Under the terms and
    conditions of the Pfizer agreement, Protalix Ltd. retained the
    right to commercialize taliglucerase alfa in Israel. In
    connection with the execution of the Pfizer agreement, Pfizer
    made an upfront payment to Protalix Ltd. of $60.0&#160;million
    in connection with the execution of the agreement and
    subsequently paid Protalix Ltd. an additional $5.0&#160;million
    upon its filing of a proposed pediatric investigation plan to
    the Pediatric Committee of the EMEA. Protalix Ltd. is also
    eligible to receive potential milestone payments totaling
    $50.0&#160;million for the successful achievement of other
    regulatory milestones. Pfizer and Protalix Ltd. will also share
    future revenues and expenses for the development and
    commercialization of taliglucerase alfa on a 60% and 40% basis,
    respectively, and have also agreed to a specific allocation of
    the responsibilities for the continued development efforts for
    taliglucerase alfa.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On July&#160;13, 2010, we announced that the French regulatory
    authority had granted an Autorisation Temporaire
    d&#146;Utilisation (ATU), or Temporary Authorization for Use,
    for taliglucerase alfa for the treatment
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    62
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    of Gaucher disease. An ATU is the regulatory mechanism used by
    the French Health Products and Safety Agency to make
    non-approved drugs available to patients in France when a
    genuine public health need exists. This ATU allows patients with
    Gaucher disease in France to receive treatment with
    taliglucerase alfa before marketing authorization for the
    product is granted in the European Union. Payment for
    taliglucerase alfa has been secured through government
    allocations to hospitals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On August&#160;10, 2010, Pfizer entered into a $30&#160;million
    short-term supply agreement with the Ministry of Health of
    Brazil pursuant to which Protalix and Pfizer have provided
    taliglucerase alfa to the Ministry of Health of Brazil for the
    treatment of patients with Gaucher disease. Revenue generated
    from the Ministry of Health of Brazil will be recorded by Pfizer
    and we are entitled to our share of the revenue in accordance
    with the terms and conditions of the Pfizer Agreement. In
    addition, we and the Ministry of Health of Brazil are in
    discussions relating to a possible long-term supply agreement
    that contemplates, among other matters, providing certain
    components of our manufacturing technology to the Ministry of
    Health of Brazil for implementation by it in Brazil. At this
    time, we are unable to assess whether these discussions will
    result in an agreement and we can make no assurances that we
    will be able to enter into such an agreement on favorable terms,
    if at all. In any event, we do not expect to enter into a
    long-term supply agreement with the Ministry of Health of Brazil
    until we receive marketing approval of taliglucerase alfa from
    the FDA or ANVISA, if at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to taliglucerase alfa, we are developing an
    innovative product pipeline using our ProCellEx protein
    expression system. Our product pipeline currently includes,
    among other candidates, (1)&#160;PRX-102, a therapeutic protein
    candidate for the treatment of Fabry disease, a rare, genetic
    lysosomal disorder in humans, (2)&#160;PRX-105, a plant cell
    expressed pegylated recombinant acetylcholinesterase product
    candidate for biodefense and other indications,
    (3)&#160;pr-antiTNF, a plant cell expressed recombinant fusion
    protein made from the soluble form of the human TNF receptor
    (TNFR) and an antibody portion, which is being developed as a
    treatment of certain immune diseases such as rheumatoid
    arthritis, juvenile idiopathic arthritis, ankylosing,
    spondylitis, psoriatic arthritis and plaque psoriasis,
    (4)&#160;an orally administrated glucocerebrosidase enzyme for
    treating Gaucher patients utilizing the oral delivery of the
    recombinant enzyme produced within carrot cells and
    (5)&#160;additional undisclosed therapeutic proteins, all of
    which are currently being evaluated in animal studies. In March
    2010, we initiated a preliminary phase I clinical trial of
    PRX-105, our plant cell expressed pegylated recombinant
    acetylcholinesterase product candidate for biodefense
    indications, which we completed in June 2010. We are currently
    preparing for further efficacy trials of this product candidate
    in larger animals and with live nerve gas.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In December 2010 we held a pre-IND meeting with the FDA with
    respect to PRX-102. We expect to submit an IND to the FDA within
    the next 12&#160;months in connection with an anticipated phase
    I/II study of PRX-102 and to initiate the trial once the IND is
    approved, if at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our business is conducted by our wholly-owned subsidiary,
    Protalix Ltd., which we acquired through a reverse merger
    transaction effective December&#160;31, 2006. The merger
    transaction was treated as a recapitalization for accounting
    purposes and, as such, the results of operations discussed below
    are those of Protalix Ltd. Prior to the merger transaction, we
    had not conducted any operations for several years. Protalix
    Ltd. was originally incorporated in Israel in December 1993.
    Since its inception in December 1993, Protalix Ltd. has
    generated significant losses in connection with its research and
    development, including the clinical development of taliglucerase
    alfa. Since we do not generate significant revenue from any of
    our product candidates, we expect to continue to generate losses
    in connection with the continued clinical development of
    taliglucerase alfa and the research and development activities
    relating to our technology and other drug candidates. We except
    that our expenditures in connection with the research and
    development activities will continue to represent a significant
    portion of our expenses for the next several years, and will
    require further financial resources if the activities are
    successful. As a result, we believe that our operating losses
    may continue to be substantial over the next several years.
    However, if taliglucerase alfa is launched successfully, we
    anticipate that we will generate revenues to offset any such
    losses. We may need to obtain additional funds for the
    commercialization of our lead product, taliglucerase alfa, and
    to further develop the research and clinical development of our
    other programs.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    63
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Critical
    Accounting Policies</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our significant accounting policies are more fully described in
    Note&#160;1 to our consolidated financial statements appearing
    at the end of this Annual Report. We believe that the accounting
    policies below are critical for one to fully understand and
    evaluate our financial condition and results of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The discussion and analysis of our financial condition and
    results of operations is based on our financial statements,
    which we prepared in accordance with U.S.&#160;generally
    accepted accounting principles. The preparation of these
    financial statements requires us to make estimates and
    assumptions that affect the reported amounts of assets and
    liabilities and the disclosure of contingent assets and
    liabilities at the date of the financial statements, as well as
    the reported revenues and expenses during the reporting periods.
    On an ongoing basis, we evaluate such estimates and judgments,
    including those described in greater detail below. We base our
    estimates on historical experience and on various other factors
    that we believe are reasonable under the circumstances, the
    results of which form the basis for making judgments about the
    carrying value of assets and liabilities that are not readily
    apparent from other sources. Actual results may differ from
    these estimates under different assumptions or conditions.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Functional
    Currency</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The currency of the primary economic environment in which our
    operations are conducted is the dollar. As we have no
    significant source of revenues, we considered the currency of
    the primary economic environment to be the currency in which we
    expend cash. Most of our expenses and capital expenditures are
    incurred in dollars, and a significant source of our financing
    has been provided in U.S.&#160;dollars.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Revenues</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We recognize revenue when the earnings process is complete,
    which is when revenue is realized or realizable and earned,
    there is persuasive evidence a revenue arrangement exists,
    delivery of goods or services has occurred, the sales price is
    fixed or determinable and collectability is reasonably assured.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We recognize revenue and milestone payments received pursuant to
    the Pfizer Agreement in accordance with guidance regarding
    revenue recognition and accounting for revenue arrangements with
    multiple deliverables. Pursuant to this guidance, we determine
    whether our arrangement with Pfizer involves multiple
    revenue-generating deliverables that should be accounted for as
    a combined unit of accounting or separate units of accounting
    for revenue recognition purposes. If we determine that there are
    multiple units of accounting, the consideration from the
    arrangement is allocated among the separate units based on a
    relative fair value allocation. If the arrangement represents a
    single unit of accounting, the revenue is recognized over the
    performance obligation period. As the arrangement with Pfizer
    requires our continued involvement with respect to the proposed
    commercialization of taliglucerase alfa, the non-refundable,
    up-front license payments we received from Pfizer are deferred
    and recognized over the related performance period. We estimated
    the performance period of 14&#160;years based on the date that
    the last relevant patent relating to taliglucerase alfa expires.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the terms and conditions of the Pfizer Agreement, we are
    entitled to 40% of the profits or loss from sales of
    taliglucerase alfa, and related expenses incurred, except with
    respect to sales in Israel. We recognize our share of net profit
    or loss under the Pfizer Agreement based on reports we receive
    from Pfizer summarizing the results of the collaborative
    activities under the agreement for the applicable period. Under
    the terms of the Pfizer Agreement, for its subsidiaries
    operating outside the United States, financial information is
    included based on the fiscal year ending November&#160;30, while
    financial information for the U.S.&#160;entity is included based
    on the fiscal year ending December&#160;31.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We recognize revenues received from the sale of a product to
    Pfizer upon delivery to Pfizer. The revenues represent our cost
    with respect to the product sold.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    64
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Research
    and Development Expense</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We expect our research and development expense to remain our
    primary expense in the near future as we continue to develop our
    product candidates. Research and development expense consists of:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    internal costs associated with research and development
    activities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    payments made to third party contract research organizations,
    investigative sites and consultants;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    manufacturing development costs;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    personnel-related expenses, including salaries, benefits,
    travel, and related costs for the personnel involved in research
    and development;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    activities relating to the advancement of product candidates
    through preclinical studies and clinical trials;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    facilities and other allocated expenses, which include direct
    and allocated expenses for rent and maintenance of facilities,
    as well as laboratory and other supplies.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table identifies our current major research and
    development projects:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="33%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="31%">&nbsp;</TD> <!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="31%">&nbsp;</TD> <!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Project</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Status</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Expected Near Term Milestone</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
    taliglucerase alfa for the treatment of Gaucher disease
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    NDA and MAA (EMEA, ANVISA and the Israeli MOH) filed
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    PDUFA date (February 25, 2011)
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    PRX 102&#160;&#151; alpha-GAL-A
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Preclinical
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    File IND and initiate phase I clinical trials
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Acetylcholinesterase
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Phase I clinical trial
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Additional phase I clinical trials
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    pr-antiTNF
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Research
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    File IND and initiate phase I clinical trials
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    All of our projects, other than taliglucerase alfa and our
    acetylcholinesterase product, are in the preclinical or research
    phase with relatively immaterial costs. Most of our research and
    development costs were incurred in connection with our
    phase&#160;III clinical trial of taliglucerase alfa. Our
    internal resources, employees and infrastructure are not tied to
    any individual research project and are typically deployed
    across all of our projects. We currently do not record and
    maintain research and development costs per project.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The costs and expenses of our projects are partially funded by
    grants we have received from the OCS. Each grant is deducted
    from the related research and development expenses as the costs
    are incurred. For additional information regarding the grant
    process, see &#147;Business&#160;&#151; Israeli Government
    Programs&#160;&#151; Encouragement of Industrial Research and
    Development Law, 1984&#148; in Item&#160;1 of this Annual
    Report. There can be no assurance that we will continue to
    receive grants from the OCS in amounts sufficient for our
    operations, if at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At this time, due to the inherently unpredictable nature of
    preclinical and clinical development processes and given the
    early stage of our preclinical product development programs, we
    are unable to estimate with any certainty the costs we will
    incur in the continued development of the product candidates in
    our pipeline for potential commercialization. Clinical
    development timelines, the probability of success and
    development costs can differ materially from expectations. While
    we are currently focused on advancing each of our product
    development programs, our future research and development
    expenses will depend on the clinical success of each product
    candidate, as well as ongoing assessments of each product
    candidate&#146;s commercial potential. In addition, we cannot
    forecast with any degree of certainty which product candidates
    may be subject to future collaborations, when such arrangements
    will be secured, if at all, and to what degree such arrangements
    would affect our development plans and capital requirements. See
    &#147;Risk Factors&#160;&#151; All of our product candidates
    other than taliglucerase alfa and our acetylcholinesterase
    product are in pre-clinical or research stages. If we are unable
    to develop and commercialize our product candidates, our
    business will be adversely affected&#148; and
    &#147;&#151;&#160;We may not obtain the necessary U.S.&#160;or
    worldwide regulatory approvals to commercialize our drug
    candidates in a timely manner, if at all, which would have a
    material adverse effect on our business and results of
    operations.&#148;
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    65
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We expect our research and development expenses to continue to
    be our primary expense in the future as we continue the
    advancement of our clinical trials and preclinical product
    development programs for our product candidates other than
    taliglucerase alfa. The lengthy process of completing clinical
    trials and seeking regulatory approval for our product
    candidates requires expenditure of substantial resources. Any
    failure or delay in completing clinical trials, or in obtaining
    regulatory approvals, could cause a delay in generating product
    revenue and cause our research and development expense to
    increase and, in turn, have a material adverse effect on our
    operations. We filed an NDA for taliglucerase alfa with the FDA
    in the last quarter of 2009 and received a PDUFA date of
    February&#160;25, 2011. In addition, we submitted a marketing
    application to the Israeli MOH and an MAA to each of the EMEA
    and ANVISA in the fourth quarter of 2010 regarding taliglucerase
    alfa. Due to the factors set forth above, we are not able to
    estimate with any certainty when we would recognize any net cash
    inflows from our projects. See &#147;Risk Factors&#160;&#151;
    Clinical trials are very expensive, time-consuming and difficult
    to design and implement and may result in unforeseen costs which
    may have a material adverse effect on our business and results
    of operations.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Share-Based
    Compensation</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The discussion below regarding share-based compensation relates
    to share-based compensation paid by Protalix Ltd., our
    wholly-owned subsidiary.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In accordance with the guidance, we record the benefit of any
    grant to a non-employee and remeasure the benefit in any future
    vesting period for the unvested portion of the grants, as
    applicable. In addition, we use the straight-line accounting
    method for recording the benefit of the entire grant, unlike the
    graded method we use to record grants made to employees.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We measure share-based compensation cost for all share-based
    awards at the fair value on the grant date and recognition of
    share-based compensation over the service period for awards that
    we expect will vest. The fair value of stock options is
    determined based on the number of shares granted and the price
    of our ordinary shares, and calculated based on the
    Black-Scholes valuation model. We recognize such value as
    expense over the service period, net of estimated forfeitures,
    using the accelerated method.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For purposes of determining the fair value of the options to
    purchase common stock granted to employees and non-employees
    during the fiscal year ended December&#160;31, 2010, including
    shares held by non employees that vested during such period, our
    management used the fair value of our common stock which was the
    closing sale price of our common stock on the NYSE Amex on the
    date of calculation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The guidance allows companies to estimate the expected term of
    the option rather than simply using the contractual term of an
    option. Because of lack of data on past option exercises by
    employees, the expected term of the options could not be based
    on historic exercise patterns. Accordingly, we adopted the
    simplified method, according to which companies may calculate
    the expected term as the average between the vesting date and
    the expiration date, assuming the option was granted as a
    &#147;plain vanilla&#148; option.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In performing the valuation, we assumed an expected 0% dividend
    yield in the previous years and in the next years. We do not
    have a dividend policy and given the lack of profitability,
    dividends are not expected in the foreseeable future, if at all.
    The guidance stipulates a number of factors that should be
    considered when estimating the expected volatility, including
    the implied volatility of traded options, historical volatility
    and the period that the shares of the company are being publicly
    traded. As we do not have any traded shares or options, the
    expected volatility figures used in this valuation have been
    calculated by using the historical volatility of traded shares
    of similar companies. In addition, we examined the standard
    deviation of shares of similar biotechnology companies that
    engage in research and development, generally with no
    significant revenues. We found that the volatility of our shares
    and the shares of comparable companies was in the range of
    40%-75% over periods of three to six years. The volatility used
    for each grant differed based on its expected term. For the term
    of each grant of our options, the historical volatility was
    calculated based upon the overall trading history of the common
    stock of comparable companies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The risk-free interest rate described above has been based on
    the implied yield of U.S.&#160;federal reserve zero&#160;&#151;
    coupon government bonds. The remaining term of the bonds used
    for each valuation was equal to the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    66
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    expected term of the grant. This methodology has been applied to
    all grants valued by us. The guidance requires the use of a
    risk&#160;&#151; free interest rate based on the implied yield
    currently available on zero&#160;&#151; coupon government issues
    of the country in whose currency the exercise price is
    expressed, with a remaining term equal to the expected life of
    the option being valued. This requirement has been applied for
    all grants valued as part of this report.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Year
    Ended December&#160;31, 2010 Compared to the Year Ended
    December&#160;31, 2009</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><FONT style="font-family: 'Times New Roman', Times">Revenues</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We recorded revenue of $6.6&#160;million for the year ended
    December&#160;31, 2010 compared to revenue of $388,000 for the
    year ended December&#160;31, 2009. The increase resulted
    primarily from the amortization of the $65.0&#160;million of
    upfront and milestone payments received from Pfizer over the
    entire fiscal year. Such payments were amortized over one month
    for the year ended December&#160;31, 2009. The payments were
    recorded as deferred revenue and the amounts will be amortized
    over the performance period, estimated at approximately
    14&#160;years, at a rate of approximately $1.1&#160;million per
    quarter. The amortization during the year ended
    December&#160;31, 2010 resulted in the recognition of revenue of
    $4.6&#160;million, or an increase of $4.2&#160;million, from
    $388,000 recognized during the year ended December&#160;31,
    2009. In addition, we recorded revenues in the amount of
    approximately $2.0&#160;million in connection with products
    delivered to Pfizer under our license agreement. No products
    were sold during 2009.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><FONT style="font-family: 'Times New Roman', Times">Our share
    in the Collaboration Agreement</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We recorded $4.6&#160;million of income as our share in the
    collaboration under the Pfizer Agreement during the year ended
    December&#160;31, 2010. This income resulted primarily from our
    share of the approximately $21.8&#160;million of revenues
    generated by Pfizer&#146;s sale of taliglucerase alfa to the
    Ministry of Health of Brazil under the short term supply
    agreement during Pfizer&#146;s 2010 fiscal year. No share in the
    collaboration was recorded for the year ended December&#160;31,
    2009. Under the terms and conditions of the Pfizer Agreement, we
    recorded revenue equal to 40% of the profits realized from sales
    of taliglucerase alfa, and related expenses incurred based on
    reports we received from Pfizer summarizing the results of the
    collaborative activities under the agreement for the applicable
    period. Under the terms of the Pfizer Agreement, for its
    subsidiaries operating outside the United States, financial
    information is included based on the fiscal year ending
    November&#160;30, while financial information for the
    U.S.&#160;entity is included based on the fiscal year ending
    December&#160;31.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><FONT style="font-family: 'Times New Roman', Times">Research
    and Development Expenses</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Research and development expenses were $37.7&#160;million for
    the year ended December&#160;31, 2010, an increase of
    $10.3&#160;million, or 38%, from $27.4&#160;million for the year
    ended December&#160;31, 2009. The increase resulted primarily
    from an increase of $2.7&#160;million in development expenses
    related to salaries for personnel involved in research and
    development, and $4.1&#160;million in related subcontractors and
    consultants expenses, mainly in connection with our expanded
    access program for taliglucerase alfa. The increase in research
    and development expenses was partially offset by the recognition
    of grants from the OCS and Pfizer&#146;s reimbursement of us,
    collectively equal to $7.7&#160;million. The offsets to our
    research and development expenses for the year ended
    December&#160;31, 2010 represent an increase of approximately
    $2.0&#160;million, or 35%, compared to the recognition of grants
    from the OCS equal to $5.7&#160;million that offset our research
    and development expenses for the year ended December&#160;31,
    2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We expect research and development expenses to continue to be
    our primary expense as we enter into a more advanced stage of
    preclinical trials for certain of our product candidates and
    into clinical trials for PRX-102, our product candidate for the
    treatment of Fabry disease, our acetylcholinesterase product
    candidate and our antiTNF product candidate.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><FONT style="font-family: 'Times New Roman', Times">General
    and Administrative Expenses</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    General and administrative expenses were $6.9&#160;million for
    the year ended December&#160;31, 2010, a decrease of $268,000,
    or approximately 4%, from $7.1&#160;million for the year ended
    December&#160;31, 2009. The decrease
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    67
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    resulted primarily from a $389,000 decrease in salaries expense
    during 2010. We expect that our general and administrative
    expenses will increase as we add additional personnel and
    continue to comply with the reporting and other obligations
    applicable to public companies in the United States.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><FONT style="font-family: 'Times New Roman', Times">Financial
    Expenses and Income</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Financial income was $968,000 for the year ended
    December&#160;31, 2010, an increase of $439,000, or approximately
    83%, compared to $529,000 for the year ended December&#160;31,
    2009. The increase resulted primarily from increases in the
    exchange rate that resulted in income of approximately $546,000.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Year
    Ended December&#160;31, 2009 Compared to the Year Ended
    December&#160;31, 2008</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><FONT style="font-family: 'Times New Roman', Times">Revenues</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We recorded revenues of $388,000 during the year ended
    December&#160;31, 2009. The revenue represents the pro rata
    amortization of the $60.0&#160;million upfront payment and
    $5.0&#160;million milestone payment we received in connection
    with our license and supply agreement with Pfizer. The payments
    were recorded as deferred revenue and the amounts will be
    amortized over the performance period, estimated at
    approximately 14&#160;years, at a rate of approximately
    $1.1&#160;million per quarter. No revenues were recorded during
    the year ended December&#160;31, 2008.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><FONT style="font-family: 'Times New Roman', Times">Research
    and Development Expenses</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Research and development expenses were $27.4&#160;million for
    the year ended December&#160;31, 2009, an increase of
    $5.3&#160;million, or 24%, from $22.1&#160;million for the year
    ended December&#160;31, 2008. The increase resulted primarily
    from an increase of $1.2&#160;million in development expenses
    related to salaries for personnel involved in research and
    development, and $2.2&#160;million in related subcontractors and
    consultants expenses, mainly in connection with our
    phase&#160;III clinical trial of taliglucerase alfa. The
    increase in research and development expenses was further
    increased by the recognition of grants equal to
    $5.7&#160;million from the OCS during 2009, an increase of
    approximately $1.0&#160;million, or 22%, compared to the
    recognition of grants equal to $4.7&#160;million during 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We expect research and development expenses to continue to be
    our primary expense as we enter into a more advanced stage of
    preclinical trials for certain of our product candidates and
    into additional clinical trials for PRX-105.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><FONT style="font-family: 'Times New Roman', Times">General
    and Administrative Expenses</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    General and administrative expenses were $7.1&#160;million for
    the year ended December&#160;31, 2009, an increase of $374,000,
    or approximately 6.0%, from $6.8&#160;million for the year ended
    December&#160;31, 2008. The increase resulted primarily from a
    $543,000 increase in salaries expenses during 2009.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <I><FONT style="font-family: 'Times New Roman', Times">Financial
    Expenses and Income</FONT></I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Financial income was $529,000 for the year ended
    December&#160;31, 2009, a decrease of $1.2&#160;million, or
    approximately 70.0%, compared to $1.8&#160;million for the year
    ended December&#160;31, 2008. The decrease resulted primarily
    from a lower interest rate for deposits in 2009 which
    contributed to lower financial income during 2009.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Liquidity
    and Capital Resources</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Sources
    of Liquidity</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As a result of our significant research and development
    expenditures and the lack of any approved products to generate
    significant product sales revenue, we have not been profitable
    and have generated operating losses since our inception. To
    date, we have funded our operations primarily with proceeds
    equal to $31.3&#160;million from the sale of shares of our
    common stock and from sales of convertible preferred and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    68
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    ordinary shares of Protalix Ltd., and an additional
    $14.1&#160;million in connection with the exercise of warrants
    issued in connection with the sale of such ordinary shares,
    through December&#160;31, 2008. In addition, on October&#160;25,
    2007, we generated gross proceeds of $50&#160;million in
    connection with an underwritten public offering of our common
    stock. Furthermore, on November&#160;30, 2009, we entered into
    an exclusive license and supply agreement with Pfizer, pursuant
    to which Pfizer made an upfront payment to Protalix Ltd. of
    $60.0&#160;million in connection with the execution of the
    agreement and subsequently paid to Protalix Ltd. an additional
    $5.0&#160;million upon meeting a certain milestone. Protalix
    Ltd. is also eligible to receive potential milestone payments of
    up to $50.0&#160;million for the successful achievement of other
    regulatory-related milestones. We are also entitled to payments
    equal to 40% of the net profits earned by Pfizer on its sales of
    taliglucerase alfa, if any. In calculating net profits there are
    certain agreed upon limits on the amounts that may be deducted
    from gross sales for certain expenses and costs of goods sold.
    We believe that the funds currently available to us as are
    sufficient to satisfy our capital needs for at least
    12&#160;months.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table summarizes our past funding sources:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="63%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Security</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount(1)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ordinary Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1996-2000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,801,527
</TD>
<TD nowrap align="left" valign="bottom">
    (2)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;A Convertible Preferred Shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,635,090
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;B Convertible Preferred Shares(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2004-2005
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,175,621
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,500,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Series&#160;C Convertible Preferred Shares(4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2005
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,513,422
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,700,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Ordinary Shares(5)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2006
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,367,880
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    16,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Common Stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    50,000,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Gross proceeds; does not include proceeds from warrant exercises.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes the issuance of ordinary shares to founders.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    During 2005, 1,035,569 Series&#160;B Preferred Shares were
    converted on a 1:1 basis into Series&#160;C Preferred Shares for
    no additional consideration. Also, in connection with such
    funding, warrants to purchase 181,228 Series&#160;B Preferred
    Shares were issued for no additional consideration with an
    aggregate exercise price of $103,000. As of the closing date of
    the merger, 168,034 of such warrants were exercised for net
    proceeds equal to approximately $96,000 and 13,194 of such
    warrants were forfeited.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    In connection with such funding, warrants to purchase an
    additional 8,862,803 Series&#160;C Preferred Shares were granted
    to the investors for no additional consideration with a total
    exercise price equal to $9.0&#160;million. As of the closing
    date of the merger, 5,296,279 of such warrants were exercised
    for net proceeds equal to $8.7&#160;million, 3,384,502 were
    assumed by our company and 182,022 expired.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (5) </TD>
    <TD></TD>
    <TD valign="bottom">
    In connection with such funding, warrants to purchase 3,875,416
    ordinary shares were issued for no additional consideration with
    an aggregate exercise price equal to $5.3&#160;million. These
    warrants were exercised in full on January&#160;31, 2007.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Cash
    Flows</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Net cash used in operations was $38.5&#160;million for the year
    ended December&#160;31, 2010. The net loss for 2010 of
    $29.0&#160;million was further increased by an increase in
    accounts receivable of approximately $6.9&#160;million and a
    decrease of $4.6&#160;million in deferred revenues. Such net
    loss was partially offset by non-cash charges for share-based
    compensation of $1.3&#160;million, and depreciation of
    $3.1&#160;million. Net cash used in investing activities for
    2010 was $8.0&#160;million and consisted primarily of purchases
    of property and equipment. Net cash provided from financing
    activities for 2010 was approximately $501,000 due to option
    exercises.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Net cash provided from operations was $44.5&#160;million for the
    year ended December&#160;31, 2009. The net loss for 2009 of
    $31.4&#160;million was reversed by $65.0&#160;million received
    under the license and supply agreement with Pfizer. Such
    reversal was partially offset by non-cash charges for
    share-based compensation of $2.7&#160;million, and depreciation
    of $2.0&#160;million. Net cash used in investing activities for
    2009 was $6.2&#160;million and consisted
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    69
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    primarily of purchases of property and equipment. Net cash
    provided from financing activities for 2009 was approximately
    $293,000 due to option exercise.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Future
    Funding Requirements</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We expect that our operating losses may continue to be
    substantial over the next several years. However, we anticipate
    that we will generate revenues to offset any such losses upon
    the successful launch of taliglucerase alfa, if at all. We
    expect to incur significant research and development expenses,
    including expenses related to the hiring of personnel and the
    advancement of our additional pipeline of product candidate into
    the various clinical trials. We expect that general and
    administrative expenses will increase as we expand our finance
    and administrative staff, add infrastructure, and incur
    additional costs related to our preparation for the commercial
    phase for our lead product candidate, taliglucerase alfa. In
    addition, we are working on the expansion of our manufacturing
    facility that would meet approximately half of the market for
    our lead product candidate, which would increase our capital
    expenditures significantly and is estimated to cost
    approximately $25&#160;million in total.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We believe that our existing cash and cash equivalents and the
    regulatory milestone payments we anticipate receiving from
    Pfizer will be sufficient to enable us to fund our operating
    expenses and capital expenditure requirements at least for the
    next 12&#160;months. We have based this estimate on assumptions
    that are subject to change and may prove to be wrong, and we may
    be required to use our available capital resources sooner than
    we currently expect. Because of the numerous risks and
    uncertainties associated with the development and
    commercialization of our product candidates, we are unable to
    estimate the amounts of increased capital outlays and operating
    expenditures associated with our current and anticipated
    clinical trials.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our future capital requirements will depend on many factors,
    including the progress and results of our clinical trials, costs
    of commercialization activities, including product marketing,
    sales and distribution and whether these efforts will be
    performed internally or through some form of collaboration with
    third parties, the duration and cost of discovery and
    preclinical development, and laboratory testing and clinical
    trials for our product candidates, the timing and outcome of
    regulatory review of our product candidates, the costs involved
    in preparing, filing, prosecuting, maintaining, defending and
    enforcing patent claims and other intellectual property rights
    and the number and development requirements of other product
    candidates that we pursue.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We may need to finance our future cash needs through public or
    private equity offerings, debt financings, or additional
    corporate collaboration and licensing arrangements. We currently
    do not have any commitments for future external funding, other
    than the potential regulatory-related milestone payments from
    Pfizer. We may need to raise additional funds more quickly if
    one or more of our assumptions prove to be incorrect or if we
    choose to expand our product development efforts more rapidly
    than we presently anticipate. We may also decide to raise
    additional funds even before we need them if the conditions for
    raising capital are favorable. The sale of additional equity or
    debt securities will likely result in dilution to our
    shareholders. The incurrence of indebtedness would result in
    increased fixed obligations and could also result in covenants
    that would restrict our operations. Additional equity or debt
    financing, grants or corporate collaboration and licensing
    arrangements may not be available on acceptable terms, if at
    all. If adequate funds are not available, we may be required to
    delay, reduce the scope of or eliminate our research and
    development programs, reduce our planned commercialization
    efforts or obtain funds through arrangements with collaborators
    or others that may require us to relinquish rights to certain
    product candidates that we might otherwise seek to develop or
    commercialize independently.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Effects
    of Inflation and Currency Fluctuations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Inflation generally affects us by increasing our cost of labor
    and clinical trial costs. We do not believe that inflation has
    had a material effect on our results of operations during the
    years ended December&#160;31, 2008, 2009 or 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Currency fluctuations could affect us by increased or decreased
    costs mainly for goods and services acquired outside of Israel.
    We do not believe currency fluctuations have had a material
    effect on our results of operations during the years ended
    December&#160;31, 2008, 2009 or 2010.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    70
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Off-Balance
    Sheet Arrangements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have no off-balance sheet arrangements as of
    December&#160;31, 2009 and 2010. See Note&#160;6 of the
    consolidated financial statements for a full description of
    certain contingent royalty payments.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Recently
    Issued Accounting Pronouncements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In April 2010, the FASB issued ASU
    <FONT style="white-space: nowrap">No.&#160;2010-17,</FONT>
    <I>Revenue Recognition&#160;&#151; Milestone Method </I>(ASU
    <FONT style="white-space: nowrap">2010-017).</FONT>
    ASU <FONT style="white-space: nowrap">2010-017</FONT>
    provides guidance in applying the milestone method of revenue
    recognition to research or development arrangements. Under this
    guidance, we may recognize revenue contingent upon the
    achievement of a milestone in its entirety, in the period in
    which the milestone is achieved, only if the milestone meets all
    the criteria within the guidance to be considered substantive.
    ASU <FONT style="white-space: nowrap">2010-017</FONT>
    is effective on a prospective basis for research and development
    milestones achieved in fiscal years, beginning on or after
    June&#160;15, 2010, which for our company means the year ending
    December&#160;31, 2011. Early adoption is permitted; however, we
    have elected to implement ASU
    <FONT style="white-space: nowrap">2010-17</FONT>
    prospectively, and as a result, the effect of this guidance will
    be limited to future transactions. We do not expect adoption of
    this standard to have a material impact on our financial
    position or results of operations as we have no material
    research and development arrangements which will be accounted
    for under the milestone method.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In December 2010, the FASB issued ASU
    <FONT style="white-space: nowrap">No.&#160;2010-027,</FONT>
    Fees Paid to the Federal Government by Pharmaceutical
    Manufacturers (ASU
    <FONT style="white-space: nowrap">2010-027).</FONT>
    ASU <FONT style="white-space: nowrap">2010-027</FONT>
    provides guidance concerning the recognition and classification
    of the new annual fee payable by branded prescription drug
    manufactures and importers on branded prescription drugs which
    was mandated under the health care reform legislation enacted in
    the United States in March 2010. Under this new accounting
    standard, the annual fee would be presented as a component of
    operating expenses and recognized over the calendar year such
    fees are payable using a straight-line method of allocation
    unless another method better allocates the fee over the calendar
    year. ASU
    <FONT style="white-space: nowrap">2010-027</FONT> is
    effective for calendar years beginning on or after
    December&#160;31, 2010, when the fee initially becomes
    effective, which for our company means the year ending
    December&#160;31, 2011. As this standard relates only to
    classification, the adoption of this accounting standard will
    not have an impact on our financial position or results of
    operations.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Contractual
    Obligations</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table summarizes our significant contractual
    obligations at December&#160;31, 2010:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="50%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>    <!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Less Than<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>More Than<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>1&#160;Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>1-3&#160;Years</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>3-5&#160;Years</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>5&#160;Years</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Operating lease obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,360
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,265
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,668
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Purchase obligations(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,753
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,753
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Certain clinical contract and building contractor obligations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,995
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,456
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    539
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Other long term liabilities reflected
    on the balance sheet under GAAP
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,704
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,569
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,804
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,668
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents open purchase orders issued to certain suppliers and
    other vendors mainly in connection with certain improvements to
    our manufacturing facility that were outstanding as of
    December&#160;31, 2010.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    71
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Selected
    Quarterly Financial Data (unaudited)</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="36%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>     <!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=06 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>    <!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=06 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>     <!-- colindex=06 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=07 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>    <!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=07 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>     <!-- colindex=07 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=08 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=08 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>     <!-- colindex=08 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=09 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=09 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=09 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>     <!-- colindex=09 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="31" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Three Months Ended</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="15" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="15" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>March&#160;31</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Sept.&#160;30</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Dec.&#160;31</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>March&#160;31</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>June&#160;30</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Sept.&#160;30</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Dec.&#160;31</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="31" align="center" valign="bottom">
    <B>(U.S. dollars in thousands)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,141
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,141
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,184
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,427
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5,894
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,936
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,955
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,041
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,474
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,528
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock, basic and diluted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.07
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.08
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.12
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.03
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;7A.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571113'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Quantitative
    and Qualitative Disclosures About Market Risk</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Currency
    Exchange Risk</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The currency of the primary economic environment in which our
    operations are conducted is the dollar. We are currently have no
    significant source of revenues; therefore we consider the
    currency of the primary economic environment to be the currency
    in which we expend cash. Approximately 50% of our expenses and
    capital expenditures are incurred in dollars, and a significant
    source of our financing has been provided in U.S.&#160;dollars.
    Since the dollar is the functional currency, monetary items
    maintained in currencies other than the dollar are remeasured
    using the rate of exchange in effect at the balance sheet dates
    and non-monetary items are remeasured at historical exchange
    rates. Revenue and expense items are remeasured at the average
    rate of exchange in effect during the period in which they
    occur. Foreign currency translation gains or losses are
    recognized in the statement of operations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Approximately 35% of our costs, including salaries, expenses and
    office expenses, are incurred in NIS. Inflation in Israel may
    have the effect of increasing the U.S.&#160;dollar cost of our
    operations in Israel. If the U.S.&#160;dollar declines in value
    in relation to the NIS, it will become more expensive for us to
    fund our operations in Israel. A revaluation of 1% of the NIS
    will affect our income before tax by less than 1%. The exchange
    rate of the U.S.&#160;dollar to the NIS, based on exchange rates
    published by the Bank of Israel, was as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="77%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="11" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Average rate for period
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.5878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.933
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.733
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Rate at year-end
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.8020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.775
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.549
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    To date, we have not engaged in hedging transactions. In the
    future, we may enter into currency hedging transactions to
    decrease the risk of financial exposure from fluctuations in the
    exchange rate of the U.S.&#160;dollar against the NIS. These
    measures, however, may not adequately protect us from material
    adverse effects due to the impact of inflation in Israel.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Interest
    Rate Risk</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our exposure to market risk is confined to our cash and cash
    equivalents. We consider all short term, highly liquid
    investments, which include short-term deposits with original
    maturities of three months or less from the date of purchase,
    that are not restricted as to withdrawal or use and are readily
    convertible to known amounts of cash, to be cash equivalents.
    The primary objective of our investment activities is to
    preserve principal while maximizing the interest income we
    receive from our investments, without increasing risk. We invest
    any cash balances primarily in bank deposits and investment
    grade interest-bearing instruments. We are exposed to market
    risks resulting from changes in interest rates. We do not use
    derivative financial instruments to limit exposure to interest
    rate risk. Our interest gains may decline in the future as a
    result of changes in the financial markets.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="8%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;8.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571114'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Financial
    Statements and Supplementary Data</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    See the Index to Consolidated Financial Statements on
    <FONT style="white-space: nowrap">Page&#160;F-1</FONT>
    attached hereto.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    72
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="8%"></TD>
    <TD width="92%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;9.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571115'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Changes
    in and Disagreements with Accountants on Accounting and
    Financial Disclosure</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    None.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;9A.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571116'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Controls
    and Procedures</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Evaluation
    of Disclosure Controls and Procedures</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We conducted an evaluation of the effectiveness of the design
    and operation of our disclosure controls and procedures as of
    the end of the period covered by this
    <FONT style="white-space: nowrap">Form&#160;10-K.</FONT>
    The controls evaluation was conducted under the supervision and
    with the participation of management, including our Chief
    Executive Officer and Chief Financial Officer. Disclosure
    controls and procedures are controls and procedures designed to
    reasonably assure that information required to be disclosed in
    our reports filed under the Exchange Act, such as this
    <FONT style="white-space: nowrap">Form&#160;10-K,</FONT>
    is recorded, processed, summarized and reported within the time
    periods specified in the Commission&#146;s rules and forms.
    Disclosure controls and procedures are also designed to
    reasonably assure that such information is accumulated and
    communicated to our management, including the Chief Executive
    Officer and Chief Financial Officer, as appropriate to allow
    timely decisions regarding required disclosure.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The evaluation of our disclosure controls and procedures
    included a review of the controls&#146; objectives and design,
    our implementation of the controls and their effect on the
    information generated for use in this
    <FONT style="white-space: nowrap">Form&#160;10-K.</FONT>
    In the course of the controls evaluation, we reviewed identified
    data errors, control problems or acts of fraud, and sought to
    confirm that appropriate corrective actions, including process
    improvements, were being undertaken. This type of evaluation
    will be performed on a quarterly basis so that the conclusions
    of management, including the Chief Executive Officer and Chief
    Financial Officer, concerning the effectiveness of the
    disclosure controls and procedures can be reported in our
    periodic reports on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    and
    <FONT style="white-space: nowrap">Form&#160;10-K.</FONT>
    The overall goals of these various evaluation activities are to
    monitor our disclosure controls and procedures, and to modify
    them as necessary. Our intent is to maintain the disclosure
    controls and procedures as dynamic systems that change as
    conditions warrant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Based on the controls evaluation, our Chief Executive Officer
    and Chief Financial Officer have concluded that, as of the end
    of the period covered by this
    <FONT style="white-space: nowrap">Form&#160;10-K,</FONT>
    our disclosure controls and procedures were effective to provide
    reasonable assurance that information required to be disclosed
    in our Exchange Act reports is recorded, processed, summarized
    and reported within the time periods specified by the
    Commission, and that material information related to our company
    and our consolidated subsidiary is made known to management,
    including the Chief Executive Officer and Chief Financial
    Officer, particularly during the period when our periodic
    reports are being prepared.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Management
    Report on Internal Control over Financial Reporting</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our management is responsible for establishing and maintaining
    adequate internal control over financial reporting to provide
    reasonable assurance regarding the reliability of our financial
    reporting and the preparation of financial statements for
    external purposes in accordance with U.S.&#160;generally
    accepted accounting principles. Internal control over financial
    reporting includes those policies and procedures that:
    (i)&#160;pertain to the maintenance of records that in
    reasonable detail accurately and fairly reflect the transactions
    and dispositions of our assets; (ii)&#160;provide reasonable
    assurance that transactions are recorded as necessary to permit
    preparation of financial statements in accordance with
    U.S.&#160;generally accepted accounting principles, and that
    receipts and expenditures of our company are being made only in
    accordance with authorizations of management and our directors;
    and (iii)&#160;provide reasonable assurance regarding prevention
    or timely detection of unauthorized acquisition, use or
    disposition of our assets that could have a material effect on
    our financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Management assessed our internal control over financial
    reporting as of December&#160;31, 2010, the end of our fiscal
    year. Management based its assessment on criteria established in
    Internal Control&#160;&#151; Integrated Framework issued by the
    Committee of Sponsoring Organizations of the Treadway
    Commission. Management&#146;s assessment included evaluation of
    elements such as the design and operating effectiveness of key
    financial reporting controls, process documentation, accounting
    policies and our overall control environment.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    73
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Based on our assessment, management has concluded that our
    internal control over financial reporting was effective as of
    the end of the fiscal year to provide reasonable assurance
    regarding the reliability of financial reporting and the
    preparation of financial statements for external reporting
    purposes in accordance with U.S.&#160;generally accepted
    accounting principles. We reviewed the results of
    management&#146;s assessment with the Audit Committee of our
    Board of Directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our independent registered public accounting firm has audited
    management&#146;s assessment of our internal control over
    financial reporting, and issued an unqualified opinion dated
    February&#160;23, 2011 on such assessment and on our internal
    control over financial reporting, which opinion is included
    herein.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Inherent
    Limitations on Effectiveness of Controls</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our management, including our Chief Executive Officer and Chief
    Financial Officer, does not expect that our disclosure controls
    and procedures or our internal control over financial reporting
    will prevent or detect all error and all fraud. A control
    system, no matter how well designed and operated, can provide
    only reasonable, not absolute, assurance that the control
    system&#146;s objectives will be met. The design of a control
    system must reflect the fact that there are resource
    constraints, and the benefits of controls must be considered
    relative to their costs. Further, because of the inherent
    limitations in all control systems, no evaluation of controls
    can provide absolute assurance that misstatements due to error
    or fraud will not occur or that all control issues and instances
    of fraud, if any, within a company have been detected. These
    inherent limitations include the realities that judgments in
    decision-making can be faulty and that breakdowns can occur
    because of simple error or mistake. Controls can also be
    circumvented by the individual acts of some persons, by
    collusion of two or more people or by management override of the
    controls. The design of any system of controls is based in part
    on certain assumptions about the likelihood of future events,
    and there can be no assurance that any design will succeed in
    achieving its stated goals under all potential future
    conditions. Projections of any evaluation of controls
    effectiveness to future periods are subject to risks. Over time,
    controls may become inadequate because of changes in conditions
    or deterioration in the degree of compliance with policies or
    procedures.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Changes
    in internal controls</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    There were changes in our internal control over financial
    reporting (as defined in
    <FONT style="white-space: nowrap">Rules&#160;13a-15f</FONT>
    and <FONT style="white-space: nowrap">15d-15f</FONT>
    under the Exchange Act) that occurred during the period ended
    December&#160;31, 2010. The changes relate to the processes
    associated with the evaluation of our new revenue contracts and
    accounting for inventories.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;9B.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571117'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Other
    Information</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    None.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    74
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='Y04571118'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PART&#160;III</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;10.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571119'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Directors,
    Executive Officers and Corporate Governance</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our directors and executive officers, their ages and positions
    as of February&#160;23, 2011 are as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=quadright -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="52%">&nbsp;</TD> <!-- colindex=03 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Age</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Position</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Directors</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Zeev Bronfeld
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    59
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Interim Chairman of the Board
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David Aviezer,&#160;Ph.D., MBA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    46
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director, President and Chief Executive Officer
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yoseph Shaaltiel,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    57
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Director and Executive VP, Research and Development
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alfred Akirov(1)(2)(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    70
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amos Bar Shalev(1)(2)(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    58
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yodfat Harel Gross(1)(2)(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    38
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Roger D. Kornberg,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    63
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Eyal Sheratzky
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    42
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    Director
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Executive Officers</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Einat Brill Almon,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    51
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Senior Vice President, Product Development
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yossi Maimon, CPA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    40
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Vice President, Chief Financial Officer, Treasurer and Secretary
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sandra L. Lauterbach
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    42
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Vice President, Sales and Commercial Affairs
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tzvi Palash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    54
</TD>
<TD>&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="bottom">
    Chief Operating Officer
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Member of Nominating Committee</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Member of Audit Committee</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Member of Compensation Committee</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Zeev Bronfeld.</I>&#160;&#160;Mr.&#160;Bronfeld has served as
    a director of Protalix Ltd. since 1996 and as our director since
    December&#160;31, 2006. Mr.&#160;Bronfeld brings to us vast
    experience in management and value building of biotechnology
    companies. Mr.&#160;Bronfeld is an experienced businessman who
    is involved in a number of biotechnology companies. He is a
    co-founder of Biocell Ltd. (TASE:BCEL), an Israeli publicly
    traded holding company specializing in biotechnology companies
    and has served as its Chief Executive Officer since 1986.
    Mr.&#160;Bronfeld currently serves as a director of Biocell
    Ltd., D. Medical Industries Ltd. (NASDAQ:DMED, TASE:DMDC),
    Biomedix Incubator Ltd. (TASE:BMDX), Flowsense Medical Ltd.
    (TASE:FLSN), E.T. View Medical Ltd. (TASE:ETVW), NextGen Biomed
    Ltd. (TASE:NXGN), D.N.A. Biomedical Solutions Ltd. (TASE:DNA),
    and Gefen Biomed Investments Ltd. (TASE:GEFEN), all of which are
    public companies traded on the Tel Aviv Stock Exchange (except
    D. Medical which is dual-listed on the Tel Aviv Stock Exchange
    and the Nasdaq Stock Market LLC. Mr.&#160;Bronfeld is also a
    director of each of the following privately-held companies:
    Ecocycle Israel Ltd., Contipi Ltd., Spring Health Solutions
    Ltd., G-Sense Ltd., Sindolor Medical Ltd., L.N. Innovative
    Technologies, A.T.I Ashkelon Industries Information Technologies
    Ltd., The Trendlines Group, MOFET B&#146;Yehuda&#160;&#151;
    Industrial Research&#160;&#038; Development in Judea Ltd.,
    Incubator for Management of Technological Entrepreneurship
    Misgav Ltd., A.Y.M.B. Holdings and Investments Ltd., Spring-Set
    Health Solutions Ltd., Sindolor Holdings Ltd., TransBiodiesel
    Ltd., Nanutra Ltd. and Entera Bio Ltd. Mr.&#160;Bronfeld
    received a B.A. in Economics from the Hebrew University in 1975.
    We believe Mr.&#160;Bronfeld&#146;s qualifications to serve on
    our Board of Directors include his years of experience in the
    management of private and public Israeli companies, including
    life science companies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>David Aviezer,&#160;Ph.D.,
    MBA.</I>&#160;&#160;Dr.&#160;Aviezer has served as Chief
    Executive Officer of Protalix Ltd. since 2002 and its director
    since 2005 and as our director since December&#160;31, 2006. On
    December&#160;31, 2006, he became our President and Chief
    Executive Officer. Dr.&#160;Aviezer has over 15&#160;years of
    experience in biotechnology management, advancing products from
    early-stage research up to their regulatory approval and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    75
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    commercialization. Prior to joining Protalix Ltd., from 1996 to
    2002, he served as General Manager of ProChon Biotech Ltd., an
    Israeli company focused on orthopedic disorders. Previously,
    Dr.&#160;Aviezer was a visiting scientist at the Medical
    Research Division of American Cyanamid, a subsidiary of Wyeth
    which was subsequently acquired by Pfizer (NYSE:PFE), in New
    York. Since 1996, Dr.&#160;Aviezer has served as an Adjunct
    Lecturer at Bar Ilan University. Dr.&#160;Aviezer is the
    recipient of the Clore Foundation Award and the J.F. Kennedy
    Scientific Award. He holds a Ph.D. in Molecular Biology and
    Biochemistry from the Weizmann Institute of Science and an MBA
    from the Bar Ilan University Business School. We believe
    Dr.&#160;Aviezer&#146;s qualifications to serve on our Board of
    Directors include his position as our President and Chief
    Executive Officer as well as his previous experience in the
    management of biotechnology companies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Yoseph
    Shaaltiel,&#160;Ph.D.</I>&#160;&#160;Dr.&#160;Shaaltiel founded
    Protalix Ltd. in 1993 and has served as a member of our Board of
    Directors and as our Vice President, Research and Development
    since December&#160;31, 2006. Prior to establishing Protalix
    Ltd., from 1988 to 1993, Dr.&#160;Shaaltiel was a Research
    Associate at the MIGAL Technological Center. He also served as
    Deputy Head of the Biology Department of the Biological and
    Chemical Center of the Israeli Defense Forces and as a
    Biochemist at Makor Chemicals Ltd. Dr.&#160;Shaaltiel was a
    Postdoctoral Fellow at the University of California at Berkeley
    and at Rutgers University in New Jersey. He has co-authored over
    40 articles and abstracts on plant biochemistry and holds seven
    patents. Dr.&#160;Shaaltiel received his Ph.D. in Plant
    Biochemistry from the Weizmann Institute of Science, an M.Sc. in
    Biochemistry from the Hebrew University and a B.Sc. in Biology
    from the Ben Gurion University. We believe
    Dr.&#160;Shaaltiel&#146;s qualifications to serve on our Board
    of Directors include his role in founding our company and his
    continued role in the management of our company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Alfred Akirov.</I>&#160;&#160;Mr.&#160;Akirov has served as
    our director since January 2008. Mr.&#160;Akirov is the founder,
    chairman of the Board of Directors and chief executive officer
    of the Alrov Group (TASE: ALRO), an Israeli publicly-traded
    company listed on the Tel Aviv Stock Exchange. Mr.&#160;Akirov
    founded the Alrov Group in 1978 and it is currently one of
    Israel&#146;s largest real-estate companies. The Alrov Group
    holds 80% of the capital stock of Techno-Rov Holdings
    (1993)&#160;Ltd., one of our shareholders. Mr.&#160;Akirov
    serves in different capacities, including chairman, chief
    executive officer and director, for a number of private
    companies in the Alrov Group and Techno-Rov portfolios.
    Mr.&#160;Akirov serves on the Executive Council and the Board of
    Governors of the Tel Aviv University. We believe
    Mr.&#160;Akirov&#146;s qualifications to serve on our Board of
    Directors include his years of experience in the management of
    Israeli businesses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Amos Bar Shalev.</I>&#160;&#160;Mr.&#160;Bar Shalev has
    served as our director since July 2008. Mr.&#160;Bar Shalev
    served as a director of Protalix Ltd. from 2005 through
    January&#160;31, 2008, and as our director from
    December&#160;31, 2006 through January&#160;31, 2008.
    Mr.&#160;Bar Shalev was not nominated for reelection at our
    annual meeting of shareholders on January&#160;31, 2008. On
    July&#160;14, 2008, our Board of Directors appointed
    Mr.&#160;Bar Shalev to serve on the board. Mr.&#160;Bar Shalev
    brings to us extensive experience in managing technology
    companies. Currently, Mr.&#160;Bar Shalev manages the Technorov
    portfolio. Since 2011, he has served on the board of directors
    of Aposense Ltd. (TASE: APOS), an Israeli publicly-traded
    company listed on the Tel Aviv Stock Exchange. From 1997 through
    2004, he was a Managing Director of TDA Capital Partners, a
    management company of the TGF (Templeton Tadiran) Fund. From
    2004 through 2007, he was the President of Win Buyer Ltd. From
    2000 through 2007, Mr.&#160;Bar Shalev served the Director of
    Technorov Holdings (1993)&#160;Ltd. and from 2004 through 2007
    he served as a director of Golden Wings Investment Company Ltd.
    He has served on the board of directors of many companies, such
    as Golden Wings Investment Company Ltd., Win Buyer Ltd. and Sun
    Light. He received his B.Sc. in Electrical Engineering from the
    Technion, Israel in 1978 and M.B.A. from the Tel Aviv University
    in 1981. He holds the highest award from the Israeli Air Force
    for technological achievements. We believe Mr.&#160;Bar
    Shalev&#146;s qualifications to serve on our Board of Directors
    include his years of experience in the management of Israeli
    businesses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Yodfat Harel Gross.</I>&#160;&#160;Ms.&#160;Harel Gross has
    served as our director since June 2007. Since 2006,
    Ms.&#160;Harel Gross has been a Managing Director of Tamares
    Capital Ltd., a private investment group with interests in real
    estate, technology, manufacturing, leisure and media. At Tamares
    Capital, Ms.&#160;Harel Gross serves as the Business Development
    Director and the head of the Israel office. Prior to joining
    Tamares Capital, from 2004 to 2006, she was the Head of the
    Medical Desk of Orbotech, Ltd. (NASDAQ:ORBK), a company
    providing high-tech inspection and imaging solutions for bare
    printed circuit board (PCB), flat panel display (FPD) and
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    76
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    PCB assembly manufacturing worldwide. Prior to that, from 1994
    to 2003, she was a Managing Director of Harel-Hertz Investment
    House Ltd., a business investment company with offices in Tel
    Aviv, Israel and Tokyo, Japan. In 2002, Harel-Hertz Investment
    House became the Israeli representative office for ITX
    Corporation, a publicly-traded company in Japan. Ms.&#160;Harel
    Gross currently serves on the board of directors of Tamares
    Capital, Tamares Hotels, Tamares Real Estate, Storewiz and
    Halman-Aldubi Provident Funds, Ltd. Ms.&#160;Harel Gross holds a
    B.A. in Communication and Political Science from Bar Ilan
    University and an executive M.B.A. from Bradford University,
    Great Britain. She has also completed programs in
    Directors&#146; Studies and Advanced Advertising and Marketing
    at the Israel Management Center. We believe Ms.&#160;Harel
    Gross&#146; qualifications to serve on our Board of Directors
    include her experience in the management of Israeli and other
    businesses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Roger D. Kornberg,&#160;Ph.D.</I>&#160;&#160;Professor
    Kornberg has served as our director since February 2008. He has
    served as a director of Teva Pharmaceuticals (NASDAQ: TEVA,
    TASE: TEVA) since 2007. Professor Kornberg is a member of the
    U.S.&#160;National Academy of Sciences and the Winzer Professor
    of Medicine in the Department of Structural Biology at Stanford
    University, Stanford, California. He has been a member of the
    faculty of Stanford University since 1972. Prior to that, he was
    a professor at Harvard Medical School. Professor Kornberg is a
    renowned biochemist and in 2006 he was awarded the Nobel Prize
    in Chemistry in recognition for his studies of the molecular
    basis of eukaryotic transcription, the process by which DNA is
    copied to RNA. Professor Kornberg is also the recipient of
    several awards, including the 2001 Welch Prize, the highest
    award granted in the field of chemistry in the United States,
    and the 2002 Leopold Mayer Prize, the highest award granted in
    the field of biomedical sciences from the French Academy of
    Sciences. He received his B.S. in Chemistry from Harvard
    University in 1967 and his Ph.D. in Chemistry from Stanford
    University in 1972. He holds honorary degrees from universities
    in Europe and Israel, including the Hebrew University in
    Jerusalem, where he currently is a visiting professor. We
    believe Professor Kornberg&#146;s qualifications to serve on our
    Board of Directors include his expertise in chemistry and
    medicine and his experience in the academic arena.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Eyal Sheratzky.</I>&#160;&#160;Mr.&#160;Sheratzky has served
    as a director of Protalix Ltd. since 2005 and as our director
    since December&#160;31, 2006. Mr.&#160;Sheratzky has served as a
    director of Ituran Location&#160;&#038; Control (NASDAQ:ITRN), a
    publicly-traded company listed on the Nasdaq, since 1995 and as
    a Co-Chief Executive Officer since 2003. Prior to such date, he
    served as an alternate Chief Executive Officer of Ituran from
    2002 through 2003 and as Vice President of Business Development
    from 1999 through 2002. Mr.&#160;Sheratzky is the Chairman of
    the Board of Directors of Biocell and serves as a director of
    Moked Ituran Ltd. and certain of Ituran&#146;s other
    subsidiaries. Mr.&#160;Sheratzky also serves as a director of D.
    Medical Industries Ltd. (NASDAQ:DMED, TASE:DMDC), as well as of
    Nilimedix Ltd., its subsidiary. From 1994 to 1999 he served as
    the Chief Executive Officer of Moked Services, Information and
    Investments Ltd. and as legal advisor to several of
    Ituran&#146;s affiliated companies. Mr.&#160;Sheratzky holds
    LL.B and LL.M degrees from Tel Aviv University School of Law and
    an Executive M.B.A. degree from Kellogg University. We believe
    Mr.&#160;Sheratzky&#146;s qualifications to serve on our Board
    of Directors include his years of experience in the management
    of Israeli public and private businesses.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Einat Brill Almon,&#160;Ph.D.</I>&#160;&#160;Dr.&#160;Almon
    joined Protalix Ltd. in December 2004 as its Senior Vice
    President, Product Development and became our Vice President,
    Product Development on December&#160;31, 2006. Dr.&#160;Almon
    has many years of experience in the management of life science
    projects and companies, including biotechnology and agrobiotech,
    with direct experience in clinical, device and scientific
    software development, as well as a strong background and work
    experience in Intellectual Property. Prior to joining Protalix
    Ltd., from 2001 to 2004, she served as Director of R&#038;D and
    IP of Biogenics Ltd., a company that developed an autologous
    platform for tissue based protein drug delivery. Biogenics,
    based in Israel, is a wholly-owned subsidiary of Medgenics Inc.
    Dr.&#160;Almon has trained as a biotechnology patent agent at
    leading IP firms in Israel. Dr.&#160;Almon holds a Ph.D. and an
    M.Sc. in molecular biology of cancer research from the Weizmann
    Institute of Science, a B.Sc. from the Hebrew University and has
    carried out Post-Doctoral research at the Hebrew University in
    the area of plant molecular biology.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Yossi Maimon, CPA.</I>&#160;&#160;Mr.&#160;Maimon joined
    Protalix Ltd. on October&#160;15, 2006 as its Chief Financial
    Officer and became our Vice President and Chief Financial
    Officer on December&#160;31, 2006. Prior to joining Protalix,
    from 2002 to 2006, he served as the Chief Financial Officer of
    Colbar LifeScience Ltd., a biomaterial
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    77
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    company focusing on aesthetics, where he led all of the
    corporate finance activities, fund raisings and legal aspects of
    Colbar including the sale of Colbar to Johnson and Johnson.
    Mr.&#160;Maimon has a B.A. in accounting from the City
    University of New York and an MBA from Tel Aviv University, and
    he is a Certified Public Accountant in the United States (New
    York State) and Israel.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Sandra L. Lauterbach.</I>&#160;&#160;Ms.&#160;Lauterbach has
    served as our Vice President, Sales and Commercial Affairs since
    December&#160;18, 2009. Prior to joining our company,
    Ms.&#160;Lauterbach was the Vice President of Marketing,
    Endocrinology of EMD Serono, Inc., from July 2008 through July
    2009. Prior to that, from August 2003 through July 2008, she
    served in a number of positions at Genzyme Corporation, the last
    position being the Senior Director, Global Marketing of
    Fabrazyme. Ms.&#160;Lauterbach holds a B.Sc. in Molecular
    Biology from the University of Wisconsin and an MBA from the
    University of South Florida.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Tzvi Palash.</I>&#160;&#160;Mr.&#160;Palash has served as
    Protalix Ltd.&#146;s Chief Operating Officer since
    September&#160;6, 2010. Prior to joining Protalix Ltd., from
    2006 through 2010, Mr.&#160;Palash served as a General Manager
    of ColBar LifeScience Ltd., a biotechnology company specializing
    in reconstructive medicine and tissue engineering that was
    acquired by a division of Johnson&#160;&#038; Johnson in 2006.
    In that position, Mr.&#160;Palash served as a member of the
    Global Aesthetic Management Team at the Consumer Group of
    Johnson&#160;&#038; Johnson. Prior to that, from 2001 through
    2006, Mr.&#160;Palash served as the Vice President, Operations
    of ColBar LifeScience. Mr.&#160;Palash holds an M.Sc. in
    Biochemistry from the Hebrew University, and a B.Sc. in Biology
    from the Tel Aviv&#160;University.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Section&#160;16(a)
    Beneficial Ownership Reporting Compliance</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Section&#160;16(a) of the Exchange Act requires our directors,
    executive officers and holders of more than 10% of our common
    stock to file with the Commission reports regarding their
    ownership and changes in ownership of our equity securities. We
    believe that all Section&#160;16 filings requirements were met
    by our officers and directors during 2010. In making this
    statement, we have relied solely upon examination of the copies
    of Forms&#160;3, 4 and 5, Schedule&#160;13s and written
    representations of our former and current directors, officers
    and 10% shareholders.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Audit
    Committee</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We require that all Audit Committee members possess the required
    level of financial literacy and at least one member of the Audit
    Committee meet the current standard of requisite financial
    management expertise as required by the NYSE Amex and applicable
    rules and regulations of the SEC. Messrs.&#160;Bar Shalev and
    Akirov, and Ms.&#160;Harel Gross have been appointed by the
    Board of Directors to serve on the Audit Committee until their
    respective successors have been duly elected.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our Audit Committee operates under a formal charter that governs
    its duties and conduct.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    All members of the Audit Committee are independent from our
    executive officers and management.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our independent registered public accounting firm reports
    directly to the Audit Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our Audit Committee meets with management and representatives of
    our registered public accounting firm prior to the filing of
    officers&#146; certifications with the Commission to receive
    information concerning, among other things, effectiveness of the
    design or operation of our internal controls over financial
    reporting, as required by Section&#160;404 of the Sarbanes-Oxley
    Act of 2002.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our Audit Committee has adopted a Policy for Reporting
    Questionable Accounting and Auditing Practices and Policy
    Prohibiting Retaliation against Reporting employees to enable
    confidential and anonymous reporting of improper activities to
    the Audit Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Messrs.&#160;Bar Shalev and Akirov qualify as &#147;audit
    committee financial experts&#148; under the applicable rules of
    the SEC. In making the determination as to these
    individuals&#146; status as audit committee financial experts,
    our Board of Directors determined they have accounting and
    related financial management expertise within the meaning of the
    aforementioned rules, as well as the listing standards of the
    NYSE Amex.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    78
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Code of
    Business Conduct and Ethics</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We have adopted a Code of Business Conduct and Ethics that
    includes provisions ranging from restrictions on gifts to
    conflicts of interest. All of our employees and directors are
    bound by this Code of Business Conduct and Ethics. Violations of
    our Code of Business Conduct and Ethics may be reported to the
    Audit Committee.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Code of Business Conduct and Ethics includes provisions
    applicable to all of our employees, including senior financial
    officers and members of our Board of Directors and is posted on
    our website (www.protalix.com). We intend to post amendments to
    or waivers from any such Code of Business Conduct and Ethics.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;11.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571120'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Executive
    Compensation</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Discussion and Analysis</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The primary goals of the Compensation Committee of our Board of
    Directors with respect to executive compensation are to attract
    and retain the most talented and dedicated executives possible,
    to tie annual and long-term cash and stock incentives to
    achievement of specified performance objectives, and to align
    executives&#146; incentives with shareholder value creation. To
    achieve these goals, the Compensation Committee intends to
    implement and maintain compensation plans that tie a portion of
    executives&#146; overall compensation to key strategic goals
    such as developments in our clinical path, the establishment of
    key strategic collaborations, the
    <FONT style="white-space: nowrap">build-up</FONT> of
    our pipeline and the strengthening of our financial position.
    The Compensation Committee evaluates individual executive
    performance with a goal of setting compensation at levels the
    committee believes are comparable with executives in other
    companies of similar size and stage of development operating in
    the biotechnology industry while taking into account our
    relative performance and our own strategic goals.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Elements
    of Compensation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Executive compensation consists of following elements:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Base Salary.</I>&#160;&#160;Base salaries for our executives
    are established based on the scope of their responsibilities
    taking into account competitive market compensation paid by
    other companies for similar positions. Generally, we believe
    that executive base salaries should be targeted near the median
    of the range of salaries for executives in similar positions
    with similar responsibilities at comparable companies. The
    companies reviewed by the Compensation Committee in making its
    compensation decisions in February 2010 were as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Keryx Biopharmaceuticals, Inc.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Savient Pharmaceuticals, Inc.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Biomarin Pharmaceutical Inc.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Amicus Therapeutics, Inc.
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Mannkind Corporation
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Nektar Therapeutics
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Theravance, Inc.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Compensation Committee intends to continue reviewing and
    revising the peer group periodically to ensure that it continues
    to reflect companies similar to us in size and development
    stage. The Compensation Committee also reviews an executive
    compensation report and analysis of publicly-traded
    biotechnology companies prepared by a third party for additional
    data and other information regarding executive compensation for
    comparative purposes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Base salaries are usually reviewed annually, and adjusted from
    time to time to realign salaries with market levels after taking
    into account individual responsibilities, performance and
    experience. The
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    79
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Compensation Committee intends to perform its review for 2010
    after the anticipated FDA approval of our lead product
    candidate. The base salaries of our named executive officers are
    set forth in &#147;Employment Arrangements.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Annual Bonus.</I>&#160;&#160;The Compensation Committee has
    the authority to award discretionary annual bonuses to our
    executive officers. For 2010, the Compensation Committee
    established a formal bonus plan for certain milestones, as
    described below. The discretionary annual bonus awards were
    intended to compensate officers for achieving financial,
    clinical, regulatory and operational goals and for achieving
    individual annual performance objectives. For any given year,
    the compensation objectives vary, but relate generally to
    strategic factors such as developments in our clinical path, the
    execution of a license agreement for the commercialization of
    product candidates, the establishment of key strategic
    collaborations, the
    <FONT style="white-space: nowrap">build-up</FONT> of
    our pipeline and financial factors such as capital raising.
    Bonuses are awarded generally based on corporate performance,
    with adjustments made within a range for individual performance,
    at the discretion of the Compensation Committee. The
    Compensation Committee determines, on a discretionary basis, the
    size of the entire bonus pool and the amount of the actual award
    to each named executive officer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Compensation Committee selects, in its discretion, the
    executive officers of our company or our subsidiary who are
    eligible to receive bonuses for any given year. Any bonus
    granted by the Compensation Committee will generally be paid in
    the first quarter of the year, unless such bonus was, by its
    terms, made payable upon the achievement of a specific
    milestone. The Compensation Committee has not fixed a minimum or
    maximum award for any executive officer&#146;s annual
    discretionary bonus, unless specified in the officer&#146;s
    employment agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each of our executive officers is eligible for a discretionary
    annual bonus under his or her employment agreement. The
    Compensation Committee determined the discretionary annual bonus
    to be paid to our executive officers for performance in 2008,
    2009 and 2010. The Compensation Committee has not fixed a
    minimum or a maximum amount for any officer&#146;s annual
    discretionary bonus, nor is any executive officer entitled to a
    minimum or maximum bonus amount under his or her employment
    agreement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On February&#160;25, 2010, our Board of Directors, acting upon
    the resolution of a majority of our independent directors,
    decided to pay bonuses to our executive officers and other
    employees in two tranches. The aggregate amount of all of the
    bonuses awarded or reserved for award by the Board of Directors
    pursuant to the resolution was approximately $2.6&#160;million.
    The first tranche of bonus payments awarded in February 2010 to
    our named executive officers and other employees was for
    approximately $1.1&#160;million in the aggregate. These bonuses
    were made on a discretionary basis to acknowledge and compensate
    our executive officers for their contributions towards the
    completion of our phase&#160;III clinical trial of our lead
    product candidate, taliglucerase alfa, the upgrade of our
    manufacturing facility during the years 2008 and 2009, and
    specifically with the execution of the license and supply
    agreement with Pfizer relating to taliglucerase alfa. The
    decision to grant the awards constituting the first tranche of
    bonuses in 2010 was not based on any predetermined goal set for
    any named executive officer. However, in making this
    compensation decision, the Compensation Committee took into
    account the Board of Directors&#146; decision to refrain from
    awarding bonuses to our executive officers and others in 2009
    due to the general market conditions and our cash balance at
    that time. Of the approximately $1.1&#160;million made available
    for the first tranche of the bonuses, our Board of Directors
    awarded Dr.&#160;Aviezer $500,000; Dr.&#160;Shaaltiel $160,000;
    Dr.&#160;Brill Almon $160,000; and Mr.&#160;Maimon $160,000.
    These bonus payments were made in March 2010.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    80
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The remaining $1.5&#160;million approved by our Board of
    Directors in February 2010 was reserved for future payment to
    our named executive officers and other employees. The second
    tranche of bonus payments will generally become payable upon the
    achievement of the milestones described in the following tables,
    if at all:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">First
    shipment of taliglucerase alfa</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Anticipated Bonus<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Named Executive Officer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David Aviezer,&#160;Ph.D., MBA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yoseph Shaaltiel,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Einat Brill Almon,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    20,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yossi Maimon
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    20,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    140,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Approval
    of taliglucerase alfa by the FDA</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Anticipated Bonus<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Named Executive Officer</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David Aviezer,&#160;Ph.D., MBA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    400,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yoseph Shaaltiel,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    140,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Einat Brill Almon,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    140,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yossi Maimon
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    140,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    820,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The first shipment of taliglucerase alfa was made in 2010 and
    bonuses were paid accordingly. Other than the achievement of the
    corporate milestones set forth above, the anticipated amounts
    allocated to each executive officer were not based upon any
    predetermined goals with respect to any individual named
    executive officer. Further, no individual goals have been
    communicated to any individual named executive officer with
    respect to the eventual payment of the bonuses. The remaining
    approximately $500,000 was allocated to other employees, subject
    to the same criteria.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Options.</I>&#160;&#160;Our 2006 Stock Option Plan authorizes
    us to grant options to purchase shares of common stock to our
    employees, directors and consultants. Our Compensation Committee
    is the administrator of the stock option plan. Stock option
    grants are generally made at the commencement of employment and
    following a significant change in job responsibilities or to
    meet other special retention or performance objectives. The
    Compensation Committee reviews and approves stock option awards
    to executive officers based upon a review of competitive
    compensation data, its assessment of individual performance, a
    review of each executive&#146;s existing long-term incentives,
    and retention considerations. The exercise price of stock
    options granted under the 2006 Stock Incentive Plan must be
    equal to at least 100% of the fair market value of our common
    stock on the date of grant; however, in certain circumstances,
    grants may be made at a lower price to Israeli grantees who are
    residents of the State of Israel. We have not awarded stock
    options to any of our executive officers since February 2010,
    except in connection with the hiring of our Chief Operating
    Officer.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Severance and Change in Control
    Benefits.</I>&#160;&#160;Pursuant to the employment agreements
    entered into with each of our executive officers based in
    Israel, the executive officer is entitled to be insured by
    Protalix Ltd. under a Manager&#146;s Policy in lieu of
    severance. The intention of such Manager&#146;s Policies is to
    provide the Israel-based officers with severance protection of
    one month&#146;s salary for each year of employment. In
    addition, stock option agreements with each of our named
    executive officers, as amended, provide that all of the
    outstanding options of each Named Executive Officer are subject
    to accelerated vesting immediately upon a change in control of
    our company.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Other Compensation.</I>&#160;&#160;Consistent with our
    compensation philosophy, we intend to continue to maintain our
    current benefits for our executive officers; however, the
    Compensation Committee in its discretion may revise, amend, or
    add to the officer&#146;s executive benefits if it deems it
    advisable. As an additional benefit to all of our Israel-based
    Named Executive Officers and for most of our employees, we
    generally contribute to
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    81
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    certain funds amounts equaling a total of approximately 15% of
    their gross salaries for certain pension and other savings plans
    for the benefit of the Named Executive Officers. In addition, in
    accordance with customary practice in Israel, our Israel-based
    executives&#146; agreements require us to contribute towards
    their vocational studies, and to provide annual recreational
    allowances, a company car and a company phone. We believe these
    benefits are currently equivalent with median competitive levels
    for comparable companies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Executive Compensation.</I>&#160;&#160;We refer to the
    &#147;Summary Compensation Table&#148; set forth in
    Section&#160;11 of the Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for information regarding the compensation earned during the
    fiscal year ended December&#160;31, 2010 by: our President and
    Chief Executive Officer, our Executive Vice President, Research
    and Development, our Senior Vice President, Product Development,
    our Vice President and Chief Financial Officer and our Vice
    President, Sales and Commercial Affairs, who we refer to
    collectively as the &#147;Named Executive Officers.&#148; There
    are no other executive officers for 2010 whose total
    compensation exceeded $100,000 during that fiscal year other
    than the Named Executive Officers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee Report</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>The above report of the Compensation Committee does not
    constitute soliciting material and shall not be deemed filed or
    incorporated by reference into any other filing by us under the
    Securities Act of 1933 or the Securities Exchange Act of
    1934.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Compensation Committee has reviewed and discussed the
    Compensation Discussion and Analysis set forth below with our
    management. Based on this review and discussion, the
    Compensation Committee has recommended to our Board of Directors
    that the Compensation Discussion and Analysis be included in our
    Annual Report on Form&#160;10&#160;&#151; K and our annual proxy
    statement on Schedule&#160;14A.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Respectfully submitted on February&#160;23, 2011, by the members
    of the Compensation Committee of the Board of Directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Yodfat Harel Gross
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Alfred Akirov
</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Amos Bar Shalev
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Summary
    Compensation Table</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table sets forth a summary for the fiscal years
    ended December&#160;31, 2010, 2009 and 2008, respectively, of
    the cash and non-cash compensation awarded, paid or accrued by
    us or Protalix Ltd. to each of our President and Chief Executive
    Officer, our Executive Vice President, Research and Development,
    our Senior Vice President, Product Development, our Vice
    President and Chief Financial Officer and our Vice President,
    Sales and Commercial Affairs, who we refer to collectively as
    the &#147;Named Executive Officers.&#148; Our employment of Tzvi
    Palash, our Chief Operating Officer, commenced in September
    2010. Accordingly, he is not a Named Executive Officer for the
    year ended December&#160;31, 2010. There were no restricted
    stock awards, long-term incentive plan payouts or other
    compensation paid during fiscal years 2010, 2009 and 2008 by us
    or Protalix Ltd. to the Named Executive Officers, except as set
    forth below. All of the Named Executive Officers
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    82
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    are employees of our subsidiary, Protalix Ltd., except for
    Ms.&#160;Lauterbach who is an employee of Protalix
    BioTherapeutics, Inc. All currency amounts are expressed in
    U.S.&#160;dollars.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="35%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=06 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>    <!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=07 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>    <!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=08 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>    <!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=09 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>    <!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=10 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=10 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Nonqualified<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Deferred<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Name and<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Principal<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Salary<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Bonus<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Award(s)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Award(s)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Earnings<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Position</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(1)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    David Aviezer,&#160;Ph.D., MBA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    508,868
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145,537
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    107,972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    762,377
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    <I>President and</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    427,970
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    500,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    529,951
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,167
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,520,088
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    <I>Chief Executive Officer</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    486,305
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    565,394
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    93,224
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,144,923
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>


<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Yoseph Shaaltiel,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    292,095
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    70,286
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,491
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    538,872
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    <I>Executive Vice President,</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    196,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    160,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    225,336
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,981
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    619,588
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    <I>Research and Development</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    226,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163,328
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,704
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    444,684
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>



<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Einat Brill Almon,&#160;Ph.D.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    251,940
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    97,007
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    66,591
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    435,538
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    <I>Senior Vice President,</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    172,210
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    160,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    283,388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    36,927
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    652,525
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    <I>Product Development</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    195,559
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,932
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,862
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,223
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    529,576
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>


<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Yossi Maimon, CPA
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    268,154
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63,175
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,156
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    419,485
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    <I>Vice President,</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    186,478
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    160,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    253,030
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    41,051
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    640,559
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    <I>Chief Financial Officer</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    203,097
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    30,659
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    238,194
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,808
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    555,758
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Sandra L. Lauterbach(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    186,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    405,562
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    62,248
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    654,220
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: 0pt; margin-left: 7pt">
    <I>Vice President, Sales and</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2009
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="top">
<DIV style="text-indent: -7pt; margin-left: 22pt">
    <I>Commercial Affairs</I>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes employer contributions to pension and/or insurance
    plans and other miscellaneous payments.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Ms.&#160;Lauterbach joined our company in December 2009.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table summarizes the grant of awards made to the
    Named Executive Officers during 2010 as of December&#160;31,
    2010.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">GRANTS OF
    PLAN-BASED AWARDS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 7pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="21%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=07 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=08 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=09 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>    <!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=10 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=10 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=11 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=11 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>    <!-- colindex=11 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=11 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=12 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=12 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=12 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=12 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>All<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Grant<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Date Fair<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>or Base<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Estimated Future Payouts Under<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>Estimated Future Payouts<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Price of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Non-Equity Incentive Plan Awards</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Under Equity Incentive Plan Awards</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>and Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Grant<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Threshold<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Target<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Name<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Date<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>($)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>($)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Maximum($)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Threshold($)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Target($)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Maximum($)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Stock or Units (#)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>(#) (1)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>($/Sh) (2)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>($)(3)<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>(a)</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(b)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(c)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(d)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(e)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(f)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(g)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(h)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(i)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(j)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(k)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(l)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    David Aviezer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Feb. 25, 2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    250,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,395,820
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>


<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Yoseph Shaaltiel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Feb. 25, 2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    809,576
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>


<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Einat Brill Almon
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Feb. 25, 2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    130,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    725,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>


<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Yossi Maimon
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Feb. 25, 2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    130,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    725,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>


<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -7pt; margin-left: 7pt">
    Sandra L. Lauterbach
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    Feb. 7, 2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    160,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.81
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    739,623
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents outstanding options at December&#160;31, 2010.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents the range of the exercise price of the stock options.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents the fair value as recorded on the grant date of the
    stock options.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    83
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Outstanding
    Equity Awards at Fiscal Year-End</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table sets forth information with respect to the
    Named Executive Officers concerning equity awards as of
    December&#160;31, 2010.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->

<TR style="font-size: 1pt" valign="bottom">
    <TD width="31%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="3%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=06 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=06 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=07 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=08 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=08 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=08 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=08 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=09 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=09 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=09 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=09 type=hang1 -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=10 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=10 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=10 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=10 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Option Awards</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock Awards</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Market or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Payout<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Value of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unearned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Awards:<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Market<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unearned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Value of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Units or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of Securities<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of Shares or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Units or<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Underlying<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Units<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>or Units<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Rights<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercised<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Rights<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>That<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unearned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>That Have<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>That Have<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>That Have<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Have Not<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercisable<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Unexercisable<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Expiration<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Not Vested<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Not Vested<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Not Vested<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Vested<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 6pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Date</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->

<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    David Aviezer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    326,267
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/1/2013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    977,297
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/10/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    399,996
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200,004
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/7/2018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    100,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.65
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/25/2019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    250,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/25/2020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Yoseph Shaaltiel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122,162
</TD>
<TD nowrap align="left" valign="bottom">
    (1)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6/30/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    175,816
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    87,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/7/2018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.65
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/25/2019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    145,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/25/2020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Einat Brill Almon
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    116,848
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8/13/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    207,520
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    103,752
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/7/2018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.65
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/25/2019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    130,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/25/2020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Yossi Maimon
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,964
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9/19/2016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    116,668
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    58,332
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/7/2018
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.65
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/25/2019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    130,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/25/2020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Sandra L. Lauterbach
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    160,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.81
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2/7/2020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">


<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>


<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Pursuant to a divorce settlement, Dr.&#160;Shaaltiel is required
    to transfer 50% of these options to his former spouse.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Option exercises during 2010 and vested stock awards for Named
    Executive Officers as of December&#160;31, 2010 were as follows:
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">OPTION
    EXERCISES AND STOCK VESTED</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->

<TR style="font-size: 1pt" valign="bottom">
    <TD width="51%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->

<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Option Awards</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock Awards</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Shares<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Acquired on<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Received on<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Acquired on<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Received on<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Vesting<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Vesting<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name (a)</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)(b)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(c)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>(#)(d)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)(e)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>

<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->

<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David Aviezer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yoseph Shaaltiel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yossi Maimon(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    140,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,040
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Einat Brill Almon
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    120,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    113,919
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="color: #000000; background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sandra L. Lauterbach
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">


<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>


<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Some of the options were exercised through net exercise with no
    value received by our company in connection with the exercise.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    84
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Potential
    Payments upon Termination or
    <FONT style="white-space: nowrap">Change-in-Control</FONT></FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Each of our Named Executive Officers is entitled to be insured
    by Protalix Ltd. under a Manager&#146;s Policy in lieu of
    severance upon termination. The intention of such Manager&#146;s
    Policies is to provide the Israel-based officers with severance
    protection of one month&#146;s salary for each year of
    employment. We do not provide any change in control benefits to
    our Named Executive Officers except that their stock option
    agreements, as amended, provide that all of the outstanding
    options of each Named Executive Officer are subject to
    accelerated vesting immediately upon a change in control of our
    company, as defined in our 2006 Stock Incentive Plan. If we had
    experienced a change of control on December&#160;31, 2010, the
    value of the acceleration of the stock options held by each of
    Dr.&#160;Aviezer, Dr.&#160;Shaaltiel, Dr.&#160;Brill Almon,
    Mr.&#160;Maimon and Ms.&#160;Lauterbach would be
    $1.8&#160;million, $884,000, $917,000, $691,000 and $507,000,
    respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Employment
    Arrangements</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>David Aviezer,&#160;Ph.D.,
    MBA.</I>&#160;&#160;Dr.&#160;Aviezer originally served as
    Protalix Ltd.&#146;s Chief Executive Officer on a consultancy
    basis pursuant to a Consulting Services Agreement between
    Protalix Ltd. and Agenda Biotechnology Ltd., a company
    wholly-owned by Dr.&#160;Aviezer. On September&#160;11, 2006,
    Protalix Ltd. entered into an employment agreement with
    Dr.&#160;Aviezer pursuant to which he agreed to be employed as
    Protalix Ltd.&#146;s President and Chief Executive Officer,
    which agreement supersedes the Consultancy Services Agreement.
    Dr.&#160;Aviezer currently serves as our President and Chief
    Executive Officer. Dr.&#160;Aviezer&#146;s current monthly base
    salary is NIS 148,000 (approximately $40,360) and he is entitled
    to an annual bonus at the Board&#146;s discretion. The monthly
    salary is subject to cost of living adjustments from time to
    time. Dr.&#160;Aviezer is eligible to receive a substantial
    bonus in the event of certain public offerings or acquisition
    transactions, which bonus shall be at the discretion of the
    Board, and certain specified bonuses in the event Protalix
    achieves certain specified milestones. In connection with the
    employment agreement, in addition to other options already held
    by Dr.&#160;Aviezer granted to Dr.&#160;Aviezer options to
    purchase 16,000 ordinary shares of Protalix Ltd. at an exercise
    price equal to $59.40 per share, which we assumed as options to
    purchase 977,297&#160;shares of our common stock at $0.97 per
    share. Such options vest quarterly retroactively from
    June&#160;1, 2006, over a four-year period. In addition, in 2008
    we granted to Dr.&#160;Aviezer an option to purchase
    600,000&#160;shares of our common stock at an exercise price
    equal to $5.00 per share. The option vests variably over a
    five-year period that commenced on January&#160;1, 2008. In
    2009, we granted Dr.&#160;Aviezer an option to purchase
    100,000&#160;shares of our common stock at an exercise price
    equal to $2.65 per share. As of December&#160;31, 2009, all of
    those options had fully vested. In 2010, we granted
    Dr.&#160;Aviezer an option to purchase 250,000&#160;shares of
    our common stock at an exercise price equal to $6.90 per share,
    which option vests quarterly over a three-year period commencing
    upon FDA approval of taliglucerase alfa, if at all.
    Dr.&#160;Aviezer&#146;s employment agreement is terminable by
    either party on 90&#160;days&#146; written notice for any reason
    and we may terminate the agreement for cause without notice.
    Dr.&#160;Aviezer is entitled to be insured by Protalix Ltd.
    under a Manager&#146;s Policy in lieu of severance, company
    contributions towards vocational studies, annual recreational
    allowances, a company car and a company phone. Dr.&#160;Aviezer
    is entitled to 24 working days of vacation. All stock options
    that have not vested as of the date of termination shall be
    deemed to have expired.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Yoseph
    Shaaltiel,&#160;Ph.D.</I>&#160;&#160;Dr.&#160;Shaaltiel founded
    Protalix Ltd. in 1993 and currently serves as our Executive Vice
    President, Research and Development. Dr.&#160;Shaaltiel entered
    into an employment agreement with Protalix Ltd. on
    September&#160;1, 2001. Pursuant to the employment agreement,
    his current monthly base salary is NIS 85,000 (approximately
    $23,180) per month. The employment agreement is terminable by
    Protalix Ltd. on 90&#160;days&#146; written notice for any
    reason and we may terminate the agreement for cause without
    notice. In 2008 we granted to Dr.&#160;Shaaltiel an option to
    purchase 263,728&#160;shares of our common stock at an exercise
    price equal to $5.00 per share. The option vests variably over a
    five-year period that commenced on January&#160;1, 2008. In
    2009, we granted Dr.&#160;Shaaltiel an option to purchase
    50,000&#160;shares of our common stock at an exercise price
    equal to $2.65 per share. As of December&#160;31, 2009, all of
    those options had fully vested. In 2010, we granted
    Dr.&#160;Shaaltiel an option to purchase 145,000&#160;shares of
    our common stock at an exercise price equal to $6.90 per share,
    which option vests quarterly over a three-year period commencing
    upon FDA approval of taliglucerase alfa, if at all.
    Dr.&#160;Shaaltiel is entitled to be insured by Protalix Ltd.
    under a
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    85
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Manager&#146;s Policy in lieu of severance, company
    contributions towards vocational studies, annual recreational
    allowances, a company car and a company phone.
    Dr.&#160;Shaaltiel is entitled to 24 working days of vacation.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Einat Brill Almon,&#160;Ph.D.</I>&#160;&#160;Dr.&#160;Brill
    Almon joined Protalix Ltd. on December&#160;19, 2004 as its
    Vice&#160;President, Product Development, pursuant to an
    employment agreement effective on December&#160;19, 2004 by and
    between Protalix Ltd. and Dr.&#160;Brill Almon, and currently
    serves as our Senior Vice President, Product Development.
    Pursuant to the employment agreement, her current monthly base
    salary is NIS 73,500 per month (approximately $20,044). She is
    also entitled to certain specified bonuses in the event that
    Protalix achieves certain specified clinical development
    milestones within specified timelines. In connection with the
    employment agreement, Protalix agreed to grant to Dr.&#160;Brill
    Almon options to purchase 7,919 ordinary shares of Protalix Ltd.
    at exercise prices equal to $24.36 and $59.40 per share, which
    we assumed as options to purchase 483,701&#160;shares of our
    common stock at $0.40 and $0.97 per share. The options vest over
    four years. In addition, in 2008 we granted to Dr.&#160;Brill
    Almon an option to purchase 311,272&#160;shares of our common
    stock at an exercise price equal to $5.00 per share. The option
    vests variably over a five-year period that commenced on
    January&#160;1, 2008. In 2009, we granted to Dr.&#160;Brill
    Almon an option to purchase 50,000&#160;shares of our common
    stock at an exercise price equal to $2.65 per share. As of
    December&#160;31, 2009, all of those options had fully vested.
    In 2010, we granted Dr.&#160;Almon an option to purchase
    130,000&#160;shares of our common stock at an exercise price
    equal to $6.90 per share, which option vests quarterly over a
    three-year period commencing upon FDA approval of taliglucerase
    alfa, if at all. The employment agreement is terminable by
    either party on 60&#160;days&#146; written notice for any reason
    and we may terminate the agreement for cause without notice.
    Dr.&#160;Brill Almon is entitled to be insured by Protalix Ltd.
    under a Manager&#146;s Policy in lieu of severance, company
    contributions towards vocational studies, annual recreational
    allowances, a company car and a company phone at up to NIS 1,000
    per month. Dr.&#160;Brill Almon is entitled to 22 working days
    of vacation. All stock options that have not vested as of the
    date of termination shall be deemed to have expired.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Yossi Maimon, CPA.</I>&#160;&#160;Mr.&#160;Maimon joined
    Protalix Ltd. as its Chief Financial Officer pursuant to an
    employment agreement effective as of October&#160;15, 2006 by
    and between Protalix Ltd. and Mr.&#160;Maimon and currently
    serves as our Chief Financial Officer. Pursuant to the
    employment agreement, his current monthly base salary is NIS
    73,500 (approximately $20,044) and Mr.&#160;Maimon is entitled
    to an annual discretionary bonus and additional discretionary
    bonuses in the event Protalix achieves significant financial
    milestones, subject to the Board&#146;s sole discretion. The
    monthly salary is subject to cost of living adjustments from
    time to time. In connection with the employment agreement,
    Protalix agreed to grant to Mr.&#160;Maimon options to purchase
    10,150 ordinary shares of Protalix Ltd. at an exercise price
    equal to $59.40 per share, which we assumed as options to
    purchase 619,972&#160;shares of our common stock at $0.97 per
    share. The first 25% of such options shall vest on the first
    anniversary of the grant date and the remainder shall vest
    quarterly in 12 equal increments. In addition, in 2008 we
    granted to Mr.&#160;Maimon an option to purchase
    175,000&#160;shares of our common stock at an exercise price
    equal to $5.00 per share. The option vests variably over a
    five-year period that commenced on January&#160;1, 2008. In
    2009, we granted to Mr.&#160;Maimon an option to purchase
    50,000&#160;shares of our common stock at an exercise price
    equal to $2.65 per share. As of December&#160;31, 2009, all of
    those options had fully vested. In 2010, we granted
    Mr.&#160;Maimon an option to purchase 130,000&#160;shares of our
    common stock at an exercise price equal to $6.90 per share,
    which option vests quarterly over a three-year period commencing
    upon FDA approval of taliglucerase alfa, if at all. The
    employment agreement is terminable by either party on
    60&#160;days&#146; written notice for any reason and we may
    terminate the agreement for cause without notice.
    Mr.&#160;Maimon is entitled to be insured by Protalix Ltd. under
    a Manager&#146;s Policy in lieu of severance, company
    contributions towards vocational studies, annual recreational
    allowances, a company car and a company phone. Mr.&#160;Maimon
    is entitled to 24 working days of vacation. All stock options
    that have not vested as of the date of termination shall be
    deemed to have expired.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <I>Sandra L. Lauterbach.</I>&#160;&#160;Ms.&#160;Lauterbach
    joined our company as our Vice President, Sales and Commercial
    Affairs, pursuant to an employment agreement effective
    December&#160;18, 2009. Pursuant to the employment agreement,
    Ms.&#160;Lauterbach&#146;s annual base salary is $180,000 and we
    may elect to pay her an annual discretionary bonus in an amount
    and based upon criteria determined by either the Compensation
    Committee of our Board of Directors, or the entire Board of
    Directors, at their sole discretion. She is also entitled to
    certain health care insurance benefits and contributions to
    retirement plans, and allowances for car and cell
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    86
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    phone expenses. In connection with the employment agreement, the
    Board of Directors granted to Ms.&#160;Lauterbach stock options
    to purchase 160,000&#160;shares of our common stock at an
    exercise price equal to $6.81. The options vest over a four-year
    period, with 25% of the options vesting upon the lapse of one
    year from the date of grant and the remainder of the options
    vesting on a quarterly basis in 12 equal installments,
    commencing on the initial vesting date. The unvested portion of
    the option will vest automatically upon a change of control of
    our company. The employment agreement is terminable by either
    party with 60&#160;days&#146; written notice for any reason and
    we may terminate the agreement for cause without notice.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">2006
    Stock Incentive Plan</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our Board of Directors and a majority of our shareholders
    approved our 2006 Stock Incentive Plan on December&#160;14, 2006
    and cancelled our 1998 stock option plan (no options were
    outstanding under the 1998 plan at that time). We have reserved
    9,741,655&#160;shares of our common stock for issuance, in the
    aggregate, under the 2006 Stock Incentive Plan, subject to
    adjustment for a stock split or any future stock dividend or
    other similar change in our common stock or our capital
    structure. As of December&#160;31, 2010, options to acquire
    3,064&#160;shares of common stock remain available to be granted
    under our 2006 Stock Incentive Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our 2006 Stock Incentive Plan provides for the grant of stock
    options, restricted stock, restricted stock units, stock
    appreciation rights and dividend equivalent rights, collectively
    referred to as &#147;awards.&#148; Stock options granted under
    the 2006 Stock Incentive Plan may be either incentive stock
    options under the provisions of Section&#160;422 of the Internal
    Revenue Code, or non-qualified stock options. Incentive stock
    options may be granted only to employees. Awards other than
    incentive stock options may be granted to employees, directors
    and consultants.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The 2006 Stock Incentive Plan is also designed to comply with
    the provisions of the Israeli Income Tax Ordinance New Version,
    1961 (including as amended pursuant to Amendment 132 thereto)
    (the &#147;tax ordinance&#148;) and is intended to enable us to
    grant awards to grantees who are Israeli residents as follows:
    (i)&#160;awards to employees pursuant to Section&#160;102 of the
    tax ordinance; and (ii)&#160;awards to non-employees pursuant to
    Section&#160;3(I) of the tax ordinance. For this purpose,
    &#147;employee&#148; refers only to employees, office holders
    and directors of our company or a related entity excluding those
    who are considered &#147;Controlling Shareholders&#148; pursuant
    to, or otherwise excluded by, the tax ordinance. In accordance
    with the terms and conditions imposed by the Tax Ordinance,
    grantees who receive awards under the 2006 Stock Incentive Plan
    may be afforded certain tax benefits in Israel as described
    below.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our Board of Directors or the Compensation Committee, referred
    to as the &#147;plan administrator,&#148; will administer our
    2006 Stock Incentive Plan, including selecting the grantees,
    determining the number of shares to be subject to each award,
    determining the exercise or purchase price of each award, and
    determining the vesting and exercise periods of each award.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The exercise price of stock options granted under the 2006 Stock
    Incentive Plan must be equal to at least 100% of the fair market
    value of our common stock on the date of grant; however, in
    certain circumstances, grants may be made at a lower price to
    Israeli grantees who are residents of the State of Israel. If,
    however, incentive stock options are granted to an employee who
    owns stock possessing more than 10% of the voting power of all
    classes of our stock or the stock of any parent or subsidiary of
    our company, the exercise price of any incentive stock option
    granted must equal at least 110% of the fair market value on the
    grant date and the maximum term of these incentive stock options
    must not exceed five years. The maximum term of all other awards
    must not exceed 10&#160;years (or five years in the case of an
    incentive stock option granted to any participant who owns stock
    representing more than 10% of the voting power of all classes of
    our stock or the stock of any parent or subsidiary of our
    company). The plan administrator will determine the exercise or
    purchase price (if any) of all other awards granted under the
    2006 Stock Incentive Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the 2006 Stock Incentive Plan, incentive stock options and
    options to Israeli grantees may not be sold, pledged, assigned,
    hypothecated, transferred or disposed of in any manner other
    than by will or by the laws of descent or distribution and may
    be exercised during the lifetime of the participant only by the
    participant. Other awards shall be transferable by will or by
    the laws of descent or distribution and to the extent and in the
    manner authorized by the plan administrator by gift or pursuant
    to a domestic relations order
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    87
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    to members of the participant&#146;s immediate family. The 2006
    Stock Incentive Plan permits the designation of beneficiaries by
    holders of awards, including incentive stock options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If the service of a participant in the 2006 Stock Incentive Plan
    is terminated for any reason other than cause, the participant
    may exercise awards that were vested as of the termination date
    for a period ending upon the earlier of 12&#160;months from the
    date of termination (or such shorter or longer period set forth
    in the award agreement) or the expiration date of the awards
    unless otherwise determined by the plan administrator. If the
    service of a participant in the 2006 Stock Incentive Plan is
    terminated for cause, the participant may exercise awards that
    were vested as of the termination date for a period ending upon
    the earlier of 14&#160;days from the date of termination (or
    such shorter or longer period set forth in the award agreement)
    or the expiration date of the awards unless otherwise determined
    by the plan administrator.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the event of a corporate transaction, all awards will
    terminate unless assumed by the successor corporation. Unless
    otherwise provided in a participant&#146;s award agreement, in
    the event of a corporate transaction and with respect to the
    portion of each award that is assumed or replaced, then such
    portion will automatically become fully vested and exercisable
    immediately upon termination of a participant&#146;s service if
    the participant is terminated by the successor company or us
    without cause within 12&#160;months after the corporate
    transaction. With respect to the portion of each award that is
    not assumed or replaced, such portion will automatically become
    fully vested and exercisable immediately prior to the effective
    date of the corporate transaction so long as the
    participant&#146;s service has not been terminated prior to such
    date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the event of a change in control, except as otherwise
    provided in a participant&#146;s award agreement, following a
    change in control (other than a change in control that also is a
    corporate transaction) and upon the termination of a
    participant&#146;s service without cause within 12&#160;months
    after a change in control, each award of such participant that
    is outstanding at such time will automatically become fully
    vested and exercisable immediately upon the participant&#146;s
    termination. In addition, the stock options issued to each of
    our Named Executive Officers are subject to accelerated vesting
    immediately upon a change in control of our company, as defined
    in our 2006 Stock Incentive Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under our 2006 Stock Incentive Plan, a corporate transaction is
    generally defined as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a merger or consolidation in which we are not the surviving
    entity, except for the principal purpose of changing our
    company&#146;s state of incorporation;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the sale, transfer or other disposition of all or substantially
    all of our assets;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the complete liquidation or dissolution of our company;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    any reverse merger in which we are the surviving entity but our
    shares of common stock outstanding immediately prior to such
    merger are converted or exchanged by virtue of the merger into
    other property, whether in the form of securities, cash or
    otherwise, or in which securities possessing more than forty
    percent (40%) of the total combined voting power of our
    outstanding securities are transferred to a person or persons
    different from those who held such securities immediately prior
    to such merger;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    acquisition in a single or series of related transactions by any
    person or related group of persons of beneficial ownership of
    securities possessing more than fifty percent (50%) of the total
    combined voting power of our outstanding securities but
    excluding any such transaction or series of related transactions
    that the plan administrator determines not to be a corporate
    transaction (provided however that the plan administrator shall
    have no discretion in connection with a corporate transaction
    for the purchase of all or substantially all of our shares
    unless the principal purpose of such transaction is changing our
    company&#146;s state of incorporation).
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under our 2006 Stock Incentive Plan, a change of control is
    defined as:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    the direct or indirect acquisition by any person or related
    group of persons of beneficial ownership of securities
    possessing more than fifty percent (50%) of the total combined
    voting power of our outstanding securities pursuant to a tender
    or exchange offer made directly to our shareholders and
</TD>
</TR>

</TABLE>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    88
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>
</TD>
    <TD align="left">
    which a majority of the members of our board (who have generally
    been on our board for at least 12&#160;months) who are not
    affiliates or associates of the offeror do not recommend
    shareholders accept the offer;&#160;or
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    a change in the composition of our board over a period of
    12&#160;months or less, such that a majority of our board
    members ceases, by reason of one or more contested elections for
    board membership, to be comprised of individuals who were
    previously directors of our company.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Unless terminated sooner, the 2006 Stock Incentive Plan will
    automatically terminate in 2016. Our Board of Directors has the
    authority to amend, suspend or terminate our 2006 Stock
    Incentive Plan. No amendment, suspension or termination of the
    2006 Stock Incentive Plan shall adversely affect any rights
    under awards already granted to a participant. To the extent
    necessary to comply with applicable provisions of federal
    securities laws, state corporate and securities laws, the
    Internal Revenue Code, the rules of any applicable stock
    exchange or national market system, and the rules of any
    <FONT style="white-space: nowrap">non-U.S.&#160;jurisdiction</FONT>
    applicable to awards granted to residents therein (including the
    Tax Ordinance), we shall obtain shareholder approval of any such
    amendment to the 2006 Stock Incentive Plan in such a manner and
    to such a degree as required.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 2%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><I><FONT style="font-family: 'Times New Roman', Times">Impact
    of Israeli Tax Law</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The awards granted to employees pursuant to Section&#160;102 of
    the Tax Ordinance under the 2006 Stock Incentive Plan may be
    designated by us as approved options under the capital gains
    alternative, or as approved options under the ordinary income
    tax alternative.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    To qualify for these benefits, certain requirements must be met,
    including registration of the options in the name of a trustee.
    Each option, and any shares of common stock acquired upon the
    exercise of the option, must be held by the trustee for a period
    commencing on the date of grant and deposit into trust with the
    trustee and ending 24&#160;months thereafter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the terms of the capital gains alternative, we may not
    deduct expenses pertaining to the options for tax purposes.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the 2006 Stock Incentive Plan, we may also grant to
    employees options pursuant to Section&#160;102(c) of the Tax
    Ordinance that are not required to be held in trust by a
    trustee. This alternative, while facilitating immediate exercise
    of vested options and sale of the underlying shares, will
    subject the optionee to the marginal income tax rate of up to
    50% as well as payments to the National Insurance Institute and
    health tax on the date of the sale of the shares or options.
    Under the 2006 Stock Incentive Plan, we may also grant to
    non-employees options pursuant to Section&#160;3(I) of the Tax
    Ordinance. Under that section, the income tax on the benefit
    arising to the optionee upon the exercise of options and the
    issuance of common stock is generally due at the time of
    exercise of the options.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    These options shall be further subject to the terms of the tax
    ruling that has been obtained by Protalix Ltd. from the Israeli
    tax authorities in connection with the merger. Under the tax
    ruling, the options issued by us in connection with the
    assumption of Section&#160;102 options previously issued by
    Protalix Ltd. under the capital gains alternative shall be
    issued to a trustee, shall be designated under the capital gains
    alternative and the issuance date of the original options shall
    be deemed the issuance date for the assumed options for the
    calculation of the respective holding period.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    89
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    of Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table sets forth information with respect to
    compensation of our non-employee directors during fiscal year
    2010. The fees to our current directors were paid by Protalix
    Ltd. Prior to January&#160;1, 2007, Protalix Ltd. compensated
    only certain of its directors, which compensation was limited to
    the granting of options under its employee stock option plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="38%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>     <!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=06 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=06 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=06 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>     <!-- colindex=06 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=07 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=07 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=07 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>     <!-- colindex=07 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=08 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=08 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=08 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>     <!-- colindex=08 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Fees<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Non-Equity<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Nonqualified<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Earned<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Incentive<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Deferred<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>All<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>or Paid<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Stock<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Option<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Plan<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Other<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>in Cash<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Award<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Awards<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Earnings<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Total<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 7pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>($)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    <B>Current Directors</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Eli Hurvitz(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,297
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,297
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Alfred Akirov
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Amos Bar Shalev
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Zeev Bronfeld
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Yodfat Harel Gross
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Roger D. Kornberg
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Eyal Sheratzky
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Represents amounts paid to Pontifax Management Company, Ltd.
    pursuant to a management consulting agreement. Mr.&#160;Hurvitz
    resigned from our Board of Directors in March 2010.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our Board of Directors will review director compensation
    annually and adjust it according to then current market
    conditions and corporate governance guidelines.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Compensation
    Committee Interlocks and Insider Participation</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our Compensation Committee currently consists of
    Messrs.&#160;Akirov and Bar Shalev and Ms.&#160;Harel Gross, who
    were appointed to the Committee during 2009. No member of our
    Compensation Committee or any executive officer of our company
    or of Protalix Ltd. has a relationship that would constitute an
    interlocking relationship with executive officers or directors
    of another entity. No Compensation Committee member is or was an
    officer or employee of ours or of Protalix Ltd. Further, none of
    our executive officers serves on the board of directors or
    compensation committee of any entity that has one or more
    executive officers serving as a member of our Board of Directors
    or Compensation Committee.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;12.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571121'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Security
    Ownership of Certain Beneficial Owners and Management and
    Related Stockholder Matters</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Security
    Ownership of Certain Beneficial Owners and Management</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table sets forth information, as of
    February&#160;15, 2011, regarding beneficial ownership of our
    common stock:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each person who is known by us to own beneficially more than 5%
    of our common stock;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each director;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    each of our Chief Executive Officer, our Executive Vice
    President, Research and Development, our Senior Vice President, Product
    Development, our Chief Financial Officer, our Vice President,
    Sales and Commercial Affairs and our Chief Operating
    Officer;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    all of our directors and executive officers collectively.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Unless otherwise noted, we believe that all persons named in the
    table have sole voting and investment power with respect to all
    shares of our common stock beneficially owned by them. For
    purposes of these tables, a person is deemed to be the
    beneficial owner of securities that can be acquired by such
    person within 60&#160;days from February&#160;15, 2011 upon
    exercise of options, warrants and convertible securities. Each
    beneficial
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    90
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    owner&#146;s percentage ownership is determined by assuming that
    options, warrants and convertible securities that are held by
    such person (but not those held by any other person) and that
    are exercisable within such 60&#160;days from such date have
    been exercised. The information set forth below is based upon
    information obtained from the beneficial owners, upon
    information in our possession regarding their respective
    holdings and upon information filed by the holders with the SEC.
    The percentages of beneficial ownership are based on
    81,328,699&#160;shares of our common stock outstanding as of
    February&#160;15, 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The address for all directors and officers is
    <FONT style="white-space: nowrap">c/o&#160;Protalix</FONT>
    BioTherapeutics, Inc., 2 Snunit Street, Science Park, POB 455,
    Carmiel, Israel, 20100.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="69%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="7%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="7%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="5%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Amount and Nature<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>of Beneficial<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Percentage of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Name and Address of Beneficial Owner</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Ownership</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Class</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Board of Directors and Executive Officers</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    David Aviezer,&#160;Ph.D., MBA(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,836,895
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.3
</TD>
<TD nowrap align="left" valign="bottom">
    %
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yoseph Shaaltiel,&#160;Ph.D.(2)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,076,384
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.3
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Alfred Akirov(3)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,186,046
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Amos Bar Shalev(4)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,680
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Zeev Bronfeld(5)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,466,319
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yodfat Harel Gross
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Roger D. Kornberg,&#160;Ph.D.(6)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Eyal Sheratzky
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Einat Brill Almon,&#160;Ph.D.(7)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    391,660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Yossi Maimon(8)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    252,353
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    *
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Sandra E. Lauterbach(9)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tzvi Palash(10)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All executive officers and directors as a group
    (12&#160;persons)(11) 5% Holders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    24,248,837
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Biocell Ltd.(12)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,466,319
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17.8
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Techno-Rov Holdings (1993)&#160;Ltd.(13)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,186,046
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Baillie Gifford&#160;&#038; Co.(14)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,828,161
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.2
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    *&#160;</TD>
    <TD></TD>
    <TD valign="bottom">
    less than 1%.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 1,836,895&#160;shares of our common stock issuable
    upon exercise of outstanding options within 60&#160;days of
    February&#160;15, 2011. Does not include 416,669&#160;shares of
    common stock issuable upon exercise of outstanding options that
    are not exercisable within 60&#160;days of February&#160;15,
    2011.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (2) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 763,754&#160;shares of our common stock held by
    Dr.&#160;Shaaltiel and 312,630&#160;shares of our common stock
    issuable upon exercise of outstanding options within
    60&#160;days of February&#160;15, 2011. Does not include
    268,260&#160;shares of common stock issuable upon exercise of
    outstanding options that are not exercisable within 60&#160;days
    of February&#160;15, 2011.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (3) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 6,186,046&#160;shares of our common stock held by
    Techno-Rov Holdings (1993)&#160;Ltd. Mr.&#160;Akirov is the
    Chief Executive Officer of Techno-Rov Holdings and has the power
    to control its investment decisions.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (4) </TD>
    <TD></TD>
    <TD valign="bottom">
    Mr.&#160;Bar Shalev is the Manager of Techno-Rov Holdings.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (5) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 14,466,319&#160;shares of our common stock held by
    Biocell Ltd. Mr.&#160;Bronfeld is a director and Chief Executive
    Officer of Biocell. Mr.&#160;Bronfeld disclaims beneficial
    ownership of these shares except to the extent of his pecuniary
    interest therein.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (6) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 37,500&#160;shares of our common stock issuable upon
    exercise of outstanding options within 60&#160;days of
    February&#160;15, 2011. Does not include 12,500&#160;shares of
    common stock issuable upon exercise of outstanding options that
    are not exercisable within 60&#160;days of February&#160;15,
    2011.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    91
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD width="96%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    (7) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 391,660&#160;shares of our common stock issuable
    upon exercise of outstanding options within 60&#160;days of
    February&#160;15, 2011. Does not include 216,460&#160;shares of
    common stock issuable upon exercise of outstanding options that
    are not exercisable within 60&#160;days of February&#160;15,
    2011.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (8) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 252,353&#160;shares of our common stock issuable
    upon exercise of outstanding options within 60&#160;days of
    February&#160;15, 2011. Does not include 178,611&#160;shares of
    common stock issuable upon exercise of outstanding options that
    are not exercisable within 60&#160;days of February&#160;15,
    2011.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (9) </TD>
    <TD></TD>
    <TD valign="bottom">
    Does not include 160,000&#160;shares of common stock issuable
    upon exercise of outstanding options that are not exercisable
    within 60&#160;days of February&#160;15, 2011.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (10) </TD>
    <TD></TD>
    <TD valign="bottom">
    Does not include 160,000&#160;shares of common stock issuable
    upon exercise of outstanding options that are not exercisable
    within 60&#160;days of February&#160;15, 2011.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (11) </TD>
    <TD></TD>
    <TD valign="bottom">
    Consists of 21,417,799&#160;shares of our common stock and
    2,831,038&#160;shares of our common stock issuable upon exercise
    of outstanding options within 60&#160;days of February&#160;15,
    2011. Does not include 1,412,500&#160;shares of common stock
    issuable upon exercise of outstanding options that are not
    exercisable within 60&#160;days of February&#160;15, 2011.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (12) </TD>
    <TD></TD>
    <TD valign="bottom">
    The address is Moshe Aviv Tower, 7 Jabotinsky Street, Ramat Gan,
    Israel. Biocell Ltd.&#146;s investment and voting decisions are
    made collectively by its board of directors.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (13) </TD>
    <TD></TD>
    <TD valign="bottom">
    The address is Alrov Tower, 46 Rothschild Blvd., Tel Aviv,
    Israel 66883. Mr.&#160;Akirov is the Chief Executive Officer of
    Techno-Rov Holdings (1993)&#160;Ltd. and has the power to
    control its investment decisions.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (14) </TD>
    <TD></TD>
    <TD valign="bottom">
    Based solely on a Schedule&#160;13G filed by Baillie
    Gifford&#160;&#038; Co. on January&#160;25, 2011. According to
    Baillie Gifford&#160;&#038; Co., it has sole dispositive power
    over 5,828,161&#160;shares of common stock and sole voting power
    over 3,369,061&#160;shares of common stock.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Equity
    Compensation Plan Information</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table provides information as of December&#160;31,
    2010 with respect to the shares of our common stock that may be
    issued under our existing equity compensation plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="57%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="6%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="6%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>A</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>B</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>C</B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Available for<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Future Issuance<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Weighted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Under Equity<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Securities to be<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Compensation<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Issued<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Plans (Excluding<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Upon Exercise of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Price of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Securities<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Outstanding<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Outstanding<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Reflected in<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Plan Category</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Column A)</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Equity Compensation Plans Approved by Shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,174,805
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.16
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,064
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Equity Compensation Plans Not Approved by Shareholders
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    631,866
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10.24
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,806,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,064
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;13.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571122'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Certain
    Relationships and Related Transactions, and Director
    Independence</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On March&#160;17, 2005, Protalix Ltd. entered into a Management
    Services Agreement with Pontifax Management Company, Ltd. in
    connection with the purchase of Protalix&#146;s Series&#160;B
    Preferred Shares by the Pontifax Funds. Pursuant to the
    Management Services Agreement, Mr.&#160;Hurvitz served as a
    member of our Board of Directors and later as the Chairman of
    our Board of Directors until his resignation in March 2010. In
    consideration for Mr.&#160;Hurvitz&#146;s services, Protalix was
    required to pay Pontifax Management Company a fee equal to
    $3,000 per month plus required taxes on such payment. In
    addition, in connection with the execution of the Management
    Services Agreement and the later appointment of Mr.&#160;Hurvitz
    as Chairman of our Board of Directors, Protalix issued to
    Pontifax, in the aggregate, a number of options that, upon our
    December 2006
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    92
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    merger transaction, were converted into options to purchase
    3,384,502&#160;shares of our common stock. Under the terms of
    the assumed Management Services Agreement, we are obligated only
    to use our best efforts to nominate Mr.&#160;Hurvitz for
    election to our Board of Directors, which remains subject to the
    review and approval of the Nominating Committee of the Board of
    Directors and the entire Board of Directors, as applicable.
    During the year 2010 through the date of Mr.&#160;Hurvitz&#146;s
    resignation, the fee payable under this agreement was increased
    to $33,000 per annum, which is the same fee payable to the other
    non-executive directors. No further payments were due to
    Pontifax Management Company after Mr.&#160;Hurvitz&#146;s
    resignation from our Board of Directors.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On September&#160;14, 2006, Protalix Ltd. entered into a
    collaboration and licensing agreement with Teva for the
    development and manufacture of two proteins using
    ProCellEx<SUP style="font-size: 85%; vertical-align: top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>,

    our proprietary protein expression system. Mr.&#160;Hurvitz, our
    former Chairman, was the chairman of Teva&#146;s board of
    directors when we entered into the agreement. Phillip
    Frost,&#160;M.D., a former director and a major shareholder of
    our company, is the chairman of Teva&#146;s board of directors
    and Professor Kornberg, a member of our Board of Directors also
    serves as a member of Teva&#146;s board of directors. The
    agreement provides that we will collaborate with Teva on the
    research and development of two proteins using ProCellEx. We and
    Teva identified two proteins for research and development
    activities under the agreement, but in 2009 both of the projects
    were terminated for commercial reasons. Other elements of our
    collaboration with Teva are currently ongoing.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    All related party transactions are reviewed and approved by the
    Audit Committee, as required by the Audit Committee Charter.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Corporate
    Governance and Independent Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In compliance with the listing requirements of the NYSE Amex, we
    have a comprehensive plan of corporate governance for the
    purpose of defining responsibilities, setting high standards of
    professional and personal conduct and assuring compliance with
    such responsibilities and standards. We currently regularly
    monitor developments in the area of corporate governance to
    ensure we are in compliance with the standards and regulations
    required by the NYSE Amex. A summary of our corporate governance
    measures follows.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Independent
    Directors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    We believe a majority of the members of our Board of Directors
    are independent from management. When making determinations from
    time to time regarding independence, the Board of Directors will
    reference the listing standards adopted by the NYSE Amex as well
    as the independence standards set forth in the Sarbanes-Oxley
    Act of 2002 and the rules and regulations promulgated by the SEC
    under that Act. In particular, our Audit Committee periodically
    evaluates and reports to the Board of Directors on the
    independence of each member of the Board. We anticipate our
    audit committee will analyze whether a director is independent
    by evaluating, among other factors, the following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Whether the member of the Board of Directors has any material
    relationship with us, either directly, or as a partner,
    shareholder or officer of an organization that has a
    relationship with us;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Whether the member of the Board of Directors is a current
    employee of our company or any of our subsidiaries, or was an
    employee of our company or any of our subsidiaries within three
    years preceding the date of determination;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Whether the member of the Board of Directors is, or in the three
    years preceding the date of determination has been, affiliated
    with or employed by (i)&#160;a present internal or external
    auditor of our company or any affiliate of such auditor or
    (ii)&#160;any former internal or external auditor of our company
    or any affiliate of such auditor, which performed services for
    us within three years preceding the date of determination;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Whether the member of the Board of Directors is, or in the three
    years preceding the date of determination has been, part of an
    interlocking directorate, in which any of our executive officers
    serve on the Compensation Committee of another company that
    concurrently employs the member as an executive officer;
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    93
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="4%"></TD>
    <TD width="2%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Whether the member of the Board of Directors receives any
    compensation from us, other than fees or compensation for
    service as a member of the Board of Directors and any committee
    of the Board of Directors and reimbursement for reasonable
    expenses incurred in connection with such service and for
    reasonable educational expenses associated with Board of
    Directors or committee membership matters;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Whether an immediate family member of the member of the Board of
    Directors is a current executive officer of our company or was
    an executive officer of our company within three years preceding
    the date of determination;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Whether an immediate family member of the member of the Board of
    Directors is, or in the three years preceding the date of
    determination has been, affiliated with or employed in a
    professional capacity by (i)&#160;a present internal or external
    auditor of ours or any of our affiliates or (ii)&#160;any former
    internal or external auditor of our company or any affiliate of
    ours which performed services for us within three years
    preceding the date of determination;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;
</TD>
    <TD align="left">
    Whether an immediate family member of the member of the Board of
    Directors is, or in the three years preceding the date of
    determination has been, part of an interlocking directorate, in
    which any of our executive officers serve on the Compensation
    Committee of another company that concurrently employs the
    immediate family member of the member of the Board of Directors
    as an executive officer.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The above list is not exhaustive and we anticipate that the
    Audit Committee will consider all other factors which could
    assist it in its determination that a director will have no
    material relationship with us that could compromise that
    director&#146;s independence.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under these standards, our Board of Directors has determined
    that Messrs.&#160;Akirov and Bar Shalev and Ms.&#160;Harel Gross
    are considered &#147;independent&#148; pursuant to the rules of
    the NYSE Amex and Section&#160;10A(m)(3) of the Securities
    Exchange Act of 1934, as amended. In addition, our Board of
    Directors has determined that at least two of these directors
    are able to read and understand fundamental financial statements
    and have substantial business experience that results in their
    financial sophistication, qualifying them for membership on any
    audit committee we form. Our Board of Directors has also
    determined that Messrs.&#160;Akirov, Bar Shalev, Bronfeld and
    Sheratzky, Ms.&#160;Harel Gross and Dr.&#160;Kornberg are
    &#147;independent&#148; pursuant to the rules of the NYSE Amex.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The position of chairman of the board is not held by our chief
    executive officer at this time. The Board of Directors does not
    have a policy mandating the separation of these functions. We
    believe it is in our best interest that Mr.&#160;Bronfeld serve
    as the interim chairman of the board. This decision was based on
    Mr.&#160;Bronfeld&#146;s experience in the healthcare industry
    in Israel and globally and his years of experience serving on
    the board of directors of many public and private companies. Our
    non-management directors hold formal meetings, separate from
    management, at least twice per year. We have no formal policy
    regarding attendance by our directors at annual shareholders
    meetings, although we encourage such attendance and anticipate
    most of our directors will attend these meetings.
    Messrs.&#160;Bronfeld, Bar Shalev, Akirov, Aviezer and
    Shaaltiel, and Ms.&#160;Harel Gross, attended our 2010 annual
    meeting of shareholders. Mr.&#160;Hurvitz resigned from our
    Board of Directors in March 2010.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    Board&#146;s Role in Risk Oversight</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Our Board of Directors oversees an enterprise-wide approach to
    risk management, designed to support the achievement of business
    objectives, including organizational and strategic objectives,
    to improve long-term organizational performance and enhance
    shareholder value. The involvement of our Board of Directors in
    setting our business strategy is a key part of its assessment of
    management&#146;s plans for risk management and its
    determination of what constitutes an appropriate level of risk
    for the company. The participation of our Board of Directors in
    our risk oversight process includes receiving regular reports
    from members of senior management on areas of material risk to
    our company, including operational, financial, legal and
    regulatory, and strategic and reputational risks. While the full
    board has the ultimate oversight responsibility for the risk
    management process, various committees of the board also have
    responsibility for risk management. For example, financial
    risks, including internal controls, are overseen by the audit
    committee and risks that may be
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    94
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    implicated by our executive compensation programs are overseen
    by the compensation committee. Upon identification of a risk,
    the assigned board committee or our full Board of Directors
    discuss or review risk management and risk mitigation
    strategies. Additional review or reporting on enterprise risks
    is conducted as needed or as requested by our Board of Directors
    or a committee thereof.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;14.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571123'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Principal
    Accountant Fees and Services</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following table sets forth fees billed to us by our
    independent registered public accounting firm during the fiscal
    years ended December&#160;31, 2010 and 2009 for:
    (i)&#160;services rendered for the audit of our annual financial
    statements and the review of our quarterly financial statements;
    (ii)&#160;services by our independent registered public
    accounting firm that are reasonably related to the performance
    of the audit or review of our financial statements and that are
    not reported as Audit Fees; (iii)&#160;services rendered in
    connection with tax compliance, tax advice and tax planning; and
    (iv)&#160;all other fees for services rendered.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="3%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="3%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="7" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Audit Fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
289,740
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    259,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Audit Related Fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
28,353
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    78,039
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tax Fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
63,008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    197,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    All Other Fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &nbsp;&nbsp;&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">Policy on
    Audit Committee Pre-Approval of Audit and Permissible Non-Audit
    Services of Independent Auditors</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Prior to entering into the engagement letter with our
    independent registered accountants, our Audit Committee approved
    the 2010 audit fees. For fiscal year 2011, our Audit Committee
    has approved fees for certain services to be rendered by our
    independent registered accounting firm.
</DIV>

<A name='Y04571124'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PART&#160;IV</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>


<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="9%"></TD>
    <TD width="91%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">Item&#160;15.<I>&#160;&#160;</I></FONT></B>
</TD>
    <TD>
    <A name='Y04571125'></A><B><I><FONT style="font-family: 'Times New Roman', Times">Exhibits
    and Financial Statement Schedules</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The following documents are filed as part of this Annual Report
    on
    <FONT style="white-space: nowrap">Form&#160;10-K:</FONT>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    1.&#160;<I>Financial Statements</I>. The following Consolidated
    Financial Statements of Protalix BioTherapeutics, Inc. are
    included in Item&#160;8 of this Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K:</FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="95%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Page</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04571300'>Report of Independent Registered Public
    Accounting Firm</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-2
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04571301'>Consolidated Balance Sheets as of
    December&#160;31, 2009, and 2010</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-3
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04571302'>Consolidated Statements of Operations for the
    years ended December&#160;31, 2008, 2009, and 2010</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-4
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04571303'>Consolidated Statements of Changes in
    Shareholders&#146; Equity (Capital Deficiency) for the years
    ended December&#160;31, 2008, 2009, and 2010</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04571304'>Consolidated Statements of Cash Flows for the
    years ended December&#160;31, 2008, 2009, and 2010</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-6
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04571305'>Notes to Consolidated Financial Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    F-7
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    2.&#160;<I>Financial Statement Schedule. </I>Financial statement
    schedules have been omitted since they are either not required,
    are not applicable or the required information is shown in the
    consolidated financial statements or related notes.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    95
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    3.&#160;<I>Exhibits.</I>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=01 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>     <!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="37%">&nbsp;</TD> <!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="5%">&nbsp;</TD>  <!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="9%">&nbsp;</TD>  <!-- colindex=04 type=maindata -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>     <!-- colindex=05 type=align1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=06 type=gutter -->
    <TD width="17%">&nbsp;</TD> <!-- colindex=06 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=07 type=gutter -->
    <TD width="6%">&nbsp;</TD>  <!-- colindex=07 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="9" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Incorporated by Reference</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Exhibit<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>File<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Filed<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Description</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Form</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Herewith</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Articles of Incorporation of the Company
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    S-4
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    333-48677
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .4
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    March 26, 1998
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Article of Amendment to Articles of Incorporation dated
    June&#160;9, 2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-A
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    March 9, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .3
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Article of Amendment to Articles of Incorporation dated
    December&#160;13, 2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-A
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .3
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    March 9, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .4
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Article of Amendment to Articles of Incorporation dated
    December&#160;26, 2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-A
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .4
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    March 9, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .5
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Article of Amendment to Articles of Incorporation dated
    February&#160;26, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-A
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .5
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    March 9, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .6
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Amended and Restated Bylaws of the Company
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    10-Q
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    3
</TD>
<TD nowrap align="left" valign="top">
    .6
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    August 8, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    2006 Stock Incentive Plan
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    10-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    July 13, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement between Protalix Ltd. and Yoseph Shaaltiel,
    dated as of September&#160;1, 2004
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    January 8, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement between Protalix Ltd. and Einat Almon,
    dated as of December&#160;19, 2004
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .3
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    January 8, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement between Protalix Ltd. and David Aviezer,
    dated as of September&#160;11, 2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .4
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    January 8, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement between Protalix Ltd. and Yossi Maimon,
    dated as of October&#160;15, 2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .5
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    January 8, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .6&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    License Agreement entered into as of April&#160;12, 2005, by and
    between Icon Genetics AG and Protalix Ltd.
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-K/A
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .6
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    September 20, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .7&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Research and License Agreement between Yeda Research and
    Development Company Limited and Protalix Ltd. dated as of
    March&#160;15, 2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-K/A
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .7
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    September 20, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Agreement between Teva Pharmaceutical Industries Ltd. and
    Protalix Ltd., dated September&#160;14, 2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-K/A
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .8
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    September 20, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Lease Agreement between Protalix Ltd. and Angel Science Park
    (99)&#160;Ltd., dated as of October&#160;28, 2003 as amended on
    April&#160;18, 2005
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .9
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    January 8, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Merger Agreement and Plan of Reorganization made and entered
    into as of August&#160;21, 2006, by and among the Company,
    Protalix Acquisition Co., Ltd. and Protalix Ltd.
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .10
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    January 8, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .11
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Stock Option Award Agreement grant by and between the Company
    and Steven Rubin, dated as of December&#160;31, 2006
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    10-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .13
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    March 30, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    96
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=01 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=01 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>     <!-- colindex=01 type=align1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="37%">&nbsp;</TD> <!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="5%">&nbsp;</TD>  <!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="9%">&nbsp;</TD>  <!-- colindex=04 type=maindata -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="2%" align="left">&nbsp;</TD>     <!-- colindex=05 type=align1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=06 type=gutter -->
    <TD width="17%">&nbsp;</TD> <!-- colindex=06 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=07 type=gutter -->
    <TD width="6%">&nbsp;</TD>  <!-- colindex=07 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="9" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Incorporated by Reference</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
    <B>Exhibit<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>File<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Filed<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit Description</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Form</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Number</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Exhibit</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Date</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Herewith</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .12
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    First Amendment to the December&#160;31, 2006 Stock Option Award
    Agreement by and between the Company and Steven Rubin, effective
    as of February&#160;28, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    10-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .16
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    March 30, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .13
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Scientific Advisory Board Agreement dated August&#160;5, 2007 by
    and between the Company and Aaron Ciechanover,&#160;M.D.
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    August 6, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .14&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Research and License Agreement made on August&#160;8, 2007, by
    and between Yissum Research Development Company of Jerusalem,
    the Boyce Thompson Institute and Protalix Ltd.
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    10-Q
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    November 14, 2007
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .15
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Unprotected Lease Agreement
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    10-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .21
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    March 17, 2008
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .16&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Exclusive License and Supply Agreement dated as of
    November&#160;30, 2009 between Protalix Ltd. and Pfizer Inc.
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    10-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .16
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    February 26, 2010
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .17
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement by and between the Company and Sandra
    Lauterbach dated as of December&#160;17, 2009
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    December 27, 2009
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .18
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Employment Agreement by and between Protalix Ltd., and Tzvi
    Palash dated as of August&#160;29, 2010
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    8-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    September 7, 2010
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .19&#134;
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    License Agreement between Protalix Biotherapeutics Ltd. and
    Virginia Tech Intellectual Properties, Inc.
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    10-Q
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    10
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    November 8, 2010
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    21
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    Subsidiaries
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    10-K
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    001-33357
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    21
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    February 26, 2010
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    23
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Consent of Kesselman&#160;&#038; Kesselman, Certified Public
    Accountant (Isr.), A member of PricewaterhouseCoopers
    International Limited, independent registered public accounting
    firm for the Registrant
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    X
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    31
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certification of Chief Executive Officer pursuant to
    <FONT style="white-space: nowrap">Rule&#160;13a-14(a)</FONT>
    as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley
    Act of 2002
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    X
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    31
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    Certification of Chief Financial Officer pursuant to
    <FONT style="white-space: nowrap">Rule&#160;13a-14(a)</FONT>
    as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley
    Act of 2002
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    X
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    32
</TD>
<TD nowrap align="left" valign="top">
    .1
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    18&#160;U.S.C. Section&#160;1350, as adopted pursuant to
    Section&#160;906 of the Sarbanes-Oxley Act of 2002,
    Certification of Chief Executive Officer
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    X
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    32
</TD>
<TD nowrap align="left" valign="top">
    .2
</TD>
<TD>
&nbsp;
</TD>
<TD align="left" valign="top">
    18&#160;U.S.C. Section&#160;1350, as adopted pursuant to
    Section&#160;906 of the Sarbanes-Oxley Act of 2002,
    Certification of Chief Financial Officer
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    X
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    &#134; </TD>
    <TD></TD>
    <TD valign="bottom">
    Portions of this exhibit were omitted and have been filed
    separately with the Secretary of the Securities and Exchange
    Commission pursuant to the Registrant&#146;s application
    requesting confidential treatment under
    <FONT style="white-space: nowrap">Rule&#160;24b-2</FONT>
    of the Exchange Act.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    97
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='Y04571126'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">SIGNATURES</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Pursuant to the requirements of Section&#160;13 or 15(d) of the
    Securities Exchange Act of 1934, as amended, the registrant has
    duly caused this report to be signed on its behalf by the
    undersigned, thereunto duly authorized, as of
    February&nbsp;23, 2011.
</DIV>

<DIV style="margin-top: 24pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 49%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    PROTALIX BIOTHERAPEUTICS, INC.
</DIV>

<DIV style="margin-top: 48pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="49%"></TD>
    <TD width="4%"></TD>
    <TD width="47%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>&nbsp;</TD>
    <TD>    By:&#160;
</TD>
    <TD align="left">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;David
    Aviezer</DIV>
</TD>
</TR>

</TABLE>

<DIV style="font-size: 2pt; margin-left: 53%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV align="left" style="margin-left: 53%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    David Aviezer,&#160;Ph.D.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">POWER OF
    ATTORNEY</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose
    signature appears below constitutes and appoints David
    Aviezer,&#160;Ph.D. and Yossi Maimon, and each of them, as his
    true and lawful attorneys-in-fact and agents, with full power of
    substitution and re-substitution, for him and in his name, place
    and stead, in any and all capacities, to sign any and all
    amendments to this Report on
    <FONT style="white-space: nowrap">Form&#160;10-K,</FONT>
    and to file the same, with all exhibits thereto, and other
    documents in connection therewith, with the Securities and
    Exchange Commission, granting unto said attorneys-in-fact and
    agents, and each of them, full power and authority to do and
    perform each and every act and thing requisite and necessary to
    be done in connection therewith, as fully to all intents and
    purposes as he might or could do in person, hereby ratifying and
    confirming that said attorneys-in-fact and agents, or any of
    them, or their or his substitute or substitutes, may lawfully do
    or cause to be done by virtue hereof.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Pursuant to the requirements of the Securities Exchange Act of
    1934, this report has been signed below by the following persons
    on behalf of the Registrant and in the capacities and on the
    dates indicated.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="4%">&nbsp;</TD>  <!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="37%">&nbsp;</TD> <!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="37%">&nbsp;</TD> <!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="15%">&nbsp;</TD> <!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Signature</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Title</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Date</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 12pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;David
    Aviezer</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>David
    Aviezer,&#160;Ph.D.
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    President, Chief Executive Officer (Principal Executive Officer)
    and Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    February&nbsp;23, 2011
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Yossi
    Maimon</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>Yossi
    Maimon
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Chief Financial Officer, Treasurer and
    Secretary (Principal Financial and Accounting Officer)
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    February&nbsp;23, 2011
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Yoseph
    Shaaltiel</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>Yoseph
    Shaaltiel,&#160;Ph.D.
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Executive VP, Research and Development and Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    February&nbsp;23, 2011
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Alfred
    Akirov</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>Alfred
    Akirov
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    February&nbsp;23, 2011
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Amos
    Bar Shalev</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>Amos
    Bar Shalev
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    February&nbsp;23, 2011
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Zeev
    Bronfeld</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>Zeev
    Bronfeld
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    February&nbsp;23, 2011
</TD>
</TR>
</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    98
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL Table Pagebreak -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="4%">&nbsp;</TD>  <!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="37%">&nbsp;</TD> <!-- colindex=02 type=maindata -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="37%">&nbsp;</TD> <!-- colindex=03 type=maindata -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="15%">&nbsp;</TD> <!-- colindex=04 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="3" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Signature</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Title</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Date</B>
</DIV>
</TD>
</TR>
<TR style="line-height: 12pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Yodfat
    Harel Gross</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>Yodfat
    Harel Gross
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    February&nbsp;23, 2011
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" valign="top">
    <DIV style="display:inline; text-align:left;">/s/&#160;&#160;Eyal
    Sheratzky</DIV><BR>
    <DIV style="font-size: 2pt; margin-left: 0%; width: 100%;  align: left; border-bottom: 1pt solid #000000"></DIV>Eyal
    Sheratzky
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Director
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    February&nbsp;23, 2011
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>


</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    99
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">CONSOLIDATED
    FINANCIAL STATEMENTS<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="97%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=quadleft -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>  <!-- colindex=02 type=quadright -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Page</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04571300'><B>REPORT OF INDEPENDENT REGISTERED PUBLIC
    ACCOUNTING FIRM</B></A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    F-2
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>CONSOLIDATED FINANCIAL STATEMENTS</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
&nbsp;
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04571301'>Consolidated Balance Sheets as of
    December&#160;31, 2009, and 2010</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    F-3
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04571302'>Consolidated Statements of Operations for the
    years ended December&#160;31, 2008, 2009, and 2010</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    F-4
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04571303'>Consolidated Statements of Changes in
    Shareholders&#146; Equity (Capital Deficiency) for the years
    ended December&#160;31, 2008, 2009, and 2010</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    F-5
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04571304'>Consolidated Statements of Cash Flows for the
    years ended December&#160;31, 2008, 2009, and 2010</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    F-6
</TD>
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#Y04571305'>Notes to Consolidated Financial Statements</A>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    F-7
</TD>
<TD>&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The dollar amounts are stated in U.S. dollars ($)
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<A name='Y04571300'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>






<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="y04571y0457100.gif" alt="(IMAGE)">
</DIV>


<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>



<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">








    <B><FONT style="font-family: 'Times New Roman', Times">REPORT OF
    INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT></B>
</DIV>
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    To the shareholders of
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>PROTALIX BIOTHERAPEUTICS, INC.</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In our opinion, the consolidated balance sheets and the related
    statements of operations, changes in shareholders&#146; equity
    (capital deficiency) and cash flows present fairly, in all
    material respects, the financial position of Protalix
    BioTherapeutics, Inc. and its subsidiaries at December&#160;31,
    2009 and 2010, and the results of their operations and their
    cash flows for each of the three years in the period ended
    December&#160;31, 2010, in conformity with accounting principles
    generally accepted in the United States of America. Also, in our
    opinion, the Company maintained, in all material respects,
    effective internal control over financial reporting as of
    December&#160;31, 2010, based on criteria established in
    Internal Control&#160;&#151; Integrated Framework issued by the
    Committee of Sponsoring Organizations of the Treadway Commission
    (COSO). The Company&#146;s management is responsible for these
    financial statements, for maintaining effective internal control
    over financial reporting and for its assessment of the
    effectiveness of internal control over financial reporting,
    included in the accompanying &#147;Management Report on Internal
    Control over Financial Reporting&#148; appearing under
    Item&#160;9A. Our responsibility is to express opinions on these
    financial statements and on the Company&#146;s internal control
    over financial reporting based on our integrated audits. We
    conducted our audits in accordance with the standards of the
    Public Company Accounting Oversight Board (United States). Those
    standards require that we plan and perform the audits to obtain
    reasonable assurance about whether the financial statements are
    free of material misstatement and whether effective internal
    control over financial reporting was maintained in all material
    respects. Our audits of the financial statements included
    examining, on a test basis, evidence supporting the amounts and
    disclosures in the financial statements, assessing the
    accounting principles used and significant estimates made by
    management, and evaluating the overall financial statement
    presentation. Our audit of internal control over financial
    reporting included obtaining an understanding of internal
    control over financial reporting, assessing the risk that a
    material weakness exists, and testing and evaluating the design
    and operating effectiveness of internal control based on the
    assessed risk. Our audits also included performing such other
    procedures as we considered necessary in the circumstances. We
    believe that our audits provide a reasonable basis for our
    opinions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A company&#146;s internal control over financial reporting is a
    process designed to provide reasonable assurance regarding the
    reliability of financial reporting and the preparation of
    financial statements for external purposes in accordance with
    generally accepted accounting principles. A company&#146;s
    internal control over financial reporting includes those
    policies and procedures that: (i)&#160;pertain to the
    maintenance of records that, in reasonable detail, accurately
    and fairly reflect the transactions and dispositions of the
    assets of the company; (ii)&#160;provide reasonable assurance
    that transactions are recorded as necessary to permit
    preparation of financial statements in accordance with generally
    accepted accounting principles, and that receipts and
    expenditures of the company are being made only in accordance
    with authorizations of management and directors of the company;
    and (iii)&#160;provide reasonable assurance regarding prevention
    or timely detection of unauthorized acquisition, use or
    disposition of the company&#146;s assets that could have a
    material effect on the financial statements.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Because of its inherent limitations, internal control over
    financial reporting may not prevent or detect misstatements.
    Also, projections of any evaluation of effectiveness to future
    periods are subject to the risk that controls may become
    inadequate because of changes in conditions, or that the degree
    of compliance with the policies or procedures may deteriorate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="48%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="50%">&nbsp;</TD> <!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<!-- TableOutputBody -->
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Tel-Aviv, Israel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    <DIV style="display:inline; text-align:center; width:90%">/s/&#160;&#160;Kesselman
    &#038; Kesselman</DIV><BR>
    <DIV style="font-size: 1pt; margin-left: 0%; width: 100%; border-bottom: 1pt solid #000000"></DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    February&#160;23, 2011
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Kesselman &#038; Kesselman
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Certified Public Accountant (Isr.)
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    A member firm of PricewaterhouseCoopers
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    International Limited
</TD>
</TR>
</TABLE>





<DIV style="margin-top: 36pt; font-size: 1pt">&nbsp;</DIV>





<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Kesselman
&#038; Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 68125, Israel, P.O. Box
452 Tel-Aviv 61003 Telephone: &#043;972 -3- 7954555, Fax:&#043;972 -3- 7954556, www.pwc.co.il</I>
</DIV>





<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-2
</DIV>
















<!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">


    <A name='Y04571301'><B><FONT style="font-family: 'Times New Roman', Times">
    <!-- XBRL,bs -->CONSOLIDATED BALANCE SHEETS</FONT></B></A>
</DIV>
<!-- XBRL,body -->
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    <B>(U.S. dollars in thousands, except shares and per share
    amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD colspan="9" align="center" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>ASSETS</B>
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>CURRENT ASSETS:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Cash and cash equivalents
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    81,266
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    35,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts receivable:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Trade
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,013
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Inventories
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 40pt">
    Total current assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    83,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,333
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>FUNDS IN RESPECT OF EMPLOYEE RIGHTS UPON RETIREMENT</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    724
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    942
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>PROPERTY AND EQUIPMENT, NET</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,537
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    17,454
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 40pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    98,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    64,729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD colspan="9">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="9" align="center" valign="bottom">
    <B>LIABILITIES AND SHAREHOLDERS&#146; EQUITY (NET OF CAPITAL
    DEFICIENCY)</B>
</TD>
</TR>
<TR valign="bottom" style="line-height: 6pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>CURRENT LIABILITIES:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accounts payable and accruals:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Trade
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,406
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,272
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,561
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,563
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,563
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 40pt">
    Total current liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,530
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,903
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>LONG TERM LIABILITIES:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Deferred revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    60,049
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    55,486
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Liability for employee rights upon retirement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,663
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 40pt">
    Total long term liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61,258
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    57,149
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 40pt">
    Total liabilities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82,788
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,052
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>COMMITMENTS</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>SHAREHOLDERS&#146; EQUITY (CAPITAL DEFICIENCY):</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Common Stock, $0.001&#160;par value:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Authorized&#160;&#151; as of December&#160;31, 2009 and 2010,
    150,000,000&#160;shares; issued and outstanding&#160;&#151; as
    of December&#160;31, 2009 and 2010, 80,841,237 and
    81,248,472&#160;shares, respectively
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Additional paid-in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    122,252
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    124,044
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (106,450
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (135,448
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total shareholders&#146; equity (capital deficiency)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,883
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (11,323
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Total liabilities and shareholders&#146; equity (net of capital
    deficiency)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    98,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    64,729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- /XBRL,bs -->
<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">


    <A name='Y04571302'><B><FONT style="font-family: 'Times New Roman', Times">
    <!-- XBRL,op -->CONSOLIDATED STATEMENTS OF
    OPERATIONS</FONT></B></A>
</DIV>
<!-- XBRL,body -->
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="62%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>(U.S. dollars in thousands,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" nowrap align="center" valign="bottom">
    <B>except shares and per share amounts)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>REVENUES</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,642
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>COMPANY&#146;S SHARE IN COLLABORATION AGREEMENT</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,602
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>COST OF REVENUES</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,575
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,383
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>GROSS PROFIT (LOSS)</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3,187
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,861
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>RESEARCH AND DEVELOPMENT EXPENSES</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,115
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (27,390
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (37,691
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Less&#160;&#151; grants and reimbursements
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,714
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,752
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,740
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (17,401
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,638
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29,951
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>GENERAL AND ADMINISTRATIVE EXPENSES</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,770
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,144
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,876
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>OPERATING LOSS</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (24,171
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31,969
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (29,966
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>FINANCIAL INCOME&#160;&#151; NET</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,757
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    529
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    968
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>NET LOSS FOR THE YEAR</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (22,414
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (31,440
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (28,998
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net loss per share of common stock&#160;&#151; basic and diluted:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.41
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.36
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Weighted average number of shares of common stock used in
    computing loss per share of common stock, basic and diluted:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75,890,633
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    76,942,840
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80,960,300
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- /XBRL,op -->
<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">


    <A name='Y04571303'><B><FONT style="font-family: 'Times New Roman', Times">
    <!-- XBRL,se -->CONSOLIDATED STATEMENT OF CHANGES IN
    SHAREHOLDERS&#146; EQUITY<BR>
    </FONT></B>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">(CAPITAL
    DEFICIENCY)</FONT></B></A>
</DIV>
<!-- XBRL,body -->
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="49%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=05 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=06 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Additional<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Common<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Common<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Paid in<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Accumulated<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Stock</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Capital</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Deficit</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Total</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Shares</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="14" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Amount</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="18" align="center" valign="bottom">
    <B>(U.S. dollars in thousands, except share data)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Balance at January&#160;1, 2008</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>75,775,439</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>76</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>116,205</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>(52,596</B>
</TD>
<TD nowrap align="left" valign="bottom">
    <B>)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>63,685</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Changes during 2008:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Restricted Common Stock issued for future services(1)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (5,333
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (3
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,074
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,074
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exercise of options granted to employees (includes net exercise)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    167,953
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Net Loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,414
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (22,414
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Balance at December&#160;31, 2008</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>75,938,059</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>76</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>119,281</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>(75,010</B>
</TD>
<TD nowrap align="left" valign="bottom">
    <B>)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>44,347</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <B>Changes during 2009:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,683
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,683
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Exercise of options granted to employees and non-employees
    (includes net exercise)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,903,178
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    288
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net Loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31,440
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (31,440
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Balance at December&#160;31, 2009</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>80,841,237</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>81</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>122,252</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>(106,450</B>
</TD>
<TD nowrap align="left" valign="bottom">
    <B>)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>15,883</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    <B>Changes during 2010:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Share-based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Exercise of options granted to employees and non-employees
    (includes net exercise)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    407,235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">

</TD>
<TD nowrap align="left" valign="bottom">
    *
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    510
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    510
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net Loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,998
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (28,998
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Balance at December&#160;31, 2010</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>81,248,472</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>81</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>124,044</B>
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>(135,448</B>
</TD>
<TD nowrap align="left" valign="bottom">
    <B>)</B>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B>(11,323</B>
</TD>
<TD nowrap align="left" valign="bottom">
    <B>)</B>
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- /XBRL,se -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    *&#160;</TD>
    <TD></TD>
    <TD valign="bottom">
    Represents an amount less than $1.</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD align="right" valign="top">
    (1) </TD>
    <TD></TD>
    <TD valign="bottom">
    The Company issued a total of 8,000&#160;shares of restricted
    Common Stock in consideration for services provided by, and to
    be provided by, a member of the Company&#146;s Scientific
    Advisory Board. Such services were terminated in October 2008
    while the forfeiture provisions of the restricted stock were
    still in effect. Accordingly, 5,333&#160;shares of restricted
    Common Stock were forfeited.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">


    <A name='Y04571304'><B><FONT style="font-family: 'Times New Roman', Times">
    <!-- XBRL,cf -->CONSOLIDATED STATEMENTS OF CASH
    FLOWS</FONT></B></A>
</DIV>
<!-- XBRL,body -->
</A>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="71%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom">
    <B>(U.S. dollars in thousands)</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>CASH FLOWS FROM OPERATING ACTIVITIES:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net Loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (22,414
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (31,440
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (28,998
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Adjustments required to reconcile net loss to net cash
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    provided by (used in) operating activities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Share based compensation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,071
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,683
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Depreciation and impairment of fixed assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,301
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,990
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,133
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Financial income net (mainly exchange differences)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (270
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (166
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (591
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Changes in accrued liability for employee rights upon retirement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    247
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    265
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    377
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loss (Gain) on amounts funded in respect of employee rights upon
    retirement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    39
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (81
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (26
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Loss on sale of fixed assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    29
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Changes in operating assets and liabilities:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Increase (decrease) in deferred revenues (including non-current
    portion)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    64,612
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,563
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Decrease (increase) in accounts receivable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,224
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (6,860
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Increase in inventories
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,189
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Increase (decrease) in accounts payable and accruals
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,784
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (1,029
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net cash provided by (used in) operating activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (16,015
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    44,452
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (38,464
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>CASH FLOWS FROM INVESTING ACTIVITIES:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Purchase of property and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (3,371
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6,195
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (7,855
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Investment in restricted deposit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (175
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Proceeds from sale of property and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Amounts funded in respect of employee rights upon retirement, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (156
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (52
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (137
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net cash used in investing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (3,701
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (6,174
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (7,992
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>CASH FLOWS FROM FINANCING ACTIVITIES:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Issuance cost in respect of issuance of shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (56
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Exercise of options
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    501
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net cash provided by (used in) financing activities
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (51
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    293
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    501
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>EFFECT OF EXCHANGE RATE CHANGES ON CASH</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    99
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    589
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (19,217
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    38,670
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (45,366
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    61,813
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    81,266
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>BALANCE OF CASH AND CASH EQUIVALENTS AT END OF YEAR</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    42,596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    81,266
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    35,900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING
    ACTIVITIES NOT INVOLVING CASH FLOWS:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Purchase of property and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    932
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4,525
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,720
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Exercise of options granted to employees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- /XBRL,cf -->
<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The accompanying notes are an integral part of the consolidated
    financial statements.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL Pagebreak End -->
<!-- XBRL,ns -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">


    <A name='Y04571305'><B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL STATEMENTS</FONT></B></A>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    </A><B>(U.S. dollars in thousands)</B>
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;1&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">SIGNIFICANT
    ACCOUNTING POLICIES</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">a.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">General</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">Operation</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Protalix BioTherapeutics, Inc. and its wholly-owned subsidiary,
    Protalix Ltd. (the &#147;Israeli Subsidiary&#148; or
    &#147;Protalix Ltd.,&#148; and collectively with Protalix
    BioTherapeutics, Inc., the &#147;Company&#148;), are
    biopharmaceutical companies focused on the development and
    commercialization of recombinant therapeutic proteins based on
    the Company&#146;s proprietary
    ProCellEx<SUP style="font-size: 85%; vertical-align: top">tm</SUP>

    protein expression system (&#147;ProCellEx&#148;). In September
    2009, the Company formed another wholly-owned subsidiary under
    the laws of the Netherlands in connection with the EMEA
    application process in Europe. The Company&#146;s two
    subsidiaries are referred to collectively herein as the
    &#147;Subsidiaries.&#148; The Company&#146;s lead product
    development candidate is taliglucerase alfa for the treatment of
    Gaucher disease which the Company is developing using ProCellEx.
    In addition to taliglucerase alfa, the Company is developing
    other certain products using ProCellEx.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In September 2009, the Company successfully completed its
    phase&#160;III pivotal trial of taliglucerase alfa. In July
    2010, the U.S.&#160;Food and Drug Administration
    (&#147;FDA&#148;) notified the Company that it had accepted the
    Company&#146;s new drug application (NDA) for taliglucerase alfa
    for the treatment of Gaucher disease and that it granted to
    taliglucerase alfa a Prescription Drug User Fee Act (PDUFA)
    action date of February&#160;25, 2011.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In September 2009, the FDA&#146;s Office of Orphan Product
    Development granted taliglucerase alfa Orphan Drug Status. In
    addition to its phase&#160;III clinical trial, the Company
    initiated a clinical study in December 2008 to evaluate the
    safety and efficacy of switching Gaucher disease patients
    currently treated under the current standard of care to
    treatment with taliglucerase alfa. This switchover-study is not
    a prerequisite for the marketing approval of taliglucerase alfa.
    In November 2010 the Company successfully completed the nine
    month switchover trial.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On November&#160;30, 2009, Protalix Ltd. and Pfizer Inc.
    (&#147;Pfizer&#148;) entered into an Exclusive License and
    Supply Agreement (the &#147;Pfizer Agreement&#148;) pursuant to
    which Protalix Ltd. granted Pfizer an exclusive, worldwide
    license to develop and commercialize taliglucerase alfa, except
    in Israel. Under the terms and conditions of the Pfizer
    Agreement, Protalix Ltd. retained the right to commercialize
    taliglucerase alfa in Israel. See Note&#160;2.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On July&#160;13, 2010, the French regulatory authority granted
    an Autorisation Temporaire d&#146;Utilisation (&#147;ATU&#148;),
    or Temporary Authorization for Use, for taliglucerase alfa for
    the treatment of Gaucher disease. An ATU is the regulatory
    mechanism used by the French Health Products and Safety Agency
    to make non-approved drugs available to patients in France when
    a genuine public health need exists. This ATU allows Gaucher
    disease patients in France to receive treatment with
    taliglucerase alfa before marketing authorization for the
    product is granted in the European Union. Payment for
    taliglucerase alfa has been secured through government
    allocations to hospitals.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On August&#160;10, 2010, Pfizer entered into a $30&#160;million
    short-term supply agreement with the Ministry of Health of
    Brazil pursuant to which the Company and Pfizer have provided
    taliglucerase alfa to the Ministry of Health of Brazil for the
    treatment of Gaucher disease patients. Revenue generated from
    the Ministry of Health of Brazil will be recorded by Pfizer and
    the Company is entitled to its share of the revenue in
    accordance with the terms and conditions of the Pfizer Agreement.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">Liquidity
    and Financial Resources</FONT></I>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Successful completion of the Company&#146;s development programs
    and its transition to normal operations is dependent upon
    obtaining necessary regulatory approvals from the FDA prior to
    selling its products within the United States, and foreign
    regulatory approvals must be obtained to sell its products
    internationally. There can
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
(U.S. dollars in thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;1&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;SIGNIFICANT
    ACCOUNTING POLICIES (continued):</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    be no assurance that the Company will receive regulatory
    approval of any of its product candidates, and a substantial
    amount of time may pass before the Company achieves a level of
    revenues adequate to support its operations, if at all. The
    Company will also incur substantial expenditures in connection
    with the regulatory approval process for each of its product
    candidates during the developmental period. Obtaining marketing
    approval will be directly dependent on the Company&#146;s
    ability to implement the necessary regulatory steps required to
    obtain marketing approval in the United States and in other
    countries. The Company cannot predict the outcome of these
    activities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Based on its current cash resources and commitments, the Company
    believes it will be able to maintain its current planned
    development activities and the corresponding level of
    expenditures for at least the next 12&#160;months, although no
    assurance can be given that it will not need additional funds
    prior to such time. If there are unexpected increases in general
    and administrative expenses or research and development
    expenses, the Company may need to seek additional financing
    during the next 12&#160;months.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">b.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Basis
    of presentation</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company&#146;s financial statements have been prepared in
    accordance with generally accepted accounting principles in the
    United States (&#147;U.S.&#160;GAAP&#148;).
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">c.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Use of
    estimates in the preparation of financial
    statements</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The preparation of financial statements in conformity with
    U.S.&#160;GAAP requires management to make estimates and
    assumptions that affect the reported amounts of assets and
    liabilities, the disclosure of contingent assets and liabilities
    at the date of the financial statements and the reported amounts
    of revenues and expenses during the reporting period. In
    addition, the Company uses estimates and assumptions relating to
    inventory reserves in its financial statements. Actual results
    may differ from those estimates.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">d.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Functional
    currency</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The dollar is the currency of the primary economic environment
    in which the operations of the Company and its Subsidiaries are
    conducted. The Company&#146;s revenues are derived in dollars.
    Most of the Company&#146;s expenses and capital expenditures are
    incurred in dollars, and the major source of the Company&#146;s
    financing has been provided in dollars.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Transactions and balances originally denominated in dollars are
    presented at their original amounts. Balances in non-dollar
    currencies are translated into dollars using historical and
    current exchange rates for non-monetary and monetary balances,
    respectively. For non-dollar transactions and other items
    (stated below) reflected in the statements of operations, the
    following exchange rates are used: (i)&#160;for
    transactions&#160;&#151; exchange rates at the transaction dates
    or average rates; and (ii)&#160;for other items (derived from
    non-monetary balance sheet items such as depreciation and
    amortization, etc.)&#160;&#151; historical exchange rates.
    Currency transaction gains and losses are carried to financial
    income or expenses, as appropriate.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">e.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Cash
    equivalents</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company considers all short-term, highly liquid investments,
    which include short-term bank deposits with original maturities
    of three months or less from the date of purchase, that are not
    restricted as to withdrawal or use and are readily convertible
    to known amounts of cash, to be cash equivalents.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">f.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Inventories</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Inventories are valued at the lower of cost or market. Cost of
    raw and packaging materials and purchased products is determined
    using the &#147;moving average&#148; basis. Cost of finished
    products and products in process is determined as follows: the
    value of the raw and packaging materials component is determined
    primarily on a
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
(U.S. dollars in thousands)</FONT></B>
</DIV>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;1&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;SIGNIFICANT
    ACCOUNTING POLICIES (continued):</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    using the &#147;moving average&#148; basis; the value of the
    labor and overhead component is determined on an average basis
    over the production period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Manufacturing costs for product candidates are expensed as
    research and development expenses. The Company considers
    regulatory approval of product candidates to be uncertain, and
    product manufactured prior to regulatory approval may not be
    sold unless regulatory approval is obtained. As such, the
    manufacturing costs for product candidates incurred prior to
    regulatory approval are not capitalized as inventory, unless
    inventories for which there are orders or are probable to be
    sold without the regulatory approval.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">g.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Property
    and equipment</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    1.&#160;Property and equipment are stated at cost, net of
    accumulated depreciation and amortization.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    2.&#160;The Company&#146;s assets are depreciated by the
    straight-line method on the basis of their estimated useful
    lives as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="93%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="5%">&nbsp;</TD>  <!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Years</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Laboratory equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    5
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Furniture
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    10-15
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Computer equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    3
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Leasehold improvements are amortized by the straight-line method
    over the expected lease term, which is shorter than the
    estimated useful life of the improvements.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">h.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Impairment
    in value of long-lived assets:</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company tests long-lived assets for impairment if an
    indication of impairment exists. If the sum of expected future
    cash flows of definite life of long lived assets (undiscounted
    and without interest charges) is less than the carrying amount
    of such assets, the Company recognizes an impairment loss, and
    writes down the assets to their estimated fair values,
    calculated based on expected future discounted cash flows. See
    Note&#160;3c.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">i.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Income
    taxes</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">Deferred
    income taxes</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Deferred taxes are determined utilizing the assets and
    liabilities method based on the estimated future tax effects of
    the differences between the financial accounting and tax bases
    of assets and liabilities under the applicable tax laws.
    Deferred tax balances are computed using the tax rates expected
    to be in effect when those differences reverse. A valuation
    allowance in respect of deferred tax assets is provided if,
    based upon the weight of available evidence, it is more likely
    than not that some or all of the deferred tax assets will not be
    realized. The Company has provided a full valuation allowance
    with respect to its deferred tax assets.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The guidance prohibits the recognition of deferred tax
    liabilities or assets that arise from differences between the
    financial reporting and tax bases of assets and liabilities that
    are measured from the local currency into dollars using
    historical exchange rates, and that result from changes in
    exchange rates or indexing for tax purposes. Consequently, the
    above mentioned differences with respect to Protalix Ltd. were
    not reflected in the computation of deferred tax assets and
    liabilities.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">Uncertainty
    in income taxes</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Tax benefits recognized in the financial statements are at least
    more likely than not of being sustained, based on technical
    merits. The amount of benefits recorded for these tax benefits
    is measured as the largest benefit more likely than not to be
    sustained.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
(U.S. dollars in thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;1&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;SIGNIFICANT
    ACCOUNTING POLICIES (continued):</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">j.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Revenue
    Recognition</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company recognizes revenue when the earnings process is
    complete, which is when revenue is realized or realizable and
    earned, there is persuasive evidence a revenue arrangement
    exists, delivery of goods or services has occurred, the sales
    price is fixed or determinable and collectability is reasonably
    assured.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">Revenues
    from the license and supply agreement with Pfizer</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company recognizes revenue and milestone payments received
    pursuant to the Pfizer Agreement in accordance with guidance
    regarding revenue recognition and accounting for revenue
    arrangements with multiple deliverables. Pursuant to this
    guidance, the Company determines whether its arrangement with
    Pfizer involves multiple revenue-generating deliverables that
    should be accounted for as a combined unit of accounting or
    separate units of accounting for revenue recognition purposes.
    If the Company determines that there are multiple units of
    accounting, the consideration from the arrangement is allocated
    among the separate units based on a relative fair value
    allocation. If the arrangement represents a single unit of
    accounting, the revenue is recognized over the performance
    obligation period. As the arrangement with Pfizer requires the
    Company&#146;s continued involvement with respect to the
    proposed commercialization of taliglucerase alfa, the
    non-refundable, up-front license payments the Company received
    from Pfizer are deferred and recognized over the related
    performance period. The Company estimated the performance period
    of 14&#160;years based on the date the last relevant patent
    expires. The Company adjusts the performance periods, if
    appropriate, based on the applicable facts and circumstances.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">Revenues
    from selling products to Pfizer</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company recognizes revenues received from products sold to
    Pfizer when the sales price is fixed or determinable and
    collectability is reasonably assured.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">3.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">Company&#146;s
    share in the collaboration agreement</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the terms and conditions of the Pfizer Agreement, the
    Company is entitled to 40% of the profits or loss from sales of
    taliglucerase alfa, and related expenses incurred, except with
    respect to sales in Israel, where the Company retained exclusive
    marketing rights. Since Pfizer bears most of the risks and
    rewards relating to the agreement, the Company&#146;s share in
    the profits and loss in the agreement is recognized on a net
    basis. The Company recognizes its share of net profit or loss
    from the Pfizer Agreement based on reports it receives from
    Pfizer summarizing the results of the collaborative activities
    under the agreement for the applicable period. Under the terms
    of the Pfizer Agreement, for its subsidiaries operating outside
    the United States, financial information is included based on
    the fiscal year ending November&#160;30, while financial
    information for the U.S.&#160;entity is included based on the
    fiscal year ending December&#160;31.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">k.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Research
    and development costs</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Research and development costs are expensed as incurred and
    consist primarily of personnel, subcontractors and consultants,
    facilities, equipment and supplies for research and development
    activities. Grants received by the Israeli Subsidiary from the
    Office of the Chief Scientist of Israel&#146;s Ministry of
    Industry, Trade and Labor (the &#147;OCS&#148;) and other
    research foundations are recognized when the grant becomes
    receivable, provided there is reasonable assurance that the
    Company or the Subsidiary will comply with the conditions
    attached to the grant and there is reasonable assurance the
    grant will be received. The grant is deducted from the research
    and development expenses as the applicable costs are incurred.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Reimbursements received from Pfizer and other research
    foundations are recognized when the reimbursements become
    receivable, provided there is reasonable assurance that the
    Company will comply with the conditions attached to the
    reimbursements and there is reasonable assurance the
    reimbursements will be
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>(U.S. dollars in thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;1&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;SIGNIFICANT
    ACCOUNTING POLICIES (continued):</FONT></B>
</TD>
</TR>

</TABLE>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    received. The reimbursements are deducted from the research and
    development expenses as the applicable costs are incurred.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In connection with purchases of assets, amounts assigned to
    intangible assets to be used in a particular research and
    development project that have no alternative future use are
    charged to research and development costs at the purchase date.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Nonrefundable advance payments for goods or services that will
    be used or rendered for future research and development
    activities are deferred and amortized over the period that the
    goods are consumed or the related services are performed.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">l.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Comprehensive
    loss</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company has no other comprehensive loss components other
    than net loss for the reported periods.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="4%"></TD>
    <TD width="96%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">m.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Concentration
    of credit risks and trade receivable</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Financial instruments that potentially subject the Company to
    concentration of credit risk consist principally of bank
    deposits. The Company deposits these instruments with highly
    rated financial institutions, mainly in Israeli banks, and, as a
    matter of policy, limits the amounts of credit exposure to any
    one financial institution. The Company has not experienced any
    credit losses in these accounts and does not believe it is
    exposed to any significant credit risk on these instruments.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company&#146;s trade receivable represents amounts to be
    received from Pfizer, as the Company currently receives all of
    its revenues from Pfizer. The Company does not require Pfizer to
    post collateral with respect to the receivables. The Company
    performs periodic credit evaluations of Pfizer&#146;s financial
    condition and believes there is no significant risk with respect to
    Pfizer&#146;s payment of the receivables.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">n.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Share-based
    compensation</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company accounts for employee&#146;s share-based payment
    awards classified as equity awards using the grant-date fair
    value method. The fair value of share-based payment transactions
    is recognized as an expense over the requisite service period,
    net of estimated forfeitures. The Company estimates forfeitures
    based on historical experience and anticipated future conditions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company elected to recognize compensation cost for an award
    with only service conditions that has a graded vesting schedule
    using the accelerated method based on the multiple-option award
    approach.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    When stock options are granted as consideration for services
    provided by consultants and other non-employees, the grant is
    accounted for based on the fair value of the consideration
    received or the fair value of the stock options issued,
    whichever is more reliably measurable. The fair value of the
    options granted is measured on a final basis at the end of the
    related service period and is recognized over the related
    service period using the straight-line method.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">o.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Net
    Loss per share</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Basic and diluted losses per share (&#147;LPS&#148;) are
    computed by dividing net loss by the weighted average number of
    shares of Common Stock outstanding for each period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Shares of restricted Common Stock and the shares of Common Stock
    underlying outstanding options of the Company were not included
    in the computation of diluted LPS because of the anti-dilutive
    effect of doing so.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>(U.S. dollars in thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;1&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;SIGNIFICANT
    ACCOUNTING POLICIES (continued):</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Diluted LPS does not include options and restricted shares of
    Common Stock of the Company in the amount of 11,037,356,
    10,660,447 and 7,761,168&#160;shares of Common Stock for the
    years 2008, 2009 and 2010, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">p.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Newly
    Issued Accounting Pronouncements</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    1.&#160;In October 2009, the Financial Accounting Standards
    Board (&#147;FASB&#148;) issued an Accounting Standards Update
    to ASC&#160;605, ASU
    <FONT style="white-space: nowrap">No.&#160;2009-13,</FONT>
    &#147;Multiple Deliverable Revenue Arrangements&#148; (&#147;ASU
    <FONT style="white-space: nowrap">2009-13&#148;).</FONT>
    ASU <FONT style="white-space: nowrap">2009-13</FONT>
    provides guidance regarding whether multiple deliverables in a
    revenue arrangement exist, how the arrangement should be
    separated, and how the consideration should be allocated.
    Pursuant to ASU
    <FONT style="white-space: nowrap">2009-13,</FONT>
    when vendor specific objective evidence or third party evidence
    for deliverables in an arrangement cannot be determined, a best
    estimate of the selling price is required to separate
    deliverables and allocate arrangement consideration, using the
    relative selling price method. In addition, the residual method
    of allocating arrangement consideration is no longer permitted
    under ASU
    <FONT style="white-space: nowrap">2009-13.</FONT> ASU
    <FONT style="white-space: nowrap">2009-13</FONT> is
    effective for revenue arrangements entered into or materially
    modified in fiscal years beginning on or after June&#160;15,
    2010 and will be applied to future arrangements to which the
    Company becomes a party, if any.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    2.&#160;In April 2010, the Financial Accounting Standards Board
    issued an Accounting Standard&#160;&#151; ASU
    <FONT style="white-space: nowrap">No.&#160;2010-17,</FONT>
    Revenue Recognition&#160;&#151; Milestone Method (ASU
    <FONT style="white-space: nowrap">2010-17).</FONT>
    ASU <FONT style="white-space: nowrap">2010-17</FONT>
    provides guidance in applying the milestone method of revenue
    recognition to research or development arrangements. Under this
    guidance management may recognize revenue contingent upon the
    achievement of a milestone in its entirety, in the period in
    which the milestone is achieved, only if the milestone meets all
    the criteria within the guidance to be considered substantive.
    ASU <FONT style="white-space: nowrap">2010-17</FONT>
    is effective on a prospective basis for research and development
    milestones achieved in fiscal years beginning on or after
    June&#160;15, 2010. The Company is currently evaluating the
    potential impact of ASU
    <FONT style="white-space: nowrap">2010-17</FONT> on
    its consolidated financial position, results of operations and
    cash flows.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;2&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;LICENSE
    AND SUPPLY AGREEMENT</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On November&#160;30, 2009, Protalix Ltd. and Pfizer entered into
    the Pfizer Agreement pursuant to which Pfizer was granted an
    exclusive, worldwide license to develop and commercialize
    taliglucerase alfa, except in Israel. Under the terms and
    conditions of the Pfizer Agreement, Protalix Ltd. retained the
    right to commercialize taliglucerase alfa in Israel. Under the
    Pfizer Agreement, Pfizer made an upfront payment to Protalix
    Ltd. of $60,000 in connection with the execution of the
    agreement and shortly thereafter paid Protalix Ltd. an
    additional $5,000 upon the Company&#146;s filing of a proposed
    pediatric investigation plan to the Pediatric Committee of the
    European Medicines Agency (EMEA). Protalix Ltd. is also eligible
    to receive additional potential milestone payments totaling up
    to $50,000 for the successful achievement of other regulatory
    milestones. Protalix Ltd. is entitled to 40% of the profits
    earned on Pfizer&#146;s sales of taliglucerase alfa. Such profit
    will be calculated while, in addition to other adjustments,
    taking into account Protalix Ltd.&#146;s cost of goods sold and
    Pfizer&#146;s commercial expenses, with certain expenses capped
    or borne solely by one party.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company has determined that the initial, non-refundable
    upfront license fee payment of $60,000 together with the first
    $5,000 payment will be recognized on a straight line basis as
    revenue over the estimated relationship period. The Company has
    estimated that the relationship period for its arrangement with
    Pfizer will be approximately 14&#160;years based on the
    Company&#146;s last material patent relating to taliglucerase
    alfa to expire.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company&#146;s deliverables under this collaboration include
    an exclusive license to taliglucerase alfa as an enzyme
    replacement therapy for the treatment of Gaucher disease,
    certain research and development services as required under the
    Pfizer Agreement for taliglucerase alfa, manufacturing of
    taliglucerase alfa and optional participation in a joint
    steering committee.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>(U.S. dollars in thousands)</FONT></B>
</DIV>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;2&#160;&#151;
    </FONT></B>
</TD>
    <TD>

<B><FONT style="font-family: 'Times New Roman', Times">&#160;LICENSE
AND SUPPLY AGREEMENT (continued):</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    According to the terms and conditions of the Pfizer Agreement,
    the Company retained manufacturing rights and sells its products
    to Pfizer. In addition, the Company is entitled to reimbursement
    by Pfizer of certain costs incurred by the Company in connection
    with certain development expenses for taliglucerase alfa.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In connection with the payments received under the Pfizer
    Agreement, Protalix Ltd. is obligated to pay certain royalties.
    See Note&#160;6a.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;3&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;PROPERTY
    AND EQUIPMENT</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    a.&#160;Composition of property and equipment grouped by major
    classifications is as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="81%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Laboratory equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,008
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    11,478
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Furniture and computer equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    944
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,306
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Leasehold improvements
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,665
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,221
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Equipment under construction
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,615
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    19,232
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    25,043
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Less&#160;&#151; accumulated depreciation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    and amortization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (4,695
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (7,589
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,537
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    17,454
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    b.&#160;Depreciation and amortization in respect of property and
    equipment totaled $1,301, $1,990 and $3,133 for the years ended
    December&#160;31, 2008, 2009 and 2010, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    c.&#160;During the year ended December&#160;31, 2010, the
    Company recorded a total impairment of $43. The impaired long
    lived assets were mainly laboratory equipment and computer
    equipment.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;4&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;INVENTORIES</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    a.&#160;Inventory at December&#160;31, 2010 consisted of the
    following:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="83%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="13%" align="right">&nbsp;</TD>   <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Raw materials
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    553
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Finished goods
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    636
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total inventory
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    b.&#160;During the year ended December&#160;31, 2010, the
    Company recorded a $2.7&#160;million write-down of inventory
    under cost of revenues. See Note&#160;9d.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;5&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;LIABILITY
    FOR EMPLOYEE RIGHTS UPON RETIREMENT</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Israeli Subsidiary is required to make a severance payment
    upon dismissal of an employee, or upon termination of employment
    in certain circumstances. The severance pay liability to the
    employees (based upon length of service and the latest monthly
    salary&#160;&#151; one month&#146;s salary for each year
    employed) is recorded on the Company&#146;s balance sheets under
    &#147;Liability for employee rights upon retirement.&#148; The
    liability is recorded as if it were payable at each balance
    sheet date on an undiscounted basis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The liability is funded in part from the purchase of insurance
    policies or by the establishment of pension funds with dedicated
    deposits in the funds. The amounts used to fund these
    liabilities are included in the Company&#146;s balance sheets
    under &#147;Funds in respect of employee rights upon
    retirement.&#148; These policies are the
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>(U.S. dollars in thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;5&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;LIABILITY
    FOR EMPLOYEE RIGHTS UPON RETIREMENT (continued):</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Company&#146;s assets. However, under labor agreements and
    subject to certain limitations, any policy may be transferred to
    the ownership of the individual employee for whose benefit the
    funds were deposited. In the years ended December&#160;31, 2008,
    2009 and 2010, the Company deposited $161, $79 and $174,
    respectively, with insurance companies in connection with its
    severance payment obligations.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In accordance with the current employment agreements with
    certain employees, the Company makes regular deposits with
    certain insurance companies for accounts controlled by each
    applicable employee in order to secure the employee&#146;s
    rights upon retirement. The Company is fully relieved from any
    severance pay liability with respect to each such employee after
    it makes the payments on behalf of the employee. The liability
    accrued in respect of these employees and the amounts funded, as
    of the respective agreement dates, are not reflected in the
    Company&#146;s balance sheets, as the amounts funded are not
    under the control and management of the Company and the pension
    or severance pay risks have been irrevocably transferred to the
    applicable insurance companies (the &#147;Contribution
    Plans&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The amounts of severance pay expenses were $563, $488 and $1,118
    for the years ended December&#160;31, 2008, 2009 and 2010,
    respectively, of which $319, $335 and $531 in the years ended
    December&#160;31, 2008, 2009 and 2010, respectively, were in
    respect of a Contribution Plan. Gain (loss) on amounts funded in
    respect of employee rights upon retirement totaled $(39), $81
    and $26 for the years ended December&#160;31, 2008, 2009 and
    2010, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company expects to contribute approximately $841 in the year
    ending December&#160;31, 2011 to insurance companies in
    connection with its severance liabilities for its operations for
    that year, $653 of which will be contributed to one or more
    Contribution Plans.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    During the
    <FONT style="white-space: nowrap">10-year</FONT>
    period following December&#160;31, 2010, the Company expects to
    pay future benefits to eight employees upon their normal
    retirement age, which is anticipated to amount to $70, $26, $7,
    $16 and $913 during the years 2011, 2012, 2014, 2015 and 2020,
    respectively. These amounts were determined based on each such
    employee&#146;s current salary rates and the number of years of
    employment that will be accumulated upon the retirement date of
    each such employee. This expectation does not include additional
    amounts that might be paid to employees that will cease working
    for the Company before their normal retirement age.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;6&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;COMMITMENTS</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">a.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Royalty
    commitments</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    1.&#160;The Company is obligated to pay royalties to the OCS on
    proceeds from the sale of products developed from research and
    development activities that were funded, partially, by grants
    from the OCS. At the time the grants were received, successful
    development of the related projects was not assured.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In the case of failure of a project that was partly financed as
    described above, the Company is not obligated to pay any such
    royalties or repay funding received from the OCS.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the terms of the funding arrangements with the OCS,
    royalties of 3% to 6% are payable on the sale of products
    developed from projects funded by the OCS, which payments shall
    not exceed, in the aggregate, 100% of the amount of the grant
    received (dollar linked), plus, commencing upon January&#160;1,
    2001, interest at annual rate based on LIBOR. In addition, if
    the Company receives approval to manufacture products developed
    with government grants outside the State of Israel, it will be
    required to pay an increased total amount of royalties (possibly
    up to 300% of the grant amounts plus interest), depending on the
    manufacturing volume that is performed outside the State of
    Israel, and, possibly, an increased royalty rate.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company is obligated to pay the OCS royalties in respect of
    revenues of taliglucerase alfa recorded by Pfizer under the
    Pfizer Agreement. Royalty expenses are included in the statement
    of operations as a component of the cost revenues and were
    approximately $1,950 and $769 during the year ended
    December&#160;31, 2009 and 2010, respectively.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>(U.S. dollars in thousands)</FONT></B>
</DIV>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;6&#160;&#151;
    </FONT></B>
</TD>
    <TD>

<B><FONT style="font-family: 'Times New Roman', Times">&#160;COMMITMENTS
(continued):</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At December&#160;31, 2010, the maximum royalty amount payable by
    the Company under these funding arrangements is approximately
    $17,154 (without interest, assuming 100% of the funds are
    payable).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    2.&#160;The Company is a party to certain research and license
    agreements. Under the agreements, the Company is obligated to
    pay royalties at varying rates from its future revenues. The
    aggregate royalties payable under all of the agreements is equal
    to a percentages of net sales of licensed products in the teens.
    As of December&#160;31, 2009 and 2010, royalty payments in the
    amount of approximately $1,625 and $115, respectively<B>,
    </B>have become payable under the agreements due to the
    execution of, and certain sales under, the Pfizer Agreement. The
    royalties are included in the statement of operations as a
    component of cost of revenues.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under each agreement, the Company is also obligated to pay
    milestone, licensing and other payments to the counterparties of
    the agreement. The payments under the agreements are for varying
    amounts and are subject to varying conditions. If all of the
    contingencies with respect to milestone payments under the
    research and license agreements are met, the aggregate milestone
    payments payable would be approximately $950 and would be
    payable, if at all, as the Company&#146;s projects progress over
    the course of a number of years. In addition, milestone payments
    of $70 and $100, were paid in respect of the said agreements
    during the year ended 2009 and 2010, respectively.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    None of the agreements has a fixed termination date. Subject to
    earlier termination for other reasons, each agreement terminates
    after a certain number of years following the first commercial
    sale of any licensed product under the agreement or after a
    certain number of years without the initiation of commercial
    sales of any product under the agreement.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">b.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Subcontracting
    Agreements</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company has entered into
    <FONT style="white-space: nowrap">sub-contracting</FONT>
    agreements with several clinical providers and constructor in
    Israel, the United States and certain other countries in
    connection with its primary product development process and with
    expenditure of the company&#146;s manufacturing facilities. As
    of December&#160;31, 2010, total commitments under said
    agreements were approximately $5,995.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">c.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Lease
    Agreements</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company is a party to a number of lease agreements for its
    facilities, the latest of which expires in 2017. The Company has
    the option to extend certain of such agreements on three
    occasions for additional five-year periods, for a total of 15
    additional years. Under the leases, the aggregate monthly rental
    payments are approximately $71. As of December&#160;31, 2010,
    the Company provided bank guarantees of approximately $226, in
    the aggregate, to secure the fulfillment of its obligations
    under the lease agreements. The future minimum lease payments
    required in each of the next five years under the operating
    leases for such premises are approximately as follows:
    2011&#160;&#151; $853, 2012&#160;&#151; $853, 2013&#160;&#151;
    $842, 2014&#160;&#151; $834 and 2015 - $834. Lease expenses
    totaled $220, $780 and $891 for the years ended
    December&#160;31, 2008, 2009 and 2010, respectively.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">d.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Vehicle
    Lease and Maintenance Agreements</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In July 2004, the Company entered into several three-year lease
    and maintenance agreements for vehicles which are regularly
    amended as new vehicles are leased. The current monthly lease
    fees aggregate approximately $44. The minimum expected lease
    payments for the years ending December&#160;31, 2011, 2012 and
    2013 are $514, $452 and $125, respectively.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
(U.S. dollars in thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;6&#160;&#151;
    </FONT></B>
</TD>
    <TD>

<B><FONT style="font-family: 'Times New Roman', Times">&#160;COMMITMENTS
(continued):</FONT></B>
</TD>
</TR>

</TABLE>


<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">e.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Teva
    Agreement</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On September&#160;14, 2006, the Company entered into an
    agreement (the &#147;Teva Agreement&#148;) with Teva
    Pharmaceutical Industries Ltd. (&#147;Teva&#148;) under which
    the Company agreed to collaborate on the research and
    development of two proteins to be identified by Teva and the
    Company, using ProCellEx. The Teva Agreement also identifies
    additional matters for collaboration between Teva and the
    Company. Subsequently, two proteins were identified to be
    researched and developed under the agreement but in 2009, both
    of the projects were terminated for commercial reasons. Other
    elements of the Company&#146;s collaboration with Teva are
    currently ongoing. Eli Hurvitz, the former Chairman of the
    Company&#146;s Board of Directors, is also a former Chairman of
    Teva&#146;s Board of Directors, and Phillip Frost M.D., a former
    director and an indirect shareholder of the Company, is the
    current Chairman of Teva&#146;s Board of Directors.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">f.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Yissum
    Agreement</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On August&#160;8, 2007, the Company signed an agreement with the
    Yissum Research and Development Company, the technology transfer
    arm of the Hebrew University of Jerusalem, Israel, and the Boyce
    Thompson Institute for Plant Research, at Cornell University,
    Ithaca, New York, to develop a proprietary plant cell-based
    acetylcholinesterase (AChE) and its molecular variants for the
    use in several therapeutic and prophylactic indications,
    including a biodefense program and organophosphate-based
    pesticide treatment. Pursuant to the agreement, the Company has
    received an exclusive worldwide right and license to certain
    technology, including patents and additional patent applications
    relating to AChE (the &#147;Licensed Technology&#148;), for all
    therapeutic and prophylactic indications. In consideration for
    the license, the Company is required to make certain milestone
    payments upon its achievement of clinical milestones and
    royalties from sales derived from any drugs developed by it with
    the Licensed Technology. The agreement does not terminate until
    either party to the agreement elect to terminate the agreement,
    subject to certain terms and conditions set forth therein.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;7&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;SHARE
    CAPITAL</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">a.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Rights
    of the Company&#146;s Stock</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">Common
    Stock</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Company&#146;s common stock is listed on the NYSE Amex and,
    since September&#160;6, 2010, on the Tel Aviv Stock Exchange.
    Each share of Common Stock is entitled to one vote. The holders
    of Common Stock are also entitled to receive dividends whenever
    funds are legally available, when and if declared by the Board
    of Directors. Since its inception, the Company has not declared
    any dividends.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">Preferred
    Shares</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The preferred shares were authorized in the Company&#146;s
    Restated Articles of Incorporation on April&#160;16, 1998. The
    rights and privileges of the preferred stock may be established
    by the Company&#146;s Board of Directors. The directors have not
    designated any class of preferred stock and no shares of
    preferred stock have ever been issued.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">b.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Stock
    based compensation</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On December&#160;14, 2006, the Board of Directors adopted the
    Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan (the
    &#147;Plan&#148;). The grant of options to Israeli employees
    under the Plan is subject to the terms stipulated by
    Sections&#160;102 and 102A of the Israeli Income Tax Ordinance.
    Each option grant is subject to the track chosen by the Company,
    either Section&#160;102 or Section&#160;102A of the Israeli
    Income Tax Ordinance, and pursuant to the terms thereof, the
    Company is not allowed to claim, as an expense for tax purposes,
    the amounts credited to employees as a benefit, including
    amounts recorded as salary benefits in the Company&#146;s
    accounts, in respect of options granted to employees under the
    Plan, with the exception of the work-income
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>(U.S. dollars in thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;7&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;SHARE
    CAPITAL (continued):</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    benefit component, if any, determined on the grant date. For
    Israeli non-employees, the share option plan is subject to
    Section&#160;3(i) of the Israeli Income Tax Ordinance.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As of December&#160;31, 2010, 3,064&#160;shares of Common Stock
    remain available for grant under the Plan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    For purposes of determining the fair value of the options and
    shares of restricted Common Stock granted to employees and
    non-employees, the Company&#146;s management uses the fair value
    of the Common Stock.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    From January&#160;1, 2008 through December&#160;31, 2010, the
    Company granted options to certain employees and non-employees
    as follows:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">Options
    granted to employees:</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    a)&#160;Below is a table summarizing all of the option grants to
    employees for each of the three years in the period ended
    December&#160;31, 2010:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="10%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="7%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="7%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="7%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="20%">&nbsp;</TD> <!-- colindex=04 type=maindata -->
    <TD width="7%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=05 type=hang1 -->
    <TD width="7%">&nbsp;</TD>  <!-- colindex=06 type=gutter -->
    <TD width="7%">&nbsp;</TD>  <!-- colindex=06 type=maindata -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Year of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>No. of Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise Price<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Fair Value<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Expiration<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Grant</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Granted</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Range</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Vesting Period</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>at Grant</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Period</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2008
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,060,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.35-$5.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    4 -5&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,914
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    10&#160;years
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009*
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    504,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    2.65
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    Upon achievement of <BR>
    certain milestones*
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    1,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    10&#160;years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2009
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    120,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.65
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    4&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    212
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    10&#160;years
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="top">
    1,016,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    6.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD align="center" valign="top">
    3&#160;years commencing <BR>
    upon achievement of a<BR>
    certain milestone
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="top">
    $
</TD>
<TD nowrap align="right" valign="top">
    5,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    10&#160;years
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="top">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    2010
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    428,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6.32-$9.66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    4&#160;years
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    10&#160;years
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,128,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD valign="top">
    * </TD>
    <TD></TD>
    <TD valign="bottom">
    The milestone was achieved as of December&#160;31, 2009 and the
    options vested in full.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Set forth below are grants made by the Company to employees and
    certain related parties during the three-year period ended
    December&#160;31, 2010 (such grants appear in the table above):
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    1.&#160;In February 2008, the Company&#146;s Board of Directors
    approved the grant of options to purchase 1,900,000&#160;shares
    of Common Stock to the Company&#146;s Chief Executive Officer
    and certain officers and employees of the Company with an
    exercise price equal to $5.00 per share. The options vest
    variably over a five-year period. The options expire within a
    period of 10&#160;years from the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    2.&#160;In October 2008, the Company&#146;s Board of Directors
    approved the grant of options to purchase 160,000&#160;shares of
    Common Stock to a new newly-hired officer of the Company with an
    exercise price equal to $2.35 per share. The options vest over a
    four-year period. The options expire within a period of
    10&#160;years from the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    3.&#160;In February 2008, the Company amended the stock option
    agreements of certain executive officers. As amended, such stock
    option agreements provide for the full acceleration of the
    vesting period of unvested options held by such officers
    immediately upon a change of control. The Company concluded that
    there was no incremental increase in the value of the awards and
    therefore no accounting charges need to be recorded in
    connection with such modification.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>(U.S. dollars in thousands)</FONT></B>
</DIV>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;7&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;SHARE
    CAPITAL (continued):</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    4.&#160;In February, 2009, the Company&#146;s Board of Directors
    approved the grant of options to purchase 624,400&#160;shares of
    Common Stock to the Company&#146;s Chief Executive Officer and
    certain officers and employees of the Company with an exercise
    price equal to $2.65 per share. The options vest as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (i)&#160;504,000 of the options vest immediately upon the
    achievement of certain clinical and operational performance
    milestones, which milestones must be achieved within one year of
    the date of grant or the options will be forfeited. The options
    expire within a period of 10&#160;years from the date of grant.
    The vesting conditions of these options were satisfied prior to
    December&#160;31, 2009. Accordingly, these options were fully
    vested at December&#160;31, 2009 and the Company recognized all
    of the expenses for these options during 2009.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 8%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    (ii)&#160;120,400 of the options vest as follows: 25% within one
    year from the date of grant, with the remainder vesting in 12
    equal quarterly tranches over 36&#160;months. The options expire
    within a period of 10&#160;years from the date of grant. The
    Company&#146;s management assumed the simplified method to
    reflect the expected life regarding these options. The Company
    continued to use the simplified method in the first quarter of
    2009 as the Company did not have sufficient historical exercise
    data to provide a reasonable basis upon which to estimate
    expected term due to the limited period of time its equity
    shares have been publicly traded.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    5.&#160;In February 2010, the Company&#146;s Board of Directors
    approved the grant of options to purchase 1,016,000&#160;shares
    of Common Stock, in the aggregate, to the Company&#146;s Chief
    Executive Officer and certain officers and employees of the
    Company with an exercise price equal to $6.90 per share. The
    options vest quarterly over a three-year period commencing upon
    the FDA&#146;s approval of taliglucerase alfa, if at all. The
    Company will start recording these expenses following the
    FDA&#146;s marketing approval of taliglucerase alfa, if at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    6.&#160;In February 2010, the Company&#146;s Board of Directors
    approved the grant of options to purchase 160,000&#160;shares of
    Common Stock with an exercise price equal to $6.81 per share to
    a new executive officer of the Company. The options expire
    within a period of 10&#160;years from the date of grant. The
    first 25% of the options vest on the first anniversary of the
    date of grant and the remaining 75% vest in 12 equal tranches on
    a quarterly basis for three years thereafter.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    7.&#160;In September 2010, the Company&#146;s Board of Directors
    approved the grant of options to purchase 160,000&#160;shares of
    Common Stock to a new executive officer of the Company with an
    exercise price equal to $7.55 per share and options to purchase
    40,000&#160;shares of Common Stock to a new employee of the
    Company with an exercise price equal to $6.32 per share. The
    options vest over a four-year period, with the first 25% vesting
    on the first anniversary of the applicable date of the grant and
    the remaining 75% vesting in equal tranches on a quarterly basis
    for a three-year period thereafter. The options expire within a
    period of 10&#160;years from the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    8.&#160;In November 2010, the Company&#146;s Board of Directors
    approved the grant of options to purchase 68,000&#160;shares of
    Common Stock to a new officer of the Company with an exercise
    price equal to $9.66 per share. The options vest over a
    four-year period, with the first 25% vesting on the first
    anniversary of the applicable date of the grant and the
    remaining 75% vesting in equal tranches on a quarterly basis for
    a three-year period thereafter. The options expire within a
    period of 10&#160;years from the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 4%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    9.&#160;In September 2010, the Company&#146;s Board of Directors
    modified the terms of the options previously granted to an
    executive in 2001, by extending the life of the options until
    2016. At the date of modification, all of the options were fully
    vested. The Company concluded that there was no incremental
    increase in the value of the awards and therefore no accounting
    charges need to be recorded in connection with the modifications.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>(U.S. dollars in thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;7&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;SHARE
    CAPITAL (continued):</FONT></B>
</TD>
</TR>

</TABLE>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    b)&#160;The fair value of options granted during the years ended
    December&#160;31, 2008, 2009 and 2010 were $2,914, $1,280 and
    $7,820, respectively. The fair value of each option granted is
    estimated on the date of grant using the Black-Scholes
    option-pricing model, with the following weighted average
    assumptions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63%
</TD>
<TD nowrap align="left" valign="bottom">&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75%
</TD>
<TD nowrap align="left" valign="bottom">&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    75%
</TD>
<TD nowrap align="left" valign="bottom">&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.99%
</TD>
<TD nowrap align="left" valign="bottom">&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.74%
</TD>
<TD nowrap align="left" valign="bottom">&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.23%
</TD>
<TD nowrap align="left" valign="bottom">&nbsp;</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life&#160;&#151; in years
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.0&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.2&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.8&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The expected volatility is based on the historical volatility of
    the Common Stock and those of comparable companies. The
    risk-free interest rate assumption is based on observed interest
    rates appropriate for the expected term of the stock options
    granted in dollar terms. The Company&#146;s management uses the
    contractual term or its expectations, based on historical
    incidence of option exercises, as applicable (through 2008 and
    the first quarter of 2009&#160;&#151; using the simplified
    method), of each option as its expected life. The pre-vesting
    forfeiture rate of approximately 6.3% is estimated based on
    pre-vesting forfeiture experience.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The total unrecognized compensation cost of employee stock
    options at December&#160;31, 2010 is $7,317 (net of forfeiture
    rate) out of which $5,656 are expected to be recognized over a
    three-year period commencing upon the FDA&#146;s approval of
    taliglucerase alfa, if at all. The remaining compensation cost
    of $1,661 is expected to be recognized over a weighted average
    period of 1.1&#160;years.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The total cash received from employees as a result of employee
    stock option exercises for the years ended December&#160;31,
    2008, 2009 and 2010 was $5, $293 and $501, respectively. The
    Company did not realize any tax benefit in connection with these
    exercises.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    During 2010, the Company issued 407,235&#160;shares of Common
    Stock in connection with the exercise of 429,309 options by
    certain officers and employees of the Company. The Company
    received cash proceeds equal to $501 in connection with such
    exercises. Of such options, 98,081 were exercised on a
    &#147;net-exercise&#148; basis.
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Options
    and shares of restricted Common Stock granted to consultants,
    directors, and other service providers:</FONT></I></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    a.&#160;In February 2008, the Company&#146;s Board of Directors
    approved the grant of options to purchase 50,000&#160;shares of
    Common Stock to a new director of the Company with an exercise
    price equal to $3.02 per share. The options vest over a
    four-year period commencing on the date of grant and expire
    within a period of 10&#160;years from the date of grant.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    b.&#160;The fair value of options and shares of restricted
    Common Stock granted to consultants and other non-employees
    during the years ended December&#160;31, 2008, 2009 and 2010
    were $109, $0 and $0, respectively. The fair value of each
    option granted is estimated on the date of grant using the
    Black-Scholes option-pricing model, with the following weighted
    average assumptions:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="94%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend yield
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0%
</TD>
<TD nowrap align="left" valign="bottom">&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected volatility
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63%
</TD>
<TD nowrap align="left" valign="bottom">&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk-free interest rate
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.99%
</TD>
<TD nowrap align="left" valign="bottom">&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Expected life&#160;&#151; in years
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
(U.S. dollars in thousands)</FONT></B>
</DIV>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;7&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;SHARE
    CAPITAL (continued):</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The expected volatility is based on the historical volatility of
    the Company&#146;s stock and those of comparable companies. The
    risk-free interest rate assumption is based on observed interest
    rates appropriate for the expected term of the stock options
    granted in dollar terms. The Company&#146;s management used the
    contractual terms as the expected life.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The total unrecognized compensation cost as of December&#160;31,
    2010, is $14, and it is expected to be recognized over a
    weighted average period of 0.4&#160;years.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    No cash was received from consultants as a result of consultant
    stock option exercises for the years ended December&#160;31,
    2008, 2009 and 2010. The Company did not realize any tax
    benefits in connection with these exercises.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    During the year ended December&#160;31, 2009, the Company issued
    3,853,441&#160;shares of Common Stock in connection with the
    exercise of 3,866,093 options by certain consultants, directors,
    and other service providers of the Company. The Company did not
    receive cash proceeds in connection with such exercises as all
    of such options were exercised on a &#147;net-exercise&#148;
    basis.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    c.&#160;A summary of share option plans, and related
    information, under all of the Company&#146;s equity incentive
    plans for the years ended December&#160;31, 2008, 2009 and 2010
    are as follows:
</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Options
    granted to employees:</FONT></I></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>    <!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=06 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding at beginning of year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,212,686
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.830
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,890,641
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.118
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,366,729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.476
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Changes during the year:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,060,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.794
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    624,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,444,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.076
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Forfeited
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    177,237
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.405
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2.650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    13,441
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.551
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Exercised(*)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    204,808
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.565
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,146,912
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.733
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    429,309
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1.602
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding at end of year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,890,641
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.118
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,366,729
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.476
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,367,979
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.576
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exercisable at end of year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,267,607
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.995
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,680,382
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.785
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,267,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.183
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <TD>    (*)&#160;</TD>
    <TD align="left">
    The total intrinsic value of options exercised during the years
    ended December&#160;31, 2008, 2009 and 2010, was $450, $7,258
    and $3,050, respectively.
</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>(U.S. dollars in thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;7&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;SHARE
    CAPITAL (continued):</FONT></B>
</TD>
</TR>

</TABLE>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL,n -->
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Options
    granted to consultants, directors, and other service
    providers:</FONT></I></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="43%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=05 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=06 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>    <!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=06 type=hang1 -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=07 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=07 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=07 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=07 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="22" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Price</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding at beginning of year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,254,785
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.250
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,304,785
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.285
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,438,692
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.697
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Changes during the year:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Granted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Exercised(*)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,866,093
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    0.016
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Outstanding at end of year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,304,785
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1.285
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,438,692
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.697
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,438,692
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.697
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Exercisable at end of year
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,133,189
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.902
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,407,234
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.674
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,421,734
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    4.653
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    (*) </TD>
    <TD></TD>
    <TD valign="bottom">
    The total intrinsic value of options exercised during the years
    ended December&#160;31, 2008, 2009 and 2010, was $0, $41,281 and
    $0, respectively.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    d.&#160;The following tables summarize information concerning
    outstanding and exercisable options as of December&#160;31, 2010:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=01 type=lead -->
    <TD width="17%" align="right">&nbsp;</TD>   <!-- colindex=01 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=01 type=hang1 -->
    <TD width="12%">&nbsp;</TD> <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="12%">&nbsp;</TD> <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="12%">&nbsp;</TD> <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
    <TD width="12%">&nbsp;</TD> <!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=05 type=lead -->
    <TD width="6%" align="right">&nbsp;</TD>    <!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=05 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="18" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31, 2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options Outstanding</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Options Exercisable</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Number of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Weighted<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Options<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Average<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Outstanding<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercisable<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Remaining<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Exercise<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>at End of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>at End of<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B>Contractual<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Prices</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Life</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.001
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    919,207
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.42
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    917,875
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.42
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.120
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063,653
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,063,653
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.399
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.35
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    31,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4.35
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.972
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376,047
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.48
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,376,047
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5.48
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.350
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    160,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.82
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    80,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.82
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.650
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    612,204
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    553,929
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8.15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3.020
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,375
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    5.000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,765,345
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,244,490
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7.10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6.320
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6.810
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    160,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.10
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6.900
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,013,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.15
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7.550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    160,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9.660
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    68,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9.84
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    16.700
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    387,542
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    387,542
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,806,671
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,689,584
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The aggregate intrinsic value of the total outstanding and of
    total vested and exercisable options as of December&#160;31,
    2010 is $51,392 and $43,454, respectively.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>(U.S. dollars in thousands)</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;7&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">&#160;SHARE
    CAPITAL (continued):</FONT></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    e.&#160;The following table illustrates the effect of
    share-based compensation on the statement of operations:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="74%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Research and development expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,226
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,489
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    630
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    General and administrative expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,845
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,194
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    3,071
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,683
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,282
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;8&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times"> TAXES ON
    INCOME</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">a.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">The
    Company</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Protalix BioTherapeutics, Inc. is taxed according to tax laws of
    the United States. The income of the Company is, or will be,
    taxed in the United States at the rate of up to 39.4%.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">b.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Protalix
    Ltd.</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Israeli Subsidiary is taxed according to Israeli tax laws:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">Measurement
    of results for tax purposes</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Commencing in 2008, the results of the Israeli Subsidiary are
    measured for tax purposes in nominal terms. Pursuant to the
    Israel Income Tax Law (Adjustments for Inflation), 1985 (the
    &#147;Adjustments Law&#148;), the Subsidiary&#146;s results for
    tax purposes have been measured through 2007 on a real basis,
    based on changes in the Israel consumer price index.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">Tax
    rates</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The income of the Israeli Subsidiary, other than income from
    &#147;Approved Enterprises,&#148; is taxed in Israel at the
    regular rate. See 3 below. According to the provisions of the
    Law for Amending the Israel Income Tax Ordinance, 2005 of August
    2005, corporate tax rates will be gradually lowered, resulting
    in the corporate following tax rates for 2008 and thereafter:
    2008&#160;&#151; 27%, 2009&#160;&#151; 26% and for 2010 and
    thereafter&#160;&#151; 25%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Capital gain for assets purchased since January&#160;1, 2003 are
    subject to real capital gain tax at 25% and exempted from
    inflationary capital gains tax.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    On July&#160;14, 2009, the Israel Economic Efficiency Law
    (Legislation Amendments for Applying the Economic Plan for 2009
    and 2010), 2009, became effective, stipulating, among other
    things, an additional gradual decrease in tax rates in 2011 and
    thereafter, as follows: 2011&#160;&#151; 24%, 2012&#160;&#151;
    23%, 2013&#160;&#151; 22%, 2014&#160;&#151; 21%,
    2015&#160;&#151; 20% and 2016 and thereafter&#160;&#151; 18%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to the above decrease in corporate tax, the real
    capital gain tax was reduced to be in line with corporate tax in
    the year of selling the asset.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
(U.S. dollars in thousands)
</FONT></B>
</DIV>







<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;8&#160;&#151;
    </FONT></B>
</TD>
    <TD>

<B><FONT style="font-family: 'Times New Roman', Times">&#160;TAXES ON
INCOME (continued):</FONT></B>
</TD>
</TR>

</TABLE>









<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">3.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">The Law
    for the Encouragement of Capital Investments, 1959 (the
    &#147;Encouragement of Capital Investments Law&#148;)</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the Encouragement of Capital Investments Law, including
    Amendment No.&#160;60 to the Encouragement of Capital
    Investments Law as published in April 2005, by virtue of the
    &#147;Approved Enterprise&#148; or &#147;Benefited
    Enterprise&#148; status the Israeli Subsidiary is entitled to
    various tax benefits as follows:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">a.<B>&#160;&#160;</B></FONT></I>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Reduced
    tax rates</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Income derived from the Approved Enterprise during a
    <FONT style="white-space: nowrap">10-year</FONT>
    period commencing upon the year in which the enterprise first
    realizes taxable income is tax exempt, provided that the maximum
    period to which it is restricted by the Encouragement of Capital
    Investments Law has not elapsed.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Israeli Subsidiary has an &#147;Approved Enterprise&#148;
    plan since 2004 and &#147;Benefited Enterprise&#148; plan since
    2009. The period of benefits in respect of the main enterprise
    of the Company has not yet commenced. The period during which
    the Company is entitled to benefits in connection with the
    Approved Enterprise expires in 2017.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    If the Israeli Subsidiary subsequently pays a dividend out of
    income derived from the &#147;Approved Enterprise&#148; or
    &#147;Benefited Enterprise&#148; during the tax exemption
    period, it will be subject to a tax on the amount distributed,
    including any company tax on these amounts, at the rate which
    would have been applicable had such income not been exempted.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In addition to the corporate taxes in Israel, the Company might
    be subject to a withholding tax on the U.S.&#160;revenue source
    portion of the payments made to the Company for its share of
    Pfizer&#146;s net profits under the Pfizer Agreement. The
    withholding tax rate is currently 15%.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">b.<B>&#160;&#160;</B></FONT></I>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Accelerated
    depreciation</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Israeli Subsidiary is entitled to claim accelerated
    depreciation as provided by Israeli law, commencing in the first
    year of operation of each asset, in respect of buildings,
    machinery and equipment used by the Approved Enterprise.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">c.<B>&#160;&#160;</B></FONT></I>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Conditions
    for entitlement to the benefits</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Israeli Subsidiary&#146;s entitlement to the benefits
    described above is subject to its fulfilling the conditions
    stipulated by the law, rules and regulations published
    thereunder, and the instruments of approval for the specific
    investment in an approved enterprise. If there is any failure by
    the Israeli Subsidiary to comply with these conditions, the
    benefits may be cancelled and the Subsidiary may be required to
    refund the amount of the benefits, in whole or in part, with
    interest. The Company received a final implementation approval
    with respect to its &#147;Approved Enterprise&#148; from the
    Investment Center.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">d.<B>&#160;&#160;</B></FONT></I>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Amendment
    of the Law for the Encouragement of Capital Investments,
    1959</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Encouragement of Capital Investments Law was amended as part
    of the Economic Policy Law for the years
    <FONT style="white-space: nowrap">2011-2012,</FONT>
    which was passed by the Israeli Knesset on December&#160;27,
    2010 (the &#147;Capital Investments Law Amendment&#148;).
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Capital Investments Law Amendment sets alternative benefit
    tracks to those currently in effect under the provisions of the
    Encouragement of Capital Investments Law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The benefits granted to the Benefited Enterprises will be
    unlimited in time, unlike the benefits granted to special
    Benefited enterprises, which will be limited for a
    <FONT style="white-space: nowrap">10-year</FONT>
    period. The benefits shall be granted to
</DIV>
<!-- XBRL Paragraph Pagebreak -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<br>(U.S. dollars in thousands)</FONT></B>
</DIV>




<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;8&#160;&#151;
    </FONT></B>
</TD>
    <TD>

<B><FONT style="font-family: 'Times New Roman', Times">&#160;TAXES ON
INCOME (continued):</FONT></B>
</TD>
</TR>

</TABLE>








<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    companies that will qualify under criteria set in the law; for
    the most part, those criteria are similar to the criteria that
    were set in the Encouragement of Capital Investments Law prior
    to its amendment.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the transitional provisions of the Encouragement of
    Capital Investments Law, the Company is entitled to take
    advantage of the tax benefits available under the Encouragement
    of Capital Investments Law prior to its amendment until the end
    of the benefits period, as defined in the Encouragement of
    Capital Investments Law. The Company will be allowed to set the
    &#147;year of election&#148; no later than tax year 2012,
    provided that the minimum qualifying investment was made not
    later than the end of 2010. On each year during the benefits
    period, the Company will be able to elect that the Capital
    Investments Amendment apply to the Company, thereby making the
    tax rates described above available to the Company. An election
    to have the Capital Investments Amendment apply is
    irrecoverable. The amendment was not in effect as of
    December&#160;31, 2010. Accordingly, the measurement of the
    deferred income taxes, was prepared without taking the effects
    of Capital Investments Amendment into consideration. See d below.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">4.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">The Law
    for the Encouragement of Industry (Taxation), 1969:</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The Israeli Subsidiary is an &#147;industrial company,&#148; as
    defined under the Law for the Encouragement of Industry
    (Taxation), 1969 (the &#147;Law for the Encouragement of
    Industry&#148;). As such, the Israeli Subsidiary is entitled to
    claim depreciation at increased rates for equipment used in
    industrial activity, as stipulated by regulations published
    under Law for the Encouragement of Industry, and has done so.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the provisions of the Income Tax Regulations
    &#147;Accelerated Depreciation in respect of Equipment acquired
    during the Defined Period&#148; (Temporary Orders), industrial
    companies whose operations are mostly &#147;eligible
    operations&#148; are entitled to claim accelerated depreciation
    at a rate of 50% on machinery and equipment acquired from
    June&#160;1, 2008 to May&#160;31, 2009. The accelerated
    depreciation is to be claimed over two years. For the year in
    which the equipment was acquired, depreciation is recorded at
    the regular rate. In the second year and thereafter,
    depreciation is recorded at a rate that would make the aggregate
    rate 100%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Under the regulations, the Company is entitled to accelerated
    depreciation in 2010 for machines and equipment purchased in
    2008 and 2009. The effect of the change in the rates of
    accelerated depreciation was included in deferred taxes
    described below.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">c.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Tax
    losses carried forward to future years</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    As of December&#160;31, 2010, the Company had aggregate net
    operating loss (NOL) carry-forwards equal to approximately
    $54,000 that are available to reduce future taxable income as
    follows:
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">1.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">The
    Company</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The NOL carry-forward of the Company equal to approximately
    $9,000 may be restricted under Section&#160;382 of the
    Internal Revenue Code (&#147;IRC&#148;). IRC Section&#160;382
    applies whenever a corporation with NOL experiences an ownership
    change. As a result of IRC Section&#160;382, the taxable income
    for any post change year that may be offset by a pre-change NOL
    may not exceed the general IRC Section&#160;382 limitation,
    which is the fair market value of the pre-change entity
    multiplied by the IRC long-term tax exempt rate.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">2.&#160;&#160;</FONT></I>
</TD>
    <TD>
    <I><FONT style="font-family: 'Times New Roman', Times">Protalix
    Ltd.</FONT></I>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    At December&#160;31, 2010, the Israeli Subsidiary had
    approximately $45,000 of NOL carry-forwards that are available
    to reduce future taxable income with no limited period of use.
</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
(U.S. dollars in thousands)</FONT></B>
</DIV>




<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;8&#160;&#151;
    </FONT></B>
</TD>
    <TD>

<B><FONT style="font-family: 'Times New Roman', Times">&#160;TAXES ON
INCOME (continued):</FONT></B>
</TD>
</TR>

</TABLE>







<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">d.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Deferred
    income taxes:</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The components of the Company&#146;s net deferred tax assets at
    December&#160;31, 2009 and 2010 were as follows:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="82%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    In respect of:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Property and equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    161
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    143
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Holiday and recreation pay
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    200
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Severance pay obligation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    87
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    130
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Deferred revenues
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,345
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,691
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Net operating loss carry forwards
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,246
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,599
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Valuation allowance
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    10,717
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,573
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">e.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Reconciliation
    of the theoretical tax expense to actual tax
    expense</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    The main reconciling items between the statutory tax rate of the
    Company and the effective rate is the tax exemptions in
    connections with the Approved Enterprise and the provision for
    full valuation allowance in respect of tax benefits from carry
    forward tax losses due to the uncertainty of the realization of
    such tax benefits (see above).
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">f.&#160;&#160;</FONT></I></B>
</TD>
    <TD>
    <B><I><FONT style="font-family: 'Times New Roman', Times">Tax
    assessments</FONT></I></B>
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    In accordance with the Income Tax Ordinance, as of
    December&#160;31, 2010, all of Protalix Ltd.&#146;s tax
    assessments through tax year 2005 are considered final.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    A summary of open tax years by major jurisdiction is presented
    below:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="89%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="4%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <B>Jurisdiction:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="3" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Years:</B>
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Israel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2005-2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    United States(*)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2002-2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Netherlands
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2009-2010
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

<TR>
    <TD width="2%"></TD>
    <TD width="1%"></TD>
    <TD width="97%"></TD>
</TR>

<TR>
    <TD valign="top">
    (*) </TD>
    <TD></TD>
    <TD valign="bottom">
    Includes federal, state and local (or similar provincial
    jurisdictions) tax positions.</TD>
</TR>

</TABLE>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-25
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<br>
(U.S. dollars in thousands)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL,n -->
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;9&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">
    SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION:</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <B>Balance sheets:</B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="82%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="4%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom">
    <B>Year Ended<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>a. Accounts receivable&#160;&#151; other:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Institutions
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    740
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    634
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    State of Israel (see Note&#160;6a)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    832
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    878
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Restricted deposit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    213
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    226
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Prepaid expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    208
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    354
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Sundry
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    151
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    139
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>b. Accounts payable and accruals&#160;&#151; other:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Payroll and related expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,731
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    1,199
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Provision for vacation and recreation pay
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    799
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Accrued expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,931
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,030
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Royalties payable
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    884
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Property and equipment supplier
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,525
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,720
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,561
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,068
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-26
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<BR>
(U.S. dollars in thousands)</FONT></B>
</DIV>




<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="10%"></TD>
    <TD width="90%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;9&#160;&#151;
    </FONT></B>
</TD>
    <TD>

<B><FONT style="font-family: 'Times New Roman', Times">&#160;SUPPLEMENTARY
FINANCIAL STATEMENT INFORMATION (continued):</FONT></B>
</TD>
</TR>

</TABLE>





<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    Statement of operations:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="71%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="5%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>c. Revenues:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Deferred revenues from the license and supply agreement with
    Pfizer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
$
</TD>
<TD nowrap align="right" valign="bottom">
&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
$
</TD>
<TD nowrap align="right" valign="bottom">
    388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
$
</TD>
<TD nowrap align="right" valign="bottom">
    4,563
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Revenues from selling products to Pfizer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,079
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
$
</TD>
<TD nowrap align="right" valign="bottom">
&#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
$
</TD>
<TD nowrap align="right" valign="bottom">
    388
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
$
</TD>
<TD nowrap align="right" valign="bottom">
    6,642
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>

<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>d. Cost of Revenues:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Cost of products sold
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
$
</TD>
<TD nowrap align="right" valign="bottom">
    807
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Write down of inventories
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,692
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Royalties expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
$
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
$
</TD>
<TD nowrap align="right" valign="bottom">
    3,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    884
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
$
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
$
</TD>
<TD nowrap align="right" valign="bottom">
    3,575
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
$
</TD>
<TD nowrap align="right" valign="bottom">
    4,383
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>e. Research and development expenses&#160;&#151; net:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Payroll and related expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,296
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    10,479
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    13,176
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Subcontractors and consultants
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,289
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    7,469
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    11,550
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Materials and consumables
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,799
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,852
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,947
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Rent, insurance and maintenance
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,592
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,238
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,457
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Patent registration and licensing
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    182
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    387
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    571
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Depreciation and impairment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,171
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,799
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,456
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    786
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,166
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,534
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,115
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,390
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,691
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Less&#160;&#151; grants and reimbursements:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Development costs reimbursements from Pfizer
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,922
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Grants (see Note&#160;6a)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,714
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,752
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,818
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    17,401
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    21,638
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    29,951
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>f. General and administrative expense:</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Payroll and related expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,804
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2,415
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Management and consulting fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,335
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    681
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    221
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Rent, insurance and maintenance
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    347
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    463
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Professional fees
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,362
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,274
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,274
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Travel
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    472
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    251
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    308
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Depreciation
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    130
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    191
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    309
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 30pt">
    Other
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,019
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    596
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    886
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,770
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    7,144
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6,876
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">

</DIV>
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-27
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#Y04571tocpage">Table of Contents</A></H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<!-- XBRL -->
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">PROTALIX
    BIOTHERAPEUTICS, INC.<BR>
    </FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

    <B><FONT style="font-family: 'Times New Roman', Times">NOTES&#160;TO
    CONSOLIDATED FINANCIAL
    STATEMENTS<br>
(U.S. dollars in thousands)</FONT></B>
</DIV>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>
<!-- XBRL Pagebreak End -->
<!-- XBRL,n -->
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="11%"></TD>
    <TD width="89%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;10&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">RELATED
    PARTY TRANSACTIONS</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="80%">&nbsp;</TD> <!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>  <!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=02 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=03 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=03 type=hang1 -->
    <TD width="3%">&nbsp;</TD>  <!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>    <!-- colindex=04 type=lead -->
    <TD width="2%" align="right">&nbsp;</TD>    <!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>     <!-- colindex=04 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<!-- TableOutputHead -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended December&#160;31,</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2009</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>2010</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<!-- TableOutputBody -->
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>a. </B>Management and consulting fees to the Chairman of the
    Board
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    33
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    6
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>


<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>b. </B>Compensation to the non-executive directors (except
    the Chairman of the Board in 2008 and 2009)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    210
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    209
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    215
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>











<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">

    <B>c. </B>With respect to options granted to the Company&#146;s Chief
    Executive Officer and to a shareholder, see<br>Note&#160;7(b)1.
</DIV>
</TD>
</tr>




<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">

    <B>d. </B>In March 2005, Protalix Ltd. entered into a management services
    agreement with Pontifax Management Company, Ltd. in connection
    with an investment in Protalix Ltd. by affiliates of Pontifax.
    The monthly management fees under the management services
    agreement were $3. The management services agreement remained in
    full force as long as Mr.&#160;Hurvitz served as a member of the
    Company&#146;s Board of Directors. In 2008, the annual amount
    was set to $33 and in March 2010, Mr.&#160;Hurvitz resigned from
    the Company&#146;s Board of Directors. The management services
    agreement is no longer in effect.
</DIV>
</TD>
</tr>




</TABLE>





<!-- XBRL,n -->
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: transparent">

<TR>
    <TD width="11%"></TD>
    <TD width="89%"></TD>
</TR>

<TR valign="top">
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">NOTE&#160;11&#160;&#151;
    </FONT></B>
</TD>
    <TD>
    <B><FONT style="font-family: 'Times New Roman', Times">
    SUBSEQUENT EVENTS</FONT></B>
</TD>
</TR>

</TABLE>
<!-- XBRL,body -->
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    During January and February 2011, the Company issued a total of
    86,065&#160;shares of Common Stock in connection with the
    exercise of options to purchase 86,065&#160;shares of Common
    Stock by certain employees of the Company. The Company received
    aggregate cash proceeds equal to approximately $118 in
    connection with the exercise of such options.
</DIV>
<!-- /XBRL,ns -->
<!-- XBRL Pagebreak Begin -->

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: transparent">
    <BR>
    F-28
</DIV><!-- END PAGE WIDTH -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>y04571exv23w1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv23w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;23.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="y04571y0457100.gif" alt="(IMAGE)">
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">We hereby consent to the incorporation by reference in the Registration Statement on Form&nbsp;S-3 (No.
333-171615) and Registration Statement on Form&nbsp;S-8 (No.&nbsp;333-148983) of Protalix BioTherapeutics,
Inc. of our report dated February&nbsp;23, 2011 relating to the financial statements and the
effectiveness of internal control over financial reporting, which appears in this Form 10-K.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt">/s/ Kesselman &#038; Kesselman
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Kesselman &#038; Kesselman<BR>
Certified Public Accountants (lsr.)<BR>
A member firm of PricewaterhouseCoopers International Limited

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Tel-Aviv, Israel<BR>
February&nbsp;23, 2011

</DIV>



<DIV style="margin-top: 300pt; font-size: 1pt">&nbsp;</DIV>




<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Kesselman
&#038; Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 68125, Israel, P.O. Box
452 Tel-Aviv 61003 Telephone: &#043;972 -3- 7954555, Fax:&#043;972 -3- 7954556, www.pwc.co.il</I>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>y04571exv31w1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv31w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 31.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATION</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">I, David Aviezer, certify that:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is
made known to us by others within those entities, particularly during the period in
which this report is being prepared;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such internal control over financial reporting, or caused such
internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Evaluated the effectiveness of the registrant&#146;s disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report
based on such evaluation; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Disclosed in this report any change in the registrant&#146;s internal control over
financial reporting that occurred during the registrant&#146;s most recent fiscal quarter
(the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant&#146;s
internal control over financial reporting; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the
audit committee of the registrant&#146;s board of directors (or persons performing the equivalent
functions):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect
the registrant&#146;s ability to record, process, summarize and report financial information;
and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant&#146;s internal control over financial reporting.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:
February&nbsp;23, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ David Aviezer
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
David Aviezer, Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">President and Chief Executive Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>y04571exv31w2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv31w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 31.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>CERTIFICATION</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">I, Yossi Maimon, certify that:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>I have reviewed this Annual Report on Form 10-K of Protalix BioTherapeutics, Inc.;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading with respect to the period
covered by this report;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Based on my knowledge, the financial statements, and other financial information included in
this report, fairly present in all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the periods presented in this
report;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer and I are responsible for establishing and
maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e) and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is
made known to us by others within those entities, particularly during the period in
which this report is being prepared;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Designed such internal control over financial reporting, or caused such
internal control over financial reporting to be designed under our supervision, to
provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(c)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Evaluated the effectiveness of the registrant&#146;s disclosure controls and
procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report
based on such evaluation; and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">(d)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Disclosed in this report any change in the registrant&#146;s internal control over
financial reporting that occurred during the registrant&#146;s most recent fiscal quarter
(the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has
materially affected, or is reasonably likely to materially affect, the registrant&#146;s
internal control over financial reporting; and</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">5.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>The registrant&#146;s other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the
audit committee of the registrant&#146;s board of directors (or persons performing the equivalent
functions):</TD>
</TR>

</TABLE>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">a)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>All significant deficiencies and material weaknesses in the design or operation of
internal control over financial reporting which are reasonably likely to adversely affect
the registrant&#146;s ability to record, process, summarize and report financial information;
and</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="4%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">b)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Any fraud, whether or not material, that involves management or other employees who
have a significant role in the registrant&#146;s internal control over financial reporting.</TD>
</TR>

</TABLE>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:
February&nbsp;23, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Yossi Maimon
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Yossi Maimon
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Chief Financial Officer, Treasurer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>y04571exv32w1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv32w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 32.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>CERTIFICATION</U>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In connection with the Annual Report of Protalix BioTherapeutics, Inc. (the &#147;Company&#148;) on Form 10-K
for the period ended December&nbsp;31, 2010 as filed with the Securities and Exchange Commission (the
&#147;Report&#148;), I, David Aviezer, President and Chief Executive Officer of the Company, hereby certify
as of the date hereof, solely for purposes of Title 18, Chapter&nbsp;63, Section&nbsp;1350 of the United
States Code, that to the best of my knowledge:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(1)&nbsp;the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable,
of the Securities Exchange Act of 1934; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(2)&nbsp;the information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company at the dates and for the periods
indicated.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Certification has not been, and shall not be deemed, &#147;filed&#148; with the Securities and Exchange
Commission.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:
February&nbsp;23, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ David Aviezer
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
David Aviezer, Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">President and Chief Executive Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>y04571exv32w2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv32w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>EXHIBIT 32.2</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>PROTALIX BIOTHERAPEUTICS, INC.</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><U>CERTIFICATION</U>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">In connection with the Annual Report of Protalix BioTherapeutics, Inc. (the &#147;Company&#148;) on Form 10-K
for the period ended December&nbsp;31, 2010 as filed with the Securities and Exchange Commission (the
&#147;Report&#148;), I, Yossi Maimon, Vice President and Chief Financial Officer of the Company, hereby
certify as of the date hereof, solely for the purposes of Title 18, Chapter&nbsp;63, Section&nbsp;1350 of the
United States Code, that to the best of my knowledge:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(1)&nbsp;the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable,
of the Securities Exchange Act of 1934; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 2%">(2)&nbsp;the information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company at the dates and for the periods
indicated.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This Certification has not been, and shall not be deemed, &#147;filed&#148; with the Securities and Exchange
Commission.
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="63%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Dated:
February&nbsp;23, 2011</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">/s/ Yossi Maimon
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
Yossi Maimon
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Vice President and Chief Financial Officer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>y04571y0457101.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y04571y0457101.gif
M1TE&.#EA40+%`/?_`/W]_5%?;?'Q]G-LL8Z*P=74Z.;F\4U#G(-[N55,H920
MQ%Q3I-'1YN'A[NW4TL7!W]K8ZNCI\J._VZ*=RQH*@*_'WI&-P@```-[=[:BC
MSF-;J9Z;R3DMD3,GCLG(X<;%WZ"@H/CX^IB3QL&_W(2`NZVIT;6RU8R$OZ6@
MS3PQE"`2A!`0$+VZVJ2DSIJ6R$4[F$`UE<+!W;=01WYVMU)'G\_.Y+"MT_KZ
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MMH"`@'IWML#`P+^_OS`O+^_O[Y^?G[^_OB`?(/#P\$!`0.#@X+"PL-#0T/[^
M_G]_?V!@8$=_MI"0D-3=Z7!P<%!04/OU]+Q;4S`P,-_?W_KY^E.'N\_/S_+?
MW>GO]L5Q:O3W^]+?[=*2C/;JZ5Z/OW6?R*^OKX&GS6!?7^"SKXROT<Z'@=O;
M[.G)QNWM];6RT^_O]<[+Y,;7Z&EN=8^/CWQUM&)8J&]GK_O[_(:"O/?W^D)W
MJO7U^6LW,]FYML'/W8B/EF]PLZM+0K.SUF%P?5IWG'1X>]W`P4%OG+>WUW1-
M2K2XN_/S]]^RKIM;8FB'IN?H\NOK\WAJA=/3YX2'B]O;ZEUG<MO.U-?7Z<N8
MDZ1Q>7MT=,G0UO_______R'Y!`$``/\`+`````!1`L4```C_`&N-&DBPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6*LU"12<:QH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G'DRU+^;.'/JW,FSI\^?0(,*'4JTJ-&C2),J33KPU2M_4*-*G4JUJM6K
M6+-JW<JUJ]>O8,.*'4NVK-FS6FTN75NT52T0H]3F=#5K%(A9K5:Q;14*A%%6
MJUP-S?LO5"N@K&P5!2R8K>.U`]%*GDRYLN7+F#-KSBSWL6>=HU:H:@6B,4Y7
M%U3]4Q5KU`6V*^X>O3!JJ.M_K4SW5#7+*.W/P(M&WDR\N/'CR),K)]LYN.=0
MM52!:/XOEMZ;JERWLN5*.M["L6;%_U)EV-8L\B!8W70="W`H6ZSPMF(-O=9V
MTQ="Q>I^]S`(TH6U,E!JL?RWRGWHJ8>;7OJ)I]H_=)T7"W1^T99@@GG=YQQP
MPRWGX8<@ABCBB%91M^%:K+PU"V"U*/B/+=>M]]HJAAGV6BAZY3>C>.'%@M-O
M%[0BGDVIT7@;C3^.TDHJ?+7RV@JAN`)"+J.D<F0H5\;2HXR%Y5C;B[;41J,J
M%[!"FY8\]GCEB9YU2.*;<,8IYYQ=F<CF4O%-J(IILZR`$RM7LE+@C5X6.)XM
M/N8$I)A$CF+DC'+1YIJ@(+PV2BZYS)(*EX_^0R.B.=V&XS^__9/8"NZ1ZMHH
MH+Z8Z)IWLO_E)IVTUFKKK<?9&2M2/H;W)4ZUM(;7E9K64N:HM%E96VB&):DJ
M;NWEXBF6D.*T`E^U%%NFCZNHLD*V3JK2J9%0'O:/J%[>%%U[JX27"YD"ELNL
M@-7NNM2LN.8+5AQ)J#""/W4$\LD`3_D30P<43)!)#P<8,)4`*M3A3P3;4*7)
M!A0HH.]4!,#P`0"BS"!"P0H8T@$*3!S!AP=3A8#$(O[@(`!5<8@PQ0+)Z6KO
M8NOQ!.A-KHP2]+(0GBNTT##FXN.>?PX$Z)=,9W?TT#BIPHJ"M0D6](-9'SWU
M0*N9%O3303<&J'HT"@:H8$R'#:'7.RN%[\9T8V5`$Y%DP8<_;]#_D$T>&T0%
M21(`^)//!U0)D$0=V;PP\U2=")!QW2%<<T3%BF@`0`I<0"5`%H@\E8\25(70
M00G9@-(`52XH<0#.R.D<]^P0^NB*[+0KE4LMN=\Y=]W`3W5#-G648<,K9>3Q
MBC9[%#QXX8=G(L(8=[@00CXG&/`&!2QLTT04+/BSAAN[9%R'`A`\(X(3)W1.
M:P8<5/S*%7OX<P`)GH,NNA+9H.!"!A980R1.X($[4*`(T2C!"([GCP'8;P$"
ML(`BLI&!*!#`"=G`#.YZMZNS<1`X4GO0!SDTBN"9\"HA0`0="'`#0XC"']I(
M0.'\\3S#(>X`4[``!0JP!`KH8`P4$(`?__)@AA=201WE4X`!7."/,,`@`A1P
M'YT20`-(^"`;C7#@Z_(7.L,IX14(,(0V5%"))#J!`@V```?DD0<`=,,'#UQ#
M%790!"3<``9,U.`(]\C'/OIQ)[\[H0DC@8T4<((.+XSA#&MX./O1H!D44$0/
M?QA$+M!A`!#@6S?*1X(%=,,?"4C`-BC0!UK=(`D;8(,*/$`#+<+N<UT<G3\0
MT(%F3$$!-\C8&1MPR`0(X164B(']&B$&'O"-`Z\X@#8X\\=F.O.9NPJD(.G&
M@R``+`O/H$$>_"$&@D'%$X;(8!QJ\$`F4.`!DP2B``Q@A13(4!#^X.04JN`/
M!K2!""5H!ZVRP?^!"00A"9KP0?U28`&HM.-UA:M!)F;)`29T@`!F1.,:%(&(
M#M3!$3,[0",:D8!N1``.)W!!/)@)36<Z*CHI<A%A2LK2H$ASFOIJ@B$^\8DQ
MO*()'(A&)W00%3^H('Q-B(8C(7#.'L:`#1G3Q"+R\8)"W,$?W:"`#ZB@`A-8
M@`\G.$$D:B4"1SR@`X^X:#MHP`FHO&("'2A$!!;Q%%I"8`H0E6H4Z/`&(6A#
M'G0XA/+\408:8(`")'@`#;+*`)*VU(^KN(Y?<'*;PSH6D"6$J2!Q<`<"1J4&
MEI5*'+(Z,P%D-0TG0`'[)I"-$T#@$$(XP3,\L-7-6F"S)P`#!69[`%O_->$-
MJZMG]J8RVHJ%(*N:""UF10``%(R`!P-L!B<*Z]D3,""K03#$;.FP`ST^EH^5
M<D4K6"&ETKB&-08"SRS"9(O#&.97U^7@2R7+WLH$@G2[H$%[T:*`+O@C&TC0
MYV4VF-Y8I:)`_U`6E2"%+E7A:$I5ZN\'USO?!I?%!H@X`0+BX."RT*,1)R""
M?:VK8`Y6ZC"2H@V!"67@56BJPPN.;(57S.(65X6_*':.*J3UC[>`P#ZI0=0L
MCN4E''DK6S&F'8-=3.0B`P_&00:.BZ[V-E9D1Q6J&4C9!A+E),]NR$;.LI9I
MA60K>_G+PE'QEL=,9EMU&<QH3C-DR\SF-L?I_\QJCC.:L>SF.MNY,G"6LYZ3
M3.<[^_G/8LGSG@>MX#X#^M"(QHJ@"<UHQPYD$#F(M*0G3>E*6_K2F,ZTIC?-
MZ4Y[^M.@#K6H1TWJ4IOZU*CF]*(;S6IHCF(3(#B%K&=-ZUK;^M:XSK6N=\WK
M7OOZU\`.MK"'3>QB&_O8R$YVKU?=ZF;[T=")CK:TF>WL:J=8VMC.=EJLS>U"
MBUG;X`8WM;M-[FA^.]SHCO:XR\WN#4$[W?#.\KK;3>\VG3O>Q`$"&$X@!']@
MX`X%J`H32A`5$60UX"P&`@M.8`-_/`,%*%@#50!@`@I#I1ML:$+!EC-OI3C@
MXR"_1;W)_6Y\E\4$=/\X`"$`((*JF*`#67B*ZVA`@\>Q.`*&,$0FTV`"JBBA
M!Q3(`%12"(H(@*CC0A&0N6XB@Z8[W0$C[W;)33X6'2"``F+PAR:J4@`:9`$J
M&W#",XHL`#&HX!HAJ`3B'H94H?N#"`?8N(>0#A15\"XZ.''ZTZ/.[:E3/2PU
M8*H*&+#U.="<YIF$Q-<!4`8*P*#A+A9B&%2P@2)\H`^'IT'])"=T(*A`%`^H
M[H?H_I.X%.97>F_Z#T+!^M:[_O6PC[WL9_]Z&M'^]KC/?>QMK_O>^W[WOP^%
MBUQZ[[]CI@88B((A$K"!5PCA`=!_@,05[P\`/,`$+S"$Q%HL`$HH80JH_$#_
M)*+_@'YSWA]Q2!@,Z#GZV;'")L+/>^I;$0P^DGXI]U=*_OUN?*\@WQ]^0`&U
M97!9M5O4)Q5S0`"11PG^,`(J0`?0\%P%R$3G-P(48``;0#CM-SOPEQ,@MP4.
M``SO8`E_L$?HU4<GR$<I^!G\UW]<\7\`D``#6(`&^'7^X`)C-P9/L(#5]P80
M*(%918%!YV\[I`E(('<YDSLK6!C_<`O#(`/F``C"P'>MUH(NJ!7DP#+^4`..
M8!5\P`'WE00O```6,$,LQ@D3,'0P``U5<0:3`P`'8`%O$`9']T=RD0@R,`^R
M@`R_0(6,9H57>!5F<`)O,$/T4!4HD%4$\`I,D%5;_]5B9B`"N`45^9!;4M&(
M6;5V%K"(=>A'G>$+D[`/EB`+$E!_?JAG@!B(JE@K^7<4S7$+=@`,DL`+O%""
MIQAGJ;B*NOAF=L@3:H`+Z*`'LB"%MYAFN;B+R"@BK6@4=N(,N,`(OV`,>]B'
M=^(*$]),=B%">Z1=B^4<QYB,X,AQO=@3Q``,=G`+PE`,I&B*[N8M?P0"BO%'
MF[(*P\>"Q1>.^(@KRT@4M6`+W;@33H@+OO`/%4"+MK@AH9`*VCA"3)(H?20:
MJ["$LG*/^5B1=+*/0X$I"[D3>*@,_Q`,PDB,,F8+&"D4,R*10M8*HN%N%&F1
M+ODF)?D/LQ!_/%$EN`.*P_\@<M$XC<`1'33)1]UB"QOY00#&DB]YE%RV,Z/0
M(CZQ'4,)D+$XD/^0CNOH&:3QE+TS&KJQ1]O%)M^(E&!9%B7)"JWP+CO1>KR7
M>]Z`"UC0>FC`#;P`!<$WEW19EW9YEW@Y>_58>J]&"G[YEX`9F((YF(19F(9Y
MF(B9F(JYF(S9F([YF)`9F9(YF919F8D9D[AA%S^)$UWFC(R`$]L0DE-8C(XV
M"CE0"JB9FJJYFJS9FJ[YFK`9F[(YF[19F[9YF[B9F[JYF[S9F[[YF[-9DH(Q
M'SYQ9KY@CB)W$SO)AZ394E\9EM`)%B79"EU9G$@1D%)Y$U19BLWI:BT9G>"I
M&9C_"12"I@PRX)$Y49"UV)TF]9WA^9YX-HY)X0NXD),Y`9+#.)KLJ8+N"9_^
M>1;C^1.K!HO`D)W**8W,N9\C])S_V:#^$*#6R1:,@`O.L!-4J0?LJ*!"UI\.
MVJ%>`:$],6[.J`8\H9X5H*%*R*%?@`T#4%9040(+,`<.XP]%0`,]8'%8(0`A
ML`?UDQE`H``T$`9/`0!$0`.@4#$?4J,^('H*UP.YM0TQP*(N>@89H$^[<`*0
M,%+^<`<V%Q6%,!6*<'@S$!6><'B*8`;6``E<,*388(G'$0(60`-I``!`0`0(
M``=:Z@\"H``GP%/^8`83,%*[@`*0\`9/\04%-14\L'U1_[&B`^"F3T`#HG`#
M_F`%G[`'?DH%>226\LD6QWF..X&?Q:"?*&IN7!$!95`$&Z`!4@`5VY``=.!V
M@D`!@9,5!J"`"`"&FA$-_4(Z\5`&AM!O'W(&!P`#*C`&]S4`"X`!46$"*J"J
MK!H#,)`%,\,%C?`&>\,#5U`5<\`Q-$=047$`-!<Q/5`%7M`!]-`%"'`$"!`%
MR5$$([``'-``-@`#.U"N!;,!1_`!,)`-2I`%:.0/0C`%,9`"A^@"PBH53J`Q
M4I&J&_`"K>H/3%`$(D`!'U`'*J`#TNH/V+`(!$`#G\0<;.%DCS%O3C@)!HH3
M.VD,U%BJOM.?4>!#$(`$"'<#8__T=?$@!A30`OX0`A/P!A#@LRY0""ZP!@-;
M!N20JQZ01U8@`@R`A&6Q!%=`!VG@#Y6P`$E06(/*B7Y@61-P`@5``#-:&4:W
M#2H`1PK0")0:%5>G`S,;<!-`K?XP`8$@`BGP"HT@<531K5+Q!5"!",T`%;M@
M!O[PJTGT"E-P!U]P`AP`!VY*'`!`J3ZP`-N@`!1@!6'@0%!Q`%?@4,)4!`%;
M!%F;`I5@#V]0%0LK%9-$5`AG!/[P?0*@`X!E#V"(`GN0`)PHLDL1+#7F&$AG
MGHG0$Q>:H2X;'$.F`X:0!DQ`!P\@N`30!A2@!%%@`COK#R?@!A.04WV0!!J@
M`E?P.6/_B@!)@`!T$`.<``//D`5F>!9+H`Y9<``[D`8SD+4A$*,*X`+DD``M
MD`1!T`<4H`$<P`=0*QG9D`0LP`,P<``G$+A08;G*R[S^,`9RRP`)<`4^P`!5
M*Q57>@(PP%E2L0U3$+%1P09E.`5N\`H=<$5SX`*-,,";D0$SM0UQ,`5(@`V/
M4\`*X%!,M$O^4``=0`X<P`,DX+I2804GP`<)<`(3\!39D+SFU+Q0$0<P%PTA
M`+`)4%A>``.-($R<NA1PX0HTMALWP601"AST:9\E2HLG6KS>V)_98`$P\`E3
MP,`W0`!-0`%WH`!GU`(XS`4<D`9],,<P$#E9$+[(-`4N0%0D__"TD[$$'_`)
MAJ`(5@`'6<L`2*``45`&]+`!LCL"_ML,<]`(ZTL9&(`(-X"\FJ``!Z"W3%"L
M<ARX$OPX3M!R/0``CG``7+S!'7P"71H'/4`5`^"W48`$DS<!```&T0`&+JP9
M9@!T)I`->X`P;""X&>-0"LC#Z'<"5C`"VL`"KZ.W1HS$2FQ6%C`%GT`!#`P5
M**`"]=,'"+.M#4`)0E!87:P4QI(?/C&3$$*=6YD3I$>@Q-`3HDJJ;.P8=)8-
M1!`(:[L+!,`)')`"3[#'[1!T.L`!VM`''&``!Y``X,M0_O!0(+-\^H46COP!
M%$`#T4#)#."_@^4"A.`"`\`]_FL`>_]``\L<%DT06C<@`%?0#$"@""K`!3J0
MM5*!T`H=P7(;%2Q0`D+``9KP`E/!MQRCA5$!`"T<%2.`!(>8'!&05?]R7V4P
M!AO`!YC``5T$``_U5N3@#]@LN-K``XV@`$ZML`P[%420`ADD%5>0`$3U"(V@
M@9*Q:O$!`O\(&C:1*`[)6`/1&A?!$'B`"]^@$,>0#K)@#/W0V)B=V9J]V0>!
ME6O&%:]@`E-`S_Y0QZ_@`S`@#WO\"BD@`D\P!>J`T1K-T5G@"=&0JQ]-`,T@
M#TC%K)+AR&@]!Z^@TOQR`#R@`W?``8L@TQ=8TZ-<%H7P`$&0#2[P!@^@`/$`
M`VE`#QV``7O_T`3^$-JC#16Q'!4"$`C9$`-.#=7^D`DTAP0TEZ?^X`A/$05'
M\!0-L*U0P0D'@`+/31PX`'T,@`TZ8,M"0`2>0$.!\`5'(`\S4`7T,`6/P-8!
MVZP[2`-RC:S^L`$T``,<4$52P0!34`,`\-T^@`*O$%(6"`0>`-AHL6JI<`$R
M[A.F=QTQHMBCP-B<;1#?@`L_@`H*`0[J:`[LL.-&?N1(CA">#1K]^0@6L`?N
M&A4>L*STX`8[<`(4,``1,`:.``DT``1W@`0LT`%E8`38P`$ZP`=3D`])T`9Q
M(`I]\`)(>A:[8`(G0`AB@#*!0`<BT`T#8`AEH`,BX$)TH``&Q`()_Y`%QE09
M&"!=%$#?8.`(!`!120`'0J`!4`X53#`#4\!`V2`"%!8"90`)>90-Y/<`<]X-
MV^0/Y5PX(B!,N]`$B$!<("(/98`$B&`!V4`%+]`'"\`&,3`%$*`#@+.MSX#E
M+B!4_D`%;?`4&Y`'9;!]3$!^UA0S%H`(_U+`<"`&=-!*V_`Y*(`-ISL9J]8;
M1=,3IA<==C<=>[F,GYJ</6&B!0T93?X`:^NE#X`!V<`$.Q!]$;`+TO``$9`-
M0?``<0!]-_`,0;`+T)</T-<.[?``8R<9`/\`A/`(2C#MT)<-."`-O\3B.\`%
M2E#P<<`%#T`Z9!M]OOU\3\$`A%`(5'#O&O__`$R,<!+[`'F-%2'`!%!A!M5^
M"-7%\(0P(ICP`#8/`0_@MSL0!(7#!$(0`@X7?<I^"#SO#SL@!+Y]%0%^[RX?
MX`\`]7\*??^MN[J36&&\$PXB'2"`E?MXLBFK$P,][TS!H1Y:]UFQ:A.B'[Z[
M,\`+%"O;LG)O&W1O]X1/%>.VET@1DV<,[\(+"+*`H8$O^(4_^=*I%"N`&C+^
M&FR!F0`=%'^@QI%/?)0_^EPA:((!%W:Q][0SH14*%,$@`;(PJJ%/XX./*Q5_
M]!M?.@]`!:\0`7%PTR-B!OD.%0S@[U$1`>4W=-$'_)(E!&L:]M`WW1HL#:N#
M_/*=A$GQ>O&X%A#_.J)"\0O(4-F`/_OK4?NWL@LL0`$<T*H[0`-\GO-1$0)N
MH`(`@-I#OT\+0`$I\*4`"Q`4*`CQYP](F2X+-/EK(I##JX(1)4ZD6-'B18P9
M-5;,UN6`"@("3`BDL$!*Q`AS]C3@]&E*"@$;9<Z,&.K?39PY=>[,M<KGJE0[
MA0[-:9/H4:1);_H"9N>64F&`9.D)IM3J5:Q9M6[=.FH43;!AQ6)<4H9"(7_T
M#B1A8%&;"@!6PFP;6S?LH0D;*/C(]N;!B"G="K9`<B-#%@!^'\2QV]@QS4A"
MUM"@T<!/D0<N?$2,1$-!-G\Q7E6BT.#Q6*-;5?U3U4J5*ZXZ4\>F?6O8_R1?
M5O_PXE6!]F_@P84?]7K:N/$E%@R]>;6(#UM_A3R)`&!F0I@V*HP@V,.#!9$Y
MAR`@(@&)2(CC=8'X"V'H\PY_&!I!]%=DKX\K9C@LH$(__7_'``"@@2Q&R&:]
M5T@@J*`[IKBA(-`L6``T`#>:;:M:;(HEN`N'PTH9&1*Q*A@)9"E&&`]35'%%
MXKZJ\$69EHBBD10>660&MN0IPXMK:B!A"AT<@8L(#NKHH(\.+-CE@#*J0`(M
M&&E:@P,((MJ@DHA"&(""%*(QX(0#Z"#`ORC+S"@;!.C@PXN"'DF`0G^8M&``
MB`Y!(@4VS:RHPZQ"F6667*Y:;2@^63S*%UR&>?]*J5^0D<687PR5=%+@BM/S
MTH*6^$`!"BPH``ZV1J!CABQ<H($#`T@8$E5_K$#"FB4'B((.*C#-R`\%)&ID
MB8@$R&(""CJ):((D`+#U6(E<V*N@*(2%4`4?J*#CB8(B@1;9@@J]"H054FF%
M*!!FN2F44`852EM*=;K%#F"(N2JJJ:I*=UYZB;(46Q@U-8".#F[`D8$^2O,G
MFU,->`L`(E.U(`58#Y"55GS]"82",K9IP`T`(H#0$8G>>,&?.>"*Z`4X(ZY0
M60J4*.@,"NXHR(4N(@)@"A_H2:*%B/AP&5MTE1I%E5E&L=<F$%;YEJB>Z_V'
M$5R<P6JWWI26NMY[3?[_3U-_8+#&'U`9P*`#$J(I8`^V5$68@T+H&&.*AA^N
MU6I_JAC@A`$*8B#7;#KP08$R_"&@#$6FB,2?-N`NLX0.&&#@A2K]N<(`?Z3I
MH`$Q%K`YCA0LR":%QI%-&JEP<Q%WJ%&,4F455G8B-Y155G?]==ACEWUVVD/!
M`A=O:G^]'BAD22<`W8,7?GCBBS<^=:NJ-OPQ'"SX!()*%(F!#QI`V68$&BQX
M)8(W/D'`AR\02(`*#40@`0$&$('$!QJ:@+L&RCQC$`-_`-C#A&Q\.,&39X#8
MXQH+1&-Y,&*"!FA`@`?Y8QO,B4\/HL&#*X"B"/XPU37HAZ_/'246*V@%"(:&
M_Q.O@"`4R"O*U)#"%*=@I5&/BI0)79@BY0U0AC.D80UMN*??N`($JM!6Z?ZQ
M0P\B[85$N04S<),5>%%EB$ND30QO^$0H1E&*+\H@45Q!KEK8ZV>L$-I1JB@U
M$(DH*U#S#1/-B!4G3E&-:V1C&W%(FU7T9!4<.J-0')"H15V%1"9"41W]2#H7
MN5&0@R3D$[\HE%:,HA6VH.,?<W(+8+1+*RN$E",M^8\T%E*3F^2DF0ZYDUK,
MPA:!`LXGI\8T!VPEB?+*BB\<\,I+JBB3G:1E+6V)FM\`;1;FHHTIIY8(7*B!
M*V34RA"TH`5:Q!*&@;2E?"@0AD^DX`$TS`8D,I"-AO],84$1"0(!>M"`?+1A
M!CLK2`WH@A$`C.`(IDF00,I`G[P)9`*':`0)$)&/B&7C`/)D#QAF,`'ZY`-'
MVO!'.^"```((!D(UT$@V/>"/2+0!`>2LCR>PP9B"9``;I_$E3G["R%(J,R=,
M848>L;+'$V4%EB(=SBPU.08*-,,?'*#!#%_!!@IDX`L6F(`A>B`1`Z3`!@6!
M0Q7H,06-^<,`4X@)1AI@%M,`0`$/>(!I"J(#&U!5`()(039`(0HRV4H'&]`J
M`$Y`@\$5Y!6B$4,'_,&&.;P"!C$;V!AF<"8+6,$0-45`%6:6U!VH(!^:2$!!
M,("$C3ZFH^.ZR=%^LUBI%?'_B%NA9`N5LE*6!L>EA81I,U[!@4#X`Q-$T``#
M!$``&J0A`6@9@2?F<(TX`,$"V+@@@/*AEPQT8P<A:$3="@*`,,S!6/Y(`0F8
MT`%J^:,'%#C!*R9`A`Q8A`D"8T(6^(#1@@R`!A,08!4H8(,]#!5?"#B`"#@1
MG2G05:W9V,$<QB2&/;SB`%<HB!"F4`9R-,`3QJ4(>_W1B`40EP3^0&Y!"D`!
M#$1A"J_8@05@D%C'=-0G<LQB2#.+$V7@0HRJE(H2DX+9"S>1F;:$Z1YH(`+3
M6$`1D'!$-@)F`QJTP0A)V$`&D)")*_#!!@DX9WHB08YXY+0@\=A11`XQ!1>D
M80;M_Z"#`HZ;*W_`5"0<R`8'K%`13@C,#`_8PQ0($!$&F.`%65!$)!"!!$.<
M%U\0,$$".J"("4PA'W-P7T2"^H(ZT*!N!PBP/WPU`P`<@`1WR$)8(U(&!MR@
MR02&,@LH8(`HJ&`;+7A&%B#<F([&PG6C>VR(<7+'8="&F$@!\1*'0`M4LVBS
MA(3I!UZ0``$"8`Q9.(`1`F:`/21@%U/8P`9>8`0:O``4/5"9<0KQ@"!,X`#[
MA`%H;$#0B$C+`Q]`@LT4T(PIX"S*%(C&)V!`7/KZ8Q=4I5^6K?HR)`RW(`<A
M`!@6D`%#(,#04<(!59FP;CX0@`AO<H0&R$0%0XS`$74K@_\;"O+G=E!@`@UI
M:AVH^B`/$!0`2<C5%-)0D`\\^@E)@``,:&"(*;0EPI-RQ2R,T@K'GLO3.(&D
M)+F"TCX.I=0W`4$M8%-SV,PKU:H><2T[2PD**```1U#`)VI]ZURO]0TN6$,V
M$M"(&_"@QX]IP@E0P(43((`"UP!`)'SPBAI$`@5"^%HEZ(&$`O#A"C;[0D&D
MK(`4$/CB_L#!"4[``G^8.RU7%D`9GG&";;C@&5%6]M8@T0EUZRD"=A]!$V3J
MA`F@(.Z"T(!UHH&"&YPA"TJ8`!]F.O<_9R,)=T!!L>IK=R-$0AROT$$DU.Z/
M)'PA!EW@04PUD87%GV`*63BW72#_FQ2AV7P6K&`%IU6W\IR@DC:5E7DJ=>(*
M5:C"%M"7/KUVOJ)5#U($%&!H&6)?A@.\H`->"%@#YI```'`@#"<0P2L(0`%L
M+.1%`L@I#JXAD`/@@`(D(T$;K*"!&_"#3J""PBH(G"(!`>"`3&"JBK`'"M`!
M?U``%:`"(7B`@-&!)'@!`+"`!N";'6@$/\`7`$B`%&B`2FB`+^B`&&B$(NB#
M)/`#"LB"'MB:9U@`'$@`'BB(;:`!&(B!$Q"#-]B#BK@_"J"#76B&3A"`PCJ`
M#GB%-HB!-Y`_?[`TCA(.$E*Y.?J'+"P*<FD=X_E",`R>'\"%'X"%,`R%<K`$
M68"'<X"=_RW8`MFI!5O`HCD\0^*A!FHHGBM$BNQS(R:PNS=H@#BP.A.P`GI`
M@3.8@!/0!`LX`0Q8`)*(F29H/Q@)@1.(@T.PNQ.8H`R@AY=Y@^&*`::+B&PX
M@2H1@DNLB"_01-,0@1,@!W\P@S>X@3\\@;0R@;LSF5H4.7HX@3&(1<RK.C8`
MLQ.`G(CX`LS#@3N8`/B8"`'0Q`DH"!]<@]#`.W\0@1*0B`E0+TS[C56X`'"T
M(J$!*5L0H3W\A]];(I(RJ:T8M4]S/IH;H7_@-..CE.N3I9Z[)9G0)WGP!Q^P
M1GT,2#>"K%@(H:%XC7]@A59P!5=(.=E`OIV0K-R@#9A[1Z&`OO_4P4CK2R:>
M$\BPF``X.`$P*!F/+$DH@BR3"X4-021R21VO\"*(%(H,V[#88#X'P(>=X*%0
MV"%R":)TN<=E,DFA',I:@JP5F+!&BDF=`+7@2*)EX(4AJ".@])`^)$JKO,H9
M@JRCR;E.4\J(C"1W`8X*D`6RA,HSFLJ6RD>L7$NVE"'(`L=PM#"OW`GE^XU?
MX`6RE`5>0(8*L"P70DOAJ,JV'$S"C!+(`@&#E,NYU`E@$J;?&()BD(4*J`!D
MP,MB6(8_\,MZ`4S-4LO"_$S0A!'(<H58F+ZD7$R=6,??<(!+R(DAH$S+7(9I
M8*6?Y$CL\\S0S$W='#G:R)!0J+"N1,W_B#2BB>2*F;L)89``8R!+0-"#V;1'
MV\R)+N*BG^D*W-Q-[,Q.F=#*QCI-X=2)F8R-X]0)8=`#J7@4"8@Y%9G*65BD
M'QJ%6."EJQ!,[:Q/[82L6@!'X.RE[R0*IMR*\12*8)@&\R1+8Y"`J/20J5R-
ME9Q'KJ!/^XS0W(2L4%A(H@":+C)'(>K/H6BYL,2*`#V*8/B#98C,O:R`!/T-
MM%2%(`*:![U."8U1[(2L55B-<Z2Y?[`%XO-)0N'0HZC+JPA11B%1O.0%S-1,
MK+@^#?5)$+A1GX%1&8U2T(2L5$!*I%&%4:@%4I*-+K1#+_W2XEF'<=`'XGE#
M,`V%>T`#-.`&_Q-9!B@(A^+!0]C1-)5DG==Q4J&`4"G=4Z+L*%90!3IMT)QD
MTE%PA>I\2!\]E$DH*:L04JYXS>64A>9\SJ3@S$J!4C[-U*OL*%MXR80DBF\9
ME%9@!4.53W1,5*20R,N"1Q9)SDAM3O7<"4O]#3W55%N])0D#"BO="1$*A2NR
MT`U%U:-0`PW[,%:5E`$M4/2,U7^851';!%*(5FF=5FJM5FN]5FS-5FW=5F[M
M5F_]5G`-5W$=5W(M5W,]5W3E5C^U4Y7T3F&UHT0AM6--EV2-3%G@RP1=AF4P
M%*_(@5+X5X`-6($=6((M6(,]6(1-6(5=6(9M6(=]6(B-6(F=6(JM6/^+5=AT
M'(Z,C4EB`,NA,"9D<J%?(%$3/<]EH,VT5`536%F6;5F7?5F8C5F9G5F:K5F;
MO5F<S5F=W5F>[5F?_5F@#5JAM=F-===W'8IAP(5YO0E'G9=?*)&\+*.@O%6J
M;<O?^U/A*%JE!"9EL*-Y+3Y;P-)1X-%)^0.RW-?;K%JUQ4K\W)#]C`VM54I?
M6%1VG+G5&*$-03EZJ0`)X%=,75O`W:3#+-0MY<^CO8HB`H;B_(?C'`5&FB,?
MTKGHG-K`K=R`Q$]P3,>XG4MBW3#,*ITN2J0-&=N-]%O+/5U<_0U2S4C%/-Q&
MQ05&8-IY_9EOV:5=FA=?.*:E[4R:"($[H('_:PB#!;BWC0B!/=B#;"""N=,3
M(%``&@@#B$"8ZIFZ*;*.>"@(&*.!N)(('("#;/@$&MB#:!"!!<`N?00`%`!(
M?QB!'O@`B0""._`$*VB$$Q.`.9@+#/J-5%@!'<H%/B&^FP#@8'7=J^C826"7
MIK"#G.`BG("^S9Q<JOS;@@@!.DB`!D@!#2#)BT``#@""!`@#6XF&)%`!E2$R
M0]@F-5*"+!"8'3`Q&J`H`!B`+/`'"%`!&G@%!@A!@52"Y8HN]D`!&N`"H$($
M!(B`7;``"@"#:RPVGGFLL267+LJ)AM31A@16E2-@E9(!+=[BLX3@M`2+B4._
M1GB!=@`"+A`"]#`#_P]X!(A@@@<X+P[F@0R(@@AX8RZH@X)PXWESC"5H`PJ(
M&4IH!.@```;H#QI^`#P.@@=X!"J@QN5Y1H&I`0((`HKX@`.887]($R[8@)(4
M`)SR82)`@LXI"&LX`/H0`"2`@7QXJ(@AR%"PA=8A6YS8I9445$3%XB#=8BXV
M(V>-#<$4O4:H@2G0G#S0ABP@@3K0@!'0AFRH@3*8`$>0!PZ.`!@8@#J@@*=[
M)V>^@W!+CR6HA!18@$GS!+8(@1F8`U$H@2A(`!+@G#N@``Z&@SW&%B<0F.TS
MA&MH*G^(@"*`!$S&@0[H@+;K9"%[!A5`@A.XLH(PZ`50@,&K#PK`&),Y3/\=
MW4D^&84:S<(MQ(G5\<(S_6B0_L(?T&4MEH.0!D,Y)1X\W8E?3@(.\#:\0X$X
M"`0:R(<I:(-#R(8!6``#.(`FX.!8V04*N`)R4`&='EX*:(>K^8!/,`1%L(*N
M80`D4(`H*`-ZV``=H(`1")AFF(-&2#RKJ>=S0P$D<!8``"M_'A8*<`&3I+_H
MRNHV*`$5P&-_T`$DT($%*,"LH8"DRM]>VM4\=85:B+Y:T-!;QF6E\`4[0.#%
MQ@5@2`1VE)I>?E&P$#WT&X#)J0,X2($#`(#MXP`!.``."$D/`&J'$6JJI@-]
MX@"[<^3CT!2@.P`EZ)J`28`38+H6V`,*8`&DN^'_`1)KB7@`D8D`DJ"`+_.'
M%DB")B3HZ!J!H-,!0]"V$4`5!3`])MB^S6CEW_#?=A4*$$@DU@"!'1I@Q&Y4
M>$P$.X#=#Y5L+PY,":Z?)"@L`E`!#S@`!0B$`XB'2)@`%?`#1^@`+L"!.C#M
M`4#M6<F&_[Z!"*#>Q]"4;$""&^X:15"!.;B!!B`'#GB"W>YML#89X!8"OBL#
M,S@!'K"[+)B"6HF!9P`#"J@S@73K^*``,;"92H@!%CBL`G`!)'B%;&B!S4DW
M[::-H"'=UBUO8TW-I+4#IV%OTYV);%`$"H"!,=";;D""`VB$#J`"0>B#1HB&
M&D"")"""-9@#),@'&%B`_R^@@#:P`#HXA"]_`1<WCEW`14(0`Q1@@D"@`Q'H
MA@$PA#+0`1$P!%%HLG=F@03(@APTG+];Z\LSA!-8!":(`0IH''\&`!?0`$*(
M@`Y0@1$02#/H`OCCA%=`@"Q0@`4P@@7@`P`0@QX8`!2@)S8``$V@`!K0YV-Y
M2[@T6B/WSZ6]!668A$E0@\B6E,FV3IK(!D6F*E8N!`RH@R#HAFAX@`LZMGC(
M!JHZA`?P@`;(]@JDGT+@@GFNBUV0A@<@A$=0`C>FJFS``6D0@E<``@_8`2Y0
M`D6.`RYX`":VFF>@J@>(AAVHP"K9@0<8KD,(`@"@@G*OX\7P='Y7,PCH=W]@
M@O][,^,X>(5M'_@*A/@FI@WD6>FKV-S^#%$'8`89&(;=7<_VYEW477E.&DTL
MTO5=]]JD(`9B?>QA5]"4OU26W_E"HE$Y@OF87\J3WPGT3I3U3I%BUXI:Y7FF
MG^C?2"3W+/*@EWFL((8DI\GA2/JL6/JF[_I;_XU0&B6@GWK9W8I;2`1@5X.C
M5]&<I]7W]GJX]QPK''NR;UK_'(:2'_HD;7L1VXAL<(,HCX,)0`)KC(!&6&M_
M8`$8&,:Z"`'1CGO(I]%<EWJRSPF[/PJ:!W;(9OLFUXA=^`0D$`(JP*>(^``8
M2`)JD<*ZX&#(CWN"3,R<G(4*,SD\!?GOO/RD*/IA6/O_J]!Z-/I;3E"!!%@$
M,JD!*U"!%-B&A=B!-P@#-.Z#!$@#/C`!1"`",4"`!J"!-_"'.B"!.0A!UF]]
MK^\H<@G4H4@=7\W2E;9]X<1]I;!Z7+`#K%>*UZ0$OJ?LF<"&W9Z(&@`(#"0H
M$-#D;\R<`DA*T$LB9L&B`P=0J/!T)0D`,0-((`&`@(._D")'DBQI\B3*E"I7
MLFSI\B7,F#)GTJQITV2H?SIW\NSI,]>JH*MR^=PY*M8_5JURJ?(9ZNFJIU*G
M4JUJ]2K6K%JW<NTZ=<L6KV+YX9DTZ4?8KK#`B@W%JBC<4:->]E$Q)]O(&A@B
M'>AP)42"3P8H.&I(H,Z9`P,B_U"`%H5.-B9QPM#)]/$FYLR:-W/N[/FSYYQP
M1^]L-4JGJZ:C9[G2:1J$6Z>D9].N;?LV[MP.'.36/4S&,-ZU=\-E]3;I\=QR
M788HHD!%D;P8_$52<:!;F1F<*-!HV,+?+L6,'4..PT$!'2.70;-O[_X]_/B=
M1??^9^OT/U6SX#8=I:IU*ZH515]]!1IX((+$(4@;,6J8E<@MLRG8DRNMV,+*
M**VTDMQMR[$$0`NOX)`$#*^(I%=(=QS@SQL#0$"!`MZ!)UYCCV5#0R.BI+>>
M?#WZ^".0069&H'(\[5>4AF\E21J1"SKY))3_3!@E7(G8@<LPQ(PV94^SJ-)*
M+`'VYO^A2ME@T\$($61!`0DFFM$('P#X@\,;_KS)QQUK5*+")]ODT\%$%%A3
M!05]##"%!11P<8`AS0CY**212NICD[>UPE,M3E9*):>=2BB<IT41,PPN=B12
M%)=&K:***J'84A^9D\HZ*ZVUVNK2IK7%,HM<M2"U8*ZA"NMIJL/J=$LB9JFA
MY4Y3LA(*"#J-XLJK(!R)6ZRW:KLMM]W*%^QLK.1RP05,:6HLNL,6FZZ4OS'C
MS&[**.,`LSN!8-H_K8``0FO*S>4MP`$+/'!,X-+F"H<(&LPNP[J!VC!/#4XB
M`\44J]%IM@1KO#''W"[,[L<0B[SEPR/KI$;%%F/\;\<MN_S_\J,AHRNSR35+
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MOS[U!KJ2R@J_CY9IOG3#)?[X5)Z?_^[^_FZ""@`#*,`!$K"`!CP@`A.HP`4R
ML($.?"`$(RC!"5*P@A:\X`+Q!R4-YN])_3/6!SM$BE*DHH0F/"$*4ZC"%;*P
MA2Y\(0QC*,,9TK"&-KPA#G.HPQWR$(8<U%H'MQ9"80VQ-M!C'Q*3.),?`LLH
MR8`%%*,HQ2E2L8I6O"(6KY@,^2W/>4CSXN72I\0QDG&)>://*$@1,%)PD5A@
M;%ZHCEC&.=+1'TQ4F%'4"#`V&LL7NWDCNXI(&SG6L9!)O..!T*C'D_QA""[1
M134&80I3G.(4NGBB/W1!!E.,Y!C^X.1(8$&&19*$CT'L8AS%:,A5TA&1!E(D
M2OX@"UG\H?\EG(2%)B=)!ECH48VZT`4G?YD,8/9BDE`D!2EZX0]2FO*4Y`,D
M^E@IS3JZLD"P](<$LJE-/<QREGK09C8K<!)2#,(?.0A)#G@9$E+HHA2D&.8Y
MSTD&7?3B%+V`Q3'4N,E2@+*9SM0?-,>D2I1$(0%E^(!(,C"%*3C*'XDZ0!Q6
MTH`0'``D[,$!`2A0!A-E8P$4.,(V"):-"<P@)-D@0@9&(H`U$:"C%#A`--XP
MA8A.+1L]2*D_/,`'3QA$)-KHP0$:\`0D$&2E?`@ID*K)D^,8CW8[N69)@@&(
M62XC&"[)9S)"\L1>FK.K\5SF,&'A#UCD0)F5%.LZV_A/)PER-D?_Q$`'8L`&
M&B!U%XZ`44CR0('OJ,0+)>41:);0`0H8P!\-*$,2&$`P`"2``B5M``<H@-.0
MB.`5>9C"G)+`@5=PH;!3@ZQD_9$-A]1@"D8("5P;`(=&^,,/%+"`/_@:)*7J
M1!5$^9):GYI'E$AU&2XAA2D\V8MC'*,7NA"K<;WJU7M"4JSX'`0DDRD2?Z[5
M@P'U5TNB0`$=0``)!0C)+K2A@BSX(QYBV*L_0C"!-T!`O2XHA`O6((0IE*$+
M'_&`"T(2!1$PP$2:6<(5Z)`&?U1B`8D%#PH(8"(_G,`#_IC`"0I!`,].Z@PP
M**D_SA#:D``@!/X@P1%"`@8*+&+`:M-P_THQ0($K,"&N(>D#!PRP`22\(ALI
M0((5OA`S8XDN7[F@7T_D<A0ASX*4-M'%(G\9$E,`-Y/)?+(I=)')8G(RF;T8
M+BF*NTY>";G+7OXRF,,LYC&3N<QF%C(6L'!F(0MHD`,UR2$0A0D5*"(D-R``
M`BB`@2)T`;W8J((-.H"!/AC"!PY9Z5^3X`<5D`,"')!''N3T7TK0(`M*T,0,
M$AN-`W@B#5=H0AGV)(0^4,`'9="`?R6%Z)`(8,,B2=0";A"2`U```FMK=4JI
M`*,6*R`D$%`!&R:@`KS8@PX'D/1LAY6:X?VC%OWBB9!C060CSVJ7BR0%E]>L
M[6USN]M>3O.VV__LUC>7!``LF,,U8.#971#`"A79@!/V&@(5B$`''!!!'SIP
MV`6L^C)34``G4I"`)N#EOQ\@@`I<H`,X)-8#AE!`#090APQH-PJD;@`?$H#L
M2*W:'[@FR0Y<H`(OB%@%8DBUU#X^`A@U8PKY]0<`++"'%[S`3=>@`$*%1-M9
MA()[TG(%;&@'U6Y1M[H+:FOMR&V22)2AUW8F0`@Z@01ZQ+L%\YX`%3J`[Q@?
M(`']!DD'"+"&"'B4$YM9P@<$8`@89(/A#!@!'3P!``'$`09-H``+2&V`/=!@
MXY#J^,=W\(!M/$!.,#`[!`Z!`#HX.&T?WPX)&L(`)DR'.E/H`LP7(0__))1(
MY^A27"@T=#=I45M;13?Z@9`>.J63I`Y[T`!2_=$-$OC#!`F0@@DHL`%_8(,$
M:9C"H#G`B3(D``@':`0#_$T`!FB"!Q1XQ&9X8`5_',`'_@"%(800`1@D(0-/
M0,`4KD"!,9":$WR@`<HA%8TL>"(DT:#`'?P1`PIH-PQ60,0K#*"-.2'A!=U(
MV_O%'P#0@!OHP`L8P0+,P2L(02-80#9D0Q/H6!I0P`1X'MX,';><'NH5B.K%
M!>N)1"&<P&F-1!.<``N$0`R8P0FL8!S@P!V<0!RHUPEHP@H:P1>@0#NL8"6<
MP!O$0R2<0$-EA@N>``04``;$P`J>P#9$P!U4_U8\B,`S6``&0-@86,`)5%ZD
M9$,2C@$3)"$5F,$;W$`)EH!H$0`1TL,*CL'4=.$*YEP,Q)?\C8`0H("L^0,5
M\.`-N,`*-D"R7>!N[5%N;6!O=&!1$-(T'6+FT%9N8*!(A(TC)D)+D((E49(E
M85(N==(GD80HE=XR!:(@X@8A`L\'(B(I)N(9_6%)I(P,V`%+D`):;9(I6-LZ
M91(PT>(PF0*5'9-T,9,G?J)MA&*0C6(I#J/:*")N7),C.J(J3D(RJH$[F,0@
M'`,LG,(YF9,Z+5,[O9,N?-4\U=,]Y9,_[%,_]:(OSH8?`:-1"",QKB/4&.-M
M,&)(J"(KKD16F5,];O_5+'[55VFC<Y65/YS5=)%C.9J,(;*C0;J,.]H&//J#
M'31D0S)"*Q:71!;7<?E#<NFC.3%7-3C7,4!7-4A76@UD_D`/`'#!`SQ`!!S"
M`U0>$)SD,_@#$SP`)M1$-CR`$!PD3L['*9+>9M!32"C9)S49DO4"E$D9/4W2
M,ET9EFE9)XKD^)#D&/1?'41!#[`D$5#``-S`%PS`3-)$-O"!1>6D6-Z$.XK;
M_:!BK<AB2#JEY,C1<Q2!.O#`2.B`1XF`/_1430#66.YEP1C+4[#*OIBE;O$D
M(+)E6ZKCB'``.9!$#<1!$B!!-!B$&5P#'Z2!GJB`*$S!!G1`(\``#>C:`OC_
M@Q`(0A98GU[R)6JR!&V!P"I<2BVP"I#)ADX\"^S4IE@XE6$2I#KZPPF,'V-B
M0`90P!X8Q!OT`!/`2$.(0A68P`$L0"&LF"8,VP#,`<)Y1%BF)G:JA"*JPBJP
MPO`PVU/9IGB.)WF6IWEV!6X6XFX^`0R\@#Q(1S98`!TL0#N401@PQ@$T1`6&
MQV+4"&2\PA,DP(Y<9W86:$D8HUS\2BP$76XV:-[(D3Q\0!'0@=.%!(JT`P<<
M`&"$00,0AHSPYWC8R"*4@0@,J(&>Z($."PA<S3]42"L\FX/&Z-$<T2-HPROL
M0@I,@5R&1`S05!<DP$$<00TLQ(<>`"2$*&0<P`NX_P$%-,!'I!^*%BAM8<A.
M&(>,7NF,CF(V7`$BI,GY59:=#$`8R,DN5((_[``)A($BA$`?)(`20@`B0`(8
MT``!^``-L,`&\`$+T``&[$$"!&&4&FA"8FE<1,5.V,)KD@:K+"BA8LMN!BJD
MPL>@-NI/7("2Y`*X$(6A4JH1/6JD?BIH3"JG/E4JY$0K&*J&>,FI6H@KS,(%
ML&8LU$).W$OVC&HZ@BJN6J"M,DPHS,(*;$A4L,(%_$,HU,(H#&M4'"OQ^,ZP
MKD`HP.BN%F2N3BM9[FK#A((JK`!2).NPAL(J*"NW+JNRCD(N$(6U2HNG4JNZ
MFM&YHHLJ9$J8_,./R2LKA*@)N#[KJX;KMK9KW:3KNOXKKO"KL1@/JR2%7#0%
MZ!B/\9P&PLA%4Q$LOTHKP$ZL=@JLQ:Z5Q%*LQJ;HQ79L!V7LQH:L'7DLR2H/
MR(JLQHIJR:ZL!Z*LR[Z$RK*LS-[JR]9LQ<XLSC;,R=JLNAJKM_TLT`:MT`XM
MT1:MT1ZME_'*)B`3TS:MTSXMU$:MU$XMU5:MU5XMUF:MUFXMUW:MUWXMV(:M
'V%YM0```.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>y04571y0457102.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y04571y0457102.gif
M1TE&.#EA4@+2`/?_`%!%G:6]V&J6PJ.<RLS*XI:$O"47AOCX^I.,P6-C87MR
MM(N$O<&^V^.\N+;,XIJ3Q<3!W;ZZV79ML:FDSH1\N<S!VUE1H_'P]FQCK%9+
MH*:/N[FSUK:QU>;D\*ZIT#,EC=NHH_S\_7%FKH^.C:6AS.[M]>GH\M+?[.CF
M\0,#`]71YFM+C\K%X#@LD+:,B-#0T.#@X/KZ^^+A[;"PL+902-'-Y,=W<.'=
M[=S9ZF1<J>3B[]G6Z(I]NN[K]$$TE!T.@DL^FMK8Z2L?BK^_OYZ:R$J!MR`@
M():0Q#PRE)^?G_3S^+JVV+FHS))RB-'1YO3T^;"LTD4[F&-^F_[^_O#N]=[<
M[/;V^H^*P.C*Q]73Y_;JZ=;.X9!%9.SJ\[:NU7]VMFE=J5]4I)UD:?;V^-S<
MZI9=6&)9I]G4Y^3C[]WG\IR8Q\?7Y\[-X["IT8>`N^_O[]?5Y\R(@[RXV(.G
MRZNGSX!YN$,WEV-%@NWL\Z^;Q'!P<(Z&OO+R^*"@H)%VKJB>S-_?W^GO]F=E
M8[2ITK.MTZ*:R/3T]L[(X<K(X/3W^^':Z>W4TFYM:YZ4QM_>Z_CW^M3.Y7V$
MF_;S^+RTQM;(R;JGI>#;[&MKD%=54[.OT\;#R.#?[,*XV:JEL_O[_//R]\.T
MTTDZF-*2C.KI\YN6QM71Y,*^U\?$WM+/Y+BOU')JL-[;ZZ&7R**/C:ZFS]O;
MYX"`@,S'T3TNDD!`0#\_/^'?W(."@<K)R+FXM?#P\)"0D(9IIW]_?U!04#`P
M,->=F)BWUOOU]*^OKV!@8,_/S_W]_8ROT?[]_4]/3_+?W?[]_NGF\&EP=E)A
M<./?[KNUM,"!?L'!P8.#@]/3Y4QODI.(FHY[H\_,X_7U^8J&BH"-K/?W^GI<
MFV)@7GEU?<S+RH)@7&98IK>>OMC$TLO%Q,7(R[.KNJFPMI".C>#@WZBGII>-
MHHJ6LW^7L,:_W,6NOL*KK4<WEGQ!<]O<Z_O\_(=XN/[^_?W^_K9]>'%J>K^5
MG7E95L&ZR<#`P/_______R'Y!`$``/\`+`````!2`M(```C_`/O!&DBPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&!7"P)6QH\>/($.*'$FR9,1L_E+Z@_6OI<N7
M,&/*G$FSILV;.'/JW,FSI\^?0(,*G=FOWQM`2),J7<JTJ=.G4*-*G4JUJM6K
M6+-JW<JUJU>D*E<.'4NVK-FS:-.J55LTK-NW<./*G4NWKMV[>//JW<NWK]^_
M@`/;9;FVL.'#B!,K3MM6L./'D"-+GDRYLF6ZA!=KWLRYL^>RC2^+'DVZM.G3
MI3-_7LVZM6O-H5'+GDV[MNW1JE_KWLV[M\[8M_WNB9>AD8A00#`@X%'/1P8P
M069+4M7BP11/%%1QF.(O%8`/!72`_QG@]@@A*Z?<3ED@X0.4X'%CN!-1*$0;
M57L.^+,4Y@,&'0BHHI]*<&3@R32;N,7``CY$0%MNOD4HX6NY!%4A6_W`!Y@,
M`*ABP@$6A/.)#C(\$@\%5O`Q6Q96'"%+,1.H,DH+%_CS"09"=.'/-1TLHP,*
MR\2PA`I'6+",)\[PX0D>"D#Q`PG.+%.,#I984F-P5X2CWS(`!"&"@_X0\0,#
M_J#``!4W='!###<T<DT&#(2P3!?Z*;")+!ST<(,G752I(VZZP3#,#/WTTL\P
MLPS5BRXRY8),"OW`8(01,+P$"*1KO6"3IKKT@A,LP^C1$Z(Z$0-IISC-H"E-
MLU0(@R^P2/]JQ*JY,,I8AAKZQ:$J,?B3@1D#'A`%!;:Q`,0#_H"A`!Y"G.$/
M'SCJ>`T:"WSP`!*G9("``@#@``4%1Z"QQ"E.#E!'#0N(H$`4)@07@Q!@6+#*
M!K)4H0H"*9'R`P1E,L"``5\@4<@`'V3BPP:D`#"`'!?480*>$1S!0`:D&*`"
M:1!ZEDL*MA8%2Z)"P7!A3+"DT-(L(+^4PA!JS9"R3'JPE$NE-Z4@3#\]?;S3
MRC/?!$/&+L'@Z<DLH?Q2/WW<FJNN'?8:8K##VM;%`D*@@<$770@QC8T8&-##
MCAT<`00;LF1B`0(+A.$/`]5=0,HG3I[M3QAN#`"`)\$Y\@$;=8C_P($/F]R;
MDIADFLF&$%``0`$='YP"1!`>V($!#G(@\C`&&,0P0`8$5(WQ:WVD$,U+L/BB
MBQ&Y]-'','WDXLLPP_22RRPS&,%2+S.(^H_KL"210NTXM\0+I/WXDFC,O22:
MPL=)M_0"J+KTHTOTKL/NJ>JS"+1Z+L.8COHL1O3C.Z+/PZ*'I+,(>GP_HG9_
M^H5#I##,I8*DD(L>[/_C?@I]F.Y2Z1_+1?GTD`O<Q6H8ND@:I!!U*5WX#Q;;
M:PG^_K$Z6,S*>.%+X.SZ5[27_<,72EL:7W;E-&"E1%C$HLTANE`"`(Q"#3)"
M`A[\D0@W&``-_CA%"<1&-D*<+6W^Z,`?_Y``A2-,H0T_,`,24,`!!>SA%-RY
M32`:=P0)..)QJEA"2B;P`P[X@PS3N`;B`%`'QCDN"*N(0`;<L`=LF*`%W)I`
M!Q2``"(4XW.NT<7*2*>\(2205+.`13]28*I_!+)_@P0$T09IR,R4;`C%4YXF
M=+:R&9BL)>%[`?#Z881&)M)D,[#D$'S1!TH.06>,?(%`]-C(?S`O4;,H91]=
MLL>5O4`=M#"D+/\A.IVU1&>F6R4A4\`+02&PDRLSY<=@L#)2G@QGO1"DR0(I
M,E^D#I8=A,DESP(<$=YE`++(`!K0X(-07&QM'PC#GV1C!@"P8@+W.(`(W("`
M>_AC"BBP0`X*P?\"3WRA.D(X`@!$0`([1(`$#P`#*<BD@!]0``@9$($0/@`$
M'<#'#9C;1#$00`$%?"(E:%``$@8`A1!PP`!U:`$&CB`$1`#@"@CHVQ&.<(]3
M"&$/1S```B;Z`7?@L35HX%C0*"F0@6`S?OKK`P%/!Y-`(C60+AG>R1*E5%AH
M"E)#Z&1+?K?5?FABFK"(7_PJ9"J:$55G2/W'#(8A#+"Z<A:Z@*4NB$I+G&$J
MKH:<J_($DC*=P76M;<T%)XW0BV'4]:RS*.M+#/6/%RQJ!JT4VEM;:;1_]*-"
MVS1+-[U9%T(,8`(HT,$`_@"'E$#@#W]8)VIJ,(`V1+$&?U!"6"SQV1C_T(,3
M`^#``-PQ"$*8P!4_V@`$@E"C5`Q@"8,8P!4^\`$#D``^76@#F'X+B;!8X0\#
MN($_(#$`5PS`"RSXPRC<P0`9L*`-,HC.#@:P@5,,(!5VF*@"?MJ:VH52%[DP
M90HPT;W92?,?X;OLQKS!BPL%DI%0E6`*WO!!$"(P4KS$!2]&X!(]^*(?+]"%
M.I+`J`.;['61FD4TG]?'TQ%JP?_H!:Q2`(CDD7AVALSO++<J#%[6&,:M4F9?
M6V5-%9<L":W+7@JD@5^;Z=B0(VZ)ZB@X#`P;4E0)_(>D^F=8XS46A#!(0`@Y
MRV7.4H`'?UA`![HL&4Y(8`!'\"F@=N-DRV(X_QHO@('(1%8450H-95IE64L$
MB^$^!X_/<2[*SU"6`A@80LXPB7-+$`UH"%_6>16JLY-QIDI-";"QN]-442+=
M$DFO"@:"+HI+@N?I3>_9LGO6U`L$&#Q#:`K4JNQSK"NT:M*I%<_1N^RJI/R"
M5Q>ESA2D&3=Q1>9BP\<*-["2L2$SA0Y88LSTG1!-7F#8^PVE5?_0@R&D+6W!
M]J)2?0B>3F"PZV$O^]SH3O?2@,;ME\!Z+((=7;O;;>K7;%;=<[%""084@D^$
M`-\Q.`!W#E""'L@6WWHI!C;"\H@2W+$V[)ZWQ"=.<9[<&^%ON4`&#*"`8O#'
M#E50=RHR\(<[7N$'/__8`\;QX@P)F($[GI@8`AYAFXA7_.8XS_G%B]V!"2#W
MWW"APD8S4`QG``$)(7?7'SCPAT/0A04M(,$Q8B""+USCHPCG!`<F,`B@QZ4#
M(L@`=]J0@:_=QN8Y3[O:I;US,J.@!1000A!V,(BZ>^'@_B!`*!00@V)D`.GP
M*88/5*$*'^@G!"RH>]UED))E^$#J.`C%!^)Q3GR[(0HG=T1*=*#X0=0@)<5P
M0P;N$0,+@`$,>XCB@];.^M;3F]CJ+L'C/P`!NML=[T]`0`MVH(PP`!X^4=A#
MM52$^,XSWA\FL(/48]"#0X1!`AB_0@:XB(K-=_[S_BC&`C)@CPLH#`I"V$;_
MS5U/_O*S&?;I+H'R:1^74^A@%!+HPA1R@`0<:"CXU;I27'H`A`'<HP=+(`F(
M0`31EP%T\`/7,!=3('WWX`DYX`8,@`3T,'Z*H2KF=X$8V&GHAVX[X`,B(`N-
ML'!OL0>RL`"(X`^N$`\M4`_B=QN/$`I@$`ZR$!UR@0#A5`@W$`KA,`"]@G!?
M``0*\`&N,!<;D`$^T`;84`,8(`).1X&(44#BEH%2R'IMMW)6>(58.!=H!QJ"
M%!._%FZ_%H9B.(9D6(9F>(9HF(9JN(9LV(9N^(9P>(:QL`5TJ`EP6&XP4859
MN(=\N');.!9RUH5Y6!1-AB@H<XB(F(B*N(B,V(B.__B(CBA(<3B)E%B)EGB&
MUC")>'@T&]B'GOB)^/:'0\%7AC43+`$+?"B*4Q@4>;!EH/B*L&ALJC@4?;")
M_^-*J;B*A]&*:*&'L?B+P(@:LU@8IYB+NE@8O&ANP;B,S+AZKE&,=K$&B5`7
M@*`+R/`&;S`];Y!5@.`/O#`$WI@$O%`7PS`$X@@7;_`6PWB,.Y&,FM4/ZB`(
M\CB/]%B/]GB/^)B/^KB/_-B/_OB/`!F0`CF0!%F0!GF0""D(C!`6ZZ@6T$@7
M#E`$`C"-<]&-O``(>H"->N`/M)`2X.@/>C`$O$`,X/@&Q!`6@'"2WRB2*F&2
M_C`$PW`4)YD2#<F...&.H/_1#^EP"SS9DS[YDT`9E$(YE$19E$9YE$B9E$JY
ME$S9E$[YE%`9E5)Y"]_`D*_QD">0E5JIE<90!%XI`%L9EH'@D;0`"!W)D6CY
MDOY`#$D@DDF`C;R@"QOI#]6H!X"PDN/H#TG`5K3`DGJ0!"I1DS9I$SA)%K[8
MC(B9F(`AF&>!E6&IE0'@E1+YF%HYEBE!#+R`#"FAF6<)CAF95<+@#V^@!\+P
MD?X@#.6(EQXYCGTYCJ$2F(.9%H4Y%H>IF+9YFX-QE;A8%Q%I#!0I%]VXC<)`
M#,00FC&IEALIDL-`#&\@#-V8$KH@#*2IFB\YCB'YC8#0EC09FV@QFZ/8B;@9
MGN+_61>,:18/21=I8!=L.9-#\)'-.038"([F2`RZ@)F\D)?9.`3"T);FZ)'E
MF(Y)0)*F69[<"1/>*12U.9X*>IL$2A;G.1NZT):A21<L*1<-6J`M<:!!D:`J
MX0D3<`0;<!D;(`)#Z`]N(`*L@'5\H01+<`\AT`@#$`1?@`%M,""B(5HA&A8J
MP`/N@#=P,06'\`?I$18QX`$H8&Q9(`$*4`(IX0E5(`+U8%%R80*%\``/EQ)6
M\`"$,!L7.A0/.AO$\)QT09+I&!==&IM:L`@:L`C!H(Q[00)@H`,W9!EO%PI+
M`@!"\%PAT`/ZP7Q4$`+,]PD7<*56T`,]\%$,4`C_AP`8_W``&?`#3E`:+'4%
M*C$%$!`*D'"E(?`'3Z`2'=`USZ42,4`!,UAL(6`*+"`+R.(/FT`*9_`!7Z`2
M!U`(ZQ0#C?`#`'"E4S``!N`&7*J;J+B'9\J=(."*>:$`9O`N9%(97=`U<+`$
M5R`$$^`/+"`$KA`"&_`!0H`*#/`#%@`$1^H/(?`%!O`#(G`,JE!>!@``C?JH
MD4H:!_!2*H$-`-`(SJ"II(!W-O(!?Q`6AT`!=D"#Q58,(J`&;I$#=:`2VW`$
M[2*JZWJE2J``0N"KLC&L0/&E?HBA95&LO0B>=3$!0"`#0@`FE-$%$U""I#``
M>=H!!F`"&(`(+2`#.?`%.O`!2__0`F!2`U&`"!^`"#)@!HZ0`\*'`8G@KJ6Q
M#?*:?8=@`!L0"J30;`-0"&#0"!L011?P`:'J#]LP`&>T;'P0!E*J$F%0?9O*
M"N%P!#QX0@\+>G20"A/[J\^XFUEHL8/)L6ZJ%P?``='*I,R*"'7@'D0@K03P
M`Q/P!S(P``@P4#+P`5#G1?[@#.X$!!W@`2SP"8]W!.T*J?Y`!0UK&3&0`90J
MKJ9@`'.4`S&`#9:``VZ@`AT016,0=2J!`"(0#A.K#*:Z`1$@?RKA"BQP`5.@
M##=P!A1P");P<)X@!+F:$CN0`>%@`*$@@J=!MSZ!L1@GO>QHM^_H%RR``8Y;
M&29``-7_B@:DD*<F8``1L`D$8`#9H@J+BPAEDQ*?(`$BT`AX0`';4`P(2P$6
M@`?N>@`/8'^78049L`#^<`5[,`I`(`<28$0FX`5>0*(08+6RH`;%,`!?<`:<
M\`"R0`BJQV41@!P2P`!F0`6(X`-`(`%3@*UM@`%_X`4]>`!"``0'L+PXP`F-
M8`!@T(/1FRG"MCNB9HIR^QA#T(WM69W=J)T"6A=)``A%G)L:.Q;8FY-]L01_
MH'^5\0>-P$14P`,\<`0E@`H\<`J?<`2NL`$(<`@\4`@\H$7(AP0&8`#A,*1=
MP`,#<`W7P!P%4`![8,64\0=<O`D;L`'%,`H%0`>]PGR&V@.^_^L/.E``]<`#
M.P`!KL`=.L`*JL59,<`*]5`/%1`$#Q`$S%$/(3H%!9?(W+$-$_#(J8`&5V`%
MC%P`)+O#::%*W^82I0190!RL<]$`(-#+(*`%<S&:W5B:^IF6'WF==4&=;C&A
M5OG$0Q'%ANFQ68@#"@`*@Y"U"YK->$&W%0(+(S,+PS`R)!/$<6$#-'#.-+`(
M<W&?;ZF9_L"9'BF:UYD$H2D,O#"A;W".U.E'][R7^:P+L.G,0@'-M"G-6#@%
MJU`#9V"[VMS03LP8V?,2:T4R1@4J*N'+&`T"OV#.Z"P*&>W+6("6@#`,9]F1
MG:F7)(D,X'B7?I02VYB:[9F7+.D++/_9ERH12"8A$;NPT[O`"SD=$F)@$<TC
M$QSJT$8-BM:;7S#!;M0;%AQ]SNHL%QGYSADYFN\<S\F)#,.0$O=<IFSYC?OL
MFB)IDLCPG-;[$[M`<03]G4?=U@S*%N06B*`&:C31U"K!R[X,S,#)"P&:SV^I
MEVW)G!NYE[JPG'IPSRF!FH<]#$FPE_YICB/=V$N\G;N1UA.WU@AJT'C!`!%P
M`Q^PK)1A`BRE"IL+!M;*QS4@"P!0`F&@><;6`WL@`E$T!6<@"[(0RYX8`ZD`
M!#.D$I^P`.'0A+G"S8\F99;5P^.LR[0A#.G(S')1H6;*&Y8M<9B]H>"Y#)R@
M`IR``RRP`_[_<`"'4`$7L`WN<`B<<``,(`0B$`18>PA6H`2<H`,J`ADRL'%6
MP`8Y8``U0@7N,&8WL`%`(+D(T`-4D-U3T`/970$Z#!\X$`YBEQ)30`93,,"P
M2`4(\`-FYP\Q```><`S>=-8[8=>D00Q_.9-S8<]E"A<@WA/3/6_5#13WM@D_
M\`"J8`>%T`(E<`5U0`$N!`!@$`69$`$_H`!ZLP<^X`&%L`"L\*Z/(5H_D`D<
M@`#ZS0<*!09X``!'T`)`H`(M8`H6``4?L`-5(`3+Q0)+$P*BU\&IX`-L_(J'
M@.$J00A"0`$2$*[##:S&J!LMWFXO_A/W5@(_P`97``!P0+K]1P<&_\`&:V0!
M5S`-/X``)?`!<A`%1P!^'A(9.C`Q`+`!)*#?!/`!/)`!$=`"B!#@.-`"+/``
MMQH!BPL!']"]@2=Z]J02CI`!%L#0H/CFO>T/V[<)4="OZX;GPBK=:FVL*@'H
M@@X`KV``,J!\B(X(BWX%6?#HD3[I1_`(&/`#'H#I[O7DB'X!I]`"U1?N!&#J
M+7`-!FP`<M#J!;,T]X``#QX6',!]L.@$7A.[47#E!AOL<:O<5[CB/+'GW!;%
MY/82EV9QX&D"/W`*"["S!J`#;.0&']!"%+!&\\!Q65`P=H``4.`,&#"MC^$)
M6<`!5"`$.*`&I$L%0'`%!"`#2$`$+2#N4?]G`![P`U!`!D(@!^[1P;>A!'4`
M!%10>@H0"@Q`"'0`BS$@Y'#P"6[0VA\0`6:0(/S>&B*>;@"_$P(O;=@+:A"T
M:#,P5P@?%SK@!:<0`1S``EZ`!N2]!"9@!4L@!UX0`9X``4M`!5[``&??!7*P
M'9!Q`1"P`3%``%VP`>"%#3K``=6W`TO``"C0`1R``Q&`".X@!XH0]UZ@`E<:
M'#O@P"QP`(A0!6B?!3S?AUW@P$OP"#A``%.P"1P0MG?>[WG^&EGO&R;0$L4J
M"9*P.VKU9RTQ-+^AV6X=_)YX]3<AXLNP!?Z`_)]0`9#AW()!_#DQ^[U1`1J@
M!'FP#`6@"(NV*)S_&/;"__W`"/TU4?5YP`1Y\`E^H`BFD9?;3.SSI@@%X`=^
MD/LOH3L^W!-%#?[Z?V[B#Q#_!`X<".L?+'\)MRQ+Z._3%HA;-*SP\\G?PH8/
M,0I+,NR-+V&TWA`3I@<02&3"D`&BY4_8D&$)2_+B=1*0KI<-=>[T9Y#@3Z!!
MA0XE2G!74:1)E2YELD+10!C]8+R``2O7L'XS<BW]UZ\?3[!AQ8XE6S:ACAII
M(1TPVV%',;-QY8Z-T2.&3D\EV#KLL=>?E2D)+WP*[.]"B+F)%<^U4@)NPP,]
M$/_M`;?8!26/0UAI*.GN8M`-?7(ES=4@0H4,$VJ$.+'B1=4.(3)\,\27_[^6
MO(;H&:(+]V_=+6,"2CB$E[_;+?7P>F-V=&GH2H]&IQY=4AYNH/)H`#50JD`8
M4?N](.TU]/GS/0;\..3CBZ>RI'R,05]?YS8*1,`\21A#%:LO3,@"#!(H,*&#
M<"0(+((OZEC""A;"@"`+^RJ,BP]5CJ!@KPY$(&(!3]#`H!`W/*'C"PR.\,0=
M`!;P9Y1#%ECB!@OE>JXZ'`4ZK2SN\OC$#T7&TN.-EG(;`AE_`"$2N"&*].>-
MYHSS)Z:6B$G"M[)NS''+Z;;T,JCK--#@*7'^`:6"+[OZJD8VP^+@AR[H:&&'
MA);Q0HY1-E`"!R^6N(<('[)()0LO4/&G!"]&:?_3+`:BB,$.!A+*X@,JPB!!
M@06*L8"$$C(0H9@Q@.!@`@MZD``(,`98M$UEG.'@"#=$,*&%(P(;((,#6B#@
MB!QB$`(1"Y;8HX4@;O#!#7]0424#,"!8=2PMTR1MQ[&6"7*+A"H8ZTH]A!D&
M$%XXX@V0;[_EI2-`8!JBN&&&(,8?7HC1Q5WGI.727GO')`@$?,U[=M4-?L"!
M@@PZ2`@%``!`X0LV1)A`B!H`9<``.@R0@(\PCKCBD7_#&L`.>J(@)2$Y6KC`
M@CHL.$)3%\'XU!$A(J!#EC%8(00,%3JN+X8)&MG#"V<PD*`'(3*@QQ\W+/#D
M`R)4P8`>`XB(`H(K#&#_@)Y0D+5BCP?`V$9GGJ)5:JLTJ04[+BE!$QO?I;ID
M&U]^[?7W[`K?%(&""YZPQ)(+H&CA%!0ZN((#(08`%`ZKA9!@XC_"<8;NAD@`
M.0H2$HJ@!8R3)D73*_S!0(1CT(B9#A\^@SRT`Q#@@0<6_!%!@D"$,".P!2R(
MX8,))!`!:A*`H%J(4T(``MG3PZ8N%SV&6:H//6`8RNSBPQHBB>866_MMI-S&
MGC103!@J;FGGCAZT@!4U+*TNN@```W]4L`".#PSW`7$&%$?D!RIB@._T+#+8
M)@HG>(`$.FA!"7*P`02X(09F6((_%("!$$P!#)F8@"KN,;[03`$/KI#`!#!@
M_X(HR&$#&^"`_WP@`RCD(%>;P,`&KA`%$]`C`\3#8$]PI`NED*<?.!0*]&I8
MH>MM;RC:$Z)2MD`4\*5)?#^,"R$L\`-5^"4AQ2#%!/S!@!8L``!F<,,'X."#
M'!@``'S`0`:@8#K(9:(>)#A&'42P#4+4PQ4'N$`]>$"(`UPC#&'P@C],4(\]
MR(")Z'E`/2)UA3WP80#U.(4_ME'(UF7!CJB(02HR$(X:_#"(0"$/0?JQ%!CT
MHI.>]`I6AC$+5*92E:MD92M=^4I8QA*6L/!*+6UY2USF4I>[Y"4WAL!+8`93
MF,.\I0N(B<M1`F6)@R3+$WKPS,+H)`9W\005E/`$*O\\H02>^`05O#F%R'",
MF>,D9SEWLLF?P&*5REO*"]A)RGY@Y9CSI&<][7E/>PZ!&_CDIRW7L8))!),8
MK]#'"<I1SV3^9)GF9&A#'?K0T*"3(.I492](TX?G%5&C&X4.$3GZCRWXH3M+
M2>*7%@I1E*94I0^5*%1^XKRD5*4?9`M*2S]ZT^UY=*/7D01I2NJEDZY4J$,E
MZNEL^@_QV/)+1\5I4Z6E4Z<FY:=;"FI1K7I5K-;GJ+Q(05>[:E$O,36J8XU.
M,A;!C44$8Z<:P-%4<U35K,95KG,%RU%U2#8>;DFL9.4K::#*-DEXKSINQ1%<
MZ7I8Q%I5K'T8!BST`%:]]E7_LFS[ZV3WU:\U)5:SFU4L:?`ZBV'0-$=[M6QI
M@5+9'(4I382MCF$Y^UK8#O*H,_"%'A(:6=/FECJHK0X3@"0MUE+'M;$E;G'I
M)M89#*.V,,6M;IW+%=Y&!R)PPZQQK7O=Z(DU%Y^<05Y'^USP2B>\/PEN=(:+
M7?2F5VW0T84>!"):')%VO'V-KA'S(,3R0N>\ZN5O?Z$%G1GT`A:.7>I\#7S:
M-`EV>_DM33^B\0)<1%C"$Z9PA2U\80QG6,,;YG"'/?QA$(=8Q",F<8E-?.((
MZT2LNDCE.[][8!C_H[Y#Z2E'&5R>?B0!$SOF<8]]_&,@!UG(0R9RD8U\9"0G
M6<E+_V9RDYW\9"A'&1/=4#%T:)J+VT9'OC%NZHR!$E(TV;BZ_B5SF6T$'5@,
MP[W#Z,4,FLME\*;A!-PXP39*8X("Y*'&8I9;9LW\9T!7N32Z<.P+9N&5H(2'
M(-O]9`_A;&`O#Z0">_[HC;FRWT!GNKB+S0HL?)$53B:WT?_H`RS<[.A'CS?2
M9+7T4C"M:5AS5JQH2,$L`JP'[[ZW*WD%+7PGFFI5+R4/(QUKJY7RZH1,X1JN
M,)C.2M"&(/AC"C+`05A0\(<+K/03!.A"1A#1$$\<H@V'",&S-Q"#*>B@VE<-
MPA]8@!@5N+LP4ZC"'ZXQ!4]`0`YX^`L!HHG!+1=%%Z)-+O]0!JS.@R=<X0MG
M>,,=_G"(1USB$Z=XQ>]0<8QGG.)BT/B`,2H49/N#`!CP`!#X\R]/'$$5`*"'
M"A"`AK#`+-HIC8$$9'&-9#_`#`UA@`5.$0\GP,H"#'@"$6!NU0,\(`<M4,,C
MS=`"$R2D!*3`P`>J0``+`$`!GHB`'/X]OH`/A2H&SRBPP?O7P);6V$D)>1W"
M<``#..M?5A`!`H2`!S?(82>/0,`"CK"##ZAN%%9HPQ$&\`0$U",_5(!#/11P
MA5$@HAX/*$'Q+B`$G/NC%!;(0.0^0(@H($($))#``]J0":PJ81LF,``&+G``
M'!A@%0EYPC8>80!$>"`#80@%*J[_L#]-LNT%>LA*5:(2E;*;W;E0S<-O+;MV
MI(1\`D"0@1`B]:]B3"`#&!C`!@8``+TGY`$8P,$"4/&!R\D!"@8H!1*"X(89
M"L$=0%"#&U11!2&\@FL7A-SE<;X-$KB"SDL(*Y"`'P@'G@D'`&"`/?B^#<`J
M8+&(*U(:G0B"#/`$"P0"(C@"#@@#"5"&X"N-7*"%6F.NGW@!KW`>Y_F.Y%.^
MC^J#CQ,(78A!HP@*4"B`(S(MZ"N*D/,'"-@#`\@VL)&!!1B`%@"4A+`'"U"%
M;.N`#T`$6<B$1W"%+_@`5'"#,`!"!I``!0`#-;B?/?B#0W@,NAD#S$.:<(@'
M]$L($L"`_VGX`0Y(-@7(`@`@`CNX*D-H!"6P@F+XA$)0`@ETI'JP`L[PAV*@
M@TQP`P3X`#JIH16CI>XJ,!?\J)F:08'X)-M",*!X"MW:0:((.26(``EH(+!Y
M`@5X@@@`@)2)G!:8`!S(`NMK@39``#C\``)(&1XP@`C0#PEP!Q1H`0R0`3+X
MNHXIADT0`@ZP@BJ``%4(A4TP`Q%X@#!PPM8I!BB0@PLP@U4L*D^H@U#8HB>0
M@"@```ZX@BO`NV_D@'N8`B+8@VT@`@5H`10(05#:H1GPBE-[LTG<J'Z(0>0A
M"$X\"DF@M.?RQ*$(N?%;-[`A``_PAP.``CO(F81X!`OP@3W@!/]@;`$$N!PM
M.H)P\`$+^`"=^X$?\(%5R(0/,`-!@APJ"$D@<(6$8`4,\(0H"(-14(`,*`3X
M6`8)>()B6`([.`2K(@-9^(`/``,X*,H/P($ZH``64,K6"4<ZZ8`,X`%B-*II
M\:JNX@5)W$>.\BYWBL$**`!)V`5%X`8_4+""'#/K"H$O8(5"P`")C+5,.RH3
M%(@L0S.OY"BM@"_O4H0"6($".+`DR@7&.C7#'(9\/#8_*ZXI<(=ZJ`<6($.Z
M!#2Q2K,U:S-]W,NWZ0,!@\$^F($^F"F"D(0"N(,<G*\D@JE9``^!:,U+:\S*
MG$WB>D3;.K11JXZPX\PMV0*GV`7N,+#_GX(!&B1.'*--Y-PTZ!C-&?`T4'LQ
MWG2JZ_"#+I`Q,^'$YZ(![:0!&R"(Q?R'[V0[V00-/$"#4=B#*DA.]1RG6:NU
M6\LU+8O.J-(`!5LUI]I.[EP$_1RX\'`S_O2U3QQ/Q7B",*"\#PB_]4Q0@".-
MN[Q+W91/^AJO8&@`_.S.?W@!C\N%&<!06*!!\0R+0_B`+V`6"0"#&!@Y,#B"
M"P"`<+"#+'B`'P"`4_B`9;F&4Z@[0U%0'=69HZ*H5((LZ(30J++/C4H&$!`%
M$$B&"@T?`2V!'V"#*P"`:3``JE0#.A`".)@AE<F"'T"`$CC0*'@`!`"`#>BV
M'3W35>E15#("_U0"TO@24HUB@C#31,N:T%_XA090J\OJL[!P4B@%@!V@TB@8
M@(HA`"V]@C?T4C`]@@Z)&31]5#:Q2QUQS;""T[$B4GQ)A@:XTT7X'K;<"33X
M@0B@@*DQ`$=P@P6@`"08!0#X`@"@@"JPF$DAG3V0`Q4(@S:`5%VUCZ-J-)_(
MS3>U5*?"U"_!`E'`4RU`"H,$.0%=A0%8@D'X@P@8@!O`AE1P!1UX`E=PA0$8
MA!C8`%?H@@'P`FGM`%?X`Q#<575=+Z[@*JV$S:1@GKP\"&&UERVXK^QQ*BW8
MU%_``JY8UJ#HP74=V&<Y*D)+./=*"O+(!3?]M7KU$DG0`'S-UX_"@O\[;8!D
M+0V`528!)5B/+9ZC@B\`'8I<T)):DJ=^2EF575E>B@9^6($D&"9]8ME=B@9*
M:`!\*(-6>(8AZ-EZ,B9[FE>!_5BBU2J^]+63I5FE7=J4U81HB`9B\B6F]8I6
M*`,Q:``L4%EH@%J$.LB.+5JP+5@<&=F@F`$8R(61W<V']2M\L5,\U=,OV5B%
MB@8]2`"[O5N\S5N]W5N^[5N__5O`#5S!'5S"+5S#/5S$35S%75S&Q5M!*#7H
M""54<C&B<"=8@,^"6%OHB%B";)LT,5(D38:WD5M2"EO3/9O+U(.#ZTK-78JT
MBPYB_8=@L%ADQ:]//5W<;1.QR@I\9-W6%2+_(M543N4S)LU=X]5=Z'#76O/=
MWPV*+<#.ZH@TV@6!C*VTVSU>[(VHR'6I2FU>H8C8B16*/LBKYDPS.BV*?;U3
M?XTJTO6.KQVG&+@!2^@!'=B;O>D!^=T;9Q"G53D`2[B!NXC?0*S?&W@"9["$
MN\"&4;`$*8*<$G"&*=`;\_&'`[X!3S`!2[`($]"!9JNA"T"CN)B"+@!AL)B"
MKT$/N[K'A&->[P4IY_O$T=B*%PC/REJ$.TW2OFK?2WQ?9K("-_@!JEF"%@B#
M*W"#/:"`'Z``-\BD59&$!9"%'R`!3T"`-E"`HZL!`U``/&``4MB&>X"")?@!
M)X@>4L@`.=B&35$`_P)("%(0@B,X@!U``!2X!P60@#NL(;>$`L6P`@#X-K(H
M`2(P6JYH3A:;7!;VWCGEP1N)%H]*WWZ%VQR^WH::@!_XX"?P`0D(`6S@F2C6
MGV>)`4`,`P3(@A:@@APX@H80@@?PAQB@D!)P`Q/X@24X`KWS@`58@`CHF/'C
M`W]@`22(`5((@PN*@`\@13;P!Q2`@@>P`QDX`BA0`A*XY4V@&P^P`R!("`\8
M@".(`+:`@#>>Y5-8@"Q0`PA``06@$P)8@.N[@`5`@`=@`/4!`!68Y954#.T:
M"+(M#;5=VWY89(+0`A```3$`@080"-#%X=S28351*4HV!'^X9`EH"$JNG/^.
M>8(O$((=J)\+R`$%2.55;N7VJ8-1^(%3<(,N<`<D,,()7I08:(%0D(53D)P8
M4`,[@`MB-F9_.(4:6.9N/`,W`(,'\(%"!)L%4``#B#H$,`!2^`%4`!8O(((@
M:#T>$`(!A,4(X`,S0(`6N(MB0((?@`(`P`$,J(-/L`,$R`%VY:M]3K5$/C:#
M>`'RF&&"6(0*/=8\!2^%'EJZ:>B']H&.3HB)UID+.`(D,`,/^(`GR(&(3@A5
M9F4*V0`&B&4*D(/4`0!?=H1_>86X<P,`^#YZ4`,?@(^;3@@V4`8HP(,'0((K
M&(!["(<OD(,/4(*S00,Y0)R&/`(@"&,&<`,@X`'_('B%#X``-4`""``"-A`"
M.1A1-(B`PD""NT.""G*#`T`"\$OKTCC;LFGA?Z@`Z%4*&,2RNYKK)55-97HI
M8(T^'F8FOC8$3);H*.Z8&.`/'0B6#]AH!&B(P/,'0PB"&""!8D`!`ZC)$)`!
M()``"NB8ZHL`$O`!"/AE-;"`P("`%M!C?V`#$[B"*7B`HJ$40O!`"M>9>S@"
M+K2#TL'M@$GN,/`'3]B$X!YN1#!NY,ZZJ&L(YRZ!E%8%-Y@"1U``(3CAQ!`K
M&$@!:9#K[M5N>P&!\1ZODC*TB3IO]$ZI`[B"'W"$*=B$%@@'_MB:']@#_EV4
MPSX%#HB`&%B`#5"`:4X(_P4`@!I0`VR@@\IQ@A^8`#NX@B7P`0`(`X5<E3V0
M@#HX@A@`@$SX`KFS@C*J@0FH`@:H'#>0A7F(`@GX`CL/!R'\ERD@`%4H@2D@
M@1^@`S?P@?6@@U-``BC@`$00`BAP@Q8@`22(`(K!@RBH@TS8"R0P`!+(@$W8
M`S.``S=8@E^V'@#KBER`UR!]V,[]D@80A08(Z($NZ/$*!'9(A)^`UWYHLWEE
M5BA7@1I`@2DP@;20;2N`A!I0@2YO$RO`]E4(C`.`A![0"3BN`5Z6`2KPHQJP
MA#/(`@Z0@`50A2_0F3.8.2JH@<=I""5("X.A`FSPAU6`!`&I@:)>@!R0.TJO
M@O\:H((IP'8XP($:"`*`3S=(V`:T6(4=@(0=J`$TJ(%-V/8:Z&#G/H1Y5`)(
MP`8\P`$=L&Y7\P5?2`',C4_-S8/P-791Z-2!B%V.2H,B*`(!@/:!@%=:^@=A
M_]"P+88:.`(OH(,\G^0'\`(2F'2BL@(SL`!+J)&]DJGL?EC`[.XM.7:@KT'G
MDK,3.`$'*/JB%P""@-<9<+.&Y<'TSEZ]%XO%"LU_T(5/$PK18K06A%,3Z/FS
M_WFA$'K2:/NV=X``B'Q@B/P``(;)CWP'</PT>/NB7P/O\(7P4!X]J/OCW'O3
M_W$TFP70Q\V@(#2"*+7PS%PCCPZT'XHTJ`.DKP['=WO_RK_\RJ?\`%@#QP^$
MTGC[-.#3K/H$3G`'<4(!,V6B`U"!*4@W3N"$"KC*0>J"&4\(2("$HG(&,ZT!
MH43>TG`S#65]97J.7BO\V4^*VK?]N,_]@=A]R)?\W@=^X6][XE\P208(?P('
M$BQH\"#"A`H3CFJ$00BI&!0^<%AH\>+%#;(L^+,BXL</#,HPDBR9T!.)#Q,$
ME@CS8(?)F#(79@%"T9^:*PB(S%0(ZQ_0H$*'"HV6(H6W%+!^$NW'-.B,8427
MPII%]2K6K%JW<NWJ]6M77KN\@2T+"QPT<%UM12KBMHB``,"DT)72[&XS9F;W
M\L4JIB_5/D2#]NO7\_#%3S56_T$JH;"$C"H`W,3X\Z,BXH3%@@11\60A"P`6
MIIC`(.((B\PE']604>.`0D^<#)#P%X-4C@NJ56^N$03'0AQ[#'"88F$"!P!3
M=@]\.O@YT!>&_L&`D6NPTZG0G4/O[OT[^/#BQT,/UD#4HN^)'`AXFX8\_/C=
M0<CW7I@Y?G^K/LC*H2"&0*P4,&`!HPAT@0*RG.+/`09LD!]!Q>0`!`97#!0!
M@0]8(5`(%%APCP<_&``$)!`J1(4/&-PDT!\$-M*!0)Y\0,(4F1B@``9GF!A3
M,0L8(($/70C$`H$%,#`0'@X>T(('2PBA&W[<A:?)42G,`MT,/\$`"PS]=+E=
M?6&*.?]F?<&`$$=ZW@5B##"!_.-`$>^1.2=X]-%)F&$[(H8"$A8L$`8?`19I
MH#\A>`%$!G@TB-F.JF!P1`X#,4#@$1OZ4TP=HSW2@RL61!&"G@9A`P`)H1PQ
M4(L#OBA0##/2HX`!)H"!0:@E$6$`%#X@,F211PJ$AQ`<+)F)'`;@D9^4X.DR
M0S31S`!=8=?!\(^7W25[)[;DY0'*G&:B^=T)Q@20B%"[>'==MF+:B>U]M<[4
M09]_!HI0%\!E@<$%(:S8Z*-F+%3,%1_JH((_CX!!C[L#60'``%&<JE`QLI!0
MC!H&5*&`"`E?-`"N/BRHT!@4W9/!!$M$<0^R\<V@!U5T7IO_+LS/*>+'%F1Z
MFR9TZQGCP&#F`M6'+D)5]6S,\JU[9[L:E[1**!DH$`:,"$40R@0DJ!!#*BWP
M8,*.(:@23J:P)50#&$"HL`$0C;0!G-)X3`;$'I\AY(D[/BAP`Q][[/$%`4HK
M1,\>+5P1B@<*5<&*UD]`L,`5NZ8,GRZS2"[5G"\7?3D3&D@RIIF_)*,F,,"<
M`)W/U#X%0R_]7&YTNDG[?9$5EECBC#./)'3`#9:,,D4(SEAR`S8[3J'##;X?
MHU`/LN,1@^\=+*=T#+-;L@R`"!5C@NRZ>7)##Z\G-+STA")T@>PW>.(/"E$_
M3AZZ_[S@\NKQ9]NY%MZ=`$P`;G97_WIVA,VBNOS$<S0ZN<Y[!CP@`A.H0'=9
M#CHPJ!(RX!?`"98)!+^H7W<<,`<'D.L[_.-.+AI(0:`,<$X%7"`*4ZC"%:Y0
MA(-11S1@,0.BD<F%(X2/(IC`.0MB\#F)D,OHQ/-!][U@6E^ZX7Q:ER<6,K&)
M3GPBA&PXE'X,`Q9ZZ(4$D4@G$VRN@A?L3AJ`80S]C:=T?>A#+EZ@QCZ\3XO0
M*2&93@C%.=*QCG;TAQ2'HHM<#$,PE7,C((%"O^ZL86<=A$_I`BE`)=ZQD8Y\
M)`KS*)07%(:&8Y*D(H/"K3`-TH<.,,8:Q)3(3'X'CF.2(R13J<I5[@:3_TA"
ME:[T1U**9_\9!:B9?#HYF#4!0TZBI&5X3"DF5+*RF,8\9D)<B<;H9!&8W6%"
M'KH('UT2Y7[CHM,HG3D888:)F,C\)CA7*<D^2,X7DVNF-HDB"5S"1PN_^.)@
MUK/!;&4SG4+A9GV\&<Y]\I..X\P*.NTI)BV(0A0]'$H@@)@M16R!&UN0ID"#
M@D_YZ+.?%KUH"B7Y`EBTT9*7C"A03*`(^1#4H,^Q)AFQ!8H\-"$/)@#I/1F)
MT9G25(62[(<?J>/1[KP@:&`"*1,@&IZ2'E0H&N3@ZB;J3*7"IZ(U?2I43733
MH>11EL]Q)4C="8)@Q%.A\F,J+<$ZGL+HPA9F/2M:TZK6M;*UK6[_?2M<XRK7
MN=*UKG:]*U[SJM>]\A6MZ,`C>6;0OESH83Q6%4IAJ)C8Q3*VL8Y]+&0CR]A8
M2/:QE(B#&'#AV#7,@1KGJ"QH0UL8%XBVM*8]+6E/6Y@V8J<?21@!;&,KV]G2
MMK:VO2UN<ZO;W?*VM[[]+7"#*]SA$K>XQI6M+F)('ACX@F5Z,,).NW-8/"E6
MM=85;2?N,`G35J(,(""'8]LA!0>4X[K7C08TS*M>ZZ+WNJQMRA"B*M_YA@J3
M?:@2+\@S7:HZDPD%$*IWM,K5H>@LE%H4:R81'!ZGTK?!#K8(5OO1O@4/8UI7
M!68%*C`>`1.%E[X\,$R'HF#P,/C!)CZQ_T"PFBX5!Y+#0['F(0$Y8AG+%,4V
MOG%!6(PM'<\)P`'^Q5:)<E1@SMB-1>Y.B0W"@@A4ST2*\T(0EE,#+YR""MZ#
M@Y5#P((-'"M"CDN("60P$"U[P0L14)]J0J""YZGY>0.)01"^%P0O[,#-`EG%
M$LZGM`BDYLU+\(*P%!("-M@9?5Y0@FIX'-`1*J(`XG%Q4!(J.FT>&8F5?DZ2
M!S(%0JA"`7L`E9/=80`P8,,3&3#`!*RLM`,H(`JH*(8'%-`"!1Q/(,7@0`8(
MXHYM$.0/0*@-2Z)@@!^$PQ',684(,E`,_22[U@*9PA460)`@.&,@J^!!&&2!
MBH%D00$*&(2>W?\U!0100`03>%X-A&"`#,C-'RR8ET`L(8$H.!O6"D#`)Q)-
M2D7+#])`N5^;['GI$0Z\*4LL20@RL`<""*'+.U(1(N9Q!0,XP1\Z<`4+0K")
M-@Q@!WCX`R$*(3[5;$$(J-B&D(X0A3'$:`D```!!P.!P?RS#!\#V!QJ6X(\V
MK`0_"+##LOWQ<V?[`Q4?D/9`"I&)@0A)1L!^A`\0L(,FN^L`P2(!$D`UA48@
MH`94EP#;!H*XH-/C%"UPAZHSP^\:PG01H@BR40T9T8)/D.Z(/3A)BF$:`AA`
MS'KB`!(H``4;.:$$=LB"!2!@!B=EH`L9<(,=!H"?DM=@(&ZPD$`0L83_`<!\
M"AVH00;<48.HU?SF`PD'UWP.=($,?2`H&("?_#&%+$""`@B`A*7\<0$[+$,@
MIW!0#B10:#UYP@='\,`'8&,%5<CB!POPQ!2648-P<``2X2Y$"T"]#`-T&@`H
M4_N^;V@"/_B8*(N(`]R!\D-C!!&D=O]JC4UR"CM@H`7M-A$!<@``-42`XD$P
M0#U\`!1P`"$80"B@0`8\@,/@1[IMFS]X0AU408Q`P3V0`,R%``,L@`]0P`+X
M2ND51`Q@0-`QQ\\%7>OYPSTL04M(6P@\P)_DP`*DGC^<@@>,A#]`@1TH04J$
MF[M,`!"8@7(,!!6(@!"4@#*<P@*$PKT%3X"T_T#0X<`/#``#&`"4(,;:?10%
M^5?Y"<7YI=\_!((8I93[A5A,94NF:9HSJ,(5V.".7,,$X$K_.4$5"`$#+$,'
MN,$>"$$H+$,"+B!SX,`';!L?D,(`R`$9($(0J$(8^(`00,!`R!Q!X,&O=00;
M!,\&$`*$$,'J^8,F'D,Q$$`5[$$8"($L5)Y`*-V8<8`"1``BC$(-($+#08$L
M((S&%,,.A`$'%,,U=,$96($5A(%C"`38%00=9-\%$(`)"`X!?(`AZ%LF72%X
M^(&&>8?;-<"``44A(149DM`V<J,9XAU&A``A?`$KY!Z$\,$&+$`-Y,`FP`H1
MH,#3T($3`$""?,`I1/^!"+3`%U#=8?`!#QC`%92`*H"$+'2`$.B</UB@[*G`
M(-2#*PP"P?C#!'P`&,A!*;0`*MR#*J!`?F1!#@A!(5R`1PH!(92`$"!=&$B;
M,FS`("#``PR";D#`L/W`$9"`+/"!&;B!`O"$QAS``'S!2N!!"Y``!N0`"1!`
M,4S!&0P"#_Q!*HC-#F"``3```P@!%9R"!7R!`K12^-%2-0J%SO!,-TK4-FJ!
MVRW"-9H0..(86SX8-(;)6];'5T9:Z'S86/[#^\5/`,1?6_9E@\6E?`"F4&08
M-8I"`PA%N%S378K86.[E-_HE9/YE5Q;-2T''7`+%D"WF-C4F7T:F9\Z48,+_
M1V@6YF$"A:2UGV8215ZNCF.RRUK*A!5@PPVD`J^%B@D82!!L@#/(09EM@@&9
M0)3YPPUX`1R,&2J4&0.8(P)M`P$LAPEX@0QZPI]Y07+.$2*(#1P<&D$<P@:(
MS8X(9G4(12X4QD]ABR1LTG-<)L")86HR9C>V)M*\IDF80.+MP`]PI)X<``G`
MB`D`@1QDP0_DP/"YRQ?\P!4<0PS4@P48`'Z.@K!Q'P\:T!BTP0^,1A>(`!KX
M`!0(A#.HVP^X082N$`I\@`%TCPID`!E(`*\5`RE\@0]D`!M&$<R\P!FQ5A_(
M4'G2207\5WH:9E!\DC:VYQMQYF,:Q!0<PBD<@CMT_P`G6%D7<((ET)P['`(+
M0*`!/``;_``#J(`G+`,GH(!WSL0GN`,G<((5L($;W,,9H,U_!NB`ULHV`,`5
M%`,:7``4FN(F/(`_U``KH%"'?$ARQ$`4``'*9`%,/$`6S)%,[LX`Y,`!1`$;
M^,,V3$,(#,`'\&.4P`SE4,X_S,(P3!A_T8DD%,`TFI^/_L/ZH::0#NE[=J8_
MV,,1",$1_`@&2,`%F,$`.(T*?,!$X(`;T$8-_,`#Q`,JF,$?O.-A>((JU$$.
M6,`!(,`"R,`'9((/M*F`>L\8R&FMU8`/(!J#;`@8A%T"A4"F3,$1``$]"!ML
M'$`(=($;O*D*G<(/]``]?/^!*K3*T@W$`WP!O()?NLC2847%5"R%50#&5N2#
M-_!"5NQ#6BP%,[2#`#""P4XLQ5)L*[1"$^B#-%0LQ_*%%"@L8.24P2'$1$+`
M28HB`2#!&5B`$,"!+)1L(Q@`!,#!#YR"+##`%WR`&WCK3!R`!1Q!':BH&DQ#
M)GP`"@!!!$R#F^I>O^;'`<CILA4#"6R`G6T#!F"J`86`&WS($0"`)ZCK0&P`
M`M#1[^%!O4K`DC!*!UR!#$J5I@(%IP+%RXQF`]A`:69CC*WJ=\!GB/&M6B($
M'7Q`5>[!%82!"OA`*63`!P3!RWX`!+#"5-JGS3(`&0R"$'Q,3[B"!'R!"4!`
M)J3_H!`<K;5.00Q,C-+0@P4<J#\L`040`B%D`0/$Y(.@$,!\"`-D@*":`1I`
MP'(L`.8^D1.4Z!30@:,"P#3(0;XAP!&XPLBM#[:\P`P5$9=X"0`-!H^5ZE#4
M[6&&I=["A]^"U/>>TEH60P!>@1!@0#@``39<@02$@1RPP`<H@!"P@COP*@<8
MP`)\P!_L00&$0=ORB!D8@`%>P3SH'A`H0`:XPC\"00&(@/`I#2O(`@`4`AK(
M@@`?@@2TP"G<@P2D70)102H`P-EYPKY20`>00!3DRQ&$*`OI@`@80"-@PP5@
M@`)XP8@R@/P:@"S8SG?&3'A2![58V(6%B0F@9U!H[Q?6_V7WQD?X"E03=Y-\
MII`G4,``>`$`X.=G9K%,C.9X0.-Y8,$_)"9[+G%X/'$ZF3%%13$*34$$L,(`
M($+3:K$<&P07BX<K20*`G4=Z`"D9APD:.],?-Y4:SS$A0U(=AP<F50#Y"84>
M)Q3[];&8!#(M2?)8#7(A7[(='3)XY-&HZM`1HT<8!1PD1S*1NB83(4(]_,%R
M'$`CU,/O"H0[[,$JL$!S8O(<:_)WY)$&5.8_Z#&0YNTHPT<:G$``O`(P.[&K
M*E`51($L<.2N^H"X9EZU4L`>A*DM>R8N>X<K?7$`@%(P?_/>)K,"'<$'D`*(
M`$`&3,$G#,(&Z$`QI`(*<P`"3/_``1S"!&R`)\`S(4P`UEZS6TXF=$#4>5!"
MZ(PQ.!]T4%"R>)QAPD!`#C0>$8B`][G!`N!(%7S`$OC`$F2`!)!!&#3"!^"!
M`@#!%%:;/]]8-EN+=S#!)IV'.8C+,2.T3/^#0B^8)7L/&[QA'4"`*F0`/;1`
MIV%`2ASM$EB`!.!!(U#`#^A`'4"-`9CB2:-82N<H=#1`''3"SLRT5@]&39/8
M3;\.&^@`$AC`&/0T/0"!A2B!'`A!?\J!4:-"/`S`#Z!!4W?`4T>UC4WU$#^'
M>4"#-O325@?V4'3U=S!TK;@#&$``$>P!!(2"#T0`#L2#!`A+&&``!KA#!KAO
M*'Q!**3_@@@``3F[`EY+-4`#Q19H@)F(023DCV"W=D*+\VC'M@+IM?4*A23D
M@3B`0!-H@UBZMF\3MGU\M6P/=\+0MG:$E!_H@S?,@:KZ=F`'P@F\P@F,@2D3
MMW7/=@#-D!`'A88E0C;\@R)HP3M$`C"4@'.?=]$8]G6OM[^N#HW^0V$-Q3O(
M`PUP`1>L0#LX@!6@-W_#3&'`0"T$N(`/.($7N($?.((GN((O.(,WN(,_.(1'
MN(1/.(57N(5?^(##`&#%#RRHSGY5`@W(@QE<0C4,P7J=.(JGN(JO.(NS^'M-
MT1"\UG'-.(W7N(W?.([GN([O>&VA0W(=<H=W*E'``PW<P1W0_X`+1$.++_DP
M++F35]>3LWB36]>+WQU[7[G?'/)[Q[=0C`-]<X$\:,`V&G=@CF5<JC>6ISE)
M:/)_$P4H*$$@G,(_5$!:1M1VA]B=PU2>QY%PJ[F?EP29][>@RP^:_[FAT_&@
M)WHPJW<6$``+APH*L(`."`0:\*S?C`(6AT`-@-J10@`*A,`4L$&<^<,HP$$<
MXX<.0$"@%(,SJ+JF'0($R&`)L`"4=,#_HM`H0$#W<(BDQP`BH(%`*(&QZ4F@
M*[JQ5W=,<$"GS:G26$&S9H`D=($:!*/2>,(1A`*P'8`:M``31@``3$`H<$`6
M```0[``V[`$#G/IN;,("V$$8C$$$\/^`NV^(/=2`"&P$L/M#II@!C)""!*Y0
M%2"`#UC`9^"`".P!#F1"!@!`#TP!%/0-L1^[Q*\J0Q=#!C2.52I-%;1`'<B"
M(SR`K[Q.!]C<D/S`!P1/AT1!#.@C'5@``-`!`Q3"ZY`!'QS"4ONFS4_Z`13G
M)_Q`!`@$$"R`SS-`SS$1&S3<!0"`*0A$T'Z`*00!YD7\Q$_]8E8\`-0!*O2=
MTIA`%&2P#$1@</K-R-<&-GB`B@1/"OY`^Z+"1D<!'>P!&M3`S"4,`;2`I=2]
M.5Y`%/A=!M2!`1"`*L#!FK%0#UB`&L3`<(C`SNZ!BNS`$2Q!#3"AVRI2'\Q`
ME0N4+O3"Y0O_5.5O(]!L/A3+Q!3(`1#D8Q6*VQ(\P!(H``/D`!CDJ]*,O3]X
MP`ZH@A!8R@X`@"P(X"!.`!&TO!L``;6["\7`\0.J@?$+Q`%0``/8(`N0`@$0
M`0OD0`Y0``N5P*_*`0"$PA.H1`<\P`;0`0FXP1?4@34S1[%OU#]@$9[#=[&+
M1R^(+$C=Z#\809'&Q/!(P!Z,H-(`!(,V2RS4H>`/84*%"QDV=+@0#Q`2_A18
M^/`#RHY5"DA5^2$!H2,B63YP:`'G84J5#R-08+")CQ>7FW8X.[#`#8,L"3T-
MV/,)B)L,*XD6):IC%#T@$##(\H1D`D(("I:9F0"@A%&M_F#]\_H5_VQ8L6/)
ME@4+JVL*LVO9MG4+]H6O/F_IUGT[0VX_NWOYBH6EYY_:OF3[]=N*L%A+!)(.
M-U[8X<L!&3G",'#LV).'%JH^^7NDZ@.V,%\F6)B0(9._&!(Z4,F!P0*?RUNS
MV/GQ`\<>(;=QC*9S^P>AA-?JE"B&(<.1V<L;7LG`X8$5%18&A)'AKXL$/L6.
MF+D2@[G#KH/)?T4;N'QZNKH$JW=/%JVA]N_I?\W52X^O^H7#]_?_'\``!1R0
MP`)7&J^^NE[HJI<$'9P!AG\P<3#!/KHR@L($<_%EAOT,,Q#$$$4<D<02240P
MP[;ZF.&%%-^;89A^<G'Q/5A8I%$]&'2)T/]#$WW\$<@@A3P1QR*-/!+))(_D
M;\@FG7P2RB@30E')*JV\$LLL_V&2.2NPN2&5;?[380,3I#P3S327HU++-MU\
M$\Z]N%P.BFF6^`&%_]SY(`(U_?P3T(;8C)/00@UU<\Z$ICBD@D/<Z8`3*OSI
M@1-+_%G&G4-8B.$((1ZHX8<(5/!D&4Y0.."P8L[@)(@J[!B@@F*FJ(&3,_PY
MQ%%G_/&D`DXX^40)=V(-E-AB#1STT&3Y@J&?%KUBEL>UFE7VS401FN(*(:XP
M0($<%/@$@P<L<*.&#[[X@`P*#"#EFA\0B$(%,!X@(L^MH)"@#B!P0$*!#ZIP
M10(U6J!"`2`DL.#_B3U$D,`.$Q380P$HIC"6XHK#0Y;:C-WR)04>?=%OK;E@
MF45C+:U%:((/&!!BCSW"(`"),RP0`@Y94CY%#0,8V.&'4V1A0((/CGABJWMR
MJ..3&ZKP@80/3CD%`5)^V&2!,(B0Q80P%A@``$<^V,.-+T*PF.RRM<*XY+3'
M@L4(P&;0@^1_<G&V61@BS`^&D>WVJA\89E2[R)/]21D"(1:X(@Q48L[@@QUL
M_@`"4@QP!XZ>?]ZD4Q:VFB('$>[QQ]6F(8`B#*FIMKJ%`^10I8Y#.FAA`W_X
MF-CLVFUG"&W`=;>%O7]F&'E+/6!H$!9?A.EX&%_R-KYC/5;42W<:3RZ&_P(A
MCC``@W!"L8*"+P!H@P4AOC!@`#D,J",3=X4@H8Y",NC@,`BBX&$!!CY0@'P%
M0JF>`PE"D4`('<"``0S@@Q+DJQ"GH-WM&%B[W$4O;;#(10JDT0_@]2(MQ`!>
M"H8`O`T.00\4_!L$,R0X8SV"!X7P`@94T$`7,O"!),Q85X:!(>`-(RUY(UD*
M+#B+7&PP&C"8@1%T(<,2?LALGF!`(_[``4^\$(IFBZ$1#P6#6<#@!;JXCQ'L
M9J,B)N\%*4C"#%*@"3"*<1AOBQ85Z6/"*+X1CF>:(AOI6,?`(3&.>=0CE.9H
M1S_^L8UXW.,@"6FB/@(2D8F4DR`+V4A'#LA":$B1Y"0I64E+7A*3F=3D)CG9
M24]^$I2A%.4H25E*4UY2#R_`!"U8V4I7OA*6L93E+&E92UO>$I>YU.4N>=E+
- -7_X2F,$4YBNE$1``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>y04571y0457103.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y04571y0457103.gif
M1TE&.#EA40+R`/?_`,=X<<"]V_7U^4Y#G,3!W=+1Y8N$O;Z^OOGX^K&LTM&0
MBYF3Q6J0NG5KL3`P,5AD<VQBK(-\N:FDSGMQM.W4TN#;ZI.,PB4E)?'Q]FM)
MD<K#W.[M]+2PU*^IT8^JR1H*@+VYV>.[MTQ[K5=,H5I1I/S\_3(DC;G)W+BS
MUN;E\+901^KI\C@KD/KZ_'!EKIJ#M.GG\<S)X>+@[J2/O*:AS&5=JN#@X-K9
MZ6YNC-W9ZO[^_@```*6]UCHQDR$3A4$TE9)M<<G&WVQ>J]+-Y>_K].3B[U]4
MI;BHRYZ:R8U=9Y:1Q+"PL"L=B=G6Z+&0E:EN<G!P<!8%?L#`P)"0D)Q97DD_
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MY9^6Q_+R]<O'X"D9B)Z4QDDYEX%WM^KJ\L&QNV%7IX"`@#$@BT!`0-_?WV]O
M;YJ:F>OKZG]_?_#P\-#0T._O[UTXA\_/SZ^OK_W]_8^/CY!VK?OU]/+?W?[]
M_O[]_7=C?<[1W7U>GKFVM<_,XU]!/_#P]%)'GYNDO/7W^OO[^_O\_*A?8O[^
M_;]F7SXPDV0[?QT/@A$0$)5'7^;EZ)RQRWIU=VME9"85A5U/H_#P]LK'TH]V
MK&A;J(D\-8N%A,/)U]?"QF2$KH9XN)2:P)F6E8V0J7V+IVU\G]O3WZ9+4]'+
MXTX^FM:>F>SLZ________R'Y!`$``/\`+`````!1`O(```C_`'GI&DBPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+""5)*<>KH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$G38RA=_W+JW,FSI\^?0(,*'4JTJ-&C2),J7<JTJ4\I4J1%FDJUJM6K
M6+-JW<JUJ]>O8,.*'4NVK-FS:-.JI4H&I].W<./*G4NWKMVC4/WIW<NWK]^_
M@`,+'DRXL.'#B!,K7LRXL>/'D"/W=7NWLN7+F#-K)II7LN?/H$.+'DVZM&G(
ME#>K7LVZM>N?G4_+GDV[MNW;N`FG?LV[M^_?3&/G'DZ\N/'CQG<#7\Z\^6_A
MR*-+GTZ]^F#ESK-KWWX7NO7OI)L(_]F7!H^.)K;*)-"A-XZ+?2/.P)$G1(/?
M%A`V"?`'`YE?'7QP8,0"U(4!BQ!#H'%'&9O`H-<D;(RPSQPPG,$.&RWX)0$Z
MM_BSP21__1'!!%_`41IVW*6HXHI&>0?>BY[!P`$,@WQ`@Q9YI-("&!+XYP\(
M'Y#@'PP@_#6)-2Y4$X`1I_@E1P/5?#&'=`B<L0L'`I2@Q@#:V/$%B/Y,L@\K
MI/B##`<8_,4&"S)4XTT3_TF0@!$LA''B<E),(8P-9/BT!%1+"#.%%'"1$2A2
M@A):U#"ZV##,$D,)^A.CCD+ZUA1]LLB3BS!VZE@V.OPQ1Q5_2/`("O[\4`,:
M>@40I'\K!/^``!OHT-``+*>\\D49*'S``BP5;D*+-O[$4(,_[,RQ@ATN#$%$
M>KE,X,5M$LQ"@UXXDN#/`F!LH1<"`SRRAEXHH$'*%[8TT,`&U9`X1BT?R!-'
M$/(DX*T<1OQ!9Q@TL'.(#&K(`X$0$D2&(FM+.&##%)+8P),PO$SQCS`._"/0
M6V3P`H6E1UULU`Y2+'&P3C:$`A3((L.E"R^:;BJ%IS!+AH`>)K!`0Q8^\)%J
M%1NT^JH_L?HS1I!5@*$*`B984\`'(VC#P0\@3'!*"PN,X8^415A00`D1S($%
M"PT@8)L.(S!!0RX6!,'$L0N`X\:WX8[K3[E(CQ#!!TIP$X$/!$#_\$$3?PP0
M`0>H;A&!#G1JP8$;DR2P2PH1,!&$P<#Q8NC"/4VQ@S`Y#6.Q+F1X+HP49.RI
M"Z7_A`QZZDLXG!,O%QQ`QNR>+Q%HHH,NS/GK4#0Z,>F<VTZH[9R#/+L-I_MN
MPY\Z2:$+[HKF9#P9R(<>J.VIZQ)R3H).@7G(#J^,/)^E#YJ[GJR[_MS+,;?O
MV"1\^)"'`3FG.D#/_K@J)-`!"(UW`^#(`=*4QK06!*('YT`!,F@D-G;4P`AO
M.T4#U#`);[1";+69!!-&T((:@$,):]N6#Q(`-W&1"PU(FP`!/M``'>RM;W]#
M`P1\$`$TZ$`)WJ*3&DC`J@28(!T68`4!_RCWFREL#`HVD,3S=,*+'?"$%TH,
MQS]"T1:3[6`*H0C%,)QH.1M43(HY"0;+@G&!*>A"$DL@Q@4L%L4#E)&)4)!"
M.(1!15V$PA@7$,82R!!'*SJ/95?,XC_RR`O/I8Z+4=P)R%;&1ALD462#V@$9
M3!;&-9(."O]0&",7R3(HZB(<;O3>%_'$/O>94C'((($9]/"(`.B`!5]@5?Y^
MIHHA#DT/$PC@`)<V@E/,S`0_6$$0_*`7=IC!!`.HQMR^P($JC($]M4$`&(R@
M`S5\(`L]^((_#``&G?D#7";4`0HFD4(^?*`5>N.;WYJ@@Q@,`!Q8:D`*_&$$
M,%C#!\\DP`\2(/^E/Q`1.,.8)$ZB!X7-[40@4G`BHR0!R#\*8XX.$)D#G.<Z
M1C+R'R##Z`$0RL5@,!$G(%LH+R`6CBE`,66<Q.@?$WJ`0>4DH9^#J4Y2N@1)
M8A139)"I3H2Q`U]`#"<"V>0?8]I174S4=^L[I5(+HX1]!.(4UMA$*?)0,#`@
MP4<R`$,>Q`:"-_@/E[I,VM*LH84.;$$`'PB"&MZ&K#D0P`?HP`8!-$`$#-ZF
M`2P0@`4^L(8R6$,'?N"A7I#1"G`\<P7/+.<Y7:C.#Q"@"0L0@#<F$`,7^(=.
M>[#&+-80`PL0`0,^0@US0*K'G3Q48O\H'4<'N00H-)21&W-80H4QC-W_691E
M%B/4'%?KL<\]5(VM+:0PR!`.HZ9.I4)=V4,#94B8KG:F0QUDGS26.IWJ1!*2
M^,=`<IO<3FJ/B]^E[>Y\PZFEFM<?LF#!+O;A2AV\P@4-L`(T]:(!:Z"C#($(
MDSQV\05TF(`-Z?4&"M*P"P*`(`ORB$`+&B`##]7"&GS8QR[DH8D/6/@'<JO-
M+2*`CGV420Z:F,,<[+07&)3A![:0P'X(P`(AV&(79/4O+1"QBQ$;(`+LR($5
M.."/4["#!6)8P'KE8>$/^"`+__3-,`@UA2D8<J>]>YXPE+@$7MC`%Y+@XS!X
M(3))/+0C$C,IQ^R(O%`X;&$YG;(NJCP,)>ID_PI[)!26^>@\XD%!BUMNBR2V
MW&4]WD0G;*:RE3MGN3-R+A+$^$>;O5SEZ'6.4(+:XS_N+`PH],Y[@FXS3L1,
MRO-ZNCHEL``M"!"`*ESKTXD!P0((0``2);EE14$>5"H&ZUJOIKRHSG5MD-$!
M6G3`#5:8IZX-,XTY'"$!2ABB:&U=%&%H#RK,CC9F<#WL:EO[VGH9F;2WS>W,
M4!O;X`[W4K7=[7*;6R[?%K>ZUPTC<I_[W?!&"E2D\8MZV_O>^,ZWOO?-[W[[
M^]\`#[C`!T[P@AO\X`A/N,(7SG![1\+=\8ZXQ)\B!7KXXN(8S[C&-\[QCGO\
MXR`/N<A'3O*2F_SD*/]/N<I7SO*6NQSCY8#XQ&<N\72S^^8X1X[,:<[S<]L\
MYT`/>FUVWO.B;_OG0D^ZTD-#=*,[O=9(7[K4I\Z8IC_]ZBN*.M6WSG7!6!WK
M8-<.KM,Q!C<,8;XR.`0;^-`,O11!#+``00D(HX-)M"``9P#3:9IP!C9(`)I-
M@`4;.J#W%Z&!`[#0@E[0T`$V#!Z:*P"!!J#9`@[D8"\ZP`('.(`'?\#!\6Q8
MP!!@E(X.G*$(>Q%`$%:@%S@<0@)Q8(\<.-"!5\RW!#DX!`?DT.,X2(``O+]3
MV(<O;5QK8@!:Z$&:]*(#"7S@"TWRAQX^8`1G%*8:5M.`"?PYFTU\@`G[\<?_
MW<"A3$\AP<(#R%`@F&!A"^CE#R0PP33V0@HP=&`OVK!`+AIPAQ)HH,BLT#_@
MH0,&8&&Y,'<;0`L?,'H(,`$0L`:M`")*$`'NA#_^$`9F@`1,H`<Z<`,FP`=&
MP('"1WPD"&OEA0!,T`K(,`!JP!=OX`V/,#D*X@V#,%^!$0;[X'[:QWVR805F
M\`&:H`,88``F``:A]2((L`#Z8`#G$`@ZP`%C,`1#P'M-\`,3@`5[(0/6\`'W
MIQ<WD",=X`--,`912`/6$`LO4@U(H`^VP`1:H`,!0`(+Z`\<\`@T<`H#P`%P
MX`,H``/64`:#I0FS\`9V\`-O,`>S$`8N\`/"-AI?_U>"D-@:Y34)/O`%.F`-
M>3!W>E$-=^,"VA``')`'-8@`%B`$$S`&L2`$LZ`&59`&Z;``SQ<`&L`$"\`"
M-7`+6-`*9S`(,2`:J4`S)@`#"9``+&"$_E`&K=``':`EBY@%I[``YV`$WI`+
MC7@;.M`D<6`"*0`'>7`.\W,*&/`%)L`!L@`B39`*:<"%>X$$I^(J'9`A.D``
M[O<BR#!WLN`-6.@/;C"';G!D.O`%:L`!CH4%)#`!>L$U.4,#/I`*K7`.-_!"
M(QB)$BEVI?07>(4$WC`"H14+,6`")E`$=]`$HOB$8&`%!9`'>!`!X*`)9H@%
M,?`!.C@+!=`*K?0&`S`&*/]P`[Z("*WP`6*@!&M0C,B`#":``F,`!AC@`EU`
M`DR0#4`R`C40@,8!`H=#!(H`"^S`!!P0!/8D9`$@`W>`!@78A=OD`P'@*@M@
M?73H59["`?/H#QTPAT4@!#_0`69@`9GP`5M`D':P%[*0![E`DQP0`"S0"D;P
M"/H0D4UA`X0B!>,UD9`9'!4)&'(@8'P1"]I0@+E``+<PDG;`AWO@`S*P-WP0
M`&8`!R^I@]NGDAR`#"/P`0.P![Y8`%O@*V\0!\7H#+$P"]8@!!```V&0!B;P
M"&@`)'-@`."`*L21`RZ@`W;E#T'0`PD`#EF@#23@!WM59$*P%W?02@+)`>S1
M#&K_8(/@,9/.J1=Q.7I[D0)Y\`H"&01P,`(&R1<(4`LD$'[^@`Y&\)Q,%Q=T
M]`\<DQ/(<T884:`&>J`(FJ`*&A'JHQ345@*PX`(9LA>Q4`)OP`2[L`*=68-W
M,`L=$`@LD`ZD:9JH"9/^L(.LJ05AH`8^T(*AD0H%@`Q58`:3@)M&V`*S@&2E
M\`<L4`:Y0)S&B9P\1AR#\`98D`I8H`:R60%VT`0]T`K^4`-J\`9G<`9&`),I
MX`)%4`#>(`$T\#=ZH0K-V2E8,`A%``-LE9Y[T0+HT``E``,?,`8P4`5S\`9"
M(&RJ\`&RL!=:L`_>HIA-H3T!NA./&)G$AVM[<&*OT!<R_S`)`F`-)%`"*?`#
MS5D$56`!'&`'IU`&X`"*I[DTZ#!7VS<(\%0`')`"9G!JH&$!>[H`[.!>+/`(
MDZ`#8`!D-)"G(_`#/C`-0&('I*J<N:$$L^`-WJ`'I;!!.;`',="`>7`+UC"D
M!,B%"?`!;B``=A`!6;`J_J`#J?"6X'$*:L`$/V"9_N!\HZ<#;^`"9C!ZR``!
M5E`*`Q``UL0!+0`"(W`(&8(`';`/-#"AI%&H#T-)/@&PA@IVY;4"L(`"U>@/
MI2`&X[0&-_`';I`%F%H"31!D6"`'8F``;G`S0]`"8F`!*X`"FQ``>F``"4`D
M9P`"A2<9!<`&B8<%8Y`"BK`)!O]P!@+064H@!\@@!B!``%DPL@:@!R=+K[F!
M`19@``:0!5I0`B!@`+3P3/X@!VX@!HJ`GP1@`'$0!IN0`IGG!AW0>6;2`8H'
M(W"0!9I@`"+;#"!`"P8@!G\P!`M`"ODXM6Z@"-.@`W&@"44``K!P>=^$`@L@
M0*=!L#OQ9#UAN`7[=%K7=8[[N(H[%)&[N$77N(][N50WN4&AN91+<Y:+N:";
M=)S[$Z/;N34WF:&;NI=;NHEKNJ[[N:H;N^K&NCQ!NZ[K<ZC['RC0(7N!``=B
M-82!#`$@!,#K)-%G&\AP`[:P"8?P"C=0!D+@`L)R`^09'78J!$*0!<ZP`M@K
M!+"@`S+_``L&D`-MMQ>*T+T<<`C=*P3`"C,8H`1"8`'^1!_8"P&`VP06H!^+
MM[X-X`]OD+\%4+VB8;LZ0<"WVVW4!H?@V1=QZ:V",0D?P`9_L0)?P(.U,0U5
M8")-T`7.$`<?T`/.H`D^P%;3T0*;4+_]HP_U.P0PP`($T`5,`"=Z@0$C@+T-
M(``U+`2Y``:R&3-8T`45D`4?0$SL@+TC4`5R@`4-X`VDX*]CD,/[8`<M()T%
M``;Y5;B:8<`'?'2YRQ>OP`)O@`RO4`9V(`$M$)?'609%@`PH(`]C(`O..0$-
M$`<E@%86<`@0D`!CX`)JP`>[P`1EH`4;("S!=QIN\`@_,`9X_Y"W-_#!R/`&
M8,`*/2P=,F`&+J`!O#<)1M`*&M!Y_T<`@>`#-:@7=X`.$1`'8J-X.C`&UG"$
MG>)+)<`!WL`'R"`V.I`%>L`-M6B!VRH#39(.-;`&=V`"!)`")F`'`@P:6JS%
M6QQMN'9#3(`%*_`#"Z`'X!`#<>D"Z5`%(Q``Q`P">H`,:7`'7?`#?(!6`/8!
M$0`'/6`&:,`"WO`'&S`"04`"!G"\I;$"/?D!9J!XC=P#R`!_<3H=.@`#$+`/
M'V`-@1`&#9`'3),#8<`$"1#*-<`>)9`&$+`+X.`"8#()@X`$IG0*',`$)K``
MT9<"7]!@$#`""R`$U-L7!&`-'03&QO^<B5B<&<S<S+:&:Z<P`28P"6B0!1S`
M!A\``@T<I8^0"JPP`$$0"-(T!@0`!A:`SK*@SAOP`^X,SW]0`+.``OV%AK)Q
M`[G`"G@S"?\<T%?:OM*Q!KG@`[;`'@$P`A^4#?(P`6JPDC9X!_MP#LH6!E^@
MDZ8D`&DP"WF`/R#P!0(@HUGP!A^@!OYJ)DI@!\A`)V]@S#V@B8!Z%SFMTR;8
MQ7HA`!D]"<@P#6IPI;0'DSK0"CX0!%E@`N"P`"G`5ULP"S<<P54=`5>=U?$,
M)`U@`(I0R*51!,K$!R.0!S)PUEKP`^!0`-]Q"J.BB9/0`/L#KCSL%S`P`GWI
M#PF@@DH%6&S_LJU^$(2G\`-NH`TL$*)\L0(UP`<NQ`*!D%45?=.8L=F<K2FX
MA@P1L`MH<`-,$`'G=]I!2`(W^09P,``#8*D@D`!@0`/H'`/@,`A-``:ZO0=K
M,`N*@`"!T+*CX0;S&`L0\`=GS0'@T`"N?!PR4`,]TP%^L`?HP'MNH`3LL0!%
MJ0.RL`\)0`)*T`*G8`#>U`ID&3--,`).J`9?D`T>4@-L:0<&X`\],`)%X`(6
MP!YC(`3LD0(L``)[H)6RL<SU#9G4!@*S(`,RP`+6``O@8``=,`(CT`"Y<`-K
MH`D30`*MB8/4S'@?,`$;H))&`$R3H`0K><9,D`NH=QI/:`!V,`&"__X*N?`!
MCR#''8#/T6'ELS`'$H``&_`%NS`(;M`"?&`-:B`#[($"K(`$%@`.`Y`&(,`>
M\$=B[:,%+/`!NV`%G?>$$:")LE`%#5`%*6"I\^D').P&[.`"J8#9F6T7]-WE
M*D)M:*`)RB:[SKYN7([LD?AM<C`(C_WLV&YMT2[M)9AN0;"PV1[NJ+;MW'ZH
MGBWNZ(YMY%[N80>[Z?[N[;/N[(YU[KZFLD``O$P8*7#MHP$+$'"'_I"EF\#J
MZVD'5I`."<#OR#$)%O#O&(0`!E`$&$`?$&``*\`!+C`!I;`7)<`'2F#D.:`$
MF]#L,%,"`0`!#.8/:*`(;-!@*V`!$M!@I?]0!J&7#LQ7"K_G(;0``5F@X0.<
MQ?-N[C*3CD5R&++0"B9B&GQ0,ZB7"MZ0"M4++A"P`33`G]&Q`AV02\H9!S)9
M`-9@!.B@"3+@!M6B!CZB3TR``*?@#5:``F[8/K?0!8>0@BUP!WS0`1!P"U]0
M`VQ0`RWP`TQ;!5;@=BX`#HJ`7AV0!C[PIZ8A[T'O=/6^%\Y7](91`BZP`"4.
M&@5@!YU*@"0`]9,P!F(`!P@``F*0!Q!0"HRS`HH@!C=P"KHG!NQ-'&FB"N#0
M!?Z0#19P#@6`"#J3`LP=)CV@!.4K?FG_!]1Z`ZSPXYV"`')0`B-@!`*`#OH0
M`#T0`+O0"G?`!&C_P`HD$`<CH`?,%P>&SWQ\P`3!W_A`__@&>^Y\H0-(8`TC
M@`(@4`--L`40@`YF//EI#A!V!EF3H*/%)CM%=+QBIX2#/QDF`OBC6-'B18P9
M,Q9`]*C5FU2Y4B&(0.*&&0L_;OV`4&#$)1,)6HW0]B.-K3Q8-.[DV9-GC!^Q
MD*'@<*Y`10M\=)0:P<3-J8H1F"!`\TC-#29*?&[EVG7K)#,<,/P80L`'C3P#
M[K"ZM<;'N5;(*L8!UX4B"A-F;GCE:U'7/\"!!0\F7-@PX+^'%2]FW-CQ8\B1
M)4^F7-ER8"E2NJ;[\F@/*0XWP*!HP"J&A`\@5'FK0@"<)@1V4)*0`2:+_PP#
M_M#\L*6CK]<"JB;X:(5-Y)\!`SH8R%5ETH"6UN`$L3.B2JP?%M2P"//;NT88
M<U+X(X!N`C@+"/P)R`6#8KI6/=Y4U`1&?0$]!EAI^=[?OS.'D$&C%GT(`&,,
M&=B`@(06C!!#C7/TJ.@&5A2AJ)DW\LB%&_^V2NRRQ3#YQ)Y/,`'Q1!135'%%
M%EG,S"L0/(I!@!;B2&"$#_A`3376@G@-AD=^F`.=)FKP880._)DD#R/4ZW"G
M0%1YPX0)_"$A%0%:^4&`4B+X884\2$#D)6^RJ.&Z[+8;[TGOY+"#G0FZ:(*-
M,L#1HP5_QL@"&1`D0``$/PA((QU_L@!##G_^=/]A`;G8=+2G4]RP9H(T]C!`
MEC%R2>&4(6R)`0M64+C!FPC2B$&'&QZYPQ\]""@A`C=\>S2C#UL4C`=;<]5U
M5UY[=>S%KC`0XAPU=%A!"%OLR'''U5K[T0=O8)!A!1D68*$6)?/XPLE9*SK#
M#3RRV$(?%S:!H0`(SB#@A@A@:066&":(`8)-E'"A`#LLV$2()KKUJ@(C`D:!
M(AC8X4^'5&3P!P5V#DD@#`*^6$$6>7(Y))U#DH+*7XXI@J.!@-689(5#%GA%
M@`0BD`499!(PX`P+FO@"A"+$,,(`!-1HH`,.)NG8+U]Q]75HHHN.C)D00J"@
M:&"[0B$U?Q+X0`UKEDW_#8XJ>E!6DTF^^.`.$&3PPQ\.?M#-&S]D_7EMMMMV
M^VVX^ZI55Z&-MOMNO/^A8&FF-?,*AA$V\">''VI0PILQ7#`AC0T2H)(%(521
M801KAB#"@C(:@,6?%&**^W/00Q=]]-_FMFR))6P8C`)""!&E]1#REGWV7/<V
MNFE_=5`[(V34L$4`TH,7?GCBUS:=LF'(^`>*P0A1(9]BQ%$!`-JKMQY$V_L>
MG10E$"W^>_##%Y^GXR?318I_>&E>A46*^4:%;C*3?W[ZZ[?_?OSSUW]__OOW
M_W\`!G!^AC"$`(5A&=Q]#@&-:EL3"/!`/G`K>,B8!@$$YX]26)`B<H@!H?QQ
M_PL"[,$BD]B"+"B"!CX$08(50<802K!!9_A#!UH@0!$J$@8/;C`(KVA4"?;2
MK29@HR*3X,,-EO+`->E@#QBH"!K6$(@2G"(0#R2`>RZ"@`>J1P<.7%,&X<#"
M&WAO@TWP#0WC4#H4G2]]S1-',=RXB&U(0X!S])\DZ'C'_AW#"4EP@ASQ^,?[
M$="`"/3;^!RE@SB8P1M]@(`=Q#@Z'7#@"[-`1PHFX0(W-*`(:,B%`1J``"P,
MP`T3<!(<V(`.)I0"!IL8@0\,L#N*)&!+&-C$#[+ACR`TX`<F:((J7,`"`E1$
M#NA0D"9>Z(8!S*H)U@!#*2A2!`B4H0`(&,`'F``"BO\4H`I;H,@I(F```[Q"
M"R;XP`?`$8.+.*,\X"C#)`C@C0Y8HP`@&(`$LN`S?P1@`$=14BUKP(TWZ'(6
MI^)+^223O.4-IA!N9*CT%,"WZAFT>H2X'F&R1[0$&O)))*B"#L[P"&<B@`CI
M$!`1Y$"$$N@`#T0@`A9*@`PLK/!)DT!!"QH`C@`4P`_4=,,63+"&'VQ!`CUH
M@2;X&88"8*`*?-A#$S;0@Q$PD"+5^$$/T+`"`WS@EB"`00`^T(4<".$#P:3(
M-)A0`"N88`-8L$8/8.D?`EC#!\Y$1@,X$$,X&*$!%OCB*1I@`F[Z`VL$",`=
M@@`!>4S`&W^X"#)@H(T\_$#_%09@`3)^D(H&C``;+@B$DDC@#7ZB81,FJ($.
MQM#5#Z1!JAY*4694)Q@8>,$+\Y`M/D*P"'%T(P3+J&AO`4-1WP+FHD/+J$;[
MHP..^H,-UOC##0CR"#@@`1Q98(($.E`%13QB`AM0@@5<8,5NP<(,,M##(%HP
M@`88P`0%^($?T)$';:C!`A7!0P>\(3@Y',($8\#(&M30`^"I0JL520$XCA*$
ML58$!3[@PQC`$80%N*`'W5K`7'7@U?3"H`OE9,,D6B"!.P"6(@$``Q_X,();
M^&PY;Z4(!%P@`!`PP1:M*((1?M"@3"#@#@;H`3^5-(#24B0,/@@`B\D7-,'0
MP7T._V5&<*T'W.`.UU?%->YW2,`".UBC.Z5PP8*+D``?-*&]$S"#''JPB0*8
M8!,#>$BW\&`'`NA@`6IH014@L)TW:`T=`XCO*RF"`'U&0`>3&(,9?B"#4VBA
M`EU5A"U8H!!5@..6B8*%(GSC([+Z`PM"F(`M]DN`!K`@!4;V#BWF&E\6-($)
M60C#$*RP#PF,00(2&,V(U\N'*N`)`;G@3PLJ4`$X^$8'8:B!%K8X`M84(`#[
ML%EAQ[`)8`X1R+YI`0TT0>J=2%1%=0,,#%Y0##A.;[=.EAV4?2OE7E&YRGU!
M;A5D@)))E((=8)9!`L!Q`R&-800T:$`I"C":'*R@6PC(Q/\98E"`,9C7&A;H
MP'KSX(8($#4+*`A#*?Z@L&E,8`7=`:H,\.`&18!@$];PA@\R<8I;/.*6IP"!
M/$@Q!'\$P@?!Q(-",*`!(T1``NA@P3G*L%K_T(`5I4`&$IBP`188``;CT002
M(C""?8!#"$4HQ0UZ8.*T^2->4$F'(A2Q,DW;`@5!N$$::H`(5EB@&44XA!I2
MD`MT_,`':6A"$;C1`A*4]L(&B$$`9-H3;:>(VX'Q@C(JT(E1J*`."F@RN>UF
M[MZBFU?J7K=7FE`%%@1"`J^YPP=H`(8@=`$<'&#!G4VPCWVP`0,1B``*^/,H
M!%@`'.7L`#8@D`#Q8*,&!I@#`M+_88T$_*X&WK``&-@PAA5HP@2*<`,*@)X%
M;Z`!`QP8/0(:7DX+K$`)4TL!"&BC!".<`2HZB#BV^[*'!GQU`^FH`@U($`<+
M[$("(&!B/DU`@!K\0`YJT$06YJ.#+'@%WF&#<DJU!/"&!""!`E@#(6"'-?&'
M+NB!(&`!$I"#`/`&,X@#`B"G#X"`C>F*P`,1$?&`$E$,?'"".A`WQRL:R*LH
MR=L5RJL\KE@I(L"`4V@ID9(#.1"`E<*`EMJ"1R@G;[B!$B`"/#"_OD"&=&`I
M(L`3-&C";L*"C6D!(A``'4`#.6@!+#`I?Z!"(]2(24@''3B%+20"9#@IED(`
MD4K#%D`#_Y'"DXH0@!QB$P%@0CRA0CRY02+`)W\@PU/`0ATH@7000QD2`*"3
M(1HD*1WPP19H!@P@Q(KPO5/``#0H@3+$`QK<0[GIE6'@A6%8#"[(@#Z`A\2K
M`WY`!5X9!DF0!'(#@@,X(-^R!$NXG4*2P;8Q`$W(`7U0@_JS15_\1>\(01"Y
M@&"X@,7`@R.H`,``!`5H`Q7,%1L0AAWX1-\*A49PLB6@!FI8`NT!QK7!@R`@
M@"``'F\L1W,\LET9AAT(AATPAL?P@E+`!DMX`O@A!%1L$5UP`%BLJ"6X@"0(
MAN#BA49HA%#HQG,\2(1,R)\11LM01UV8QL?XMA>`@7_H!"=P1O\%2`06L0$'
MF`+?"@9>(`2([*TE<`!**$B,JD6%7$F6;$FO8$C+($9CA`P-R(!BH`,T^(<_
M*(1MJ$?>`A%A4!Y=H,:*ZD21?*W("P=N3$F7;$JG?$J@X15CX`5WE(PCR``Z
M$`QU2#P5>*C+$`9)F`*B["U=`(*E["UA,`=ZH$6H;$NW3$B8M(RX9`Q`,`0J
M@)]Q6\'*:$'K&887U)48?$O!',SPF4O*,$S"Z`/#"PQLX`1Z[,K&T\O(X$OK
M^<M<"4S"S$S-%!W$E(S.%(P*X`)E((Q+<(*[!("\E,S&H,SJL4Q;R8Q)$`39
MG$W:K$W;O$W<S$W=W$W>[$W?_$W@#$[_X1Q.XBQ.XSQ.Y$Q.VCP>80B%\QE+
MN>053,`%(%`\QE--QF!-VG'-%LD,2;@`\`Q/\1Q/\BQ/\SQ/]$Q/]5Q/]FQ/
M]WQ/^(Q/^9Q/^JQ/^[S/\'2`XUD"*>!&E`21SS2,JSP"PG@'47!&U,3.P]#.
MV>%.%Y&"<>@%"9U0"JU0"[U0#,U0#=U0#NU0#_U0$`U1$1U1$BU1$SU1%$U1
M"MU/*)`$!V">$PG0PI"#&2B&#-``PA@'.JA.4[Q'!0T,!I4=!UT1S-Q,(SU2
MXS$,,N`%7=C'RY!1PX`!92B&%RB,20B`*T#0V/G1?PC2O!E2%2E2)!U3,GT2
MYIP"74C3--(5_R_H`\7X!%-(@GKTT17L@U#D`F4\-X@B+I4L4S_]4S,MC"FX
M`%[@!5:,45^!@2/`@\+8`$_(TJ[42,GD`G(#T];J4T#-5$T%P<(PA@,`#.BL
M#"AMC!S(@`Q0#`.]RVZPQQ6D5">S5!2A/!TH@B%XI#\8@B$`+P&(@R%H@D/,
MB!*H@#CXP+6!`5S-@8K`@`+`53C<5&=%(\)XR!W8`?5!5%^1@QQ@#$RXANKL
MRCWM+5>-LF]--TRMB")P@1'H`K4)@%H@%EDA`!8P@=[S"9@2@#E8++>1I7/8
M!UEQG'-`!\8"QF%3&']`AAL@@%ZLB"T:#P2X`;)KAO78@AAHE!:`N?]U0X8]
M<`.=\(<-&+O&DH$.L"%_2`<0F(CUX``WP":*>(.!X9CCF9^S?%*[D5(O.`QL
M.($K4-74O)YPU5.VU`@=`#(!,`.5I8@Q\($OD2$]T"XDU`$:6`!_T``3"-BV
MH056^(`UH`@_8`4FF+1?U`(U\($SD"$WJ`(0,`,^I`@M`(,$\`=;L(92,($<
M:($)@`!YDB%-:-LJ:P$W,(%9L"%9J!JHK8A3Z``6F(7.F@82^(`(H(C#^3?@
M20$C$#B7'0QAL`$;D)^8C4ZCP0,NH%**/(Q/N`8Y]=:*ZMG(&]?)*U=_B(4/
M:`!_L`824)M;6%Q8X(8;2(4\&`2Y*`(VV(3_=,``S&D"`]``.<B"#T`'#M"`
M72B`,@B`9M`!6(`%`GC`1TD%"``':VB!0-`#%@`#N=""W_69(J`%<XD4>>``
M-@B`%R(>!)"`*!C;(O"&!I"#6=@"M7F[*$B`;&""$<@&(^B`'&"!"(``);BP
MWE@WW1F!ORU8"XB"P:4(W3$"5N@L9-BPQO6'_(NT(I@$.%O(P9@"YYQ6:EW3
MN^D#F\Q*Q<"$2H!4U/S)V4%=%U1=&&1=9&`!,[B%MFK?UNT`'\@#;*"!+=A=
M5,F#+`@`"&B!,OB`&K`#(^"@#Y@O#3@')+`&$PB$&V@%&(@`/O"75(BK#P@"
M)="`[T4&'?`&YK,&_P0@X`'H`6<`@0_X@3Q@`G0JG@2(WWSR`4=B!76EB!+(
M@@[87W_PFA]@@73H&CO(A1C0@A'X.T-B8)%]X`B6X%RH8(HX`\:E"!I@@0D\
MA07(@B0E#*0,U<.4'3J08<,X@7J0T\6+3+Q!Y<JD8<!D77\H``.P`!/0!`ZA
MB%C`@EP`AU20@!0@XK#M`*S88IPJM`V(@2B.VJGU`W!`/A88`%KXHFY)A0)0
MA`\@`0YX@S*>A%TH@]&"@5<XA"IX!!A[734`AY85'1WX@Q1(`2:ZX['E`!^8
M`SE@A0,>,1`@@"AXB`!@@0\``RQ8B`7@*S4(@#"0`%G@X>_Y`RV0`2N"9/^*
MD&2,H.#.@L!,]@<,<(/FX[(B.(T`^%7_F)LE+=1"_4^9M1Y&#1%R``(MS1M8
M;DU9ODQ:IHA2V(77X^66`0<P*(!;(&);\`$4>`,?V&(&"P`S@`-FEN*IC8#1
MTX$$8`(?L)!K!FH?``,8B(,RCH5=@(5?:P',&8%'0`,XG@,#8&?208`&,`,S
MT`IZQJ5SP.=SL#2*L(-$C@(2@`$CL`/D31(9T@$K2(\!&`1O,%GP\9(><`&*
MH&A_L&B+T(%*SFA,SN`A,H(U*`46T`0FR.A9F1LT3=,TA='%R`PGC=;K*08N
M:&G%N%E(8.53M)N9WLZ:?LV;AH$)^#F+B(42&"?_%L""H!X$'>@`,.@I_8N`
MI%YJ9M:$FWOJT;N!(O@\3?#B`M`!(QB`&BGC4Y@%.T"&+4@!,'C;LC[KM&XS
MT5F[&[B!6X@:/(:!/&@%^WV%(J`[";``.X@"".`#5K@#'?@!)*B($O@=&/"\
M6<B-\$F!)F@"@D6'!GYL".["#D@`W\!HBL#@BR"`MI6:S:,!?RF?89`"4B8,
M*=`%CU2,4461P@O=QAC=9XAIHIGM!JWM[F3=(O@"=#B#9O6':7`!-A``-;""
M%"@#)F`!6FB!Y1J!3\$1.W"!71B#6V`!)B"`33B'5*BF.2B`09@#(7"F62&`
M?6"'-YB&!D"_<_B`.<``_SLX!Q,@A4DP@2]H@)E3@P^H@BI@7$<&G0WP@RCX
M`D(9@QZ@`36&W]RXL/W5`;LM`"8(6!TP`(%S!FMHA<PS+F20@1\`!PG?@%:(
M@E9H`1GP!F]`@##(`W"X@S"<@&VF6K;JW5QFA1_Z[,*0`EZ8`F$(/$D(A1`/
MC!-GD0I@[=;F@2M@95;M%1@74AE_T&?5J##8`A-;[U-X!1`0'#1`V/<@`,:J
M!L)J`HCM0@G8&#B0@!B((8UJ`0*0`!K@KP+H`!I(`#DH@9(M@7&G`0Y8@3=`
M=S?PL1AP`PDF`#48`X=VE/T4AOY4Z</H1,.P@31E4M%.>(5?>(9O>(=_>-$.
M!O^;?`:(3]-@"(8'L(<6GYY&J'B/?WB)_WB1'WF/!P(@(/DT1<K)$--C;WE#
M0D)_+PP;N(`=4$K'T`6#5Y["R/45P8,:O=''^`-RP`%5#?86&?8O+78BO6F7
M;WHR/9Y>,`8R:-+%"$IAV%S4)K<5F-*:?0P$.`%[*%VO9!&DQQM8/1&6=WJU
M'\S]M(%"+7'%&(9;QW6]W/7)``0/>`:=A>$3*?N[.7L02?NU'WRH/!XRF()P
ML`&L+V7LG`$ZX'7&0(,3N`>Q5WK&\'N[`?S+B$$T$``$R`%K5I(Y3-8<4(5^
M'Y\2R($<V$,\4'W5!R_"=U;F#`4R&'$35DT4)E#)8`3_1]CX%[X,S#<:S2<D
MGN```T@!O+8&_I+J^<"(4IB%$:!:0]H`-<@"]96`,+"`#S"!#G`QZ8]]0/5P
M^;E]+IT,3"`'RK=.5XZ,X"^:X:\,=0L$:W@%!#"#,4`O'9B&:U/8,``(&240
MF!@AHT()?R525("!;$6%#7!DM%!XL$(%!#K"5*CH[R/(D")'DB2)@D4"`9,2
M.+OQH0>R!."^""AI\R;.G#IW\NSI\R?0H$*!ZOIG].@_*3N62D+J]"E4I$6C
M4JUJ]2K6I\JX5,CJ](2]9VU4``CA%2D7I\)TZ>)EX^@2,L+.TJ5*@4+=O$ZE
M2+&)KL&D%@/&#$@CP%J8D&-&__S@0'``A`^E_+EI58/%C04?&N29Y0:9$F\0
M?(Q(L3C7@H1#<Z)@\J%&G!4Z7,*4D0=<C-6Z=_/N[?LW\)M3G2[YMT08&;U/
MARMO[OQ?!2[%7L#("\@#CB0JZO!#=38MTKG_ANN2\ESOW?-T^99$9D)3"QTN
M[`P@$,`"$0(I_`FH9<!(#0CLPH($8"B1S0`U\/%!*K)\P`(-K.12"BL3I%"%
M$=7\8``!/>P7'$@;1/:!"47X0QLR?QCQ`0H@NO@BC#'*R!-S1PUS03`.\*)>
MC>KYF%4?&62@@5[8\!"/6&29A15X:DUQE`-22/+6CUBE5^55[)&DR@>I^7,*
M$6B\`O^!'`UHPD(0LH"3B0`"$#3"'R.THH,<%42V@(-^_.%-%06`HT8LUA@1
M!#C6"`%.`C&V,`T)'QCQ!XHKC/`!"#,.I440()70!0(B!3`!#!^A,`&I$ZQ@
MJ:4!S'%J2`A(D.@MMDQ``ZHA]6B4,?^0,0R/6/J*U1%>./>)(]EMUQU5F'P2
MS2?8C#<5&53^$TI2M_YZU)770J7E2'^`X^5'1<SQQA\#2,`$+(B`X\(D_KSY
M!PFME&"`-05TZ6`$&_Q@!C>;-$"+`2G$\&<)DV`!(PA;B%J%#"@&\@@+M]3:
MDPX@3&J%/RFD,0L+<H1T!SH_G+.&/ZV,8$0>1K0[,8BGG#'_0!D??H1`&=:P
M@<$:/M``PP"#L&QM6[J(]YRUVAH-G;!Z8<+#/4DJD`A534IEU'%0"+.$>4<[
ME:W61G$K$C(LJ.'1))IPX"X$6;#`AQP#S+()!QCL8HT,D-W"@C=*?&!!`!^T
M(@,+9L!@1A:**!+`!GGLLHD$?\`H`0E\Y*>('`2\M((FWA#`,D^S:?(!QAN,
M84+'("%#``(T?.!&-C%T"@$'.G`>W+FQAZ2#&B84H(,.=WPP01@U0/`S5&3P
MH@L43YY7=->^'E',#,Z=4"P5*G1#B'=.20T7U<)<G77S1G'=]=<B;4+"P?[D
MD.A'34RPN3]X6*"(#D%,,`<2I&X@_P$;_F@"@@3NE[]-A*$*NS#!+GSPBC]L
M(@+5B-$-5M"!"6@"`:\HU00Z,#N?C`%T'\'`#THG$C>P8@\A,<'*-NB;$':A
M"S"0G3^*\(%<*$("Z<!"+3Z0AQ$\<&*W.H[7>A6^KGDA:<[1@@?ND82Q*``O
M1]G>$*\R/JV5+R0MJ$)N7-2$T@EF""K\(E`ZB#%_@%"$(5$$!)`!$AT8`8R]
MT<$/:A``$[1"C?[H(!(DP`HE^",.KF&"%H@GE:404GE$B^(0*W`$/#0'`R=`
M4O6ZH0```&`;E%P2(JLRQ:-5,21Q,,`-7`2'!DS```;0`QK<J$J=B/&#(?28
M%;M0$Y#LH?]2JUS-*;RQ`&1```P?4ET0BO"#"8#`!R"PP`>J(,BC\*694N#5
M\C+9/`T(J0_/(98KM*.";6Z3$-+4I!/#UTDK>@1$+2`"$;"@FENR<R2M).,K
MD4&#"`A`#G90`P&44)%3&.`4[12*#LR01CNPX`\6"$(3P"&!"TU`#1_0P@:L
M889E&HUYW_R1'&90C`P843E+VP8WNWG1J&S2:./\)THYIP-2I.$#7X!#$21@
M@EE(``;L8$$*Y@".#_Q.=K?X04J#XH8\+,`("4"`&9"`#$W8;`1!V(,9RD"+
M`=BR5A;UT55'JAX8*$,9Z@%`2+?91*TBI:3:.FE0TZK6M;*U)Q;_E99SLDK6
MN0H"K"&EPEBZ$8)ED-6LUT)K3M"0"VO`[Y9R8(<U$`.2!20VD",I0F)!$`8(
M%*"MEKVL;VXEA7`L94?1G&OSO)`!.EAE"6QI"M6.]T2C8.,$I@""6,,I3;_^
M"K`W$4`#!D""!32#G:>8AAD^H(&/A&%2$$AAJY!)`S[L$;/.?2Y1BE<>*13G
MLZ#M&AV\6I6Y#*.ZTTK.:IT"C4)TPWJ%@,9L94N^O@`%&7S811[BH(\"3.(5
M:-`!#(;0J2(,H10PT,)"7H'<%R%`#=YH14424(,/:,(?^!U"J)!1A%=TX`,T
M*,#[^/.&(0B@!#D8P@IN8"+HDABZMQ(&_Q38(M>KK/BZ5>I*5)@CA12'%RK,
M4$`=5``$4YQ@$D.DK:]LVYXQ,*$'8>B""1;`"@F,H0HH^$(U0,`$;]C!&VI@
M!S@B`$,8(2`5:F!%'.3``0,PV!\@L$8"O!$&&NS##9&A`0<^$`$L?"$-\SD%
M,D<P`FO(K,1^9NNMDG$!7O`"M8=T<2*+P16CV$`7X.T1%&H<E66$`*QM>(8]
M3H")K@$92T(NB19,4`5D2%D6("C``)1Y#C?$P00#0,8(U/`'TJV3P#38PRQ<
MT($8(%,3)1C`"/Q1A0CTP`B]LW`0Y(P&-A!``BQ`0(4'H046*.S/UE;KK89Q
M`*-`\]"(#I\7I/]#':1T]Q]7\YZN_J$L9CG+*C?.<1)P$`]R?,)HG:[2ITD2
MZE&#H`<R\`<,6!#L<QC`"R:PAC]&H`DLT%I&J7//.?PPB5ZCP02-X4`,9E$#
M?R0`V7)&QACL8`<45M@"*3!!83>(!3>P8`-?XD`NF.""3GUD"WF`10-R<8,4
M\/0#X%#"EIT+!Q?L(QW^:($!P+$+-X2$#RSXP`\JA0<3\!0,_Y;1K71!2,]Z
M^]OA"U(&D"*%N5S-!E,`WS^@6!5*6_H9KA"!!QC1[BK=^T?Y'LF^2=T#$Y5@
M!`/PQSE0T&J$*YSA+/!GC!X>&11PH]<E,`,3]G"*+?1@!#KH.`V2'0'_+8`A
M`C0@^=Y.GG+.(8,6LV""X\)``!V0H*`@.8,),!#J!02```3H@&*AZXP(@,,;
M1B]`!&P!#J!^1`>U7]$7XB<!VP<BZ"_2;#.]&U>O9[*C5U'[5=ZM@GB+P!6.
MT/2/S(H<7ME@"=*7!"^Z?9:[A^1T3/@!'&0*/QI4@12((<#[+S2'&X#!!*&"
MT2F0PAS$`0J4B`S8P0<<EP7,S1UH001X0P`XU":XP6O(PCF0@"TPP0W0PN_@
M'_MLD`[`02:@'G\@``*,0`.4TQF``QOP@3=P@&-Q``1H`XGAES?XGC^$08AY
M0QZLD<?<P"-L7`ZD`0WD0&_-B+48C]`($?5)_Y,R6-]38!]6L-UV7,$\=!\#
M\``@G(=?E<<_1-JN>`UXY07[:0H(G,$9Y,`9HH`:E0`IG`$<Z(`LH.$:G$$'
M3`,:QD'B=<`9H(``!$`)$``:GH$ZS6$H(0`(*,(:'$(SS*$BK``*L$T"3`(*
MG($;C,$9!(`;29GC?`DMF``$I(\_%(`W0%TFT%S)W,&?_0`.?H0,_$`6C,0M
MF(`$-(,B6(,/S((8U-KS;4N*Z8(A35\3.F$Q0"%:/(?V*0`ND$,\B$`\Q%US
M=*%Y[(@43,6,.8!>E.&U61LG:LH@@$,7@$2KJ0$XS,(8?$0U#$`3K.(/])`_
M2$`=C00%E5,8V`$K5/\6UD&%=TE?<[38,&()(U6%%-(%%>H5/IP``[S=]\V=
M5TS1,(S=>$QCM2`%&:"=5VCC-F+6>^V"$<2"F9&@',B`#A1!%8Q!"U0`'HB!
M-90`#?B`+7R$$B@!XET6!^S"+K!#3;"BT?D#-M!`.F#`*PB`%B``-[A!%B!`
M"MQ`.G0*%HP`R>3C4]B`CO#"&`KC/UZ4,M!!0$K:>20C!;26(\2#*S#`"6PA
M5@`")^!"O9$;1'HA&`Z#M"P!7%TD>V6D7=X$"LS"ORF!#[C`!+A`Y7R`'IR!
M-Z"!LYTC,N3!.JXB"X0*&K0""UA#'MQ"&2P9"#Q"8EG#!MC"")3"'J@!*L+_
MB+54HT62&VI59%5"A3]>I:_0034=HZ]4FO7LU3\P@@<TX[PQ@A3A`E6@6'+8
M`%^,1Z,M@?JM7UW>)7*"1"/*`PO00A@$``N8@!&03`RP0`?(0A4<`CLLG#^@
MP0!@@)\Y0P#4@C>(00J0@C<<T`^4P`+\P!@LP`'M`@F40`':0A=D$50ZQ110
MBU7L"(I]X="H)FN.5$9M%!P8Q4`^!RKP0XZ-U3\`0B4D)-R=``*0%&\.$48F
MIX9NZ!HYGRIIUG0%HU-08U%X852RQ?&HF(JN*(NVJ(N^*(S&J(S.*(V^:#`\
M@P.L0C!`0C&(0HW^J(H&`S6T@_7P@SL$@R[X`BB`_T+W.0(Y),.*`D$Y`"E;
MS.5Z'.=(Z,`;[$,L_D0"F(`=R`'+@>=-T$"?Z086-(`WL(`1$`@LZ00LF$"7
M<BB=NE'6;1U5[,@PE*AII>91K.:`:@L>9$`Q1$/7+&B#AA,VV"86DL,6SL`@
MQ$.">AJ6CD0V1$`$`,4DG$,-I(,$@$,GV@0"D,#_\08"#``3%$''#4)HW@2^
MU"FL?E&-2(%;'(65'H5GE:A5`&J@_HIT%$,QD%;SR*9>\=51``(S.J,CB`#<
M86BEBL2ETE"&R8`23(`%R,$IB`$;Z$&HQ$`9E($L;&H-%($M&`$?S($0=$`N
M7&L+N($!;,*_U<`<M.I0G/\J$Z0`"/S.RA0`!!B!&^#!!+Q!$%A`&LS!!N"+
M*C1``S2!"Y0!,B#`(5B`&_!BK%9L;]0(&9"!)#23B#+3%+P%<-[JU/1JE:R%
M>0C#%$S!T)#!DYB6+C3%\P`KL,)8\R"J"CCH4=R"!S`KLWJ`.#UK2%PJ!/P!
M!`S`"D"`-42`#Q!`$>1!`:A!#LB!-U@`!^0!%G`J!FS"!R!"`X!#`Y``$]3>
M+!1`*Z2!#BC!#SC6;MAK#%2!"3RE/_#2TNJ`';Q!%4"`!'Q``FB>-MS4#?S`
M2HY.$43`U5FLX?)&C?3"!1#2#G"=59(L5IF'U?RGUQ0%=Q5'!111-!11=1Q!
M!LS_0'5T#;'2YE'LK`@P`$-R$M""Q*5FJB;X0`<0`"U$`(L4`1@X63H$@@\L
M0)R%`:=6@]9R[3G<P.MVP)?)@AV8`08D`"M4V]H.@$MJ@LN%Q!R1@`"H03IT
M0`=T7"9H@)R5@-\";C80U"ODP@=:"@;(0*N6@`R$03FI0AC8T4>TP`N!!*M\
M!!K`P66E0P6((DC`006DTD>H@A;,DC\0,"KJ`!'(+Q:$*G#<RK8Q&A-"+H](
MY#]P737^J?8@!1YX;C$\8<TRZ,WBQ5W80SS@`P48*Q6M[D>TKC\H`3BXP1]$
M``(F`#>@P`^P@@:@`(,-P1#@`=8&;P/,0@HL`#A^P3F,_\$0Q$$+R$15Z8:]
MRHP>_,`/J`("=*VT(<,6C$`F=(GW1D#?8@;@"@`Z[`(!#($#RX@6D(`BD,!.
M?@0?*($%-$`J<0`-6(`?>,05C\`IZ(`,&(`0?!`?Z$$-K,%,IA4?U`<$/#',
M$4`%^0,2S(&ZGHH?1(`;N+$_O`%G&%T*#($=#,(:I#'B=@VO4C!%ZL);>"%_
M\N=$&D6-J)T&2$<4$6M8J8!ZG14+^\.ESLD@F$$1#,`^3(#>:@$(8,$^($$I
MG,,`R``?5,/O"C$1&S$-Z$T:H`$!M,#GO4%O1#%(8`%&Q$>RS4D!](`U^,X"
M?'$)N(`).)TU\).<%8`)H8H1?/^!%N1!&8#$8=Q`()B`(J"!Y@0"*YRC/U@.
M'R,`!U1!(/N#@UC##;IC2J4`"I``!.C`')C!],*`-62!#M0`"*P`.(S!+5A#
M&LC0&*R`/;,G"["`T8F!#^R#-8!#BSPP*9MRY!K','373;=RN<&F531$"-?R
M+9NLN9GH4)=F5@!6";B!'4B``;P",BR`"]#`%RA""BA"![#!!B"#!+"#"P3!
M*WS!!$Q#&1B5/.0""/R'&&"!)N1"&<1K`]!K4*R$"Q@!"E"L/TR"&H32"MA9
M`+`#&R2`$<Q!.FP!!+B`$#2`%L#!?TPLJF2#S*7``)B!'35!B;P!"[3"&RSM
M&[""'6C_,06.P#Y%0$*?`@CDPK@X`TI-`@C(@SRHP;GXC!H\`BE\!`<\`L;4
M0!;$&0%@`0E,@!Y\P&Y'MC^DPQ>H]%V?`020@`3`M6Y8RQ149(#V(TV?!\I6
M5W#F=,;.!43R=%4H0S%84_,`M6IF#5%'9#;F,JKTG1X>+D[$@M?R#!BH1@S<
MZQ:-P((0P&:30`%(@$OPL3]H@VA_!*DI`@C`[2WI``J04@?LAY^H`>Z`@RUU
M@4+YPQ?,01=OP08800.T%(8/`!B047$;W2ETP1A(P`)XZ&[\D*/]@Z$][G1'
MT:0:A1>$;M>(]W*0-]J5MW&J4AR<.'OC!!J\=Q6P@!V1PKU:__87$`I^<ZHF
ME-*#R((.G$*`LQ4LC,`9Q$$JO<&?^(/2#I<_T,"$YX(:=,$'8#@)V$$9E/D&
M5$$/Z``&A#@2ZN,23`$4M+ATOW@FQ;A3>"[H:@LA$(("C,*?9X^NH+)Y'[HK
M&S569"AP4,2/Y\0/0,`>7/8I-`$,P$#:\@$36``,@`$!\('.6``K?L`Y6($.
M`'A"LQ4"$#8Z:,(T_$`#^(.:AD$38,$K],`")%P'V$L`P$`5O,\'!$`*7#:(
M&W=^AH<D-&YQ*D<IX[ESZ#D'>S`(7\LK"&N,X;AQS(6.T^6CMQ4?6,,:*&8<
M^,`7($/L<H`U%($.\`T'C$#ZW,('@/_VT4U`L&$6%MB>&PP`-D"`$B"`-TR`
M-BA!*PB`+=P",MC!'32!-<0`K"%!'"BF/V3X+IRIB]R*M)A==.=%LSN[<D#[
M4\1R,6B+%UC[4U2WN4U!<1R'R9,A>G>[*NF`/DB`%NB``-#`;$^"!'3`_YT"
M!W3`&PL`&W``,N!!`M#"`AP"<ZO5*?#!&<A"?$A`*>A`"YQA#LQ,`AQ"$\B.
M`%S]S"/`&=`"&YQ!J?;B<EP`-H:"+O"CQG,\C/O(C%?)R$<1H[L\W=<]3MQ*
M)!P`UO!"<+HXVQ^-QUM%-!0#D:@'(*"`!:QE\\R]W3>^X_O#K9`!\DC"!1R`
MG];%QO\]703_OE5XP5:>1]P[Z^.//NG3"%0(`]KW`I2J/>9K?O-P?E:X9I\K
M1^C_;.G?/NZ/Q(E-@8I-L.MK"^QC10<3ZK371>TO?LOGOO(_>J`-6J'Y_N_[
MJM'$<MCEQ?&OU_)G_^AG6P0ONUYD?O1?WQ!I`(U?Q?6OL/:GO]W?:6=!?_A7
M2?`K!Z'2;.>3//:K/_XS_[9$G_L#Q#^!`PD6-'@084*%"QDV=&B0RT.)"[V@
M<>B%SD2-!Z5(\?<19$B1(TF6-'D294J5*UFV=/D29DR9,VG6M"E2%\)A':5L
M/)C39U"A0XD>C%C4)YT,,V`@Q(A48L>;4ZE6M7H5:U:M6VT"+2AE_T=824B]
M0C5[%NV_HVD;XCF2H9@R+P:?LDTHE6M>O7OY]O7[5V79@4O^+1%&AJQ=Q8LE
MKF6L4`.7#'0S/B:(%W!FS9LY=^XL6."P"\$<\$IL&75JQZD7'FFJ+,,DUI@]
MU[9]&W?NE*`%&OM'9MAIUL/MKB9^$"Z=8L5FS/:H&WITZ=/W\OXW15=VX<>Y
M(S7>G6`?N,OGHJ9-'7UZ]>M1\DYV@1>OL46M@[?_\/M]+LN79\!C_CGV!!R0
MP.AXL^&`T+:[CT'\&BS("R^.>"%".0`L$,,,-01,,%W"^M`TA'H2*#MA%*KO
MP10)RH_!NE([;\,899R1)L%XXHFP@X8)<?\)*8([4<4@$V+Q/A<!%`:8))5<
MDLDFG7P2RBBEG)+**JV\$LLLM=R2RRZ]_!),)?L1;!A=?LP1H1"A<``Q((5\
M<T4XC;2L(V,.N!////7<D\\^_?P3T$`%'9300@T]%-%$%5V4T48=Q5,*&]O\
MQP8T#0KQ'V%"0<B&['C)#M1011V5U%)-/1755%5=-55?&OFFD7)8G9764G%X
M)IA:;1"J(SA]_1788-&RL:#Z,+VNTTF+%39((M$:9KY_=!GQ-RD0(\/:?^9\
MK%=FO?T67'`%,VP@8:`0T0$;S.TV(13#58VU$&V09$1S_X'"AG.A$&9;QMA]
M%^"`!>9.,!L<@$+_%U\NL%0H=P=6S%FT0HQTQ$BEU6[:?A?[]^&./?Z8*-#(
M"">L8*!R&&2S(B8J68%,DV()2:8(+2==R*AY&(T5XSCEGGW^>2#KI##Q9*`7
M6]DLTVR00N;?I'VZ9FTK>Y%:HZV^6F"4Z<,Z+:21DF**7?^18E?$EM[U;*F'
MXYGKMMU^4^N0WX;*:^)TMHOMN?7>^[BXA_*;;Z/DG!K`P`T_'#7KIH"9:+D1
MUZCNX>YF*^_'+;]\(V+_H?>Z!3%7*'+6)D^K\L]-/]T@&T/Q,9R#/4>]H-!3
M&QVMTF&_'7/0.I)DZ:)Q%_Q-VL^R_??B`Q>,C"6`FV**QO\V/O;!UZX:__KJ
M#4>>]YD/>_UWV5$3WBSBK1_?:M"@V&%3LP!'O`\NW*]`2/"A$I_\^GM>WR?\
M[;=,_J^IWQ^`/].?1@880+OTKRCT,^`"Q669`C+P+`@DB@(A6,%?/?`A&+0@
M420X%`IN$(0ITF!#1AC"C7205_\SX0KAYD`62HYP=%+A"VG(H!(NY(8UI$@,
MN35#'?Z0.#EL%Q`7,X-H1,-[0?D@$9FH/A<VD2T4H,#TH%C%Q#W1BF:1(A6S
MV$6V"!$A8*SB%IWC13.>18RI.V-1R$BU-;[Q>8])8Q/;6#@XWI&`/K'!C\;&
MD#DRL8XRQ.,@,[B1I6'G7HET$R$E$L@>,A*20__4"-%"T2EIB2V,D7R((_WE
M0TT.<H`\J9D*.Z6+3]4*E:E4Y2I9V4I7A@H(0$`E)C>RQ$]F47_""(XEIV6S
M3-YR(9S<F">!^4;\"8->AHG:B99V(V<^$YK1E.8TJ5E-:UJ3CP,3YLZ(6<PS
MXJ^9/^IF=B01#'.>$YWI5.<ZV=E.=[X3GO%<Y[$$MDV\==.;7OQCT'1Q`!K%
MA)X!LR?E\)E/7#JPGU@AAC\_XL^%^K,7!R!&2"9*DE[T(B\!!=A`25=0@U9Q
MGR1*:$JPX8@3L&2AD9"$/WS!4I8>XR.1$(D_C2&27I`FHQ[C:.T\^M$FAO1B
M##6)#@#!`!&(X*0H#<;_3?VQU&`P]`"]B,0QCD&,2!"#%\8@QC'\F8Q>\,*J
M%^5J1:FBT7?M='@]]2D1@9H=H7[D!#R0ZUR->E01S!6O)2%&,$)Q@&`TU:]0
M]8<#L.H/7ABVJ7;RQTIY<8":,O8J9@T76L.GUK7^L*TC+8D.M%'4HYY`!RWQ
M!5.=*MC#GA:QQ`A%)'J1#,.&8J+!.(9,K2)9<%%V?I:];`TS^];-EI01VF#)
M5?WYU[_VHJ7&P"AJ#]M7XWK5L%C=JV,CJ],IEG&WQD2H;TG"66V$EB7&J&E#
M0;+0B48THG;J!3'82U-_+#2B!^#J,<9;UHXQ(P0AN*X=L_O-[:Y$!^#-3"\D
M_Y$,F-;6?K;L[PI[^T^8V!9W"EYP"!M\$E00`L,8#L%*K`K32!S@JJ$XKB_(
MZ@^8EOB]OC@L5R!\.PE/>(,5-@D%5%#C&@-@);!-,4NG2UZM8G2]H:BI1/T1
M"6.`-:K^X.Y-6@R[%\.X@C+^2`@RC&$%V+C&W:@RADEBC+XZ%[!/;6@O''`,
ML#H`L5YU;4NS"E,2$Q;!]7LRE!DH99+0&,LX3HDQGFM</IL6L:@]LE;9O-+%
M$J.E<2;?G.EL0#N/!,\VUG-*5AJ,O395R:XE1DV9&]VJ^L+(AC7&2KF*E2:C
MCM&-!N"C;](+^OH#O0VE;FM;:PROVNE.KGZOFOUJ3O^,5N74ITNUJNW':MT8
MPQ?R1;%-@FVZ81.;?,:FR4.53&2;]**^(<GV26JZ[8\T^W//AK;UI"V2/KC$
M%S`]1J*Y/1-BH#DE7WTW2<"-.7&/&WKE!LD1BJ&!EHC9K_XPADP_G(SV5C6K
M2H:I?(W\85A?5>%:E6]TERI>F[X:M2.I]^7NC>_BV?D(&A`P'5[0'PR`I`]'
M.$DPDG&`9#QUW2_GJB2.\57$6CJP)#XM,9(1B=7*U\`V/ZPD="T2@X<BT/1.
ML&X]ONK_HB0:_%D'2P!NSHJ*N<V=-FS`3SMQ6(,:VV9&+($]O-2/T%?K(MFX
MY3K>]-OI.S+N<Y\75I)N$R?_F^9^G6\HCN$`+P/=&%S]Z\X;.]6Q\MWO*Y:$
MMQUP``<(7>ER9KK;ZZ?OF%#[3IO&:#!8^]Z+LO>\&%5O5*.*[6J#F!@7C35M
M;:IYTO\Z)&M_7-LI?SK+5Z7`,TD&V$<BB26O1/:(HWWM/Y?9<LH3^<E7_O*5
M'_S##9_XE],?&:`0'&'P(A3.2UTSK]E][W\?_-_/IO6@'_W'X<_ZFYK"^']B
M_@1.WOT?#XHP<D*&4)SK(,+87?CYWW___Q\``U``P4_[)J+\XN]X@H)<!$(2
M]&_\]&\`(U`")Y`"*_#_"C`JX`\!W\XG#$,8B*9Y?&0#>6H$+0C])$$7F@<*
MR(9O_W:"C]*&(430>`ZP!-\&J(Q&&'8@'`;"`1R`(1##E*"'!FNP;6[0:"1A
M!Q!C":!`7JR/;(;!1"0A74Q)&,2&;#!P]C20"',G@'1!"G\C")EG&#9%/D+A
M`C9G"AU`%\(A7Y)'"X%F"+?P:HP0:*9E!\(F",.A)W9@1_II!Z3%-()P!Z0`
M"L)!%[!0^-Y0#A&'#@7H'TH#$/_A`A)D!VS@4\`"$.G/-`:Q4BX@&5!-$1?Q
M>@!("BJ)#,A`M2X@HFRF>1Q`$LB@$I=`#Z5P&)*0YGR!ENPM%$61;QJ1%^]B
M%W]Q;GQ1&`TB#HL19(@1&0?B&)>Q8Y31&9O1&0?FE%[)&A&O$1NS41NWD1M7
)B7.FT7@"`@`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>y04571y0457104.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y04571y0457104.gif
M1TE&.#EA40+O`.9_`/[^_C4HC\9U;O7U^;A22=W:ZF)9IWQSM5E/HJ6]U\O(
MX:>BS<;"WJ2=R\Z*A):VU8-[N4]#G./A[HF"O$0XERHJ*LW-S).,P?GX^T!`
M0.#@X-/1Y<*]VVI@JW9MLIJ3Q:RHT+VZV6!@8/'Q]N#=["<9A["LTM#-Y.GH
M\;;,XNW4TK6QU+FTUN[M].7D\`,#`]NGHN_O[]#0T):0P^&VLOKZ^[B*AMG7
MZ7%EKM+?[/#P\)^:R8V)P.?F\6J7Q!P,@9EI9=74Y_#N]=C4YY"'O[JVU^[K
M].OJ\NSL\]WG\F=ZDIR6Q_?W^NGO]H6>N]O8Y[*=J?S\_9R9R/3T^+VWV/;J
MZ7!IK^KI\YA=9O/R]\;7Z.?E[K>UUH"`@,#`P)^?GU]?7YZ>G;"PL'!P<*"@
MH)"0D+^_OU!04']_?_OU]-_?WZ^OKT=_MHZ/D/+?W>G)QM*_O9];5JMX<\&Q
MN[NUM-;*R?CX^9.?LR,_6YNGOV=#0%AWEOO[_&EP=O_______R'Y!`$``'\`
M+`````!1`N\```?_@")=@X2%AH>(B8J+C(V.CY"1DI.4E9:7A!E;89R=GI^@
MH:*CI*6FIZBIJJNLK:ZOL+&RLZ->?[>XN;J[O+V^O\#!PL/$Q<;'R,G*R[A=
M?L_0T=+3U-76U]C9VMO<W=[?X.'BX^3EYM>VS.KK[.WN[_#QP<[G]?;W^/GZ
M^_S]]^GR`@H<2+"@05_T_"E<R+"APX<0O0$\2+&BQ8L8<R6,R+&CQX\@0T*;
MF+&DR9,HC6T4R;*ERY<PT:6<2;-FRI4Q<^K<R;,?29M`@PI]A[.G47%\6@B)
M\@R#D2G0^`@Q8J1%E`%&!DP#D$7KM2Q9C##1"4!(%@!1S`*`AI5J#29&_T:L
ME3;E[+4H4X3(]3DTF(XQ9+R,*4/FA;HS97CI.//"RQDR9S+LTJ$A5QG#NF0P
MT]Q,Q)B^[(H>'<UMRH<2)4SX86(%AY4GSR1X^/'#PY$%`;A,ZQ$!QS,76;8:
M@%!B0DP`+3Y$F%'C0P<<(:#A_M%A`P,$5OA,ZQ`!@Q\42*B=F!"A.U_0",_<
MTE'&"^9E&G3TZF*8?A?)NC),=*]+QWMD_N7R@A@_H7>,:*0E:`T`'+@P`@4>
M^$%>%#Q$4,,S1_P0@!!^7+$`-4@8$.$1"+BPU0<;!&#<2P"0$``$8RD0``D@
M!-#",U-T4,(-SYP@`34'(("!$`A0L=4$(90W%O\_!1KXQPM=Y.+>&A5X(<,@
MGXE001L5_-5%9'^<(089ZU70A08OE%%!8K?0]X<(&=SW!QEDB!#8"R*$.29_
M8@RB`WUDMOGE'V,(IH.9[GE1&)5>`'J+>R*@*<(+?PGVYIHOD+&FD[P@J."G
MT0!PX0`4+.$'!1'XT4`)/6"HX0@=+A`%!`B`,($'`RR`P`0;H`8!'Q[@P`4)
M?@A1P!`J;F$``EN@T`$""!C`(4<M1$"!=GXP$(`+'*2&HXX\^N'C#`A<8((!
M5V0!@0<D4/!#!$7H6L0)JZ%;W@`X(+"#'Q`LBP"]YC1I()12&I8!&HU>]H><
M+YC1V'V:\G=+G$\VBM__P@.6\:=DA,%9<<2-&;:E".V]1T8&[)W\1P8G1]D8
M?P=+?$MC%<N@,LL,6\SI+IZ"ZK,?)"#PPP=VE-"!JC]LX*J-L8K[[@$_%+`%
M!0CX@0`%+GR`P!4>*.`'"$(@.P$&/##0JQ0AE#"#1U10!\$,+800`!+='O#M
MCCU*D$4)+_Y@```&!#""!R50,4`'2$P`@K@0`*#D#"8P`0("+5"``U,![ZR+
M".K=H@',78@A@ACU2=88&6-T(0.7^;FL<YOOR9E)Q:S_P5^FC\9>P2UE2)9!
M[ZZ#+G/%Q/>^<ADYRZEY,S\W7XT"T6Y!'=)*^Y&AX$V?\,,!!910@`M46XUU
M_P/4<8$$`%:$_>($*_AAP@]<I&@W1P#,\`,'*_S`@]QTES!_CG@3E]Y*@(`C
M!(`"40C<X`K'A/*L0`(`X('7K+6`#_`A"A/X%;2P50Z!H4<'O_-"&60`NC.8
MZ04:R!G)O!"?%PP&%Q1[V,7&0*E;C&%W+SB#EOPS!AFXL`RD^Y.99.!#-J&I
M/2!<V6+.X)X[K4QU:<+%@)XDAC\D$67)N]CR>N:\T42A`!RZ@0=&$(&JS2``
M*'A&"WY0`@ZYX$/:FP`)2O"$J57M:BZ0``LB$(`%W*`#?$!6D"C``"'LX#E+
M^!']=O`#!4C`:!S8U@I*$!T_X*L$07@&`Y"PMPZT(/\``4A@`+)`N"+P00$&
M*`X*$`"5\DP@-7R0``YP0(0AU,.#!B+A+4A(0B_H0#.:\8*5K'2?#*#0=KC0
M@3`_UTOY*--*C_*E!N)3F6D^Z@\DK&9EL"F?]7`&F5:T165X*4QN>FZ9Y;RF
M[8;9S.6UJ8M=!!\%.$`$(@"@"!2PPP2L,!<`="!I`&!``9PV@>X]00+A"]P*
M/G`"(5"@`3QH7XH@X((`1.`$\SS!"8[@$1?),0`-<-$-%F"A9P!@`3]H0!1&
ML(`:[,T`GPP`'Q0(M0F<8`8`0``$6(!3/UAK"GSD0+PTJLC,N7,9*"-4-X_*
M5&1P$9X]J<$*.M`!$$`%`";_($(#8`6-*2SA`$3@@!\`T(`.0&`!':!""'#`
M+A*D50$K(,("1C`!6($`!P<@P0$Z$`)WT28`7HD(``IP@`FPH`8`4``1/D`L
M:&"`!;1L0*NF>@`3/.<$1,`!`US@@0M(C@@[,(()?C2`"6AV`F9E00EH4X+J
M=;"IR7@F;&>K$JC:EB/74<`)(AF>VW*#K`O0*`+$:E3:&O>X1/&M<AFR`0,L
MH0%+F`$'EWN->UZ@`0VXP(V*B]SN>M>IU`VO>*F+R^\J0P,9^"8P9)!>#73.
MO`=YZGCG2U^>E!>^R*#9,!K#'OS&M[X`#O!H[NO?8D!)!)HA0Y_F)(;/C*F*
MC1$#_\H$\<('%]@=\A6PAC?\$`)?6!B-"4,%9(!#]XPP"P9#DS`-U@7WH'AE
MV_PP,S+,X9><H`$FT,X1L,L`:@048-G";E&;AX$0-,!K?K##`AI@HFE@``1I
MA,8)0'`%AWA8QK]XV0MB,`;2*2J'[B&0?U;\Q$0-R)=8GG&-0:4]$*RE`!"@
M1A060($X6\\`9HUR%Z-P@1(`#`0]GL8`"!=H/QS@`(%ER)73S(O3B8!+I!-#
M&:8@LM"-67B5%L-2&7V@-7^*"4+C``!ZL#@?7\#.#?!`;VV+R@#\*`0#I48-
M"/F,"WP@(HOFM)2\4$4=H$$-9-"`@C6CAC80DT"J(TRC-/]0[%SK^IV>3I`=
M(,`#"IR`U%,@PJ$/O8,I`.#4?I!J*E7#:E1V8`2P/@$$MGT`L4:!UGR8P*G#
MU1!G/_O>)Z%QM$7"!`@\V0,W`$$-%,"!@G/@!(@%]S.8$#0@=U&W4X!`!!90
M`!08O.`_FG6/MW"`$3`@`H5>B+WQ3?*+Z'O?()DV`/KM`1!@P`38Q2X5F/!M
M.YOT`$B&IV[O3($"%&#),5?:NWO<`[N-H%96+KG2^W)RE'NDWVLI0@GV96J;
M^V'.K8+JSOWPA`!.0^-^&$'C6M`!ARMDY$M/NT":[O2(#!P!/4!+`Z@NC;)X
MP`HCD$#9B^#:+DYA!SN8U@?H'2K_"00`!#0GP@J68,^DJ_WQ-VE[3YC```8,
M82T8J/)6>E!Y%T0A"`RXP5S@>83**[(%2ZK["2K/H2B8;?2*AKSL3<)VR=O^
M]FA_1XQG?^_:W_[W*,\]AGE/<M\#__@U%GX[HD3\WB/_^=!_AO)#TWSG1__Z
MOY_^.IA??4ZK#@S@#[_XQT_^\IO__.A/O_K7S_[VN__]\(^__.=/__K;__[G
MU[XZN-_]-'=A"U\0@`(X@`18@`9X@`B8@`JX@`S8@`[X@!`8@1(X@118@19X
M@1B(@/HW8_U7!2I``RI0!1]F?-A7@LHU<@I&)@2B@HKR!ROH@BWX"_Q7?3"`
M921H@C@(_T_V=B4+HP&?,08^2"A!"(0_N&D\TW^W4(,R=H,YV(0^8V\:D">$
ML#"#0(51,H4M-AG"Y`4BL(5>^(5@&(9B.(9D6(9F>(9H:(8VD(9LV(9N2(:[
M-Q]..(<"-G+"=`8\V`5D<(5[N#!]J#I:*$Q=6$P94(B&>(B(F(B*N(B,V(B-
M&!AO&(E>N(:26(F6.(9QV"ETN(GTA78M>(4+$XJ@"(HRN#"D808;2`Q*.(*<
MV(KA98><\3G5Q$)_((NU2(NER(0-@8H8L8HTX08J$(SPP$4F@'/1P`)@-5T9
M1'C7<``EY0\W`%;;]0S%6$D*4@//HAU14".K)B$XD`48,`%LU/\^+$`;M.$!
MF-,\D<1517``TP4"BW,%$2!QI>8'.5*/9S<35W@/9M`&,>`',F`&,6`&O^8'
M7V`&T1`#,D`-:_`%UL"+%^&+-2&1H8$-V$4".Y!Z`T`<L/$,(7`_%W(--6`"
M45`$S]@/(QD`%P`-05`JJ4<:!6``/X``?$!6J+%J(Q``!I`%"@`!?<9/$T`$
M,]!G.><S`+`!%%`"(Q`%.Q``'H`M1QD`.P``.!`!2'`!V^('62".^.@/J:@,
M^V@-`^`#"<`-,J`&:]`&:O`%,8`&?I`!SX"0TO"/:Y"0;0"7U0"1%D&1,\&7
M^W<7`7!Y%V"-7V,`@48A>(,!&[`!6A'_!1O0`QNP%.>R`1Q@E1O06SX7'/AP
M`@80`5<%`A10!+&Q`=JX`2?0`@!P`UE``K;D$A@P!#-9DRV02KV%`:NRDQ*`
M6`9@!9^W%BT)%<TC`5(0`4K)%1[PE,_0`S-``3M0`P&``"/`!3^P."L``=-9
M;_IHBM4PEFS`!@\`>]B@EFV`D&?PEG'I!VCP!6.`E@T)!C'P!6U@D&J0`6VI
M!C*P!@7I!WI9$7Z)$OVY#)Y2-+9$!%9G`B%P`4Q!(SLR!0U@6CQ@!*KEH!AP
M`!0P`ROP4![0."AP`!#0E>=P`CLP<5H)`@8@FD'``PB@4@M@!2(221<P`Q'`
MC"&1(0AP(:Q1_P(<%04K(",["0T=0`31\`$'`)Z?$@)!@`!*^0SKHAU9P`.\
M,95(6@`?200GL`)%<)VQ=Q/:V00)T*5>Z@3=V9T/X*5=F@+54&Q@@`8("9=X
MB9!J2I!PZI89X*9OR99^``9^4)YQ^97"\)\FX:?)X"GO)@5\()31,%H(4```
ML`1%,U)QA@$&,`'.20(;$`%1P)E\P``4(`02$`%*1@0MT'?UL'HA"@`A<`(=
M4`2`PP"JU0*):I)1$`$F\&T>0*0?0:/:P00X4`+AP0`7,$<(H$B@EG,U8`"-
M]3-"L`1#0)Q/L!9+R@<[H`!#0`%$,`#5@@`1\`,AX`$%0#X?X!TBE_^=GO(`
MW6FFW=`&:U"7>*JG;FH&<4J0"HF'\9D!/:2?!PD-^TD1@)H1^]IIUZ!W_4)X
M)N`"!L`#(U4#._(VST`$!L`',[*LE]JP'U<#6Q`!*."J5B"CYK!Z+D`Y,X`!
MJ5H#$;`"E8<!3[!N%.`X8O4!_.02-&JC5H"C?K`"Y<%&M]8#1,`%5P"N#-"R
MS1,$UK):Z,@O3]EO01L``/,$T7(#Y1$`&A)K^:BE/?,`6L`-:J"F:F"0[FJ0
M![F08!"`7PL&:O"U`=@&,A`#%:`&%="/:(`&_ZB??!H,_1J1\?!4-R`%L#>P
M-#L!4X"P-P`!+4L$Z/BPEHJI$UNQ%\L''6#_`"%I#ZL7!1!%FJG*!Q2@`*G9
M`TBK`)8*<G[`LK;J$2[P+MYQ.#^@2````#J9!2A@+644'`#@`>3F=TC*51#0
M`>#J!Q@0`?O"!$L0`1,P%E&'I>$JM3EQN@[I!W4)M[TH%'-;##W#`$0``AWY
M#$/0`4O0`U8@!78``C\P`QS@`41@`LK:*PJ`&XY4*T00`!O``@%@`G%U`1,P
M7>:``A```3<P!!!@!QP`(0%G`#C``0ZU!-7FH@50E=T($D.@-1W0`$R@`"PZ
M`T6%`Q<P`%0`+9&*>;\*54R`6E,0!<B(`R#`534``3/7H!SPDB>``"'GE>*Z
M$VV;O,I+MT'1O,30_S,NX'G28`0^AP$C@`%?5``D,``8`,07T@(%,`(N4`!7
M``!Y)`$%T`);4``2,`4N0`*-6P\#X',M\!9,[',<@@**I,-&X`(Z3`+&4@`O
MZ8H:%K<'HIU'D:\'0</Z6K=J7,>VQ<8JX<9&`<<&(<=Q3,=V',C-@\?.J\<]
MP<<%X<=]#,B"W,@*0L@U;,CGL)`*"9!FD+5FL)`)20UJD+5Y"<F\H,B)S,B.
M7,I&88?EU$O8E,JLC$MA20TP$,NQ3`/;(`._%@/BB;;/L`9O^PR5K,G0<$,/
M"<J[(,H$8<P(8<K*W!,C)QE1\H.$$LW0#,VY:`T$<,W7+`#:$`-Z>J]XVO^F
M6NN/]KD&[FD&=;D&[/6>:A`#Z>K)B'S,S$O*RSS/+H&"3-0H5IC/6/@3S\2%
M7/@,52#+LHS-V2S0L4P-;8`&:S`&:FJ>X*S0:?D%:NJ69T"GZ>6UYAF7[7&)
M;TB)'/W1D^B&F<@S]%S2]:P,A*$?5UB%6,C2_+R%72@"UDS0VIP-]YH!WIS1
M[?JN;OD%]"FG9T"7`8BO&PW2:>C11OW12(V&(ZT+-,8'(:!YSZ``'3<:5\``
M"C`%4R`!E5=Y4&O2G:@,ZJ$ZTRS-9OT9U5P-`K#6:PT#GYN0;NN/<HV>9[O3
M$RT#7VO.X_F6,4"?XRF7,;R7\3R,W`"Y*Y"W:'3_%$(`5CL``5@=`0O<`)&:
M=3H1!"9P`=?+!"&P``N023=@`A!0!$L2OM`P9Q[Z,SKZ`0`P`C.071<``);=
M`-7#U2RP`E<]`Q#PU5&+#&+0VZL,3-#$2[\-#*^,#6\]EW)9R<]`1'%)1)F,
MD.O<R5D[D&J0R6O@KLG[S@.!S`+!W9JH#;`]`>!I!!9[%";0LB5[`*;B!YWJ
M&SI1`UP``!A``1?P<5\$4RUE`NK[#&`%#4QK=<ZC=QT``!+`(5S0``,`<GPP
M`^"(`"S`%$?`!*RQDMA)O#J1IKR\I\L[P_)L#7P``9GT'1Y@`$%`WD_@`1V@
M%ZAU;B1P41U`DG-F``<0_P1\$`0>\"\-D38@$`594``3NMY?D[)D$9(X\`$S
M<#35P@#>X:HAWM_AM@,<"E4C*04##@T3H`!S]",X`%<'P``G,!<8L`!-EJ4H
M4=R'3,RZX-WRH.9.O0U($`!0@0+L<AM($`%+`*GPB`-\@``KX"(S4``EP@$=
M8`<7L`,NT'%RD\;\4`,3\)Q4(-_J#0V:FXXZD4`D(+AA-[+/P`4\L"1.[N49
M!%4GP`5H!>80(`0GP*M^8`!4$`$7L`%6$&>S20&BRL):VBB8D.N4T-3PS.&$
MK0U=QQ3749-34=[@VP(,\`'M^VY/`%0%L`)_8P)J52Y$X$D-@0$<@*14\./0
M8/_?/`$`5'#8F$Y&T0$`!04-_9T<C`[@/M,"B%?JF[[C0U`"5=8!D71YVA(%
M-?!Q54[F^8:$?\#F\"#PS*,-+E`"4*$`/2<NO)%&X)M=T)-C%-#L$?#$!]``
M"V`$'+"3J<E5"K&88;<#>!?IJ^&,QRT2)/`!4%%6`'`$$9!)+G`"Z=C?5``!
M#0`MHN8\W]L`5<D`:V$%2F-X$'0`-V!M7"=3S[`""'#R_Y"=2$CP[@#UDEP-
M(#M0^!(!#<`!1X`U?@"^]?L@#?#F!0!43[`".(!=1TP!SF4%#5'!$#0#"S``
M5F`J44"AM?X2$@`!*&`$IAD!#6P%F3<!$N#$_,T#T1#_ZK8%[U'0`5!1K";`
M4C70VJZ'`P,P``#``A3N[[0'\%+/#E(O7Z8J!<^0!3,P`2W``A!`I:G/`/)&
M!=&;^J<&`D:``_5K`-9:Z`YQL8U]V!Q0O_5+F#G1XN8(`340`M&"`O+(6I;+
M!0=D),^`^%`%[R,U%UE@`(:)NS@@(B/P`9;34HY7YIP_V,FU#1B0V^*``1Z@
M>5QPQ6!MTFA.W.'OZ^._#5G0`%+M#7P`VM@UO>T/"'Z"@X2%AH>(B8J+C(V.
MCY"'7G^4E9:7F)F:FYA=G)^@H:*CI*68,*:IJJBJG%V1?'R1A`!"1BTUL[J[
MO+V^O\#!PL/$B).MR)F>R<S-_\ZCK,_2T=*OQ=?8V=K;W-W>P\?2K<OBY>;(
MU.>MZ<[6W^_P\?+S]-_AZJ/D^/O\I_VKYMS5&TBPH,&#\.Z1TM&EX1\-7C0\
MC#A1(D2)KOYI[,=NXZ>.S`0B'$FRI,F3A!2.DD')DZ<Q?U[&_`-39D:/.,N!
MS.FOG,A95XHP0.DH2Q$`(Q3((LJTJ4&5I#20D>&23-6K,5ENTL>SZSJO'P/V
M:L%#08"A"'=06$%(0H0%AZ9X*!&%000739E\^''##P`.!A"@\!/E`P(.```H
M,&"%A)\>'1"P==H(0)$2/[@(:M#!@^,L5@X3GF```@`_@#M(2(BLC`XO+ATV
MC.U2I?^&V1EFZ][-N[?OW\"#"Q].7#B0XLB3_SZ>'.JEGY`60(AR!`/)"0@&
M85@2(%&/$GPPH(CBM$:`OD$B\-G0P4Z1#D(0G)`0``.'#W8BG)AB0`=E1B.<
MX(<)%&31`PY^-`!!#0AP,4`#&*PP`Q\S3-!"`'8H@$`N]B#CB0XPC:%!B"/2
M5.(8.MP$UHJE[+2BB^/PPH<'"(!P`P\;[.`""PV`D`43')BPPA(DA+!$7]UP
M0,$&@MPP`06$*=#`#E/X(>4')0!PP@)9;-#`!T$,P`('5(!@W4%1G.?'#@;X
M@40$"G0@A1\=S+!`=@5,,$0`1_CAP06G_;=(#0Q\@)0!"LS_P(4$)3CFP081
M%.%'"!2PZ8<+%#C6H288:9`B)AJ408D87HCQ!ZFFHGIJJ9]PQ>*KG,#HE:RI
M0.<(`$0TML,/%RSQP0X%>$"$!!Y0$&<'##1P`'G<Y&G`:45P`>4&'PR!@!0#
M2'&"%.!=$,$-<$Y@A0N1F6!`"`BEV1<1'O@Q0@0@4""I!P=,T($?*$#`00!9
M^`%!!X$*B@@?)@0``1,`%$P$$AN4T*<!+`2@@!\GE``!!'ZTH-\[SI616T-G
M].,JK"1?0BM/)Y=BJR-++,O$#P,4AH0?)$3``!<&U#`#QB<@,$(W)-QPE@M<
M/$%!%%9,K,`'4ES@QQ99!H$`"1#L_S!#FR!,8(<'/*2K)@]6^"%$!"%$P((?
M5DQ`Q+T23&!6OP<<$+#`AT2Q0``;8+#`OD>6,!BR9_G!@,$'X/LMQYK(4$$&
MC),A<LF09Y(R3I/GTTO+43`!'A_#NGL8SCKS[#/0:U(PP1$D'!V!"7Z=(.QC
MX$F]`04W@("UUEQ[W9>Y`+@P-012`&``""$@`$`0%V!Z!0`=H$NW(GP@L,$-
M")K0`1(!%```!"Y8P47""!3Q;.HS;YH)1@\]'OGZE%2^D?NAK-S(!R[_(`L$
M$T1QP@%3@'Z!Z#_CQ@T`D(4`[```J0-``R@0`@8LH0@0R$(!2O"$#2"`"A28
MP@X08(<%X/^N:P?A@YI\UX*L1<&"#,"!!(1`@2TL8`=1\(`)GM"!,SVO$$)0
M``8D<#`D6`$`)IS`#$@``OT=H`406`$3*.`"$'B`6=YPSA^\\((J9D!][(L<
M_/ZQQ5;Q(@KBHH()X(4!$GA@!SN0P!0N@(,;Q(T$2T`6-SA`!`8`8`$N<(%A
M&(`!(D0``E6Z`!&64*,%#,\*'V#C"B!P@!70:P`&B0((<+"$+!QO"4OX6118
M<($!`J``=NJ3$&;P`2;=T!`NJ-H*RE>$!BR@!WY@`B8+0!@0+,$$IQG"#';0
M`M9HH@RD8A4_1I9%%G61'\?<RBF7R<QF%D2*8AC#;+!83)(E$Q__UU2&,[?)
MS6YF0XH>8YP(J%G-5V7S'.=\CC?7R<YV1D**GTK?,,M9LG3J1"SNS*<^]RE%
M,C`N`Z*:)SUA94]Q%+0E^TRH0KL)3MV0<Z"S8M]!8[+0BEKT>?"L1$#W04R(
M4DZB^+RH2$=Z$BEVH8HO")E`/0J6B3ICHO(CJ4QGBCA->.&F7HCG)73@N(M4
MY*<^51%+N^+29L"4$2RH5"20T($(,&$!$TL$!F80A&NX,6X'F`$428(!!@A(
M$%D@TQ,$P8`-!&H(#.B7(!1`RUEL@`I4J$$4;L"!``J!`Q((%`FH$*@!<$![
MU^"#`F`IB+UR0!998,`0!,&'$]BQL!RH_U(D[$"%,Q&*"KT4!`84("#[+%80
M*%!`H,(:A+DM0HI_$,$+,H`^2\@`)C.I"4UB2UNA#C4G167&41<Q@#-&0I((
M8`()RH<(``S@`&T=1@T4T*@"'"`")L$`FR@``D&```&2\<,$/%C=+$AA!R"$
MP!(:0-A!1&$IB)``#A"``R:LX`(LZ``LK<`"#_2E`%;@`%NR@(,5'``MP^##
MW:HK""(@X`!\&``$%C`#ZRSA`CM8@N`.8`(/J%40BMEJ(0"P@A\,AG,-6,'9
M:);5#?06!!`0D!EY4%TDFN``FFJ$%$MU4\=A(@,1H4I,K+)CK'1!*YKHZ&TY
M`E*?-.(`'YB/(/^FL($3(`P%)^@!>5QP`B%,R@!,:,$`F/"$&FP`+VZ:SVDV
MT*9BH"``/S.+($;09";@:P1#T%0-GD""0/4@RJ8=QA5,$(49'(VIHKU4`/A@
M%R&8@`%,,(`$>D`!)'Q@`H4XP144,0,>G"9Z)P#``1IP!!Y$X0(34##K#-""
M%1C`;F$K1O0(?(,+N!DU':@!!P:+@"$P(0`MV&[T)B,(8J'W$';PL+LH`$L)
M\R>NDT(`'W"&@0/P8`L4&,$*.B!8`#-BQL&TL26\,,XSB($V,9&-;&R#&^68
M^]SH3C=QF*/N=ON&W<5!+4(9<0#\'8`+(]B9!Q30Z@E(00=/^)\'7!#_`BR#
MX`1#H,`)+F"%&YR@".+B`&$"D.=?'*$$CH4`@IC``PA8X0(@)N0-LK``(OP7
M``R`.`Y,>8THY,)H4="0Q0:P03^X904V\T.]%U##%1QM$+Y#5A8N0",DQ1("
M`:!``;)`@;&*CPNLL\L)LN>'"*P``1_PP^Q:7J/-4$`PS.L:`ZQ@R%Y&@`M$
MF!@/.@!%#P3@`$<X`@0,L("MUL!O?F`0#AKHAYVMP(ZE\8/0Z,.%)7+`"ACK
MP0PJ+@E.J):UF&!(3+Q`HLJ;*$0Z[<20B5ID<<14$`?8`<4H,(`;T+`(2EH"
M"O@`@0AT(``K*#@30K`!$O@L"@BXDP&:6KBJ_TMV&!>/&`BC$(0;&(`"3)@!
M`Z)`=PD@0`$FL((=$-"!#E"@`=Q8`%S\(@$*F&!M^$+`#@)'&J+S85];94$!
M:D`$2:4GQGX8P`0B,((`2&K:"T#7[#A0`EA&0"W5E3I<1V!^8`0>P'8((&$,
M@``7T`']DGL3T!<+$`%0-`3J40,&<`,H8'6$<'>#(384D"E\0`$04``&X"U.
MXP(EL`%G@0%69P!$D#'YXPCPY#@ZD'F40`9B("JJTH.LHBJVM7D:D5O)L%N+
M$'I^4``4(`03\`$<$`+K00$!(`$'4%U1,`*R1WNV-P*X=R>.@12"$`&_)PQ7
M@&8$,A1,``&*@GS*)_\\"T`A5M`!')!H=B`(KR8,`P!J1#`80%2'@^!!X.<[
M\3(4$.`!,^`!?%`$/S<(ZG<$@A&&V$<(2R0$#1`!?L1BZ*(`-H-W\$)=?A`$
M4`(,+4`$$R!ZN$>`@D<!#**`'?`!#N@'"/!]?6$8%:@>6\`O??<L@^"!@K``
MCC0#FK,%`)!4$>`T!7`>9[%$!1>#5V!I-+@)9*!2IK)20O@^G5<-1W9`2S`!
M=L%F(1`$$H`!.#`#H*88&Y"%M7=[N6<%!R!<FN$'BPA\`2`$R1<!`&`M0L``
M;+A\=*<W19!I4=`!@%(`U@8,44`""(D!(P`"1V`'=_B$D!)S$2`!RH>!)W#_
M`PC@71XP-^K7`EU')P49!0=3`Q2)`ZC3```@!4<D1P@@`2W#867V"S6`D'AQ
MBH2``A-P1\NB7\8G`>8A`>W'?"@Y"!;(!T<0``*R!,XH"+QX!!'0`G(1!7""
M<@C`&5'``6+8`0V`/2C0`$^T`4?QC)H@!J32!2K%4=7X4>MCA(JP`Q#P8D>`
MD0T`:LKB7R=@@@;``RUP`13``<`3+T4P.Q"@`%]W`%5E'F:V!#_0`%EP!08P
M`QJR`Q-@?SCP`6[1&(&!`![0`X.#`-R3#5G``P8P`1!0)"RP9RW`!XAR`9[6
M1"&`B,Q7!#O`<H+``0Q``A,H`2>@-;VV`R2@`*+5_P(OMAK,1P+(@G(>L`5:
MU0,(<`,>@(K!4`O_QP=1L`0*P`%5900=H``[P(4+1@5/]&(65%Y)^"UR=P!#
MX`&K,0A"\`/:DVA%X`+8!YXDP`,K8`3R,0&X%"<-D#\28`4;``&?)6.<,`8O
M4`$6\%!IN0]$B`XAI0@`@`(%(`L`<`1+)P$C8*$?:*%R)0$%X`(%0`(@*@%&
M$*)\T`(%$$`F(&'$,``%\**Y,`(I*J%90`*H(P$25`!'L`!/4`#YYP<6"DG9
M$*!Q0P0G5&^31AAO.0@-0`1)"D948`A,,`%U%@('P**"D(?W=AI$('J#$`0'
M\%4)TWN7<@`25PP*]$8#\O]?@T`UDS$%,Q"#?L$%$&!E'6@"$R!7DIFD&.9?
M'^!F\H=<@O!BSB-W(V8E65=8C00)\K810K:@][26#SH/`-`#5J!A\P`"!S``
MED&>-/6IQ-"H&O&HD#H-U_@,G\<-LB:D!#$%5+`##0!8H#JKX``*K84/I%JJ
M+W6J[4"KOOJKH6I3(H!3L(66NHI,O-H,J0JLS-JLC9<)9(!2+U"LN'JLR"JI
M1N:LVKJMBC!C'I&KUNJ@V.IYW%JNYBH(\)0;&C"-QAJNZ)2L(7&N\JJMT#1%
M.G!%U.BN!@6OR;"L`M,""L```LLAC0!Q`5021W`"%\98"%D(&'"'?C`%)]`G
M=T;_7"-``K_V'R3@9(4P`''&GB<`9C0C:0&#`@0[`)FU#3-6`17P`AM5K?IJ
M#@WZ%=GJ32Y`(PU0&@M+:1'P@21Q`XC4`!"+8F%J7K-IAR]V`#<P!*VHM(\!
M`AVP`79*&5%`!4U[85,P`6HS,V:T!%9P`H36`250:X\Q`QTP:5$P!"&P`!RK
M#:AU&\[Q&L<0#G1;"8T*KC';(OSJ(>VD(&Y2`BMP&@#@<-I#`ALP!4]P`C,C
M-1N+LAOP@20P!!G[#G9P`,\B&FL6``L@!0$`27]1`A.#`1,`NGG7&<R#(!Y0
MB-<G*(PF!5%0`MOG!Q%S`SMP`:)KCY9[`WQU`(L)`%A"_P&#(00!T`%$\`-?
M]4V9`!NZ0:V58!6F(A/0.ULVL15Y&ZE:-*G<Y+=94`(@(+@,4`(HN32/1B`8
M(#5[<@(MD#M#T@&F,0]"@R#%&"@+4`)"\@-5=0,S`+H`P`4_0&`D8#!^0@&]
M`P$U,K5.L0+<"X\S@&$'D#V56#/9\0%XXW(>,)%^@0#`ZQ<*<`'_1;#8`!5=
M\$^,<Y:6D`$BH`.W,7FUL<(Q<:O/4;W[.J[8R$X-4)4&@`-3&T-.LP(2P`(!
MZS=2@RD"PII\$`$ST,"L"@_?6S@1<*F"``$E$`(FD!E/L`/?H0!,@`,6<T$5
ML\`'4`)V@($$C*E$H9@21P&`0O\8"!`!/=``H#N\?K`7(9"&/V!_@H#!'V@7
M%+`$C"<,4/$I-Z4!+CPJPPINTW3(Y-80'^-NC-S(CLP;\/;([1;)PW&W?=L!
M)^!D`T`$7V<'Q=-I-1`$30C$""#$?L":2^15&T#&2?(#3/Q$H!?%4^Q?@U0"
M$1@!%*":E?(#"SP7-0``$H`$I24H,_`#B('&IX%[;.S&9G$O6((N3S6V=YS!
M8G,#))!7*KL)L.$XXQ1D*=P%L*'"XMP%@UP)>`O#H3"S`%&SWN2W@A`%!*D`
M49`%HSD4%[``1N`P0:QPI\P#YC$$QV-#\!`$`=`N$;"4W,(%"_`#^O@##FW,
M$0!=H\O_`P'0-3C0':=D`B4@*0&P>'YA!10@`958`!'0)I-I2@&9';!(S365
M"619!F/0S9:PKA`Q$RYATSC]J.>,SF$APZC:M^V""/$"242P`A43!`L(&2;@
M`@80`1MP`*T(:?/`!)8+`(<Q."$@O`O0`/SBH15C`EF`='9P`1*#`QO9`0AR
M2M!V0`$P)8V&03<PEWUDCW/W`?JAFG**Q_$`3X\'9-N&/G5+"8$=A#R]SM?[
MUP\!9!0A!MI&$=JT3DW4`&=J"%.`)$&P``RP`B80`@W``B.P`%1P`F<:`I,]
M#R@``AER0I"I&`&[GGX@7;!T!1]P`RQ@1ST``N[EJ0*C)50P_P4+8`<<L`2I
MN0*&6R4M\(;$?0(S,%Y4\&HFT``^:SZ8<`P:X-?JL-.Z6@8N09:O%4T,409D
MH`-M4`'3J,ZI0`TQ4`$1D1N4D-ZP42J>X-Y!-J_T#:S.,0:+\T\*"L,R<`9=
M\&U_4`%=4`$:4`':_0<OD`5_@`9MT#[7Z$]F$&XYF`%F@&-><$40/M_UO>&@
MZAPQX-\-8=WG@-V0^FW3]`(CT+)>4`8A\P)_(`,OL`SF;0K1D%,X)N$V[@5D
M4`$QG>,:SN%`3E*B6LZ>5]C-&\(`Y0DOP&UEX.(LKE(P[N#CF@%6).%4OEI_
MH`,54.%5_MA!_N46)44:@%(D?-U&+O_82#XB.B`",!W@+UX!,@!,(P!;,ZZW
M)1P19W`&GV+A:!#AE'#C7@[F@LY/T`@;9+G?,'Q3+YY3IR(&@CR-H0)D=4X*
M;#GHELY.,R8"73`&93[B9UZ$>QLCES[JZX1:KB$"V@:SGV[8D%/II/[JRP05
M$(%3.H[HJPX*DPX-V`OKO"XP("RM6)ZOMZ[K]00#,"``QEX%,]SKS.[KF2`#
M._@I(AX0PTX*;J`"*N``V*[LKT(`WO[M*K#LS3[N30$5,![L_T#BGRX`W^[M
M]G3MV![O\C[OV&[L]M[NWA[N/TWN_$X44!'>LY7E-N4)I.(X!;\J!E_KA%WM
MFL#N[2X`$!__\1+O\/A>\19_\1<_\16O[[W:[QY?$O_>$)J^Z4'6!2!R>2@O
M(IBW\`R/"13O[<AN[S)O[#1`[S8O[]RN"ALO[A_?\P3QZ]**KY=P4^!LR.)6
M&Z!2;I*\]$R/'&%0\93<],41]<%AR3Y_]0,!%0IA&V10!H7<8V#?!3SV8RS?
M\G^0!@Y```Y@[#'/\02UZU@?]]T@JIGP&EXO>3>=]SA=]@S_!M[^!I60ZZ+@
MZG)?^&Z+##7M4XI/$4%%O69_"560]C"0!I8@^.D,]X:?^;6Z"3)P4^RJZH__
M!S1```+@]E)^V.2J^:I_#?V$4D(/^BU?!>P^^9(3ZJK@KZN?^P2J_PD`_^*V
M?N8P0/INL`F6C^N8K_O(_PC]E-\R#?NW[@:SW].HS_/)7_W*#XT.)>QGG@;!
M+P`Y3_RV7RO6/_Z,&@I$7@W5K@+L3@.@T`0YX``YT`33O^_D7__=F@DL?E)=
MWJ[;#P@P!`)5?X:'B(DPB8R-CH^0D7^+DI6)77Z9FIN<G9Z?H*&BHZ2EIJ>H
MJ:JKK*VNK["A7HTZ&EZW7F*6NXY=O+_`P<*';P($;[^4P\N2RLR7L='2T]35
MUM?8V=2SS]U_OM[AXH]I#@0.:<#.X\_KWIC:\?+S]/7V]ZG<[,'@^_[=-`8A
M"^;NG[I]\/`I7,BPH<.'F_0UNJ5!A\%#_?\N:K14Q1B,=,(*;JPDDEE"B"A3
MJES)4I3$1%ZZD/DC8F/&D3@9!12@@EG)G(R2Y("2@]W)EDB3*EVJ[24B,6+*
MC*G)2,R8,G_$>)FIE>O6K%\AW02*TXW';C_))DJ`D*G;MW#CFG)Z2(>(%QED
M,-)A482.,7_&:``LF/#@P!8?C55[49``-][2,C;$UJC<RY@S+Z5KR(L&#7^\
MG`&-2$>7+C&_G5;MZW1KISIPB<!%N[;MV[ASZ][-^S8<8T!Z"_=B8[CQX[C-
M.$%.6JSFY]"C*^3\[<6++!F@-CHCHS49[^"_Z4T4^]9LY.C3J_=")\Z@.NMO
M%X]//[<3,\>;*Y;_SK^__VG4Z1);!K<D`IHNK7VC8(()BC6902H80\,^DDU6
MV3A'_:?AAAQ^0AT9&51PQ@MD8(5(&5Y89`MH*_[18HL./LA..><40J&,D%PH
M3H8=]NAC?]3]@>(?,H@QWC^+X3C,&P0<8U"%C.D8#H\_5FFE7-3I4(9K-BG9
M#8T.U-"8EXU(^<Z5:*8)%W5E5)!!!E1=E"29ENS4DT90JF5F-U2JZ>>?#5&7
MHB%'&C0GG9!T1,!'(^5)UI[/]`GHI)3*0UT7UN'5):*\V)F3HT!!:E*EI)9J
MZ2.TZ:+1H9PB8M:B9(&:DZC+2&KJK;BJ$N2679@H9ZO-#`)9K,#^0>LP_[;F
MJNRRH'P88@6LOE.L(Q$2,"%CLN)TK##),NNMMX)J0(9IFTY[2!J.V8AML=OR
M\^V[\')"G08DOG!&N>96>^V#V8[4+C#=QBLPI4$:HD&A2)K[!Y@@R=CO1O_^
M$O#`%*LI:*89X-LJDTYZ^;!&$?,R<<4D5\FF5KE,-(8N,A38\BPO$UE@C*U6
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M(H8,K.8%#'2@+UY@B/R-8W_[\9\&UX2J+JA*8R-AV&04B!&H5,`+%/R&"5%8
M07:U98,PW`R9S!<.)@E@("/,&)'$8!$9B*`F1>KA#UNHNA?&\(@L*5A.:/@,
M1>'L09K[@PZZ)B2_3/'_355,C`7%@<%>(/&+X9LA3J(FH_)\YA8RJ(C!T*C&
M0VPQ'%ULA/?`2$<`B5$CIU.8))C@!"84T6`BP(H&`GF(,Z0H1&K(@'5(][LZ
M.G(A2L0)$PDB+#U&@@D^8(,/_,@I':U&-8;07,K.(+_`^,X0<WRD*E<1R9%,
MDA=YM&0D,LD&3>;@EDT@DR?!L9J#$<@0LS&$#N6XRF*>RDNOK$3ZB"=+1.0@
M!0^(9BW9D();YB`!V,3F`[*9@&URTYJW9$<*G("(3Y8-#=`BTDR(Q,A&&O.=
MUV@E"+LAO68>(@G0C*86<FF(%%`S&$P`IQ:XV4UN>A.;U;1F$ASA3S8\`".\
M__3%=RJ`!AV0TA=C."4JX<G1;2R#&R_RC(M$"B/%C$-X#F"FN?"YS0>D8*&.
M>",DF@#.%!A4F]-D`ULT4(;Q\71\AOB"!L1PFEFLTXL=32HLY,D(#50`E4O#
MJ((`(]72,8-C.)Q6$[0039?"M!FM>D`M-XDAI9JU%4QEQ`+#(Q.V:A2J7S('
M.HJUU6ZZM"@'"2M9RWK6OJ(BK8G(F-@*QYIO."5^IY&@:Q;+V,8R5@^#L(%C
M)TO9REJ6LGTX`Q[VX(0$W.&REP4":$=+6M(JH;1%39Y?5SL*P"*B?8:);6`.
M0S^K_L*)#9-10.V:`+R&0Z;=B*,[64M<#PW#J18`B_\NM++<E#&W>\L@(V-V
M&\W><O)&?^1K<;<;D3L"(Y9J>69U<W#=U+5*N-#@KGK]X%I_O-(QP\*)>+>Y
M3[4`]QGH+>=ZU=M>A/RBGAIA*7WYR2\76F:_V^VO47:Q3(.PM)LOE9J!M8M@
MUBH80Y8`L#@>[-5IW9<9^<7(%KY`XA*;^,0H3K&*5\SB%KOXQ3".L8QG3.,:
MV_C&.,ZQCG>\X@OO2!(B]$9=HQEA2WYX&2'>:(6)Z^,I10*KSQCR7>WIQ@GO
M:,E,]BXC;+:HW/*"NE.F,B../(PD?P/+%M8R(J1;"3!;5\R0(+,PS)Q*-,>P
MR=)*!&XM<<WQEA?.<;;RE.S_[%<\\TD1E83$?!-07T`G0]!G(O19#0T]0X`W
M$8MNM*-#`FD^A0(`)"#!`#0!`!>$6@B:Z$&H6P"`4IAZ"M'@`PEZH`D,M"`4
M(R"!!%I]F5+S.M<NX'4F)!#J4$<A"BBX0JV##1T4%)L$42AU#X2MB2QD(1,`
M:(&H,\&':=.#TH\H:2\6EBY$<#@%!-ZT3SH=*5#P`00=.``$7)")&JP@`@&`
M0!3\P`1\X^`$U/8$``J0A1D$@`6QJ$$#.H"`(/@!`"!80"B&$(`(7#LN`)#`
M$@S`!S\,X`,4H(`"-D&!`)B<`@-@P`$,((&'FV`'`;\,#DP>``,PP004B,`&
MA%UJ_PB`(!,DP,$!=O!P!4"@!M_N4CL1T:2F-VE"Y_ZJNG_+[E%](@@E`$$+
M`C`#3=3``R4(P!$`<(((_,`$,>?$P#N``BJ</19"*$$#(G````@!!RT'A1U,
M?G&XN(`"/XA`QT_`@!#\H`.D]L`!/(``Q'<``A&8@!\DX(%]/P<`"%@\!1H@
M`1R`W0`8T(00S-Z`3%Q`Y!$``!(\L(%Z@-MSK3FET^.`A3L06>I39X><@T%G
M4(#@!ROP`P(D7V\IF/T$3%@`!,X.@"P0`0<,```#.C"!`WP@"PH(0`D\L(,?
M+&`"1-CW$0[`@A.DP@@_F+L5HG"`D7>B!SC`00&88/(%S/]`"``8/PX6,``(
M="`$1'!T?L`!\1=O4S`%'@`"'6</?R=X?E`#4:``)<``FA!M_&8`(2!\D%=Y
M!\`!T5$#2.`'1X``+M`"UW8!",`$FX`"$5!Z?G```:``%```%R!QKJ<18G-8
M33<&6(`%HM4%(C`&%X5:1&A9M5.$2(A:/YB$3'A9IX5:2M0G"O`#'L`'P^=U
M"[`"/U`$-V`"RX=V$T""`4`%>U<"!E`""\`'$1`!;?<#!F`%:.@'`2`$'V"#
MIS``".`!`;`""C`!`T`"?><'?#`#"A`!!C`"VO<!`2`%B`@!%U`")L``@6<%
M/R`%48``(,`!/Z``0F``I[<":9?_#4>0<PNX`MK7`):G"05``2KX`3A``2=0
M!$LP``7`;-#!`0B0BC,`<YO0`BV8"2%``1\``2@P`4Q`;*%8#:^W%X1!0(;@
M=$UR)_=22@^23!NQ>\#0>Y\0!0V``$10`L3G!QBP`$A``1VP`!OPA35@!0>`
MB!Z0!0%``2!0`A>@AFSH=B90!"5P`'X0`9B(`JK`!"O``"YP`"B@AZ"G"1)`
M`3U0`!LP`"8W`@B@;QQP`LNW!)*X!%-X``-``0RP`3_`!1Q0`CP0`1Z@@O4P
MB@XHCE2@?7F';0U@!?6F`">``AT@`0<P<[?V''PP`5V7"1CPCIS@BRX(`$.P
M`BY@`$'P_P$(L'FIF`W+6!4ITP@"4)5Q4)7#0D&?-$+%4W6U,@I%$``_5V\+
M$`4S0)+]=W8#0'WP:``Z$(\K0)+VV(8F,)(R*8&0V`HS\`$H8(8E\`2:\`0E
M<`.9L'<!D`69!P`*X`$=\`,S((D+<`(_8`4`X`$3@()(\'L>T``<@'0I28JD
MM@0E0`*;,``>X'[U!@%4$`0!$(R$^1P]T`$%@&TF\`%1$(A$R0E%,`,+>0`=
M0`$C<$Q*<A-::8VY%VC9=66A<`,!<`"H!I1EV9>@^(51H'A($`!$`)$4$)<\
M8(\WH(5U60+KMP(<0`$XP`H%``%VT)=G.)N9@`(4<'0N`(\!,/\"!G``1E`"
M'?`!C@F9DDF97,`"'!!Z$GB20;"`]*"2'7>94;`#$<`$'V``L'8#'?"4'*!O
M)]":%/":FA$"E)D)16``''`!-\`""'`$?I";FL`'.X`!O?F;P1D/4<D/B3"-
M;W6<PX"-OZ"-G[``$;``H2=Z,S`%`'``M$8$3@D"!O`$""`!&&"((+!Y```!
M%-"!%!`"(1!YPM=_)L`*'M!RE=EX/,<"%(")_88``X`#%P"?YFB>)R"/,C@!
M`(!O)K<"3#`!_DB:#&@`*?B"9<J&0<F&?K`"/YD)63`!P<E^QO><FK$#8]F)
M(4<!1@!RA'D%^[D)!;`$?F"6*]<`R6C_1\B4"$5R5#A*=<DY:-]2`Q]P`B=@
MBHS*49\*$3,*,*5ZC5Z)+.\2!1.P!`WP`2OPE)(FHVI6J]AU7D;D+2[`JB\9
MK/,PJQ+3*C+04\!B`Z1*)F+0!C?*+<RJ5,XJ,M#Z!_?"*60@!ZU"!F:0`,:)
M5-O*4=U:"61`-$OG)6+P-5ZB`Q5@`Q]$)F5@`WF@!P>VKO#4KI4`)_I!)R*0
MK0G4!3`@`@6+(UKB!.&JG`#[3@(K"600L9PB4HBBL/#3*DJ0KY$VL<94L7?3
M*F5@)*WB!7(`LDJB`V*0!\<JLJI$LM!%K$]RJ]HJL\747HGQ&09#&CY+),XX
M;C;[#SK*"SRJ_[./Y%I;LD-D$#AB\+2C&JVF,;2_4[1&VRI"T5O_JK2.Y%JI
M015#1!-B6Q-A4;-8*PY/,`=0,`=/D+;ZY;5+&PRIH4-8]`=WBT6IX0B(U06*
MU82`&[B".[B$6[B-%85R.[?`$+;`5+:-&QK?D:YP.[GMEKAUY%I$M4-&4B2;
M"Q54"U24&[J,46>6"S1@.RA!F[JD(0-6*[JN:RBE2T<T^[JT"[NQ^T6S6[NZ
M2V&W"T.Y*[I<HRH:D`&^X@@6T4"[JZZ]Z[O)JQ%F4`%/]0=D\`(%\U0LU+SI
MM;S,B[W_X`5?\`)FX++4*[U?`81E4!.80@8H)`:C$:UE@+!I2[K:*](POQNZ
MMP`GND"])$0@?OL'^DM!+.1`!-NPKBN_\PLO]4NYMS"]6$&]_2M!&?._H4%!
M#B0#T!L#R6O`!_PM"3RY!5(!H$&]3O4'(-R__ZL5%-P%;4#"\(NU&KS!S-+!
M<$L&,V$&H2$3(P4:)=(=L_"^,1&MZJL=&0S#_B/#W'O$W4/$_6/$2-S$OY,%
M%A#%4CS%5%S%5GS%6)S%6KS%7-S%7OS%8!S&8CS&9%S&9GS&:(S%16.X;-S&
<;OS&<!S'@.L7D5/'=GS'>)S'>KS'?*P;@0``.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>y04571y0457105.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y04571y0457105.gif
M1TE&.#EA-0(!`<00`("`@,#`P$!`0/#P\````.#@X*"@H-#0T&!@8+"PL)"0
MD#`P,'!P<%!04"`@(!`0$/___P``````````````````````````````````
M`````````````````````````"'Y!`$``!``+``````U`@$!``7_("2.9&F>
M:*JN;.N^<"S/=&W?>*[O?.__P""P4"*2!@=1P2AL.I_0J'1*K5JOV)L!@$`8
M!@H'8'1H&$0*@T&1;;O?\+A\3J_W'H!Q0D080PX/22(/`0$/=HB)BHN,C8Z*
M!@0+`2-](@("#`@#`02%GH^AHJ.DI::CA@1[$):L8PX(!YZ=@B(!>7ZGNKN\
MO;Z_*$D`#0U\?@L,$`(($(0!#BBYP-/4U=;750P&#;$#"00-1`<""0Q$`0H*
ME"?2V.[O\/'R*.LX[?/X^?K[^O?\_P`#"ASE;Z#!@P@34BFHL*'#AT&>S6,(
ML:+%BS`6(*`XC2/&CR`QYH'@@(D[CR%3_ZH\6.`!`W4"XJ%<2;,FO@0+",2"
MX`7>3)M`@U+[UF#`B`$.C)X4RK1IM01,`&":BLFDM9].LVJE`\:!@WK\L&Z5
M8L#JV*P%$(!;%5#L62?/F+T=J\#L/[=S;10Z6BA`D@7CP.:E>:!G0[R#7S!P
M0$!23!'C,#%.5F"!W<06!QA8X/*R0,282=QJ((:,8!.5E0(@\,"+TM`5'0@X
M0TTS@+H0--,6,:`8A`)J+H,./4"2EUHN&K`=,$E!SN&PL3'QS$O`K0,`-+<2
MD?-2H<<FH(_5W*#>ZQB`<.59I@1Y](`%&+2&M\!!,J7;%3`@\'L6`;OB.06&
M``0(@!L.?25H%O]SN[V'3P`-Z'2:-0,0*`!^?M2U&@2=?`)6`84DX^`)97Q1
M10#UL36B3PJ<]XY1#<SGRA^R35;<)^>!&("(#I(WH14&R.;BBK_L^`\;`##@
MAR6<!*!6$LHE(%=X#CKYP`(FP@'&D$3JTE5I_`2PS1[>W,;$+2/L%<U[!]A'
M79=!1:)<4P%^Y%<H#[`!IRE+9%5G15^JR$B;1>W92&$$N.?4GP\A\``YI/3F
M@**&QJ$99^:\Q:A#!YH21J5V)##;8)L.-,!(H&:EV9M;E0I06H_^N,L`7*;Z
M1&&Q1N<J/_(AP.HIF]5JZQ"8_MHJ4P4(^XNCE`X+1(/O[1K/J0ODHT#_(,[Z
M<*FT*G$KG:/6Z6,`MMGF@"N6RL+FK37?^/I/L^7*H!&\(ZY;#:WQKG2`H+;:
MR\NI#O`K4`+0YGO"I7C$Z^\IB);7$"!3&AS>E5F6NW`I+67Z$,02GY``O4U9
M-=V'GEW\2`$@*U19Q.465BUF6W3Q11A^&$#@`D:EL<::^`Q@%\)Z@C3`)N4B
MK'%B>.AAC!(0?).$,X>PDX\`+Y,0X6SI=KP/=5(5/%@DDU0BC<T<^C>AR7`D
MT$`>/H]0EE!9GX64-)KMF<HJV_5FE"R?('<+%_,@I5]C7@/5A8-)6O8'N,:^
M)0PQ2U^20`![.`.-U/*L)L!MX`FH470'5(MB_[%[:L/-`=Z`0X1:C5&"CCH\
M4U-`.0124L#E(ABFZN>AA0L!-[;*&@/:4F@.0`)*";`V+O+%K1)SOI$*2FXX
M:PT#\3_,S@"!*QR08%]R"ZQJD&OUA0"/UK.`?0]7'^]\^@^U-)MZN!0.?PGK
MT\")5-&_OR+R8TG9_520/WE)@@%0T1H"JA>4M+!L@#0HH`H.H``SD`&""_1?
M0]*BD\9!,`421`V!8/&V#XX``9.B"0#PH$$38@X+VJM%`EUH`@1$+R7)HJ$]
MKN`DQFRNA3J$2%J`.(]RK,V#NK@8FI2@``$&$22PRDZC$!"`V6'))W"1BG&>
M:(-1-61H.B&B/+9PA/^DO,-5*!N!?@#(11L``GT'&1H2X0$BI11`*NN@#0"$
MYXL_41"%+FFC#T+W0'ZT31^UV((1QL&C!@A`$'>$U&]RY\0DWH`)RFNB(('`
MG,[Q8UR%_%<:1K"]=71B2HKDS9U2<+MZ*,"35Y'!_@@$QTT*@1,`"5+8<!`?
MY54L"+.K!R9(V8JAY0)$<TQ!&18@`#&(411N.2`;0S&`[2TCF1VCX/$4`0`'
MV"\&F]G#'1D8`S5QR()\X(\(;,86<WYQ"[C1#6\,,#DE!(<$.G)27\P"'!1^
M\Q%M,A%.Q/>>E_```;/9$6`0\<P2,.<\"I`+,D<@%8IN9YBV*"%0K`,`[&C_
MQP\C>8!1K!.`SG7S49)X0,+(H-(&P.X4G"@#6)!B*$(U5`2`(T/5WI"6>IAS
MHCC-Q2WJ45$T>!,RC7F,S7:S3=C4YSZ1*PT!RN*?J)1D`:21WX5X4TG(!$`I
M,4T3`(QPQ]VD\@^9(.4C;5&@$=2.K>!Y*UJW=PE0/#*MZ_PE9GJS4!D`-1-"
MO>(EP+-4MQ+6B\J(&@16DXO&6+2Q_#G5HW:#40@4-JAB)2I;VF02"%6J0@7"
MT-+ZT*$.431)CF2,;`R`4$$PTJW3ZP1XMN=:O$)`260%@%G'JLI:>.^F(W#8
M49*R2LLV0!"R):7&PKHH<HG);8AU[#J]R`VA!BQ-__4`*H>R6\4T81,-C^IJ
M##2AE&>(=RXPDE$K%C`&5=RH$Z_APE<(1``E_>&KO?5%0&TAV!=@9Y&VQ00D
M=7O!+$`($RUR@W:'8=$I*6\$VE4!3EY#-C<P@(\YV`S5C@LJ)-EW1A#0#TU_
MEP`ID6`U9^@H8T((A5XN`\,QJ*,2")R[Z;UVG5+,S7=3\,HD4`NX)S#G4&$+
M7:;:3XQ!VHA&@$R#'3]13',JTX%^BUW\-<:1C@IM7IAK608@%QPG7.L?:+Q=
M.W*I,B5(API`!.'BYM2R8%(&>(9L"R*NE`94YJ$`%&O+*.23BH5PSGG?(N0]
M&M9MVW'LWPB@)UFH<[';>?]4D2D:M#0Z(71]/9FC<MSG*D@C=$$S80$>8X2=
MA8*Q`.T#DSL]@W8,;:LN).]T5RV%M(3"R:S>H0D2\!4:VFP!R*"U0=+"XEP7
MI#+%SC4,G!D'"'5&V6Z@R/:$#>T@C..H;H@1IZN-!8[P&L;<=L,S2M(&U(4[
MVBRH3*C/;0>]/D%MN&,WNEM@0VK+VP<$<]$!:EF#?3_``9VZ=Q9^LIE!"SP*
MHL(#)G=I#R\?'`Y8"=T_'XZ%AEG65SM]P2V:27$ZB&5H1.OX'+R!%%JA:LTG
M-(Y&1?X&O`B:Y7/H"7VG0@;)-"9H!H>Y$Q#3)H+J?`HE%<U7S%.(G/^\>#6H
M$+__CRZ%!C"3*O]A^A5,(F,EE.P&TY:ZUO,Q-#/$A+R]UMFZ*8H#7AM]ZV@/
M11B843F<71%JL7/C`L:>]KK[@CFJ;II*F5':Z>%/!R"WM]T'CX7>7"G$-E0%
MWV@AFCR$D@8O)[SD32$,6?`-`EAM1B'B?>(>]'SRH!=%81"@GRZK+0FO^U&I
M*I3LT+N>!>!^80^R_OK:`T-:!;>][GG!+8GO_O>E\%9O0@[\XC/"7L[!M?&7
MWP1_/2/VS(]^%!;&G-9+?_DFH_WUM^]I*N2>^^"??A5\'_[R"P%[PQ>\^<&?
MO\BO__VZO@+YX4__5K=!Z?7/__5:KCC]^Q^$</`,/O=__[57008@(J>B2:D7
M=_=G6P3X>YLQ!F/`(",P=)Q'=G(``/WW@+H'"-.#0@2V>(DB>P%X71S8@3G!
M#*J&!WWW(2%2!^EW@J]'!+J5**7Q8+/`9[_Q@G;@?C(H>>BP1]42)!5""6+'
M@',`:C\(>MA1"[@$85>7"%VG?DOX<]:'`M]6A=QWA2@P:DNGA;_'A2"4:6!8
M?&*H3`!7AL9WABE030*@?&K(<FRH`L\P<7%8=W.H`KU1*'?H>GFX`KPV@'VH
M=7^X`GM(A8-H2X7(`KQFAXDHA[W0&V_XB&FWB"Z`(G1'B3!GB2Y0362HB9M(
M#:'#`(@(BO?#B3'@'()HBO"C&?_XI495AH2_4`".!(>LN"=>B&8UECLE%DJH
M.`//D!W>\SW0=XMP<BTQ(0AJ$UG^P26_&$'U03_=9(P*5"!),#D;TH(D>`U(
M(6:70(U:PP"<,0Y:1%6?T%F.)P_6L0S)`XX&\U79X0GK,568]QVR:`U*Q5X5
MXH[Y$A^DQQ85!APKUWGQT#E!(E+\V(\U\(PU0%)]P6O8EI!<Q)`TL`722"V.
M*)$=0Y$],#01J9$?Q)$^D!8?"9+P(Y+9XT\F>8HJHY(KJ34H*00DF9$OV24Q
MV03QT5\UZ2PWZ00`LVT[62D]^01@@`RV&)1,,911D&1GAY1THA(E)4E.62\T
M,9.E.)7_*Y!/"7*5\T83U'(T6$D%FT,_OH,-2ID%-B.581D%L&1H2X$L"\1;
M:_D$;UAT.%6,66"`R=`F]64+Z:!ZXZ,1JSB7Z58(%HD)S/0`R[,*;KD($;A8
M30-IE&"!]Q@4+B.7A'D".F*1"$4UF+`\ZO"*RA`>>"E_#^!W30,-(D@I9\D5
MFX%.3MD7>6!-3P>:=ND"8ZD>9;D(H:,3P85Z9H-//#@7.;D3X-@D%NE(G@E8
MQ^-.ET2,HJD(-!@)2>!P29"#13"<@R$E`'>4W&>8>:"<3Y<'H=F4[A"$*&)9
MC:$*(:8&F=B:C$`><\>5?78JTDB3PODWM(D)2A*:WID/36@+_WUA1U'X'@7@
M'&9`GVVD3]\#2_GI>(BI/'DP.:69%_`I"@>*5>ZV=4M$`LDH)DD2H8M97`9S
MH:20H2[UGWVF3PFP'GNV#+?AG`-DHGQ20>QEGES$"3%#-=&X1_CEH"Y$HU["
M6H+);CHZ#)X9H\AU#T!J0D+:"PJ5HGVV+US03)NC#IY14M+8I"'9,<#A=`@P
M31`$HDX'HQ]33L2HHGORI-6`'52#0`H*%"#JF4K275O'IMBP<<@@IFU"%9\)
M&W/*3"\1G7BH0QL'"TW4H6[U%IR@'W2J#G&Z27B*#W_D%7OT&ERJ$B!2I<RD
M6X1J>Y.J#SO2HLVT-N2$0X$JH?5T??^AF@^*>@#C4JK'@Z-S8$U^:G#>HP!2
M`6Q7^JG;UZH/PJ1*<`L(U:E8J@MMR4<@TJ)2X9D;80"^NG[`.@^1X:?'%H2.
MQ$P;X:-J"@1M&9I_TZR>N3R%$*EV-ZT?X3W)&:$P.J%;*03#F"#2B%"/PJX.
ML#S-&:WK!ZNU(*,82'CQ2I9^RJX#6[#+6;#;JAX4VA=)D*P_J`VW,09A:F+;
M2$?YT*UV`!Y&T)CN@+'2J0N*.0:HTXP5>T;Y,*FV*AL")A/]H`N`D##:2"4G
M.[,T.Q$MZR7/40!5U7C2V+,^^[-`&[1".[1$6[1&>[1(F[1*N[1,V[1.^[10
M&[52.[54Z[3_%2H'>Y`DS#`)09>9#Y@&:V,4`NFQ7@MZ9%NV:)NV:KNV;-NV
M;ONV?M91O(%0;+$)8XL&F/!X@S(EHA)RZ&!9S^4V`_D(\I0;='M"/G-/HO*G
MI5`8(]"W8,4,T$H;KY.)C5"XB[4Y:E1%]V19+6JN.W!'KD4,@C`TN:$&\[2J
MM[8?ZZ`.$9($MD92,6%,'!L*XZ!.L#HNON$K01<N%%@*'X4&$#*"L6N/2C(,
M7\B;W/,':J"8>=6[?L&>(S@*P=LT+<IHWRB[9<,3>BN=K)L;"H`34:,&U1M2
MH'L#II4F"'D\.GN.06(@I[`A'CJ!,8%0RL`,RJ.OC;`='+*^4%%5_TH1#J8@
MOV[E!Q=BO^RH4@QF"OS+"JYC#E6U(02,"JA95+#6"E*%GP&(FH81$RVX!2DX
MP(_V&]6#NL,D8(RV0F<K!/S;P67C(4J0J8LPP:GQ&_@;$\.4"MV["/S+6KD#
M(F;3$O)E"NG+';`[):U@"0W<"$6,NIQP'R2[3CIX:H\V-/BR5725"9>WQ(^P
M'4YL).]%`*JAP7-`P%9L%-N4Q1"L'60<!]NQ;[FQCV%L%)S`7D3L=PYW*FRQ
M7NTUF'.0OH"`":QE!%'"=F=032(<7$]G:W]0+8ICQU%7"JT0R+/A+B1&L9B7
M1(]6IC@,&8Z\!")U(PSL!]V8":A[R7(Q-/_)RPCI&P94,VHDT`HB=H&,`!RZ
ME3.X`!RB84JS2GFZN@?8D0<&<`"U`%2NN,*<U**XH:MYH,NQ^!M^;`?:!,SU
MXPUM1E:=2[W*3`3,ND?3I":S@\S`M`5?8)]LLPI2MDCZ"[?LW,[N_,[P',_R
M/,_T7,_V?,_XG,_ZO,_\W,_^_,\`'=`"/=`$7=`&?=`(G=`*O=`,W=`._=`0
M'=$2/=$47=$6?=$8G=$:O=$<W=$>_=$@'=(B/=(D7=(F?=(HG=(JO=(LW=(N
M_=(P'=,R/=,T7=,V?=/&6*]^&F-=DR19PR4V4YWP(BIK@TX.5P+:8#/'4PQT
M191Y]0(#`I:(T`#_J\Q*CF0[<+H]I/@'X7"@8G(&)45%:J.95WL"!QAHM$H"
M<)P;<.`<B!G-2G#5OY'5F;`W7:T.J!O6E'-#;99TKW0^5&2X7)(U3=T"O5'5
M-`!+,AP>GE`<W<L<008*8FH";?4-9S#9EE4V8Y!B(QP$D/T'7=4)?UA2G_@"
M*X0MI/QO1G$G)K@D,3$[)V"_.=!);E/6;4@F&7<%7&!'#&?:*B4,O*':')($
MK<T'KRTPLDT#HGU;4><UGTU`G;T"E76)T`F=7)L@UUW="6)17Q5&5,U@[IDL
M$?)5E*.K+SP.94$,GQO+,7$M'S,J=T0P:;(=*.:[]'0&2Z4<P"$E2&#*_SLA
MD)0P;53=&YY`BR(2OIM`3P''5B*;"9H`&0<(UQI'C*]AW2CCD.\JH(5@$AWU
MV[GP#:2H)P3B*_AQ(72'(NPY5Q64`!5T#BR^!.K-::NA(B:'#K3"#4LE*E^%
MXV&:&WN48'LT!@+>V`#>`UM0#T?N-GMT.4=.BY;5F$G^U#CULMCQN/4%!G5%
MXL:-Y2:`XJLP#A&E!U*".M!JG`S^.R41U):U!N)-Y&I`"6!@WO4=X+/ANS\^
M4J]]/+31HO"$4$MPO$,K!O0CZ$(;-*NA'PFV9SK"'Q4EO[/Q#3!L"2#N(@?4
M&D9A"9H;6_0MQL-D0ZS@/7UP`'>T"4J<#/8+</^&`&ERINJK7E''I1.BWN5)
M?&&-30CEX*T#6PL#NU+RD>N&)<B=][+H$R$\`D9]R0I8Y0]C]6^5D`Q]V0<Z
MBQW%,.D>BIJ9JPQC0#7*4"TG/(0B55&;8PB&)L'JA.I3K`50GN[I^>1?%1-1
MSNZ"2W;";C7';KB-(2*2L#;LT!*X4R`HTPF+14^.W#F=P`W8VW?7+K_FCNVT
M>"J<'A.K42$0C\/93O$.O'@/`,1EX<>*+0.K`1881>ZL7@8?;UJM0!J4'1-$
M,2-*[`?+C5/\T>T;GKY#HP`MK^H2`H\Q#_'J=,*XDP"_+>M+LD?^T<8CB3LE
MY_&0<9JBL1VV\[JLH/+_DY0FZJ`6M''SI,5H:H+R)T:/'HK#8+_J)^S!GC#V
MD(8S(L\*@!:II$<"NF/:2S_"+\\AOP'UE3WU?NDD7M\*JQ$5XDCPEK`?ZB"/
MC%[X?+#VO@GSK;[S8A_V+=\2:E`]S423A(X+BVUE($]J8OS@$3\`(3M5)B^R
MW]`.;67S[26QI!C)<[\APX1B4)&^I#'I?8G``8,\-G\[/$\KP]0N590=WC0N
M/I7$1$\)G#$Y+2'A.Q#N??'@PV/E39\+BO/9;?4'H9;:9H3UV1$KP#SZ1]!,
M2O$QFX%Y9V#VW6Y9(A7^6%)T_T'NNE_[D?IJ>1!G^R<"W_#\(Q#]+S/]%$20
M_YX/`LX`$0`$%<\2'`J1.$)Q0D$)-41@!P4Q,!`0P&\@<"020((B,"!"!((A
M(3HU+"`+@Q6"8`P(A>>.9N/2TFKSKLU:P],%!<`P@@SH,U3RE`_4&,SM`/34
MS;4`[-4`-`$<H-2=).T-&#3NT26.)"@RHLT5&'`1(`38X1DHC.2-KO[EK4(<
M%$(DG*(PH%EBTAH$`"2DRLK&&1\CK]$!,#,+)\LI/-O2B#9"VOXJ,19V+JK.
M)!K0*I"3HRAP(>JI'=PZG;3A,1?0,QNM",:701C<]BOZ,^P.M((&3Q380?#@
MG&G3K)6;I&T$L&Z>3H";14=0HSMSN.0Y$*#8@$[^%&#,``:H0!\\309.\J2)
M3IY'-&N4B<4IP8P!"P@0>*#@1(.#1H\B3:H4Z8VE<40YC2IU*M6J4Z58S:IU
H*]>N2@]DZ<>@@4BO9L]^[8AV+=NV;H\]N?AV+MVZ60.\FX4-0@@`.S\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>y04571y0457100.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y04571y0457100.gif
M1TE&.#EA6@!&`.8``/3S\BLG)HV+B^SKZIB5E?GY^,S*R<'`P;>TL_*/M/3=
MV@H("<,?`.-%`./BX6AD8AD5%H."@O3#).UU`3LW-T5$1>0I`,4%`-\P`-B.
MAY&.C7AT=/2T;?CLY]O9V;"LJJ:AH.U=I<HA%*&=G&]L:_[Z]$U*2L;%Q<"^
MO.O$O-HN`.`R`-+2TE924M;5U6)>7>CFY*VII[.PK_#O[E%-34(]/=G7U=D5
M`*VJJ=-[;"\K*UM650\,#5U:6JBFI</"PNMR!>Y]#=73T>9"%M$:`*L$`!X;
M&UQ85Q,/$$I'2/.[">M3`?.-$^I&FO:I3O*)$>$V`-R:C_SNP>^*`N=:`+00
M`?SQZ;$<$NI%E=P:`,\-`.]TL[P$`.4L%?WTZ^^)./OGT-;4T_[W[?KOZ.F_
MO_2BS*2@G]XR%?O;LHJ(B(>&AC0P,-+0T/SDQ?*,%>KHYLO(QB4A($A%1>=&
M*M0I%/SPR/>YV<K&Q962D?;EX^A@!_K8K>92`:@"``<%!O___R'Y!```````
M+`````!:`$8```?_@'^"@X2%AH>(B8J+C(V.CY"))4Z4E9:7E&V1FYR18DR@
MH:*CH&B=IZB(GZ2LH::IL*EB3[2UMK=/;GLE);&^FUY+PL/$Q4M?',E@O\R-
MP<;0PLC*S=6)S]'&TQS+UMZ$V-G$V]W?WU90Z>KK["MZ04%,$O/T\W7FOE8K
M^_S]_AA4)DR8HJ2@P8)2\,72YZ\A/X`""1XTF%!A*H8.&T(<.)&BQ8L9'6Z4
MV+'BQTX80SX,R+&C$I,G-Z54N6*DRY<Q4=+L9],ES)R/K*@82K0H!IXL24[\
M";31&`90HTI5@33B3:9-%SV5RI7J2JL^LT+:RC6JUWT]2XI]-*:*V[=P_XG(
MG;NB00,^0/+JS9N@C%\[:Q5UZ$.XL&$N%Q(GUG+C1A8+D"-;Z(*EB>4M@1,-
M-LP9L>(+C!U+CDS9<A/,F0]MYES8L^+0CT=/KGPYM6K6AS^#;AQ[=.G:M@NM
MQNUZ,6_9LTVC#CYH..OBNT7+_GV:.2'GG77#1DY]N<4\4<*+'T\^`^[6VH]/
MIUW]))GSYZM<F4^?OHC[^.F<V3^DO_\A<X0@8`@)Q/0>?*QE8!TG!R)HF((+
M1D)&$116:.&%14`8X2,*Y.#AAR"&F$,*&Y9HXHDHIJCBBBRVZ.*+F\QPP@$4
M\("$$7\8\(`1//`0P`$`%`+`#P<4>8`'A#A@Y/\/,PCB``$](D$"(07\(`,2
M/?8(@0\G,$,#!0OX(:8?/)B`Q)ACUH"`(!K(00&:"TPIB`L!C+E`#8)$`.<@
M*%00)IIC\A!!+#\`:NBA2.``P:%Q#I(&FC;F"6@2`-3PIY@+]`AG&+"<@`02
MEV+:8ZB8]E`#!!"$VN@?/BQJ)Q*2HID$"J'RT(,,/`!J`BP.I)%&G6BVH(8`
M->0*Z!H:"*#!FW;*20.@F<8ZIAHZZ`H##&>BB:,O%0`JP"`TD.J'$(*\`.>4
M+9`:[1]Z!OJ#JM_"8.R8NW+K[2`#'*&J"^6>RT:V</(@+0\;Q&$H'G^\`0&H
M?F1JPR_=HOGM(!N0^D#_O\T>@>FE"\!:P`;3_D&JP()XH`$>&F@@`S,1CSFQ
M(`:0NJVY=IJY\:M_F&&$F#JP\,>\8I*,3\MBOOR'!X8&@/'-8LK!,1(`1+Q`
M&H*HN_+0]PY"0JT/_T$SII@&H,'3SY*)9]6&&NT-T7X830*@.@RP-)P&Q&PG
M#V$N0$&3@@"K+1M82SP(`M6B"0&27ANZP`,`P,'QGTA<+<@!ZOH@MR`SA&'&
M#FO&PO;$/^B@*@T%S"TF!%TZ?JB<@[BP,Z`0]#""`V;L>"8!]J*Y@1`TN!IH
M`'`,\O68,0BB.J`4D%M(NHS&$2KNGA\*[0(:%/+U`@NL$>0?QV-*`>)"KB$N
MF*`V0@\+V]A_FBD$-811.B$/9(F$#C`,8@"64?)P^2$PC&`$PYC"$A("0`$4
M\.U\@-K!"#X@@Q&,H'.&N$,,)A@#R?UA!A^@8`Q&P(@?C``/:P@``7<`@A%T
M#6)9R\JU8/"&`S;C<S!Z!`QCV`@YP$EM-"Q$&%I@`M_QS`0MR.$A?@`T\@G1
4$"P(0!R6R$0FKN&(4(RB0@(!`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
